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Abstract
Joram Matthias Posma, Novel Statistical and Bioinformatic Tools for Identifying
Predictive Metabolic Biomarkers in Molecular Epidemiology Studies.
(Under the direction of Professors Jeremy K. Nicholson and Paul Elliott)
A top-down systems biology approach investigating metabolic responses to
external stimuli or physiological processes requires multivariate statistical tools to
identify metabolites associated with the global biochemical changes in a supra-
organism. In this thesis I describe several tools I have developed to improve
or supplement currently used methods in molecular epidemiology studies. First,
I describe the MetaboNetworks toolbox which is able to create custom, multi-
compartmental metabolic reaction networks for a supra-organism, combining both
mammalian and microbial reactions. These networks are essentially a summary of
the supra-organisms homeostatic signature. Second, I describe a novel statistical
spectroscopy approach called STORM which aids in the elucidation of unknown
biomarker signals in 1H NMR spectra. Third, I describe the Metabolome-Wide
Association Study on obesity in U.S. and U.K. populations. Many novel metabolic
associations with obesity are described in a systems framework, among which
metabolites associated with energy, skeletal muscle, lipid, amino acid and gut
microbial metabolism. Last, I describe a new multivariate approach to adjust
for confounders, CA-OPLS. Correcting for confounders is an essential aspect in
molecular epidemiology studies as metabolites can be related to a variety of factors
such as lifestyle, diet and environmental exposures which or may not be causally
related to disease risk. In developing CA-OPLS another aim was to simultaneously
eliminate/minimize the effects of different types of sampling bias which are often
not taken into account in modelling metabonomics data with current methods.
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The following notations are used throughout this thesis; where other notations are
introduced and defined in the text.
Notation Meaning
A|B A given B
A∩B intersection of sets A and B
A∪B union of sets A and B
A3B element(s) in set A are in set B
#A cardinality (number of elements) of set A
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∀ for all
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c number of components
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δa,b Kronecker delta of a and b
∃ there exists
i sample index
j variable index
k number of times
µ true mean
n number of samples
[n,p] matrix with n rows and p columns
nc number of confounders
∅ empty set
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Notation Meaning
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P, Q loading matrix
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φ normal distribution
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U left singular vectors
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|x| absolute value of x
Y response variable
Yˆ predicted Y
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Chapter 1
Introduction and Background to
Thesis
1.1 Systems biochemistry
The interdisciplinary area of systems biology aims to provide a holistic view of
complex biological systems such as the human supra-organism using both experi-
mental and computational methods [1–3]. From the mid to late-90s onwards vast
amounts of data could be generated rapidly using several analytical techniques
ranging from genome sequencing to measuring metabolites in biological samples
to model the complexity of a biological system [4, 5]. The field of genomics is in-
volved in unravelling the hereditary (genetic) information from an organism using
genome sequencing techniques that have become more effective both technically
and financially [6, 7] in the years after the generation of human genome using the
shotgun sequencing method [8]. Genes are DNA segments that encode how cells
are build and maintained by an organism. Strands of DNA are copied to RNA by
a process called transcription and the collections of coding (gene) and non-coding
DNA and RNA in an organism make up the genome. The field of transcriptomics
aims to characterize all types of messenger RNA (mRNA) in a cell or organism [9].
mRNA plays an important role in cells where they, among other things, catalyse
biochemical reactions to direct the synthesis of proteins. Proteins are involved
in many different processes such as the catalysis of biochemical reactions in cells,
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these proteins are called enzymes, and proteins aid in controlling an organisms
immune response. The field of proteomics studies and aims to characterize all
proteins that are present in a biological system [10], and the collection of all pro-
teins is called the proteome. The next process down the systems biology ladder is
metabolism which consists of the biochemical reactions within cells that are needed
to sustain life. Different reactions can occur in different cells, thus metabolism is
affected by the genome, transcriptome and proteome [4].
Analogous to the definitions of transcriptomics and proteomics, the charac-
terization of all small molecules (metabolites) in a biological system or sample is
called metabolomics [11], which is similar to, but different from the related field
of metabonomics [12]. Metabonomics is the characterization of the metabolome
in response to pathophysiological stimuli using multivariate statistical methods.
In other words, the changes that occur in the metabolome related to an external
‘event’, which might be disease (risk), but also (a change in) diet or environmental
factors, are identified. The difference between metabonomics and metabolomics
nowadays is largely philosophical [13] and in this thesis I will use the term metabo-
nomics, as its original definition by [12] matches the approach taken in this thesis.
The different metabolites interact in a metabolic network of reactions both in
and out of cells and changes in metabolite concentrations and reaction rates, for
instance due to differential enzyme expression, can perturb the network and also
activate longer alternative biochemical pathways [14]. One of the most important
processes is the release of energy from reactions, a process called catabolism, which
is needed for every organism to survive, grow and needed to start up new chemical
reactions. Biochemical reactions that require energy are called anabolic, and they
build up tissues, organs and other cells. Investigating how the metabolic composi-
tion in a system and metabolic reaction rates are altered by biological events can
be used to potentially develop therapeutics to treat disease [13, 15].
Focussing on mammalian metabolism alone will not provide the full picture as
metabolism is known to be influenced not only by mammalian genes, transcripts
and proteins, but also by diet, environment and other factors [5, 16]. These fac-
tors can in turn influence the human microbiome [17, 18], which is estimated
to contain ten times more genetic material than all genetic material related to
Homo sapiens [19]. The microbiota are essential to human metabolism as they
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can metabolize compounds that human enzymes cannot. Thus there is important
symbiosis between the Homo sapiens and bacteria [20], but also with potential
parasitic organisms and virusses. The latter may play an important, but indirect,
role in mammalian metabolism through bacteria [21]. Modelling the interactions
between genes, transcripts, proteins and metabolites in a biological system simul-
taneously while considering all sources (mammalian, bacterial, parasitic, viral) to
study disease is still a long way ahead and new bioinformatic approaches must be
developed which use the symbiosis between organisms in modelling these inter-
actions. In particular, effectively modelling mammalian metabolism by incorpo-
rating information from metabolite reactions is of particular interest, because it
gives a top-down view from a highly complex system. Moreover, metabolites are
more closely related to biological outcomes than genes and proteins [13] thus may
have a higher biological information content. In addition, the continuous devel-
opment of efficient high-throughput techniques to generate ‘omics’ data enables
mathematical models to use more information simultaneously to more accurately
predict biological outcomes such as disease (risk).
1.2 Analytical technologies for metabonomics
In order to study the metabolic profile of biological fluid samples (biofluids) two
analytical platforms are predominantly used [13, 22–24], namely Nuclear Magnetic
Resonance spectroscopy and mass spectrometry. Both techniques have their ad-
vantages and disadvantages in detecting metabolites, but because the biologically
interesting molecules have different physicochemical properties the methods are
complementary as no single platform is able measure all metabolites in a biologi-
cal sample [25].
Nuclear Magnetic Resonance (NMR) spectroscopy measures specific quantum
mechanical properties of the nuclei from atoms with an odd number of protons +
neutrons. The simplest example of an atom that has an intrinsic angular momen-
tum, and thus non-zero spin, is hydrogen (1H) which has only one proton in the
nucleus. The quantum mechanical spin can either be up or down and it is this
property that is used to analyse molecules with NMR spectroscopy. As the name
already states, 1H NMR investigates the magnetic resonances of 1H nuclei, it is
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therefore also referred to as ‘proton NMR’. It does so by applying a very strong
magnetic field to the homogenous sample, the magnetic field forces the quantum
mechanical spins of all 1H nuclei to align with the magnetic field, thus all quantum
mechanical spins of 1H nuclei are aligned parallel (‘up’) or anti-parallel (‘down’)
to the external magnetic field. The nuclei in parallel are in a lower energy state
compared to the anti-parallel state and by supplying the exact energy needed to
jump from the low energy to the higher energy state a spin can flip from parallel
to the anti-parallel state. The energy required is dependent on the magnetic field
strength, and on the molecule the proton is attached to, as electrons shield the
protons slightly from the applied magnetic field. Therefore a different energy is
needed for each proton that is attached to the same molecule, except when pro-
tons are considered to be magnetically equivalent – two protons are magnetically
equivalent if all relationships to other atoms in the molecule are identical, this
can be studied by looking at the mirror symmetry, rotational symmetry or both
symmetries combined of a molecule.
For example, consider ethanol (H3C-CH2-OH) which has two groups of protons
(CH3 and CH2), the protons in each group are magnetically equivalent because the
molecule does not change when rotated around the C-C-OH ‘backbone’. In order
to make sure all different protons in a sample are brought into the anti-parallel
state, a broad range of radio frequency pulses are used to excite all protons and
bring them in the higher energy state. Immediately after the low energy spins
become high energy spins, they go back to the low energy state (relaxation state)
and emit the absorbed radiation which then induces a current in a coil wrapped
around the sample. The signal contains all the different frequencies observed in
the time domain and is known as the free induction decay (FID), the difference
in frequencies is known as chemical shift. In order to obtain a frequency domain
NMR spectrum the FID is Fourier transformed and this results in a spectrum
of peaks. In order to be able to compare different spectra the peaks need to be
on the same scale and referenced to an internal standard which is added to the
sample. For biofluid (aqueous) samples, the sodium salt of trimethylsilyl-[2H4]-
propionate (TSP) is added to the sample to serve as internal standard. The nine
protons of TSP are magnetically equivalent and due to the silicon atom, which
is the most electronegative atom, it has the maximum shielding of the proton
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nuclei by the electrons in the CH bonds. The protons of the propionate group
are replaced by deuterium atoms (hydrogen atoms with an extra proton, 2H).
Deuterium atoms have an even number of protons and therefore do not have an
angular momentum, thus do not give an NMR signal. This makes TSP useful as
internal standard because all its protons are magnetically equivalent and therefore
a single frequency is observed, and almost all biological molecules are less shielded
than TSP and therefore the emitted energy of TSP is higher. The TSP peak is
referenced to a chemical shift (δ) of 0 so that all other peaks have a higher chemical
shift (requiring less strong pulses to jump energy states). The chemical shift is
measured in parts per million (ppm) to standardize across machines and is defined
as the frequency of the emitted signal (in Hertz, Hz) divided by the magnetic field
strength (in mega Hz, MHz). The intensity of a peak in the NMR spectrum is
directly proportional to the number of protons, thus the integrals of the peaks
from the CH3 and CH2 protons from ethanol are always in a ratio of 3:2.
Another useful property of NMR spectroscopy is that nuclei all have a small
magnetic moment which influences the signals observed from other nuclei in the
vicinity. This is called spin-spin coupling and causes the splitting of NMR peaks
in specific patterns, also known as the multiplicity of a peak, and the relative
intensities of the peaks in the multiplet follow Pascal’s triangle. The most impor-
tant of the coupling types is scalar coupling, which is the interaction of two nuclei
through at most 3 chemical bonds. In a sample there are many molecules of the
same compound of which the protons emit different energies when excited due to
the different arrangements of the spins. In the example of ethanol there are two
groups of protons coupled to carbon atoms, a CH3 group and a CH2 group, the
protons of the CH3 group are affected by the scalar coupling with the CH2 protons.
The CH2 protons can both be spin up, both be spin down or have opposite spins.
The energy emitted by the CH3 protons is slightly different for each of these 3
states of the CH2 group. The highest energy is when both spins are down, the
lowest energy is for the state when both spins are up and the intermediate level is
when the spins are opposite and because the protons are magnetically equivalent
this energy is the same for the up/down and down/up case. In this case there
are 3 energy levels resulting in 3 peaks with ratios 1:2:1 for the CH3 group, this
type of multiplet is called a triplet. Conversely the CH3 group also influences
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the energy emitted by the CH2 protons in the same way, except there are more
states: up-up-up, up-up-down (3×), up-down-down (3×) and down-down-down,
which results in a peak splitting pattern with ratios 1:3:3:1, a multiplet referred to
as a quartet. The fine structure of peaks from each metabolite is different and this
is used to structurally identify metabolites. In 1H NMR spectroscopy chemicals
shifts of NH and OH signals are also observed, however these give weaker signals
and are typically less shielded.
The advantage of NMR spectroscopy is that it requires relatively little sample
preparation, the sample is not destroyed in the process of analysing it and it con-
tains information of the structure of the metabolite. This makes 1H NMR a good
method for the high-throughput analysis of biofluid samples. However, in 1H NMR
there is a lot of overlap between metabolite signals which makes it difficult to iden-
tify all metabolites and it is less sensitive compared to mass spectrometry (MS). MS
has the advantage over 1H NMR in that it can provide information of the mass of a
compound that can be used to identify a compound. Measuring all masses simulta-
neously in mass spectrometry can be done using direct-infusion mass spectrometry
and a spectrum can be obtained within minutes [26] which makes it a good method
for high-throughput analysis of biofluid samples. However, it has some disadvan-
tages such as reduced ionization efficiency due to the simultaneous ionization of
all compounds in the sample, which may contain less volatile compounds, and the
corresponding co-elution of metabolites into the mass detector [26], the inability
to distinguish between molecules with molecular masses that fall into the same
mass-to-charge (m/z) bin [27] and batch differences due to changed experimen-
tal conditions [28]. The former two of the disadvantages can be solved using a
separation technique before ionization, such as liquid- or gas-chromatography, or
capillary electrophoresis to separate compounds based on physicochemical prop-
erties. The separation step improves the identification of compounds not only be-
cause less metabolites co-elute, but also because additional information is available
from the separation set (retention time) that can be used to identify metabolites
based on physicochemical properties in addition to the m/z-ratio. However, these
‘hyphenated’ techniques also have important disadvantages, for example the in-
creased run-time makes high-throughput experiments less feasible, the conditions
of the chromatographic separation step can change when analysing many samples
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which then makes the identification of important metabolites more difficult and
also metabolites may ionize favourably either positive or negatively, therefore ex-
periments would have to be done using both modes of ionization. Despite recent
advances in the sample preparation, automated measurements and methodologies
for MS-based metabolic profiling [29–35] its reproducibility still falls behind com-
pared to 1H NMR spectroscopy [36, 37] for large data sets. Therefore, while it is
less sensitive than chromatographic MS, 1H NMR based metabolic profiling has
been used to generate the data that are described and used in Chapters 4 to 6.
One of the most important tasks in 1H NMR spectroscopy of biofluids is to
identify metabolites in the complex mixture. One way to do this is to run addi-
tional NMR experiments which, in addition to the 1H chemical shift, measure other
parameters such as the chemical shift in a decoupled NMR spectrum (J-Resolved
NMR spectroscopy), coupling between pairs of adjacent nuclei (homonuclear cor-
relation spectroscopy, COSY), coupling between connected nuclei at a larger dis-
tance (total correlation spectroscopy, TOCSY) and coupling between different nu-
clei, for instance the carbon isotope 13C (heteronuclear single-quantum/multiple-
bond correlation spectroscopy, HSQC/HMBC). Aside from running extensive two-
dimensional NMR experiments, another approach is to use statistical methods to
determine the likelihood of two chemical shifts in the data belonging to the same
molecule. This area of research is called statistical spectroscopy and is popular
due to the fact that it uses the multivariate data structure and does not necessar-
ily require additional experiments. The most popular method is to use statistical
total correlation spectroscopy [38] (see section 2.5) to calculate correlations be-
tween all variables in the data. The reason this works so well is because of the fact
that multiplets from different nuclei from the same molecule are always in a ratio
directly proportional to the number of protons. By using many 1H NMR spectra
of complex mixtures this will result in multiplets belonging to the same molecule
to be correlated more to each other than to multiplets from other metabolites.
However, this approach (and the 2D experiments) may prove to be difficult when
a signal is close to the noise level and/or heavily overlapped with other signals,
it then is difficult to deconvolute the data to show meaningful correlations in the
data.
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1.3 Molecular epidemiology
Due to the advancements in automated, reproducible measurements of biological
samples, a ‘data-tsunami’ has come from the various omics in the 2000s. Handling
this data, consisting from tens to thousands of samples, and from thousands to
millions of measured attributes (variables), is a monumental task. In order to
analyse these high dimensional data sets different statistical methods are used to
investigate which genes, transcripts, proteins and/or metabolites are differentially
expressed between groups or change due to external perturbations. Metabonomics
is able to show a global outcome of a biological systems response to an exter-
nal effect and human molecular epidemiology is involved in understanding these
metabolic effects underlying health-effects in well-defined populations. One of
the methods that are employed to find metabolic phenotype variation in high-
throughput metabonomics data is using the Metabolome-Wide Association Study
[39, 40] (MWAS) approach. It aims to investigate genetic and environmental in-
fluences on metabolism using molecular spectroscopy methods to measure a huge
number of samples in a high-throughput manner and uses epidemiological data
to define metabolic phenotypes related to disease risk factors, such as cancer or
cardiovascular disease.
Cardiovascular diseases (CVDs) are the leading cause of death in the world and
in 2008 they caused as many deaths as cancers and infectious diseases combined
and affect all layers of society [41]. However, the prevalence of CVDs appears to
increase more in developing countries and for people with a low socio-economic
status than it does for ‘Western’ countries [42–47]. Independent of genetic aspects
for CVD [48, 49], several metabolic risk factors [50] have been associated with
CVDs over the years, these include hypertension [45, 46, 51–54] , diabetes mellitus
[45, 48, 51, 53] (DM), high (blood) cholesterol [45, 47, 51, 53, 55] and obesity [45,
51, 56–58]. These metabolic risk factors are believed to be (partially) caused by
several lifestyle risk factors such as tobacco use [45, 51, 53, 56, 59–64], physical
inactivity [45, 56, 60], high intake of salt, fat and calories [56, 60, 65], harmful use
of alcohol [45, 56, 60, 66], low fibre intake [56, 67] and low consumption of fruits
and vegetables [45, 56, 68–70]. A decrease in CVD risk has been observed for a
number of changes in lifestyle and diet [47, 71], although not for all [72].
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The MWAS approach has been successfully applied to study blood pressure [39]
using 1H NMR data from the INTERnational study on MAcro- and micro nutrients
and blood Pressure (INTERMAP) [73]. The INTERMAP study is investigating
dietary and other factors associated with blood pressure [73], the major modifiable
risk factor underlying the worldwide epidemic of cardiovascular diseases [46, 74].
The INTERMAP study surveyed a total of 4,680 men and women aged 40-59 from
17 population samples in four countries (Japan, People’s Republic of China, United
Kingdom, and United States). Participants were randomly recruited from general
and occupational population samples in 1996-1999 and each participant made four
clinic visits. The first two on consecutive days and the second two on average three
weeks later and also on consecutive days. The data obtained include eight blood
pressure measurements (two per day), four 24hr dietary recalls obtained by the
multi-pass recall method administered by a trained interviewer, measurements of
height and weight, questionnaire information and two timed 24hr urine collections
(obtained on the second and fourth visit). The multi-pass recall method has par-
ticipants first report the times and location of drinking and eating all beverages
and foods that were consumed the previous day. Second, the interviewer goes over
the list for completeness of items and re-checks with the participant if there was
a big time gap between meals. Third, the interviewer and participant check the
list and go into more detail to record brands, quantities, processing methods, any
additions in preparation of food (i.e. spices) and the amount of food left on plates.
Visual aids were used to assist the participant in estimating portions, these aids
were specific for, and standardized within, each country [75]. If the participant was
uncertain about details, the interviewer or participant contacted the cook to obtain
the necessary information. All information was recorded using both an audiotape
of the interview and a report of the interviewer. Last, the obtained information
was then coded and analysed by country-specific nutritionists to determine the
food and nutrient composition.
Previous studies with INTERMAP data have shown how dietary intake can
have significant effects on the metabolic risk factors [39, 54, 76, 77]. In addition,
1H NMR data from the INTERMAP study has been used to study differences
between the northern and southern Chinese population [78] and between African
Americans and non-Hispanic white Americans [79] as these populations are at
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different risks for CVDs. However, obesity is one of the risk factors for CVD that
in turn can be caused by other risk factors for CVD, such as physical inactivity
and poor diet, and obesity can also cause insulin sensitivity/resistance and type-
2 diabetes [80]. Therefore, studying the metabolic phenotype associated with
obesity may give novel insights into how obesity contributes to CVD. However, it
is important to incorporate information of confounding factors in modelling the
metabolite-outcome associations to ensure these associations are related to the
outcome and not to, for instance, population structure. Information of possible
confounding factors is collected at the same time as sample collection in molecular
epidemiology studies such as the INTERMAP study [73]. The 1H NMR data from
the INTERMAP study is used in Chapters 4, 5 and 6 this thesis and described
in detail in the Materials and Methods section in Chapter 4.
1.4 Scope of thesis
The work presented in this thesis (Chapters 3 to 6) covers the development and
application of novel statistical spectroscopic, bioinformatic and chemometric tools
to aid the data analysis and exploration of molecular epidemiology studies.
No matter how well-defined the population is, there are still four main threats
to the validity of general research findings: chance, power, confounding and bias
[81]. Chance is the possibility that a process shows, or fails to show, a trend due
to random variation, for instance noise. Thus if this trend is not caused by the
outcome, but by a random process, it could be falsely associated with the effect
under study (false positive) or not be picked up (false negative). This is a common
problem in statistical analysis as all analytical techniques suffer from instrumental
noise that can affect the measurements. The second threat is power, or actually
lack thereof. If the population is too small, it could be that a small trend is not
picked up from the data; this can result in false negative findings. Confounding
and bias are often confused as being the same, however they are not. The similarity
though, is that the result of them can be falsely positively associations, which is
the case most of the time, as well as effects not being picked up (false negatives).
The concept of confounding is where an association is found that could also be
explained by another factor, for instance there is a hidden factor that explains (a
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proportion of) both the explanatory data as well as the outcome. Bias is caused by
the introduction of different types of systematic variation, for instance when the
population is not representative to study the outcome. I describe and discuss in
this thesis different approaches to avoid (or reduce) the effects from these threats
and use metabonomic NMR data to visualize the results for MWAS for molecular
epidemiology.
In Chapter 2 I describe different chemometric, graph theoretic and statistical
methods that are used in or referred to in Chapters 3 to 6. The details of ex-
perimental procedures for measuring the data as used in this thesis are described
in the individual chapters rather than in the methods section as the focus of this
thesis is on statistical, and not experimental, methods.
Chapter 3 introduces a novel bioinformatics tool, MetaboNetworks, which can
be used to construct a database of reactions between metabolites to explore trans-
genomic interactions and create custom metabolic reaction networks using data
from the Kyoto Encyclopaedia of Genes and Genomes. Being able to study a
metabolic reaction network using data from multiple organisms, for instance mam-
malian and bacteria, is very useful because of the host-bacterial symbiosis [20, 82].
It is the only software to date which not only allows the construction of a custom
database tailored to the experiment, but also allows the user to interactively alter
and explore the metabolic reaction network.
In Chapter 4 I describe a new multivariate statistical approach to recover
metabolite structural information from 1H NMR spectra in population sample sets.
Identification of 1H NMR spectroscopic signals using statistical methods is an im-
portant aspect in MWAS, as it uses the data which have been modelled to more
accurately recover information about possible biomarkers without requiring addi-
tional spectroscopic experiments [83]. A widely used statistical spectroscopy tool in
NMR-based metabonomics is statistical total correlation spectroscopy (STOCSY)
[38] (see section 2.5), which is related to generalized 2D correlation theory as used
for Infra-Red and Raman spectroscopy [84]. In the case of 1H NMR, STOCSY can
generate a pseudo-selective 1D total correlation spectroscopy spectrum based on
the correlation to the intensity of a given peak (driver), or a 2D auto-correlation
matrix to show all spectrum-wide associations in the data. Over the last few years,
STOCSY and its variants [85–90] have proven to be a valuable tool in identification
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of spectroscopic signals [91], as they can visualize both structural associations as
well as non-structural (for instance metabolic pathway) interactions [92]. I devel-
oped SubseT Optimization by Reference Matching (STORM) to find subsets of 1H
NMR spectra that contain specific spectroscopic signatures of biomarkers differ-
entiating between different human populations to more accurately show structural
correlations in 1H NMR data, thereby reducing both false negatives as well as false
positive findings. I compare the method with STOCSY as well as with a different
statistical approach to find the optimal subset, stability selection [93], to show the
benefit of STORM.
Chapter 5 describes the identification of predictive urinary molecular biomark-
ers associated with obesity using the MWAS approach. STORM (Chapter 4) is
used here to identify metabolites associated with obesity in U.S. and U.K. popu-
lations from 1H NMR data. A data analysis framework is outlined for the serial
sampling design of the INTERMAP study to limit potential false associations
and the data is modelled using several epidemiological models to correct for pos-
sible confounders. Together with targeted analysis of amino acids and related
compounds using ion-exchange chromatography I construct a network map show-
ing the homeostatic signature of obesity in two different populations using the
MetaboNetworks software (Chapter 3).
Chapter 5 has shown how different external factors can influence the associ-
ation of metabolites with an outcome (for instance obesity), it is important to
adjust for these potentially confounding factors in the data analysis. In Chapter 6
a multivariate data analysis framework is outlined which is aimed to limit the bias
in multivariate modelling of metabonomics data. In addition, a novel statistical
method is described which adjusts the data for confounders in a multivariate set-
ting called Covariate-Adjusted Orthogonal Projections to Latent Structures (CA-
OPLS). The new method is compared to two methods routinely applied in 1H NMR
based metabonomics that are able to deal with the high collinearity present in the
data, Partial Least Squares [94] and Orthogonal Projections to Latent Structures
[95].
Chapter 7 contains general conclusions and outlines future perspectives of the
research presented in this thesis.
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Methods
The work presented in this thesis is the result of the development of new sta-
tistical, chemometric and graph theoretical methods for modelling metabonomics
data. Details of experimental design, sample collection, data acquisition and pre-
treatment of the data sets can be found in the individual chapters. This chapter
focusses on introducing the basics and backgrounds of statistical methods and dif-
ferent multivariate data analysis methods that are used or referred to in Chapters 3
to 6.
2.1 Basic concepts
2.1.1 Mean and variance
In science everybody is confronted with the fact that repeated measurements of a
sample, may not always give the same results. For instance when measuring the
concentration of a compound in a biological sample multiple times using an assay,
say 10 times, most likely 10 (slightly) different concentrations are obtained. This
can occur for example due to measurement errors, sensitivity of the method or
random variation. The list containing the concentrations for the samples is called
a variable, simply because the values can ‘vary’. The number of samples from here
on forwards is referred to by the letter ‘n’ and the letter ‘p’ is used for number
of variables, for instance in the example above n=10 and p=1. The data set is
referred to by the lower case letter ‘x ’ for a single variable and by a capital case
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‘X’ for p ≥ 2, which is also called a matrix of size [n,p]. In order to give a more
reliable estimate of the real concentration the mean value can be used. The mean
(x¯) is defined as the sum of all values of a variable divided by n, see Equation 2.1,
where i indicates the i th sample (index) from x.
x¯ =
1
n
n∑
i=1
xi (2.1)
In this equation, n is also defined as the number of degrees of freedom (d.o.f.). It
indicates how many of the values can be chosen at random, until the mean can
only be one single value. If there are 10 measurements, the d.o.f. equals 10, as
the mean is dependent on all values – if 9 measurements are known (and one is
unknown) in addition to knowledge of the mean, the 10th measurement can only
be a single value.
In addition to the mean of data, another useful parameter is the variance
which indicates the spread in the data. Variance (σ2) is defined as the sum of the
squared difference from the mean divided by the number of samples minus 1, see
Equation 2.2.
σ2 =
1
n− 1
n∑
i=1
(xi − x¯)2 (2.2)
Here the d.o.f. equals n − 1, because the mean already holds information of all
measurements. Related to the variance is the standard deviation (σ), which is the
square root of the variance.
2.1.2 Parametric hypothesis testing
Consider a hypothetical example of two groups of patients, one group with an ill-
ness (n=10) and the other healthy (also n=10). The concentration of a compound
in a biological sample is measured for each patient. The mean concentrations
found for the two groups are 72 (mmol/L) and 74 (mmol/L) and the variances
of the measurements are 12.66 (mmol/L) and 14.66 (mmol/L) for group 1 and 2,
respectively. In order to determine whether the groups are similar, or different, a
test can be performed to assess whether the means are significantly different from
each other using a (two-sample) t-test. The two-sample t-test assumes the data is
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normally distributed (parametric). This means that it assumes that there is equal
probability of finding a value with a distance d to the true mean (µ) as there is
to finding a value of distance −d to µ. This becomes obvious when looking at the
probability density function (pdf) of the normal distribution (φ), see Equation 2.3,
where x ranges from −∞ to ∞ (infinity).
φ(x) =
1
σ
√
2pi
e−
1
2
(x−µ
σ
)2 (2.3)
Here it can be seen that the difference (distance) is a squared difference, and thus
that the normal distribution is symmetric around µ. The t-test uses a distribution
similar to φ, however it takes into account the d.o.f. of the data, because unless
there is an infinite (∞) amount of data available, µ cannot be known. Therefore
the data mean (x¯) is used as approximation of µ. The t-distribution [96] is equal
to φ when the d.o.f. is infinite and is increasingly lower and wider when the d.o.f.
becomes smaller. For the t-distribution the d.o.f. is defined as the number of
observations (samples) minus 1. To determine if the two means are significantly
different, a standardized value, the t-score, is calculated as in Equation 2.4.
t =
(x¯1 − x¯2)2√
(n1−1)σ21+(n2−1)σ22
(n1−1)+(n2−1)
(2.4)
Where x¯1 and x¯2 are the data means, σ
2
1 and σ
2
2 the variance and n1 and n2
the number of samples for groups 1 and 2, respectively. The t-score is a value
between −∞ and ∞ and is exactly zero if the two means are exactly equal. For
the example of the two patient groups a t-score of -1.21 is obtained. In order
to determine whether the groups are significantly different this value must be
compared to a frequency distribution of samples drawn from a normal population.
For this purpose the appropriate t-distribution is chosen using (n1− 1) + (n2− 1)
for d.o.f. and a specific significance level (α). The significance level indicates the
accepted probability that the finding (difference in mean) could be a false positive
finding (or type I error). Often 5% (0.05) is used for α and using the t-score and the
t-distribution, a level of confidence in the result of the test can be found. This level
is the probability (P -value) that a more extreme t-score can be found using the
49
CHAPTER 2. METHODS
specified t-distribution. The P -value is a value between 0 and 1 and if the P -value
is higher than α the ‘null hypothesis’ of no difference of the means is accepted.
The resulting P -value is calculated using the cumulative density function (cdf) of
the t-distribution, see Equation 2.5, where the straight bars around t indicate the
absolute value. The result is multiplied by 2 as a priori there is equal chance of
the concentration in group 1 being higher than group 2, and vice versa. This is
referred to as a two-sided t-test.
p = 2× tcdf (−|t|, d.o.f.) (2.5)
With a P -value of 0.24, there is a chance of almost 25% that the difference is caused
by a random process. Thus the assumption is made that there is no significant
difference in the concentrations of the compound in the two groups.
The previous example was a two-sample t-test to compare two means. Logi-
cally, there also is a one-sample t-test. It tests whether the results are in accordance
with an accepted reference value (µ0), see Equation 2.6.
t =
(x¯− µ0)2√
σ2
n
(2.6)
In essence it is the same as the two-sample t-score as a single number (µ0) al-
ways has a variance of 0. Thus the variance term of the second variable can be
neglected from Equation 2.4. The one-sample t-test can be used to determine if
a concentration of a group is significantly different from, for instance, the known
concentration of a group. Say the known concentration in a healthy population
for the compound is 75 (mmol/L), the hypothesis that the mean of first group is
not different from the reference is rejected, as the P -value is 0.03. In other words,
there is something systematically different between the two values and the differ-
ences cannot be explained by a random process alone. The P -value of the second
group is 0.43, which does not reject the hypothesis that the means are different.
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2.1.3 Non-parametric alternatives
Not all types of data are normally distributed, they can be exponential or of an
unknown distribution. Before resorting to non-parametric alternatives, sometimes
the data are log-transformed and tested for normality. Common tests for normal-
ity include the Kolmogorov-Smirnov and Lilliefors tests [97, 98]. If the data are
considered to be normally distributed after a transformation, standard paramet-
ric tests can be used. However, when they are not normal, non-parametric tests
should be used. Non-parametric tests do not use the mean as it can be prone
to outliers, but they often use the rank or median as more robust metrics. The
median value is defined as the middle value of sorted data, thus if there are an
uneven number of samples this is the value of the ((n+ 1)/2)th value of the sorted
data. For an even number of samples the median is the mean of the two central
values, the (n/2)th and (n/2 + 1)th values of sorted data. The Wilcoxon rank sum
test [99] and Mann-Whitney U-test [100] are non-parametric alternatives for the
one- and two-sample t-tests, respectively.
2.1.4 Comparison of binary outcomes
Instead of continuous variables, there also exist categorical variables with binary
variables (0/1) as special case. In order to compare whether two groups are dif-
ferent for a binary variable, a χ2 test [101] can be performed (Equation 2.7).
χ2 =
∑ (T − E)2
E
(2.7)
Where T is the true frequency observed for the two classes and binary variable.
T is a 2 × 2 matrix, where T11 is the number of times the binary variable (x) equals
0 when the class (Y) also equals 0 and T21 is the number of times the binary variable
equals 1 when the class equals 0, etc. E, also a 2 × 2 matrix, is the frequency
expected to be observed based on the data and is calculated as in Equation 2.8,
where P(Y = 0) is the marginal probability of the class (Y) being 0, P(x = 1) the
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marginal probability of the variable x being 1, etc.
E =
[
n× P (Y = 0)× P (x = 0) n× P (Y = 0)× P (x = 1)
n× P (Y = 1)× P (x = 0) n× P (Y = 1)× P (x = 1)
]
(2.8)
2.1.5 Covariance and correlation
In order to determine whether there is an association between two (continuous)
variables, a scatter plot of the paired values of the two variables can be used. If
there is a true association, it is expected that as the values of the first variable
increase, the values of the second variable also increase. A scalar metric of this
association is the covariance. It resembles the variance in such a way that the
covariance of a variable j with itself is the variance of variable j. For two different
variables, say j and k, it is expressed as the joint variance of the two variables, see
Equation 2.9.
cjk =
1
n− 1
n∑
i=1
(xij − x¯j)× (xik − x¯k) (2.9)
Variables with a high co-expression have a high covariance. However, similar to
the variance, the covariance is also affected by the means of the variables. In order
to compare variables with difference variances, the (Pearson) correlation [102] can
be used (Equation 2.10). It is defined as the covariance divided by the product of
the standard deviations of variables j and k.
rjk =
1
n− 1
∑n
i=1(xij − x¯j)× (xik − x¯k)
σj × σk (2.10)
The correlation shows how similar two variables are on a scale ranging from −1
to 1, where 1 indicates perfect coherence, 0 complete incoherence and −1 perfect
inverse coherence. It essentially is a least squares fitting of the data to a straight
line (see section 2.2.1). Using the correlation, a t-score can be calculated shown
in Equation 2.11.
t = r ×
√
n− 2
1− r2 (2.11)
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Inserting t into Equation 2.5, with (n− 2) d.o.f. (mean and variance are used to
calculate the correlation), will give a P -value for the correlation.
2.1.6 Non-parametric alternatives for the correlation
For data that is expected to be non-linear, a non-parametric alternative such as
the Spearman [103] rank correlation can be used. As the name suggests, it uses
the rank and therefore does not assume a linear relation between variables. To
calculate the rank correlations the observations are ranked based on their values for
variables j and k and ties are given the mean rank. The Spearman rank correlation
(ρ) uses the differences between the ranks of the variables to calculate the rank
correlation, see Equation 2.12.
ρjk = 1− 6
n3 − n
n∑
i=1
(rank(xij)− rank(xik))2 (2.12)
For the perfect linear case, the Pearson and Spearman correlations are the same.
Another method, Kendall rank correlation [104] (τ) uses the sign of the difference
instead of the squared difference in rank. Other more sophisticated methods exist
that are able to deal with non-linear relations such as maximal correlation [105],
principal curve-type smoothers [106], mutual information estimation [107] and
maximal information coefficient [108].
2.1.7 Partial correlation
A correlation between two variables could potentially be caused by a third variable,
a co-factor. This effect is called confounding, where a third independent variable
influences the association. The effect of confounding can go both ways, it can cause
a higher correlation as well as decrease the correlation, however the former case is
more likely. Partial (Pearson) correlation [109] adjusts the correlation between two
variables (j and k) given the correlation with other variables (h), see Equation 2.13.
rjk|h =
rjk − rhj × rhk√
1− r2hj ×
√
1− r2hk
(2.13)
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Hence, if there is perfect correlation between j or k and h, the partial correlation
of j and k is 0. Equation 2.11 cannot be used for calculating the t-score of the
partial correlation as new information is used; the t-score for partial correlation is
shown in Equation 2.14.
t = r ×
√
(n− 2)− 1
1− r2 (2.14)
In this case there was one confounder h, thus the d.o.f. is (n − 3) instead of the
previous (n−2). Different formulae exist for partial rank correlation methods [110].
When more factors are to be adjusted for, these can be added to the equation in
the same way correlations with h are listed.
2.1.8 Multiple testing correction
When multiple comparisons are made simultaneously, for instance t-tests looking
at differences between groups for multiple variables or correlations between mul-
tiple variables, the problem of multiple testing arises. As the number of tests
increases, it also becomes more likely that there is a test that is considered statis-
tically significant. Consider testing 20 comparisons at α=0.05, the Family-Wise
Error Rate (FWER) of the experiment gives the probability of an incorrect rejec-
tion (Equation 2.15) and is 64.15%.
FWER = 1− (1− α)nt (2.15)
Thus the chance of finding a false positive error increases with the number of tests
(nt). In order to correct for multiple testing a correction of the significance level
can be done where the significance level is divided by nt (Equation 2.16) [111],
known as the Bonferroni correction, which is a form of the FWER and the most
conservative significance threshold.
α
′
=
α
nt
(2.16)
However, the Bonferroni correction assumes all individual tests are independent,
whereas in practice they may not be, i.e. some variables may be correlated (for
instance as is the case for 1H NMR data).
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Instead of focussing on the probability of an incorrect rejection, a different ap-
proach to multiple testing can be used which focusses on controlling the expected
proportion of incorrectly rejected null hypotheses – the False Discovery Rate [112]
(FDR). It is less stringent compared to the Bonferroni correction. The basic for-
mulation of the FDR takes a sorted descending list of P -values and transforms
them to pFDR-values (Equation 2.17), where Pk denotes the k
th sorted P -value.
Note that the pFDR of the highest P -value is equal to the P -value.
pFDRk =
nt × Pk
nt − k + 1 (2.17)
Next, the pFDR-values are assessed using the Benjamini-Hochberg step-up pro-
cedure [112] to ensure all pFDR-values are, as with P -values, between 0 and 1
(Equation 2.18).
pFDRk =
{
pFDRk : pFDRk < pFDRk−1
pFDRk−1 : pFDRk ≥ pFDRk−1
(2.18)
In a real experiment often a specific proportion of the variables are expected to
be significant, this disturbs the natural distribution of P -values, which for random
data are expected to follow a uniform distribution between 0 and 1 [113, 114].
Storey and Tibshirani [114] proposed to determine the proportion (pi0) of null
pFDR-values using a bootstrap approach. The pFDR-values are then scaled to
follow a uniform distribution again (Equation 2.19) which gives rise to the q-value,
“the pFDR analogue of the P -value” [114].
qk = pi0 × pFDRk (2.19)
A different approach to multiple testing is to determine a dataset dependent
cut-off based on simulations. Analogous to the Genome-Wide Significance thresh-
old [115], the Metabolome-Wide Significance Level [116] (MWSL) can be defined
by running multiple simulations of random comparisons (with equal power to the
real data set) and determining the P -values for all variables. The lowest P -value
found for each simulation is the threshold of null hypothesis for each. Using the
lowest P -values found for all comparisons a P -value distribution of no association
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can be determined, and a threshold analogous to the FWER can be chosen by
taking the P -value that is smaller than 99 or 95% of the null P -values [115, 116].
2.1.9 Statistical shrinkage
Calculating an auto-correlation (or covariance) matrix using a lower number of
samples than variables (n < p) can lead to finding false-positive associations in
addition to the true correlations even when controlling for multiple testing. In
order to correct for this statistical shrinkage can be used. Statistical shrinkage
penalizes the correlation using James-Stein-type [117] shrinkage estimators [118]
and has previously been shown to improve the estimation of the true discovery
rate [119]. The method described by Schafer and Strimmer [120] is to shrink the
off-diagonal elements of the correlation matrix using a weighted average (Equa-
tion 2.20) towards a target matrix, in this case the identity matrix (I ).
r
′
= (1− λ)× r + λI (2.20)
Here, r denotes the standard correlation matrix, λ the shrinkage parameter and r
′
the shrunk correlation matrix. If λ obtains its maximum value of 1 (Equation 2.21),
the shrunk correlation matrix r
′
is the identity matrix, this means all off-diagonal
correlations were shrunk to 0 (no statistical dependence between variables). The
limits of 0 and 1 for λ are set to rule out any possible over- or under-shrinkage.
λ = max(0,min(1, λ)) (2.21)
To determine the value for λ, the fraction of the sum of squares of the off-diagonal
covariance of the auto-scaled X matrix (X˜) with the total sum of squares of the
off-diagonal correlations is determined (Equation 2.22 and Equation 2.23) [118,
120], where Equation 2.23 is the variance of the element-wise multiplication of
variables j and k.
λ =
∑p
j=1
∑
k≤j vjk∑p
j=1
∑
k≤j r
2
jk
(2.22)
vjk = var(Π
n
i−1X˜ij × X˜ik) (2.23)
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The resulting shrunk correlation matrix is positive definite, and thus easily in-
vertible and to calculate the shrunk covariance matrix (Σ), the diagonal standard
deviation matrix σii is multiplied with the correlation matrix which is then multi-
plied with σii again (Equation 2.24 and Equation 2.25).
Σ
′
= σii × r′ × σii (2.24)
σii =
{
σi, i ∈ [1, ..., p] : i = j
0 : i 6= j (2.25)
The shrunk covariance matrix is an accurate and reliable estimate of the population
covariance matrix [120] and the shrunk correlation and covariance matrices can be
used for different methods (see for instance 2.3.6) that require inverting matrices
of size n < p.
2.1.10 Hierarchical cluster analysis
An auto-correlation matrix can also be used to determine similarity between vari-
ables or between samples. Hierarchical cluster analysis (HCA) aims to cluster the
data in a hierarchical way, hence the name, by consecutively grouping the most
similar variables or samples. To avoid confusion, in this paragraph I will refer to
the ‘entities being clustered’ as objects. Objects can be both variables or samples
depending on the context. HCA is one of the clustering methods that do not re-
quire a priori knowledge of the number of classes. Rather it uses the similarity
of objects, for instance using the correlation, to find a similarity structure in the
data. Instead of using the correlation, other metrics can also be used that may
have different ranges; therefore the metrics are converted to distances, where a dis-
tance of 0 indicates two identical objects and the upper bound of the distance is
dependent on the metric, but for correlation this is 2, as the (Pearson) correlation
distance is defined as 1 minus the correlation (Equation 2.26).
d = 1− r (2.26)
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HCA starts off by finding the two most similar objects (smallest distance) and
places these two in the same group. Next, it recalculates the distance of this group
with all other objects. A number of methods exist to determine how distance is
calculated between a group and object (and between groups). The three most
common ones are single linkage [121], average linkage [122] and complete linkage
[123]. Single linkage determines the distance as the smallest distance to a member
(object) of a group, whereas complete linkage does the opposite by considering the
distance to the group as the largest distance to a member of a group. Average
linkage is the distance to the average of the group. As a more robust alternative to
the mean, median linkage can also be used. Using the chosen type of linkage HCA
continues by combining objects to groups, or merging groups, until all objects are
in one big group. The resulting structure (dendrogram) shows a structure of how
different objects are merged and shows the merging of objects as the distance at
which they are merged, this resembles the roots of a tree as it branches out the
more similar objects become. Different methods exist to determine the number of
clusters, one being the modularity which is described in section 2.4.5.
2.2 Regression and discriminant analysis
2.2.1 Univariate linear regression
In order to quantify a linear association between two variables, linear regression
can also be used. Say it is assumed that a response variable (Y), an ‘outcome’, can
be explained by a variable x, i.e. the correlation (rxy) does not equal 0, a linear
equation can be used to describe the association as well, see Equation 2.27.
Yi = β0 + β1 × xi + ei (2.27)
Here, Yi is the i
th value in Y, xi the i
th value in x, β1 the slope of the line, β0 the
offset and ei the error of this fit. This equation has to be solved for each sample
individually; however that would most likely result in k different values for β0 and
β1. In order to obtain a single value for both β’s, also termed regression coefficients,
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a generalized fit is calculated. First the slope is calculated as in Equation 2.28.
β1 =
∑n
i=1(xi − x¯)× (Yi − Y¯ )∑n
i=1(xi − x¯)2
(2.28)
This fit is optimized in the least squares sense; this means that it aims to minimize
the squared error of the fit. The slope is related to the correlation by a scaling
factor, see Equation 2.29.
rxy = β1 ×
√∑n
i=1(xi − x¯)2∑n
i=1(Yi − Y¯ )2
(2.29)
The next step is to calculate the offset using Equation 2.27. In Equation 2.30, Yi
and xi are substituted by Y¯ and x¯ and the error is neglected.
β0 = Y¯ − β1 × x¯ (2.30)
The next step (Equation 2.31) is to calculate the predicted response, Yˆ , using β0
from Equation 2.30 and β1 from Equation 2.28.
Yˆi = β0 + β1 × xi (2.31)
The error of the fit can be calculated by looking at the difference between Y and
Yˆ (Equation 2.32).
ei = Yi − Yˆi (2.32)
The sum of the squared error is often used as quality measure of the prediction.
The quality of the fit can be assessed by calculating the variance of each variable, in
this case there is only x, and divide the regression coefficient (β1) by the variance.
This results in a t-score that can be converted to a P -value using n− 2 d.o.f. and
Equation 2.5. The P -value indicates whether or not the coefficient is significantly
different from 0 (i.e. no association between x and Y).
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2.2.2 Multiple linear regression
The regression model can be expanded to include more than one variable. This
is called multiple linear regression (MLR) as multiple linear relationships between
the data and the response are considered simultaneously. MLR is solved using the
least squares method for each variable, as described above. However, the matrix
notation of the model is more efficient (Equation 2.33), with  being the random
variation in Y (size [n,1]) that cannot be explained by X (size [n,p]).
Y = Xβ +  (2.33)
This can be rewritten in the least squares sense as in Equation 2.34, here e replaces
 as e is an estimation of it.
e = Y −Xβ (2.34)
The sum of the squared error can be obtained from Equation 2.34, and is shown in
Equation 2.35 where the superscript ‘T’ indicates the transposition of the matrix.
While β, e and Y are vectors, they can be seen as one column matrices.
eT e = (Y −Xβ)T (Y −Xβ) (2.35)
When 2.35 is simplified (Equations 2.36 and 2.37) the derivative can be taken to
obtain the fit with minimal squared error (Equations 2.38 and 2.39).
eT e = Y TY − βTXTY − βXY T + βTXTXβ (2.36)
eT e = Y TY − 2βTXTY + βTXTXβ (2.37)
d(eT e)
d(β)
= −2XTY + 2XTXβ = 0 (2.38)
2XTXβ = 2XTY → XTXβ = XTY (2.39)
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This can be rewritten to the form as shown in Equation 2.40 which is the solution
to the least squares problem. The superscript ‘−1’ indicates the matrix inverse.
β = (XTX)−1XTY (2.40)
For univariate linear regression a constant term (β0, the offset) is included in
the model, however this is not the case as standard for the MLR method above.
Therefore a constant variable (column of ones) can be added to the data matrix
X beforehand to obtain β0 for the MLR model.
2.2.3 Logistic regression
The response variables can be both continuous as well as discrete. The logistic
model, where for each sample Y is either 0 or 1, is different from the linear models.
Rather, Y is treated as a probability (pi) of an outcome with the bounds of the
possible values between 0 and 1 (Equation 2.41).
pii =
exiβ
1 + exiβ
(2.41)
This is solved using a different methodology than for MLR, despite the fact that
the data can be linear. First, pi is initialized as in Equation 2.42 and a diagonal
weight matrix, W, is determined using pi as in Equation 2.43.
pii =
Yi + 0.5
2
(2.42)
Wii =
√
pii(1− pii) (2.43)
The solution for β is found using an iterative process that optimizes β (Equa-
tion 2.44) in each step until it does not change. β is initialized as a vector with
zeroes. After each iteration pi is updated using Equation 2.41, followed by updating
W using Equation 2.43.
β = β + (XTWX)−1XT (Y − pi) (2.44)
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2.3 Multivariate methods and concepts
When the number of variables is larger than the number of objects (n < p),
variables are no longer linearly independent and thus XTX might become (close
to) singular. Different methods exist that are able to deal with this type of data and
will be discussed – these methods rely on finding variations in the data consistent
with the response and therefore scaling of variables is important as otherwise the
offset of a variable may become more important in the model than the variance,
if the offset is large.
2.3.1 Scaling
More often than not, the magnitude of a variable has no direct relation to the
response under investigation, whereas the information of interest is how the vari-
ation of the variable is related to the variation of the response. The most basic
data transformation technique used for multivariate methods is to centre the mean
of the variable on 0. This operation is called mean-centring as this ensures that
variables with a high offset (high abundance/concentration) influence the model
based on their variance and not abundance. The resulting mean-centred data ma-
trix X is denoted by X¯ with x¯j denoting the mean of variable j in Equation 2.45.
X¯ij = Xij − x¯j (2.45)
If the data are not normally distributed, the data can also be log-scaled prior to
mean-centring, or the median of the variable can be used instead of the mean. The
variances of the individual variables are most likely all different. This will result
in variables with higher variance having larger weights in the regression model.
In order to ensure that all variables are, in principle, considered to be equally
important in the model, the variances can be scaled to unity, i.e. the variance
of each variable is scaled so that the variance is 1 after the transformation. The
combination of mean-centring followed by variance scaling (Equation 2.46) is called
auto-scaling.
Xˆij =
X¯ij − x¯j
σj
(2.46)
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This gives all variables equal importance, however in data with variables that can
contain (random) noise this also gives equal importance to the noise. In order to
avoid introducing bias into the model by some type of variable selection to remove
noisy variables, another type of scaling can be used which is an intermediate
between mean-centring and auto-scaling. It is involved with applying a scaling
factor (λ) ranging from 0 to 1 to the standard deviation as in Equation 2.47.
Where λ = 0 is mean-centring and λ = 1 is auto-scaling.
Xˆij =
X¯ij − x¯j
σλj
(2.47)
The case where λ = 0.5 is called pareto-scaling and this divides the data by the
square root of the standard deviation. A nice overview of scaling methods com-
monly used in metabonomics is given in [124], which also discusses the advantages
and disadvantages of each method.
2.3.2 Unsupervised methods for dimension reduction
For some data sets it may be beneficial to reduce the dimension. This is especially
useful for data sets with n < p. For this purpose Principal Component Analysis
[125] (PCA) can be used. PCA defines a new set of variables by finding multiple
orthogonal linear combinations of the original variables. The new variables as
defined by PCA are called principal components (PCs), hence the name Principal
Component Analysis. A more general name for linear combinations of original
variables is latent variables – this term is commonly used for other multivariate
techniques as well (see section 2.3.9). The central algorithm behind PCA is the
singular value decomposition (SVD) which is fast and numerically stable, and
decomposes the data matrix into three parts: the left singular vectors (U), a
diagonal matrix with the singular values (Σ) and the right singular vectors (V) as
shown in Equation 2.48.
X = UΣV T (2.48)
For data where n < p at most n PCs can be found, as PCs are orthogonal (linearly
independent) to each other. The first component is defined as the multidimensional
direction in the data with the largest variance (‘most interesting’), the second
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as the direction in the data with the next largest variance, etc. It is therefore
important to note that the data must be centred or otherwise the offset of variables
are taken into account as SVD searches for the components from the data origin
(0p). Both U and V are orthonormal, which means that, in addition to each column
being orthogonal to all others, the sum of the squared elements of each column is
equal to 1, this can be easily shown as in Equation 2.49.
UTU = V TV = I (2.49)
The sum of the squared elements of Σ is equal to the total variance of X. The left
singular vectors are of size [n,c] where n is the number of samples as before and
c is the number of components, Σ is of size [c,c] and V is of size [p,c]. U and Σ
combined make up the PC scores (T), in this sense V is referred to as the loadings
(P) (Equation 2.50).
X = (UΣ)V T = TP T (2.50)
In data analysis, often a number (< c) of PCs are chosen to be retained as these
components explain most of the original variance of X. Arbitrary cut-offs of 80
or 90% are commonly used for this to show the dominant underlying information
structures in the data.
A method related to PCA, called Independent Component Analysis [126] (ICA),
can be used to find interesting directions in the data, with the difference that each
component is equally important (same variance explained). The most popular im-
plementation of ICA is fastICA [127] due to its speed (hence the name). In ICA
the data is de-correlated and the components are sought so that they are as far
from normal in distribution as possible (while still being orthogonal to each other),
whereas for PCA the multivariate distribution does resemble normal distributions.
The rationale behind ICA is that it is assumed noise can be normally distributed,
thus anything that is far from normal may be considered to be something else
than noise. Exploratory Projection Pursuit [128] is a method similar to ICA in
that it also aims to find non-normal underlying structures in the data, however it
is different from ICA in that it is not constrained to find orthogonal components
(projections).
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2.3.3 Training and test sets
Instead of finding latent variables with respect to interesting data structures (vari-
ance, non-normality), one can look for interesting data structures with respect to
the response variable using multivariate regression techniques. However, the data
used to construct a regression model cannot be used to evaluate the generalizabil-
ity of the fit, as the model is constructed to optimally fit this data. In order to
determine whether the model finds a meaningful projection of the data structure
in relation to the response, an external set of data that is not used in the modelling
is often used to give an unbiased estimate of the error of prediction. Often the
data set is split before modelling in a so called training set, used for calculating
the model, and a test set, used to validate the model. The partitioning of the data
into a training and test set can be done in many different ways, one of which is
to simply randomly split the samples to go into either the training or the test set.
However, splitting the data randomly can, in theory, result in overly optimistic
splits (i.e. where the data structure of the test set is perfectly encapsulated within
the training data structure) or very poor fits (i.e. when the test set structure lies
completely out of the training data structure). Therefore many different methods
can be used to ensure the data is split in similar structures.
The Kennard-Stone (KS) partitioning algorithm [129] is one of those types of
methods. Using the KS method, the Euclidean distances (D) between all samples
in the data set are calculated, including the distance of all samples to the mean
of the data. The first training set object is the sample that has the shortest
distance to the mean of the data. The next samples are added to the training set
in an iterative fashion where the minimal Euclidean distance of each sample to the
training set objects is determined and the new training set object is chosen that
has the largest minimal distance. In other words, the KS algorithm maximizes
the minimal Euclidean distances between training set objects and the remainder
of the samples. Using this approach the training set data is spread over the entire
data structure and samples are added to the training set until an a priori specific
number is reached, the remainder of the samples are then used as test set. The KS
method nicely distributes the samples over the data structure. The disadvantage
is that if outliers are present, these will most likely be included in the training
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data. Therefore, a more robust method is the duplex method [130] which follows a
similar approach of sample selection to KS, however it starts by selecting the two
objects that have the largest distance to each other to be placed in the training
set. The two objects with the next largest distance to each other are placed in the
test set. After this initial partitioning the duplex method uses the same method
as KS to determine the next object to be included in the training set, using the
maximal minimal Euclidean distance. With the exception that after selecting a
new training object, a new test object is selected the same way. The maximal
minimal Euclidean distance to the test objects are used for determining the new
test object. This procedure is repeated until the test set has a previously specified
number of objects and the remaining samples are placed in the training set.
2.3.4 Cross-validation
The KS and duplex methods, and random partitioning result in a single training
and a single test set. Despite the fact that the KS and duplex methods in theory
are less biased than random partitioning, the fit and predictive ability of the data
is dependent on the sampling of a single training and a single test set to validate
the model. Another approach is to define multiple training and test sets and
calculate a model for each training set and evaluate the error of each of these
models using the data that was left out at each step, this is called cross-validation
(CV). The simplest case is to leave one sample out as test set and build a model on
the remaining samples, ‘leave-one-out’ (LOO) CV. Each sample is left out exactly
once and the error in prediction is assessed using the left-out samples, this is
also known as jack-knifing [131]. However, this method is slightly biased, because
leaving out a single object does not change the data structure much [132]. Leaving
out more samples at each step will result in less biased models, while at the same
time result in a lower number of models to be calculated. K -fold CV [133] still
leaves each sample out once, however multiple samples are left out simultaneously.
However, a regular deletion pattern for CV [134] may result in biased estimations
if the data is somehow regularly structured as well. Random sampling can avoid
this, however, as already discussed, it can result in slightly biased estimations.
A different, and more robust, approach is to use Monte Carlo (MC) CV [135],
66
CHAPTER 2. METHODS
also referred to as repeated learning [136]. For MCCV a large number of models
are calculated with the test set being chosen at random for every model. This is
computationally more expensive than LOOCV and k -fold CV; however MCCV will
give a prediction that is averaged over many models, thus less prone to sampling
bias.
With all of these methods the original data is divided into two sets, thus re-
ducing the size of the data and fewer samples are used to fit a model (less power).
Instead of sampling without replacement, as with LOOCV, k -fold CV and MCCV,
sampling can also be performed with replacement. This means that as a sample
is selected to be part of the training set it is allowed to be selected again until n
samples are chosen to make up the training set. This procedure is called boot-
strapping [131] and is a good way to obtain models with the same statistical power
as models that use all samples simultaneously, while still being able to set a part
of the data aside for validation purposes.
2.3.5 Error of predictions
Two different types of regression methods have been described, linear regression for
continuous response variables and logistic regression for discrete responses. Aside
from calculating a model, it is of interest how well the model describes the data.
A number of different metrics exist for different types of methods. For continuous
responses, the deviation of the fitted response from the original response can be
quantified by the root mean squared error (RMSE) (Equation 2.51), where Yˆ
indicates the predicted response and Y the (real) response, both of the training
data (as indicated by the addition of ‘tr’).
RMSE =
√∑n
i=1(
ˆY tri − Y tri)2
n
(2.51)
The same can be done for the test set predictions and this is referred to as the
root mean squared error of prediction (RMSEP) (Equation 2.52).
RMSEP =
√∑n
i=1(
ˆY tei − Y tei)2
n
(2.52)
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For discrete responses different metrics can be used depending on the goal.
If classification, the accuracy of predicting a sample to be of a specific class, is
the goal, the results from the test set can be represented in a confusion matrix,
where on the rows the true class is indicated and in the columns the predicted
class. If there are two classes, this results in a 2 × 2 matrix with the number
of correct predictions shown on the diagonal (class 1 correctly predicted as class
1 and class 2 correctly predicted as class 2) and the off-diagonal elements are
the misclassifications (class 1 predicted as class 2 and vice versa). The overall
prediction accuracy is the sum of the diagonal divided by the total number of
samples, n, or, in the case of MCCV, the number of predictions made. For logistic
regression the decision boundary usually is chosen at exactly 0.5 (equal probability
of class 0 and class 1), however when the group sizes are not equal another value
between 0 and 1 can also be used.
Another goal can be to investigate, similarly to the RMSE(P), how well the data
set is fitted/predictive. For this purpose the goodness of fit (R2y) (Equation 2.53)
and cross-validated error of prediction (Q2y) (Equation 2.54) are often used. It is
important to note that for the Q2y the mean of the response of the training set
is used in the denominator and ¯Y tr is assumed to be exactly 0 if the response is
correctly scaled and thus centred.
R2y = 1−
∑n
i=1(
ˆY tri − Y tri)2∑n
i=1(Y tri − ¯Y tr)2
(2.53)
Q2y = 1−
∑n
i=1(
ˆY tei − Y tei)2∑n
i=1(Y tei − ¯Y tr)2
(2.54)
Some regression techniques that model discrete responses are not forced to give
predictions between 0 and 1. For these methods the response is scaled (centred)
and the two classes are often represented by a positive and a negative number. For
the formulae above (Equations 2.53 and 2.54), a predicted value (Y¯i) that is higher
than the actual value (Yi) is also penalized. The same goes for a negative Y¯i that
is more negative than Yi. This can be avoided relatively easily by not penalizing
predictions that lie on the ‘right’ side of the decision boundary [137], this will be
discussed in more detail in Chapter 6.
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Other metrics used for regression models include the coefficient of determina-
tion (R2) and the adjusted coefficient of determination (adj. R2). R2 is the amount
of variance of the response explained by the model and adj. R2 is the R2 adjusted
for the number of variables included in the model.
2.3.6 Linear Discriminant Analysis
In order to differentiate groups (classification) using the data, a collection of mul-
tivariate methods can be used that are referred to as ‘discriminant analysis’ (DA)
methods. One of the oldest DA methods is (Fisher’s) Linear Discriminant Anal-
ysis [138] (LDA), which, by the original definition, defines groups as separable if
within-group variation is smaller than the between-group variation. It assigns a
class to a sample based on the smallest distance to the centre of classes. Important
to note here is that before a sample can be assigned to a class (‘classified’), the
class centres must be known a priori. Therefore additional information must be
used, namely the knowledge of the class labels of the samples and for this reason it
is considered a ‘supervised’ technique, because the class labels determine the clas-
sification. The data is split in two parts before calculating the model, a training set
to build the classification model and a test set to validate the model using any of
the partitioning methods described in sections 2.3.3 and 2.3.4. Two main versions
of LDA exist, namely the original Fisher’s LDA (FLDA) and maximum likelihood
LDA (ML-LDA), and while they take different approaches to solve the problem,
they are identical for the two class case (but not for three or more classes). For
FLDA the between-group (Equation 2.55) and within-group (Equation 2.56) co-
variance matrices are calculated, where x¯k represents the mean of all samples in
class (group) k, X¯k the mean-centred data matrix of all samples in class k and nk
the number of samples in class k.
B =
2∑
k=1
nk(x¯k − x¯)(x¯k − x¯)T (2.55)
W =
2∑
k=1
X¯Tk X¯k (2.56)
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The linear combination of variables that maximizes the ratio of W to B is consid-
ered to be the optimal separating hyperplane (remember the data is multivariate)
between the two groups. This combination can be found by looking at the eigen-
vectors of the largest eigenvalue of the decomposition of W−1B.
ML-LDA assumes the data is normally distributed whereas FLDA does not,
however both methods pool the covariance of the groups. This may be a problem
when one of the groups has a different data structure than the other. In this case a
different method can be used called Quadratic Discriminant Analysis (QDA) which
instead of pooling the covariances, describes each class with their own covariance
matrix. If the covariance matrices are equal, QDA will give the same result as
LDA. The difference between the methods is that LDA will give linear separation
bounds between the groups, whereas QDA gives non-linear bounds. However,
LDA and QDA can sometimes fail to properly classify the data, for instance when
there are multiple clusters in the groups. Therefore it is often helpful to determine
whether there are underlying clusters using unsupervised methods such as PCA
or HCA before applying supervised methods. Also, when the number of variables
exceeds the number of samples (n < p), both LDA and QDA will fail as the
matrix inversion of W will be (close to) singular. Two different methods can be
used to circumvent this problem, first, PCA can be used to reduce the dimensions
of the data after which LDA/QDA is performed on the PCA scores, and second
the covariance matrix can be shrunk (see section 2.1.9) so that matrix inversion is
possible.
2.3.7 Principal Component Regression
Aside from applying LDA on the PCA scores, other multivariate methods ex-
ist that are able to deal with collinear data and avoid requiring computation of
the inverse of the singular square matrix XTX. Principal Component Regression
(PCR) performs regression on the scores from PCA which has two major advan-
tages. First, the number of variables is lower than when the full data set is used
and second, more importantly, the scores are orthogonal, hence there are no prob-
lems with correlated variables. For PCR only the number of principal components
to include has to be estimated and this can be done using a CV procedure. The
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standard formulation for regression (Equation 2.33) can be rewritten in terms of
the scores and loadings (Equation 2.57), where P Tβ are the regression coefficients
of the loadings.
Y = TP Tβ +  (2.57)
P Tβ can be rewritten into Equation 2.58 by using only the scores and the scaled
response variable.
P Tβ = (T TT )−1T TY (2.58)
Regression coefficients for the original variables can be easily found by back-
transforming P Tβ to span the original data space (Equation 2.59).
β = P (T TT )−1T TY (2.59)
Equation 2.59 can be simplified in terms of the singular value decomposition (Equa-
tions 2.60 to 2.62).
β = V ((UΣ)T (UΣ))−1(UΣ)TY (2.60)
β = V (ΣUTUΣ)−1ΣUTY = V (ΣIΣ)−1ΣUTY (2.61)
β = V Σ−2ΣUTY = V Σ−1UTY (2.62)
2.3.8 Cross-model validation
When cross-validation is used to determine the optimal number of PCs in PCR
it will result in using all data – no test set is available after CV. To circumvent
this issue, cross-model validation [139] (CMV) can be used. In CMV the data
is first divided into a training and test set, as is done in normal CV. Next, the
training set is divided into two parts called a model set and an optimization set
(to avoid confusion with using training and test set again). The model set is used
to construct a model, in the case of PCA/PCR it is used to decompose the data
into PCs. The optimal number of components is determined by prediction the
optimization set and determining the number of components needed to give the
best representation of the optimization set (lowest prediction error). Instead of
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defining a single model and optimization set, this can also be done using CV. Then,
using the full training data, a model is constructed using the optimal number of
components found using CMV. The test set is used to validate the data in an
unbiased way, because the test set is not used in determining the optimal number
of components, constructing the model or scaling of the data. CMV is a good
method to use for estimating parameters of different multivariate methods.
2.3.9 Partial Least Squares
High variance does not necessarily equal high information content, so the first
few PCs, that combined explain most of the variance of the data, may not per
se explain the most relevant information. Therefore it is of interest to define
orthogonal components directly with relation to the response variable. Partial
Least Squares [94, 140] (PLS) seeks direction in the data with high (co-)variance
and high correlation with the response variable and as with PCA it calculates
multiple orthogonal components. The difference between the SVD version of PCA
and PLS is that in SVD all components (c) are obtained in one step, whereas
in PLS they are calculated sequentially, for instance using the NIPALS [94] or
SIMPLS [141] algorithms. Essentially, PLS decomposes the data (X and Y) into
score (T, U) and loading (P, Q) matrices (Equations 2.63 and 2.64).
X = TP T + ex (2.63)
Y = UQT + ey (2.64)
Here, X is of size [n,p] and generally the response variable is univariate ([n,1]),
therefore the resulting matrices T, P, U and Q are sized [n,c], [p,c], [n,c] and [1,c],
respectively. In the NIPALS algorithm, the decomposition of X and Y into T are
made to maximize the covariance and a weight vector (w) is calculated using the
cross-product XTY (Equation 2.65). For a multivariate Y, w is defined as the first
left singular vector from SVD of XTY .
w = XTY (2.65)
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The first X score (t) is obtained as in Equation 2.66.
t = Xw (2.66)
Next, the first X and Y loadings are calculated (Equations 2.67 and 2.68) and
normalized by dividing by sum of the squared scores t. The Y score is calculated
using the Y loadings as in Equation 2.69.
p =
XT t
tT t
(2.67)
q =
Y T t
tT t
(2.68)
u = Y q (2.69)
Next, the X and Y matrices are deflated by subtracting the information explained
by t and p/q from the data (Equations 2.70 and 2.71) and by saving w, t, u, p
and q of component k in the k th columns of W, T, U, P and Q (Equations 2.72
to 2.76).
X = X − tpT (2.70)
Y = Y − tqT (2.71)
Wk = w (2.72)
Tk = t (2.73)
Uk = u (2.74)
Pk = p (2.75)
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Qk = q (2.76)
Next, the cross-product XTY of the deflated X and Y is calculated using Equa-
tion 2.65 and the scores and loadings are calculated as before (Equation 2.66
to 2.69). This procedure – deflating X and Y after each component is calculated
and saving the individual weights, scores and loadings – is followed until all com-
ponents are calculated (for n < p the maximum number of components equals n)
or until a previously specified number of components are calculated. The opti-
mal number of components for PLS can be estimated using CMV as described for
PCA/PCR in section 2.3.8. When all (required) scores and loadings are calculated,
the same procedure as for PCR can be followed to obtain the regression coefficients
(see section 2.3.7) and matrices W, T, U, P and Q can be used to predict the test
set.
The SIMPLS approach is generally preferred over NIPALS, because the regres-
sion coefficients are directly computed in terms of the original data and X and
Y are not deflated, but the cross-product of XTY is. Therefore SIMPLS is also
faster than NIPALS [141]. Also, SIMPLS actually optimizes the PLS criterion
(covariance of X and Y), whereas the NIPALS method is a good approximation of
it. See Algorithm 4 in Chapter 6 for pseudo code of SIMPLS for n < p data sets.
2.3.10 Orthogonal Signal Correction and Orthogonal Pro-
jections to Latent Structures
One of the approaches to improve the PLS modelling is to remove variations from
X, for instance noise or baseline offsets, that are not related to Y. Orthogonal Signal
Correction [142] (OSC) is a technique that iteratively removes variation from X
that is orthogonal to the variation in Y, thus uninteresting for the regression model.
It ensures that more relevant variation is captured by the first components of the
PLS model.
OSC is initialized by calculating the first PCA score (t, first column of T) of
X, the direction with highest amount of variance in the data. Next, t is orthogo-
nalized to Y to give a new score vector (to) that captures the direction in the data
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orthogonal to Y with most variance (redundant information) (Equation 2.77).
to = (1− Y (Y TY )−1Y T )t (2.77)
Next, the loading (po) corresponding to to is calculated as in PLS (Equation 2.67).
Then the data is adjusted and the components are saved (Equations 2.78 to 2.80),
before the next orthogonal component is calculated.
Xo = X − topTo (2.78)
Tok = to (2.79)
Pok = po (2.80)
When all required orthogonal components are calculated the data can be ad-
justed, or ‘orthogonal signal corrected’, and the resulting corrected data (Xosc)
(Equation 2.81) can be used for modelling with PLS.
Xosc = X − ToP To (2.81)
The combination of OSC with PLS is termed Orthogonal Projection to Latent
Structures [95], as Partial Least Squares was deemed an inappropriate name for
the method. It has previously been shown that OSC coupled to PLS results in
equal or slightly better models [143] and often only one predictive component is
sufficient for OPLS modelling [144].
2.3.11 Penalized regression methods
PLS is a useful method that aims to solve the problem of highly collinear data
in a different way compared to classical regression (Equation 2.40). However, as
with LDA, another way of tackling the problem of the singular XTX matrix is to
use shrinkage methods. Ridge regression [145] stays true to the classical regression
case and it adds a constant to the diagonal of XTX to ensure the matrix becomes
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invertible (Equation 2.82).
β = (XTX + λI)−1XTY (2.82)
The shrinkage parameter λ, a value between 0 and 1, must be optimized with
respect to the prediction; again this can be done using CMV to avoid biasing
the results. Ridge regression shrinks the low variance directions more than the
higher variance directions, whereas PLS also shrinks (in a different way) the low
variances. There is a slight risk with NIPALS that PLS can also inflate the high
variance directions [146], however it has been debated that this may be dependent
on the type of data [147, 148].
Other shrinkage methods exist such as the lasso [149] (least absolute shrinkage
and selection operator), also known as basis pursuit [150], which shrinks some
coefficients and sets others to 0. Lasso uses least-angle regression [151] to select
which variables to shrink and which to set to 0 to reduce the dimensionality of
the data so that there are at most n non-zero coefficients. The elastic net [152]
is a trade-off between two different penalties (λ2 for the ridge penalty and λ1 for
the lasso) to allow the inclusion of multiple correlated variables (owing to the
λ2) yet still provide a sparse model (due to the λ1), the ratio between the two
penalty terms determines the sparseness of the model. A penalized version of
PLS has also been proposed [153]. Tuning λ to find the optimal least squares
solution takes much more time than finding the optimal number of components
(scalar) for PLS (for penalized PLS both λ and the number of components must
be estimated). However, the difference in terms of predictive ability between PLS
and ridge regression is small [146]. It has been recommended [146] to assess the
variability of the LVs in PLS by bootstrap methods before interpretation.
2.3.12 Other multivariate data analysis methods
A number of different methods exist that have different ways of handling high-
dimensional data, of which I will briefly describe two of the most widely used
types of methods. First, there is the use of kernel functions [154] to map data into
a new multi-dimensional ‘feature’ space. A kernel is defined as a transformation of
the original data to a new space (the feature space) that represents the similarity of
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samples. This is a clever way to be able to use linear methods to model non-linear
data. Many different methods are able to use kernel transformations, including
the already discussed PCA [155], LDA [156], PLS [157] and ridge regression [158],
however the most popular method is Support Vector Machines [159, 160]. Despite
the fact that these methods are (very) good classifiers they are considered ‘black
boxes’ since the assessment of variable contributions in the models (of interest in
metabonomics studies) is not straightforward, see for instance [161, 162]. Artificial
neural networks have the potential to be the most powerful classifiers and are used
mostly for classification alone, however, compared to SVMs, they are essentially a
‘gigantic black box’ and assessing the variable importance is dependent on back-
propagation of the network [163] or randomization approaches [164], which may
be tricky as there is no sure way of knowing whether the network parameters are
for a local or global minimum of the prediction error, although a grid search may
give a good estimation of the optimal parameters.
The second group of methods that is widely used for classification and regres-
sion are recursive partitioning methods [165]. These include tree-based methods
such as Classification And Regression Trees [166] and Random Forests [167], as
well as smoothing type methods such as Multivariate Adaptive Regression Splines
[168]. The tree-based methods are especially popular due to their ability to deal
with continuous, discrete and categorical variables. They consider all variables
for inclusion in the models and often end up with a subset of important variables.
However, at each step in the tree (where samples are split into ‘branches’) only one
variable is considered for the splitting, so these methods are somewhat ‘pseudo-
multivariate’ by design. However, these methods are not ideal to use for analysing
1H NMR data, partly because of the difficulty of dealing with large p, but mostly
because of their inability to properly deal with highly collinear data.
2.4 Network and graph theory
Graph theory is involved with different things, from calculating network structures
and optimizing network layouts to pairwise comparing similarities of groups. Here,
I will explain briefly a few general concepts of graph theory, and in the individual
chapters, where necessary, more elaborate descriptions of individual aspects are
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given.
2.4.1 Sets
A set is a collection of properties of an object. For instance, the properties can be
the absence or presence of mutations in specific genes, what biochemical reactions
can occur in different systems or what samples are highly correlated with each
other. The collection of elements of a set are noted within curly brackets, for
instance a = {1,2,...,n} implies all numbers between 1 and n are contained in set
a. The overlap between two sets, for instance sets a and b, can be described by the
intersection (a∩ b). The intersection of two sets is the elements that the sets have
in common. Alternatively, the union (a ∪ b) of two sets is defined as all element
that one or both of the sets have. If the number of elements in set b is equal to
the number of elements in a∩ b, then b lies completely within a (i.e. b is a subset
of set a, b ⊂ a). The notations b ∈ a and a 3 b are equivalent and are used to
indicate that b is an element in set a. In this context b is a single element opposed
to a (sub)set, or a subset containing a single entry. The same goes for the negated
case b /∈ a, which states that b is not in set a.
2.4.2 Networks
For networks/graphs objects are called nodes (or vertices), whereas links between
nodes are commonly referred to as edges. To represent the graph structure each
node has a set which contains other nodes to which it has an edge. For practicality,
the sets are listed in a matrix structure called an adjacency matrix. The adjacency
matrix (A) is a binary matrix (see example in Table 2.1) where the value for Ajk
indicates whether or not there is an edge from node j to node k, i.e. an edge
between two nodes indicates they are connected (‘adjacent’) in the network.
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Table 2.1: A simple adjacency matrix. If entry Ajk (and Akj) is 1 then there is an
edge between node j and k.
A B C D E F
A 0 1 0 0 1 1
B 1 0 1 0 1 0
C 0 1 0 1 0 0
D 0 0 1 0 1 0
E 1 1 0 1 0 0
F 1 0 0 0 0 0
When A is symmetric the resulting graph is ‘undirected’ (Figure 2.1), how-
ever when it is not symmetric (Table 2.2), it is referred to as a ‘directed graph’
(Figure 2.2).
Figure 2.1: A simple undirected graph based on the adjacency matrix in Table 2.1.
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Table 2.2: The adjacency matrix for a directed graph. If a specific entry Ajk is 1,
then an edge is drawn from node j to node k.
A B C D E F
A 0 1 0 0 0 0
B 0 0 1 0 1 0
C 0 0 0 1 0 0
D 0 0 0 0 1 0
E 1 0 0 0 0 0
F 1 0 0 0 0 0
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Figure 2.2: A simple directed graph based on the adjacency matrix in Table 2.2.
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2.4.3 Breadth-first search algorithm
In order to draw a graph, the coordinates of the nodes in the graph must be
known. The coordinates can be optimized based on the distance between nodes
based on the adjacency matrix. One of the most common algorithms used to cal-
culate distances based on an adjacency matrix is the breadth-first search (BFS)
algorithm. BFS is an iterative procedure that aims to find the shortest path dis-
tances (D) between all nodes using the adjacency matrix. The procedure described
in Algorithm 1 works for both undirected and directed graphs.
For calculating the distances (d) of node i to all other nodes it starts by creating
2 sets: a visited (v) and unvisited (u) set. Where v is a set that contains only
node i and u contains all other nodes. It then iteratively calculates the distance
by updating v and u (Algorithm 1). All nodes in u that are connected to i are
removed from u and put in v. The nodes in v are at distance d from node i
and the distance matrix D is updated by setting these nodes at a distance of
1 to node i. The next steps are repeated until v or u becomes an empty set,
where ∃ is the mathematical notation for ‘there exists’. If v is an empty set
at any stage, all remaining elements in u are thus unconnected to node i and
placed at infinite (∞) distance. The BFS algorithm can be used for both directed
and undirected adjacency matrices. Table 2.3 shows the elements in v and u at
each stage (distance) of BFS on the (undirected) adjacency matrix as shown in
Table 2.1, resulting in the distance matrix as shown in Table 2.4.
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Algorithm 1 Breadth-First Search
1: for i = 1 to n do
2: d← 0
3: v ← i
4: u 3 k : k 6= i
5: Di,v ← d
6: d← d+ 1
7: v 3 uk : (Ai,uk = 1)
8: u← u /∈ (u ∩ v)
9: Di,v ← d
10: d← d+ 1
11: while v 6= ∅ and u 6= ∅ do
12: vo 3 uk : ∃j(Avj ,uk = 1)
13: v ← vo
14: u← u /∈ (u ∩ v)
15: Di,v ← d
16: d← d+ 1
17: end while
18: if v = ∅ then
19: d←∞
20: Di,u ← d
21: end if
22: end for
Table 2.3: Calculating the distances between all nodes using the adjacency matrix
from Table 2.1.
d(A) v u d(B) v u
d=0 {A} {BCDEF} d=0 {B} {ACDEF}
d=1 {BEF} {CD} d=1 {ACE} {DF}
d=2 {CD} {} d=2 {DF} {}
d(C) v u d(D) v u
d=0 {C} {ABDEF} d=0 {D} {ABCEF}
d=1 {BD} {AEF} d=1 {CE} {ABF}
d=2 {AE} {F} d=2 {AB} {F}
d=3 {F} {} d=3 {F} {}
d(E) v u d(F) v u
d=0 {E} {ABCDF} d=0 {F} {ABCDE}
d=1 {ABD} {CF} d=1 {A} {BCDE}
d=2 {CF} {} d=2 {BE} {CD}
d=3 {CD} {}
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Table 2.4: A simple distance matrix for the adjacency matrix from Table 2.1.
A B C D E F
A 0 1 2 2 1 1
B 1 0 1 2 1 2
C 2 1 0 1 2 3
D 2 2 1 0 1 3
E 1 1 2 1 0 2
F 1 2 3 3 2 0
2.4.4 Spring-electrical embedding
The simplest network layout is a so called circular network, where all nodes are
placed equally spaced on a circle and then edges are drawn between the nodes using
the adjacency matrix. This type of network does not require a distance matrix to
be calculated. However, if nodes are not ordered in a specific pattern, the circular
graph can quickly appear crowded with overlapping edges. As alternative, many
different network layout algorithms exist that make use of the distance matrix as a
guide to place the nodes and the adjacency matrix to draw edges. One of the most
commonly used techniques is to consider edges as springs that are connected to the
nodes and subsequently minimize the energy of the ‘physical system’ [169–171].
One of these methods is spring-electrical embedding (SEL), which sequentially
updates the coordinates (S) of nodes ordered in descending order by their degrees
(the degree of a node is the number of edges it has). First, a stiffness matrix (K)
is calculated using the distances and the natural length of the springs (R) which
follows Hooke’s law. Hooke’s law states that the energy required for compress-
ing/extending a spring is directly proportional to the distance (Equation 2.83).
Kjk = D
−R
jk (2.83)
Most algorithms start off by initializing S as a circular graph for when a two-
dimensional network is calculated. The energy of the system (E) is determined
by first calculating the Euclidean distances (d) of the node coordinates (Equa-
tion 2.84). Second, using K, the stiffness constraint is applied on the difference
between d and D and then summing this over the entire system gives E (Equa-
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tion 2.85).
djk =
√∑
(Sj − Sk)2 (2.84)
E =
n∑
j=2
j∑
k=1
Kjk(djk −Djk)2 (2.85)
The coordinate for each node is updated sequentially by finding a new coordinate
that minimizes E using the simplex non-linear optimization algorithm [172]. This
process is repeated until E does not change, or the change is smaller than a thresh-
old (for instance the floating point accuracy). Important to note is that SEL can
only be used on systems where the distances are finite and therefore distances that
are infinite should be replaced prior to optimization.
Instead of starting the optimization of S from a circular graph, PCA can be used
to give a good starting point with a lower energy state than the circular network.
PCA decomposes D and the first n PCs are used to define the n-dimensional coor-
dinate system S, this is also referred to as high-dimensional embedding. When D is
symmetrical (undirected graph) the PCA decomposition is actually the eigenvalue
decomposition as U and V are identical.
Alternatively, D can be converted to a similarity matrix and multi-dimensional
scaling (MDS), for instance using Sammon’s mapping criterion [173], can be used
to calculate S. MDS takes a (dis-)similarity matrix and aims to find a multivariate
space in which the Euclidean distances of the objects closely matches the dissimi-
larity between the objects. Aside from using PCA and MDS to provide an initial
coordinate system for SEL, they can also be used on their own to determine the
node coordinates.
2.4.5 Modularity
From the dendrogram that is obtained from HCA (see section 2.1.10), an ordering
(network structure) of the objects is established. For instance, the network shown
in Figure 2.1 can be clustered in three ways, as visualized in Figure 2.3.
Determining the optimal number of clusters is often done visually. However, a
better method is to use the network structure in determining the optimal number
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Figure 2.3: A simple undirected graph with 3 sets of clusters. Set 1 is shown in
red and consists of a single cluster with all nodes ({ABCDEF}), set 2 is shown in
blue and consists of 2 clusters ({ABCDE}{F}) and set 3 is shown in green (dashed
line) and consists of 3 clusters ({ABE}{CD}{F}).
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of clusters, for instance by calculating the modularity using Equation 2.86 (Qn)
[174] or alternatively using Equation 2.87 (Mn) [175]. The modularity is defined as
the partitioning of the network into clusters so that the number of within cluster
edges is maximized while simultaneously minimizing the number of between cluster
edges.
Qn =
n∑
k=1
(
ak
ne
)
−
(∑
∀j 6=k akj
ne
)2
(2.86)
Mn =
n∑
k=1
(
ak
ne
)
−
(∑
∀g∈Ck Dg
2ne
)2
(2.87)
In Equations 2.86 and 2.87 Qn and Mn are defined as the modularity for the
partitioning in n clusters, ak is the number of edges within cluster k, akj is the
number of edges from cluster k to cluster j (these edges form a bipartite graph
between clusters k and j ), ne is the number of edges in the complete network, Ck
is the sub-network of cluster k and Dg is the degree of node g within Ck. Note
that Dg is only identical to the degree of node g in the full network if all edges of
node g are to nodes within Ck.
For the clusters as shown in Figure 2.3 the modularities are Q1=1, Q2=0.82
and Q3=0.28 and M1=0, M2=0.12 and M3=0.36. The large difference between Qn
and Mn is that values for of the former are bounded between -1 and 1, whereas for
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the latter they are bounded between 0 and 1. The benefit of Mn over Qn is that
the optimal partitioning is not only dependent on maximizing ak and minimizing
akj, but also on the difference from a random partitioning. Mn=0 if there is a
single cluster or if there are as many clusters as nodes (each node is a cluster).
The optimal modularity can be chosen as the one that maximizes the difference
between ak and Dg [176].
A clustering tree can be obtained using the correlation distance between objects
using HCA. Using the clustering tree to define clusters and by defining significant
correlations as edges in the network a modularity can be calculated for each level
of the dendrogram. However, this depends on a threshold for whether or not there
is an edge between two nodes or not (for instance by applying a multiple testing
correction threshold, see section 2.1.8). When Dg is replaced by the sum of all
weighted edges of nodes in Ck and ak is replaced by the sum of all edges within
Ck, no hard threshold is needed as the weight of an edge implicitly determines
the overall strength. However, in this case care must be taken when choosing the
highest modularity as optimal value, as random networks also have non-zero values
for the modularity [174, 177]. Therefore, comparing a weighted network clustering
to random networks of the same degree distribution [178] and then choosing the
optimal modularity as the maximum value that is also higher than all random
alternatives is a better option.
2.5 Statistical spectroscopy
After the construction and validation of a model, the next step is to determine
which variables significantly contribute to the model and then identify these sig-
nals. The different 1H NMR signals from the same metabolites are intrinsically
highly correlated and this is an aspect that can be used to identify metabolites
using multiple 1H NMR spectra. Statistical Total Correlation Spectroscopy [38]
(STOCSY) makes use of the covariance and correlation between variables in 1H
NMR data, and as the covariance and correlation are simple to calculate, STOCSY
is a fast method.
In Equation 2.88, X¯ and X¯d denote the mean-centred data matrix ([n,p]) and
mean-centred driver (d) signal ([n,1]), respectively, where d ∈ [1,...,p]. The sub-
85
CHAPTER 2. METHODS
script j indicates the j th variable and ◦2 denotes each element in the matrix is
squared.
rj =
1
n− 1
X¯Tj X¯d√∑
X¯◦2j
√∑
X¯◦2d
(2.88)
Naturally, variables that are adjacent to the driver and those that belong to the
same multiplet are expected to have the highest correlations as these will most
likely be affected similarly by possible overlapping compounds. The other multi-
plets of a metabolite will also have high correlations with the driver and this is
utilized to identify a metabolite. Several other statistical spectroscopy methods
exist that can be used to elucidate the structure of unknown metabolites, some of
these methods are extensions of STOCSY and are discussed in Chapter 4. Robi-
nette et al. give an excellent overview of current statistical spectroscopy methods
used in NMR spectroscopy and mass spectrometry in [91].
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Chapter 3
MetaboNetworks, an Interactive
MATLAB-based Toolbox for
Creating, Customizing and
Exploring Sub-networks from
KEGG
Summary
MetaboNetworks is a tool to create custom sub-networks in MATLAB using main
reaction pairs as defined by the Kyoto Encyclopaedia of Genes and Genomes
(KEGG) and can be used to explore trans-genomic interactions, for example mam-
malian and bacterial associations. It calculates the shortest path between a set
of metabolites (for instance biomarkers from a metabonomic study) and plots the
connectivity between metabolites as links in a network graph. The resulting graph
can be edited and explored interactively. Furthermore, nodes and edges in the
graph are linked to the KEGG compound and reaction pair webpages.
87
CHAPTER 3. METABONETWORKS
3.1 Introduction
Investigating the dynamic metabolic responses in living systems due to external
perturbations gives complementary information to genomic and/or proteomic ap-
proaches. Metabonomics [12] of biofluids provides a ‘top-down’ view of the living
system to show global changes instead of interactions between genes, proteins
and/or metabolites at the cellular level. Metabolic pathway information can aid
in interpreting how significant differences in metabolite concentrations are related
biologically. The effective transformation of metabolic spectroscopy data to bio-
logical knowledge presents a significant bioinformatics challenge. In particular the
increased interest in clinical applications of metabolic phenotyping makes practical
data visualisation in a biological/medical framework of great importance [24].
A number of databases, resources and software programs exist that collect
and use systems information for human metabolic network reconstruction among
which the Kyoto Encyclopaedia of Genes and Genomes [179], MetaCyc [180],
BioCyc [181], HumanCyc [182], the Edinburgh human metabolic network [183],
MetaNetwork [184], Biochemical Genetic and Genomic knowledgebase [185], RE-
CON1/RECON2 [186, 187] and Reactome [188].
The Kyoto Encyclopaedia of Genes and Genomes (KEGG) [179] is an online
resource where the interaction-information of genes, proteins and metabolites is
integrated and it can be used to investigate molecular networks in specific organ-
isms or for all organisms combined [189]. KEGG provides many static pathways
and metabolic reaction networks, as well as a global metabolic map.
MetaCyc [180] and BioCyc [181] integrate information of multiple sources on
creating metabolic pathways for multiple organisms of which complete genomes are
available, whereas HumanCyc [182] is a database that uses only the human genome
and enzymes coded by human genes to predict the human metabolic network using
data from BioCyc and MetaCyc.
The Edinburgh human metabolic network is a manually constructed network
combining information from different databases and literature [183].
MetaNetwork [184] uses metabolite quantitative trait loci (mQTL) data to
construct a metabolic network by analysing the correlations of mQTL profiles and
plotting them using the Cytoscape software [190].
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The Biochemical Genetic and Genomic knowledgebase (BiGG) is a manually
curated database combining information from different databases and literature
for different organisms [185] among which data from KEGG and RECON, and
BiGG networks can be plotted using an external package in R.
RECON2 [187] is a consensus reconstruction of a human metabolic network
using multiple sources and is an updated version of RECON1 [186]. While the
curators of RECON2 did note that microbial metabolism must ideally also be
taken into account in modelling human metabolism, they focussed their attention
on the Homo sapiens metabolic network alone.
The last of the big freely available resources is Reactome [188], which is a
manually curated collection of human pathways and reactions; however it also
focusses only on human proteins and related reactions from literature.
Plenty of additional software packages exist that are able to use information
from the publically available resources for analysing pathways with graph theory
algorithms [191], draw custom metabolic reaction sub-networks for a specific or-
ganism [192] or editing pathways [193]. However, rarely do metabolic networks,
databases and programs consider that the typical mammal is not a single organism,
but rather a complex system comprising of a combination of mammalian, bacterial
and potential parasitic organisms. Specifically, there is symbiosis between a host
organism and its gut microbiota and gut microbes have functions and enzymes
that are not found in mammalian organisms [18, 20]. Therefore it is important to
be able to combine metabolic reaction networks from different organisms to show
the metabolic perturbations to the whole system. Also, being able to draw custom
metabolic reaction networks and being able to explore and edit the networks, all
ideally in a single software program, are what is currently lacking from currently
available tools. MetaboNetworks aims to fill this gap for metabolic reaction net-
works and combines the database generation, the ability to draw custom maps and
being able to edit the networks inside the MATLAB environment.
MetaboNetworks has the option to include data from multiple organisms and
investigates whether reactions can occur in any of the selected organisms. Metabo-
Networks is demonstrated here using an NMR-based toxicological biomarker in-
put data set. This is an area of particular importance as metabolic phenotyping
has shown to be particularly useful for studying toxicological processes as mod-
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els for human disease [15, 16]. However, MetaboNetworks can also be used to
provide a systemic overview of metabolic changes in a perturbed biological sys-
tem. MetaboNetworks [194] only requires the basic version of MATLAB (The
Mathworks, Natick, MA, USA) and does not require any additional toolbox. Al-
though, the MatlabBGL toolbox [195] has a number of graph layout algorithms
in mex/c++ code that can be used to speed up the calculation of large graphs in
MetaboNetworks. All MetaboNetworks’ functionalities are implemented using a
simple graphical user interface (GUI) and MATLAB code.
3.2 Basic methods and features
3.2.1 Database collection
First the appropriate data from KEGG has to be imported into MATLAB. In
MetaboNetworks this is done using a function (MetaboGetworks) that uses the
KEGG REST application programming interface (API) to calculate a metabolite
adjacency matrix that can later be used to draw the graphs. The user can select
one or multiple organisms for which complete genomes are available in KEGG,
and it then finds all the enzymes (with E.C. numbers) that are associated with
genes from any of the selected organisms. Using this list of enzymes, all reactions
in KEGG are queried and enzymes involved in the reactions are matched against
the enzyme list. Only reactions that require an enzyme from the list or those that
are listed as ‘non-enzymatic’ or ‘spontaneous’ are considered to possibly occur in
the system. For each of these reactions the main reactant pairs are found and the
compounds from these reaction pairs are considered ‘adjacent’. Each row/column
in the adjacency matrix indicates a specific compound (with a KEGG compound
ID). The KEGG IDs are linked to the names listed in KEGG to allow the user in
MetaboNetworks to search for as many metabolite names for each compound as
possible.
A reaction database has previously been collected using a similar approach [196]
to MetaboNetworks, however that database includes reactions from all species,
whereas MetaboNetworks focusses on organisms of interest as not all reactions
can occur in all systems.
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3.2.2 Network construction
When the data collection is complete, MetaboNetworks can be used to create and
explore custom networks. A list of metabolites, for instance biomarkers arising
from a metabonomic experiment, can be passed to MetaboNetworks and it searches
for the shortest paths between each of these metabolites using a breadth-first search
algorithm (see section 2.4.3) to show the resulting sub-network. All compounds
that are part of a shortest path between any of the metabolites are included in
the network. By default, MetaboNetworks plots the network as a circular graph.
Other graph layouts include spring-electrical embedding (see section 2.4.4), high-
dimensional embedding and two types of uniform edge-length layouts, the last
aiming to place nodes with as little overlap as possible. If the MATLAB statistical
toolbox is installed, multi-dimensional scaling can also be used. All graph layout
algorithms, except the circular graph, use the shortest path distances to optimize
node placement.
3.2.3 Network customization
The graph layout can be manually adjusted. Supported adjustments include node
position, node/edge removal, highlighting nodes (see green edges of nodes in Fig-
ure 3.1), and displaying shortest paths (orange edges in Figure 3.1), changing node
text and nodes/edge/text properties (font, width, size, etc.). If additional data is
supplied, the association of the metabolites with a response variable can be shown
as node colour (see Figure 3.1). Furthermore, the network can be exported as a
tif, png, pdf, eps or other image formats. Another option is to click on a node
to open a web browser showing the compound entry in KEGG or show reactions
pairs in KEGG of selected nodes. Also, see the full page figure in Appendix A.
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Figure 3.1: Shows the graphical user-interface of MetaboNetworks with a custom
network drawn for significant metabolites from a hydrazine toxicity study in rats
[197]. Metabolites higher in hydrazine-dosed rats compared to controls are shown
in red and metabolites lower in hydrazine-dosed rats are shown in blue. The white
nodes are part of shortest paths between the coloured nodes. The edges shown
in orange are part of the shortest-path (4 reactions) between taurine and glycine.
Aside from the rat (Rattus Norvegicus), all Bacteroidetes and Firmicutes species
were included in the database.
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3.3 Detailed features of MetaboNetworks
Each of the functions available in MetaboNetworks will be outlined below, starting
from the left and finishing with the last button on the right of the toolbar.
Save – Opens a save dialog screen where the user can choose the filename,
location and image type. All default image formats in MATLAB can be chosen:
bmp, eps, emf, jpg, pcx, pbm, pdf, pgm, png, ppm and tif. As well as the MATLAB
image format .fig. Choosing the .fig option will automatically save the database
(in .mat format) in the same location with the same name. If MetaboNetworks is
closed, the user can then continue editing and exploring the network from where
it was saved using the .fig and data in the .mat file.
Reset – This will reset the network to the original graph layout; all node and
edge deletions, node positions, and other changes are lost.
KEGG compound – This allows the user to choose a metabolite and it will open
a web browser showing the KEGG compound page for the selected metabolite.
KEGG reaction pair – This will let the user choose two metabolites and, de-
pending on whether there is a link in the network, a web browser will be opened
showing the reaction pair web page for the selected metabolites. If multiple
metabolites are selected prior to pressing the button, MetaboNetworks will evalu-
ate which are directly linked and open all reaction pairs in one web page.
Circular layout – This is the default layout, nodes are placed on a circle starting
with the supplied metabolites. The metabolite name is displayed on the outside
of the circle.
MDS – This layout can only be chosen if the MATLAB statistics toolbox has
been installed, if not this option is disabled. It uses multi-dimensional scaling to
calculate node positions using the distance matrix as similarity matrix.
High-dimensional embedding – This calculates node positions based on the first
two scores of principal component analysis using the adjacency matrix as input.
SEL – This uses the adjacency matrix to calculate the node positions aiming to
minimize the spring-electrical forces (see section 2.4.4). Because this is an iterative
process, it can take a long time when the network contains a very large number of
compounds. However, the user can exit the optimization at any time by pressing
the ‘ok’ button. The algorithm will finish the current iteration and then show the
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optimized node positions. Ordinary spring-type algorithms are not able to cope
with networks that are not fully connected. Therefore, SEL places nodes without
connections on the outside of the network.
Uniform edge length (UEL) – This uses the distance matrix to calculate node
positions, it starts with the node with the highest degree which is placed in the
centre. In each following step the metabolite with the highest degree is placed at
a position which is as close as possible to the actual distance of this metabolite to
those already in the network.
UEL ellipse – This algorithm uses the same procedure as UEL, except it takes
into account the length of the text of the node. It aims to place nodes as far
from each other as possible, while preserving the distances, to end up with as little
overlap of node labels as possible. Because overlap of node labels can become
problematic for very large networks.
Colour nodes based on association – If a vector of the same size as the metabo-
lite list is supplied to MetaboNetworks this option is enabled. Each selected
metabolite has a value, for instance the correlation with the response variable
of the study, the regression coefficient or some other metric. Choosing this option
changes the node colours of biomarker metabolites based on the value in the vec-
tor. The colour scheme uses colours on a continuous scale, ranging from dark blue
via white to dark red. If no vector is supplied, this option is disabled.
Maximum (additional) path length – When a network is created for a single
metabolite instead of two or more the default network style is a breadth-type net-
work which shows all metabolites directed connected to the biomarker. Changing
the maximum path length lets the user widen the network by including metabolites
at different distances. When a network is created for two metabolites, the default
network is a shortest path spanning network, however when the maximum addi-
tional path length is changed the algorithm includes other paths that are longer
than the shortest path by exactly the specified additional path length. For three
or more metabolites this function is disabled as it has the potential to create overly
crowded graphs otherwise.
Move nodes – When enabled, the user can move nodes by holding the (left)
mouse button down and releasing it where the node should be moved to. The
node that was closest to the position of the mouse when the button was pressed
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is moved to the new location. The user can continue to move nodes as long as
a movement or click is detected every 30 seconds. After 30 seconds of inactivity
the function is disabled and needs to be enabled again if more nodes are to be
moved. When the move node function is timed out, the node positions are saved
and locked (see next button for description).
Lock node positions – This button locks the node positions until an action is
performed which resets or changes node positions. The move node button auto-
matically calls this function when timed out. This ensures the positions are fixed
and are not changed when other functionalities are called which in turn may call
graph layout algorithms. If this function is enabled and the network is changed,
for instance due to deletion of nodes, the nodes stay in the positions they were at
and new nodes are optimized based on the ‘locked’ positions.
Delete (selected) node(s) – This will allow the user to select a node to delete
from the network, this will immediately recalculate the node positions using the
same layout algorithm as was used to calculate the previous network. To delete
multiple nodes at once, the user must select nodes first (see ‘select nodes’ button).
Delete edges between (selected) nodes – This will ask the user to choose 2
nodes in the network and, if there is an edge between them, this edge will be
removed and a new network is calculated. If multiple nodes are selected, this will
remove all edges between them.
Select nodes – This will let the user select nodes in the network, at each mouse
click the node closest to the position of the mouse will be added to the list of
selected metabolites. As with the move node button, there is a time-out of 30
seconds.
Deselect nodes – This lets the user de-select nodes. The selected node closest
to the position of the mouse click will be de-selected.
Deselect all nodes – This will de-select all nodes at once.
Highlight degree of (selected) node(s) – The user is asked to select a node first
after which all edges from this node are highlighted. If there are one or more nodes
already selected this automatically highlights all their edges.
Show shortest path between nodes – This highlights the shortest path between
selected nodes. If no nodes are selected, the user is asked to select two nodes. If 2
or more nodes are already selected, this will immediately show the shortest paths
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between all of them.
Un-do edge colouring – This will un-highlight the edges, either from the degree
or shortest paths buttons.
Change node colours of supplied metabolites – By default the biomarker meta-
bolites are coloured grey to distinguish them from the metabolites part of the
shortest paths (white). Clicking this button will open a dialog box in which the
user can choose another colour for the biomarker metabolites.
Change node colours of other metabolites – By default metabolites part of the
shortest paths have a white background to distinguish them from the biomarker
metabolites. Clicking this button will open a dialog box in which the user can
choose another colour for the background of the other metabolites.
Change edge colour – By default the edges are shown in black. Clicking this
button will open a dialog box in which the user can choose another colour for the
edge colouring.
Change edge colour of highlighted edges – In order to distinguish highlighted
edges from non-highlighted edges, the default colour for highlighted edges is orange.
Clicking this button will open a dialog box in which the user can choose another
colour for showing the highlighted edges.
Change node box colour – By default the box colour of all nodes is black. Click-
ing this button will open a dialog box in which the user can choose another colour
for the outer boxes of nodes.
Change node box colour of selected nodes – By default the box colour of se-
lected nodes is red to distinguish between selected and un-selected nodes. Clicking
this button will open a dialog box in which the user can choose another colour for
the outer boxes of selected nodes.
Change colour of text – By default the text colour of nodes is black. Clicking
this button will open a dialog box in which the user can choose another colour for
the text on the nodes.
Reset colours – This resets all colours back to the defaults.
Increase line width – Increases the line widths of edges and node boxes by 1
point (default is 1, maximum is 5).
Decrease line width – Decreases the line widths of edges and node boxes by 1
point (minimum is 1).
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Change font – This opens a dialog box in which the user can change the font
type, size and emphasis (bold, italic).
Edit text of a node – This will ask the user to select a node first, after a node
has been selected the text can be edited. This can be used to manually shorten
names to create more space in the graph or to re-name metabolites.
Replace text in all nodes – This will allow the user to make changes to names
of all nodes with a search string simultaneously. For instance, to change hydroxy to
OH. Optionally, this process can be performed for a case-sensitive case by quoting
the first string (“hydroxy”), this will not change ‘Hydroxy’ to OH, but only the
lower case string.
3.4 Step-by-step walkthrough of the software
First the MetaboGetworks function has to be called from MATLAB to start
database collection:
>> MetaboGetworks
The software will then automatically query the KEGG database for the names
and classes of all complete genomes. Once it has finished a GUI pops up with all
complete genomes (Figure 3.2).
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Figure 3.2: OrganismFindGUI lets the user search and select species to include in
the database.
Here, the user can search for species to include. In the example in Figure 3.3,
a search is performed for all Firmicutes species and the lactococcus are selected
and added to include in the database generation.
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Figure 3.3: Searching, selecting and adding specific species to use for generating
the database.
The user can always remove species from the selection list and to retrieve a list
with all genomes the user can simply search for the letter ‘T’, as that is included
in the genome codes in KEGG. Once the user is happy with the selection, the list
of organisms is saved and the user is queried to choose a name and location to
save the database to. Once this has been chosen the software checks if the correct
file format (.mat) has not been changed. If the file format has been changed,
the software exits immediately, otherwise the MetaboGetworks function starts the
process of collecting the database.
First, the software finds all enzymes (with E.C. numbers) in KEGG. Next, the
software loops through all enzymes and matches the associated organisms (listed
in the ‘genes’ section of an enzyme entry or in the ‘references’ section) with the
user specified list of organisms. If no match with an organism from the list is found
the enzyme is excluded from the list.
Next, when all enzymes have been queried, a list containing all enzymes in the
‘system’ remains, MetaboGetworks then queries all reactions and finds the enzymes
associated with each reaction. If a match is found between the system enzyme list
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and the enzymes for a reaction, or if the reaction is listed as ‘spontaneous’ or
‘non-enzymatic’, the main reactant pairs of the reaction are considered adjacent
and the adjacency matrix is updated accordingly.
Last, the software loops through all compounds listed in KEGG and finds all
associated names for each compound, this list is later used by MetaboNetworks’
sub-functions to allow the user to search for metabolites. At this point the data
(adjacency matrix, KEGG compound ID list, full metabolite name list) is saved
at the previously specified location with the specified filename.
Now the database has been created, it can be used to create networks using
MetaboNetworks. To start the software the main function has to be called from
MATLAB:
>> MetaboNetworks
The biomarker metabolite lists are saved in cell structures in the workspace
after calling MetaboNetworks, thus if no cell structures exist in the workspace,
MetaboNetworks assumes a list will have to be generated and asks the user to
select a database (Figure 3.4). If a cell structure does exist the user can select the
variable with biomarker metabolites in SelectMetaboliteNamesGUI (Figure 3.5).
When a list has been chosen, MetaboNetworks searches the workspace for variables
of the class ‘double’ with the same dimensions as the cell structure. This optional
variable can contain information of the significance of the metabolites, such as the
correlation with the response/outcome, that can be used to add another layer of
information to the network. If no association vector of the same size is found, or
if none is selected, the ‘colour nodes based on association’ button is disabled. If a
cell structure exists, but the user wants to create a new list, the ‘create new list
with metabolite names’ button can be clicked in the SearchMetaboliteNamesGUI
which will then continue as if no cell structure was found and ask the user to select
a database.
In Figure 3.4 the database generated by MetaboGetworks is selected and by
pressing ‘open’ the software continues to the SearchMetabolites dialog if a valid
database is selected. A valid database has all the required variables from Metabo-
Getworks and if another file is selected, or if the ‘cancel’ button is pressed, the
software exits. In the SearchMetabolites function (Figure 3.6) the user can search
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for metabolites and add them to the list.
Figure 3.4: Selecting a database to use for MetaboNetworks.
Figure 3.5: SelectMetaboliteNamesGUI searches the current workspace for cell
structure that may contain lists of metabolite names, if a new list of metabolites
is needed the user can create a new list by searching for metabolites.
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Figure 3.6: SearchMetabolites function uses the selected database and the list
with all metabolite names found in KEGG to let the user search for metabolites
to include.
When multiple entries in KEGG match the search term, they are listed in
a dropdown menu, after which the user can select the metabolite they wish to
include (Figure 3.7). When one or more metabolites are selected, the user can
save the list and exit (Figure 3.8). This will start up MetaboNetworksGUI with
a default circular graph layout (Figure 3.9). For two or more selected metabolites
the shortest path network is shown. However, when a single metabolite is selected,
a breadth-type network is calculated.
Figure 3.7: SearchMetabolites function shows the list of metabolites selected (now
only creatinine) and the search for new metabolites. The dropdown menu shows
all metabolites that match with the search term.
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Figure 3.8: Multiple metabolites are selected and the dropdown menu shows all
compounds that are related to the search term and that are not already in the
selected set of metabolites.
Figure 3.9: Default MetaboNetworksGUI layout of the shortest path network for
the selected metabolites.
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Only main reaction pairs are included in the database; however this can still re-
sult in edges that may not make (biological) sense. For instance, the L-Asparagine
– NH3 – Glycine path indicates that L-asparagine can be metabolised to glycine
via NH3, and vice versa. The user can manually delete nodes from the network, in
the example below NH3 is selected (red box colour of node) and when the delete
button is pressed, MetaboNetworks immediately updates the network as shown in
Figure 3.10. The updated network shows some new metabolites in the shortest
path network.
Figure 3.10: Left panel shows NH3 is selected in the network, right panel shows
the updated network after the selected metabolite is deleted from the network.
In order to investigate the shortest path between metabolites, two metabolites
can be selected and by clicking (enabling) the shortest path button it highlights the
shortest path between selected metabolites, for instance L-arginine and succinate
(Figure 3.11).
While the circular network is used as default due to its simplicity, other graph
layout algorithms can be used as well. Figure 3.12 shows the result of SEL.
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Figure 3.11: Highlights the shortest path between selected metabolites.
Figure 3.12: Spring-electrical embedding graph layout of the network.
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At any point the user can manually move nodes by enabling the move node
button. Figure 3.13 shows the same network as in Figure 3.12, however, without
overlapping node labels.
Figure 3.13: Customizing the graph by moving nodes of the network.
When the network becomes crowded (see for instance Figure 3.1) it may be
beneficial to use abbreviations for metabolite names. MetaboNetworks uses the
supplied biomarkers names and for all metabolites part of a shortest path it uses
the shortest name (number of characters) in KEGG. When pressing ‘text edit’
and then selecting a metabolite, a dialog box pops up and the user can change the
name, for instance for N -acetyl-L-citrulline (Figure 3.14). Alternatively, using the
‘repl. all’ button a specific search term can be replaced in all nodes containing it.
Alternatively, the user may wish to change the default biomarker node colours
(grey). Clicking the appropriate button will show a dialog box in which the user
can select a custom colour (Figure 3.15).
For clarity, or publication purposes, the user may wish to change the font styles.
A dialog box pops up when the ‘T→T ’ button is pressed (Figure 3.16) that lets
the user select a different font, emphasis type and font size.
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Figure 3.14: Changing display text on node labels.
Figure 3.15: Changing the background colour of nodes in the network.
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Figure 3.16: Changing font style of node labels.
After changing font styles, nodes may overlap and need to be moved again
for clarity (Figure 3.17). The line width can also be changed using the ‘+1’ and
‘−1’ buttons to increase or decrease (right panel in Figure 3.17). When the user
is satisfied with the network it can be exported as an image file when the save
button is pressed. A dialog pops up in which the user can chose the file format,
name and location (Figure 3.18).
In order to explore the network, a single metabolite can be selected and the
corresponding KEGG compound page is then opened (Figure 3.19). Or the user
can select multiple nodes and look at the reaction pairs in KEGG (Figures 3.20
and 3.21). This opens a web browser and shows the reaction pairs if a link exists
between selected metabolites. In this example, two links are found between selected
metabolites and both reaction pairs are shown in the web browser (Figure 3.21).
As an alternative to deleting a node from the network, the user can also delete
edges between (selected) nodes, for instance the edge between L-alanine and L-Asp
(L-aspartate) can be deleted. This immediately calculates a new network layout
and replaces previous node positions if the network is not locked (Figure 3.22).
This results in a new network where L-alanine is no longer present, however, be-
cause L-Asp is (still) part of a shortest path from L-arginine to glycine it remains
part of the network.
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Figure 3.17: Moving nodes to avoid overlap between node labels and increasing
the line width.
Figure 3.18: Exporting the network.
109
CHAPTER 3. METABONETWORKS
Figure 3.19: KEGG compound entry page opened within the MATLAB browser.
Figure 3.20: Selecting multiple nodes to query the reactions in KEGG.
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Figure 3.21: Showing the KEGG information of the selected reactions
Figure 3.22: Left panel shows selected metabolites. Right panel shows updated
network where no link exists between L-alanine and L-aspartate.
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If a single metabolite is selected in the SearchMetabolites function (Figure 3.6),
or if from a larger network biomarkers are removed from the network so that one
remains, a breadth-type network can be calculated. Figure 3.23 is an example for
choline (highlighted in grey) showing all metabolites that are at a distance of at
most 3 reactions.
Figure 3.23: A breadth-type network layout shown for choline with a maximum
path length of 3 reactions.
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3.5 Discussion
MetaboNetworks can be used to investigate and modify complex metabolic reac-
tion networks. It improves the visual interpretation of metabonomic experiments
with coverage across disparate metabolic pathways. The network should ideally
be viewed as a connected network of probabilistic events (reactions) [198] that lie
on the shortest path between two metabolites.
The database can be tailored to the study by including specific organisms as
was done for the hydrazine toxicity network by including all Bacteroidetes and
Firmicutes species, the most common microbiota in the gut [17], as it has been
shown that germ-free rats react differently to hydrazine compared to normal Han
Wistar rats [199].
MetaboNetworks can also be used for identifying unknown metabolites by gen-
erating a network of metabolites correlated to the unknown metabolite. The un-
known can be part of the shortest path between the known metabolites as the
correlation can be due to a similarity in structure. The breadth-type network is
particularly useful for this purpose as it is able to expand the network for one
or two metabolites that may highly correlate to the unknown. The user could
then test (experimentally) whether the identity of the unknown corresponds to
any metabolite in the network.
MetaboNetworks uses data from KEGG as it is the database which has the
largest number of complete genomes included (>3000). However, as no database
is devoid of errors, merging different databases to create a consensus network [200]
may be a future avenue to pursue, but as different databases use different methods
and data structures it will require a lot of manual data curation in order to create
one.
MetaboNetworks is freely available from the MATLAB File-Exchange.
Note that use of the KEGG-API is free for academic use, however non-academic
users should ask for permission (see http://www.pathway.jp).
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Chapter 4
SubseT Optimization by
Reference Matching, an
Optimized Statistical Approach
for Recovery of Metabolic
Biomarker Structural Information
from 1H NMR Spectra of
Biofluids
Summary
A new multivariate statistical approach to recover metabolite structure informa-
tion from multiple 1H NMR spectra in population sample sets is described. SubseT
Optimization by Reference Matching (STORM) was developed to select subsets
of 1H NMR spectra that contain specific spectroscopic signatures of biomarkers
differentiating between different human populations. STORM aims to improve the
visualization of structural correlations in spectroscopic data using these reduced
spectral subsets containing less overlap between metabolites that may otherwise
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confound the structural correlations. STORM is not only useful to identify small
metabolite signals, it also improves the visualization of more abundant NMR peaks
compared to STOCSY. STORM is a useful new tool for biomarker discovery in
the ‘omic’ sciences that has a widespread potential applicability. It can be applied
to any type of data, provided that there is interpretable correlation among vari-
ables, and is also demonstrated for data with more than 1 dimension (for instance
2D-NMR spectra).
4.1 Introduction
Metabolome-Wide Association Studies [39] (MWAS) are a powerful means to find
connections between disease risk factors and metabolic phenotypes in large pop-
ulations [40]. Advancements in automated reproducible measurements of samples
using 1H NMR spectroscopy [37] have given rise to increasingly large data sets
such those available from the INTERMAP [39, 73] study. INTERMAP combines
measurements of blood pressure, extensive dietary information, questionnaire data
and urinary metabolite excretion data from 1H NMR spectroscopic analysis of
24hr urine collections [39, 73]. Statistical analyses of large data sets such as IN-
TERMAP yield many ‘nominally’ significant associations of a risk factor with
spectroscopic signals that can be assigned to specific metabolites after structural
elucidation. 1H NMR peak intensities are intrinsically highly correlated stoichio-
metrically with peaks from the same molecule; however peaks from different com-
pounds can overlap reducing the correlation. Therefore, 2D-experiments are often
needed for structure elucidation [201].
Identification of 1H NMR spectroscopic signals using statistical methods is
an important aspect in MWAS, as it uses the data that have been modelled to
more accurately recover information about possible biomarkers without requiring
additional spectroscopic experiments, which has obvious advantages in terms of
efficiency and in usage of samples where volume is limited [83]. A widely used
statistical spectroscopy tool in NMR-based metabonomics [12] is statistical total
correlation spectroscopy (STOCSY) [38] developed by Cloarec et al. and which
is related to generalized 2D correlation theory as used for Infra-Red and Raman
spectroscopy [84]. In the case of 1H NMR spectra, STOCSY can generate a pseudo-
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selective 1D-TOCSY spectrum, based on the correlation to the intensity of a given
peak (driver), or a 2D auto-correlation matrix to show all spectrum-wide associa-
tions in the data. A related method, covariance NMR, uses the covariance matrix
as a substitute for a second Fourier transformation in two-dimensional (2D) NMR
spectroscopy [202].
Over the last few years, STOCSY and its variants have proven to be valuable
tools in the identification of spectroscopic signals, as they can visualize both struc-
tural associations as well as non-structural (for instance metabolic pathway) inter-
actions [92]. STOCSY makes use of the covariance and correlation between vari-
ables and as these are simple to calculate (see Equations 2.9 and 2.10), STOCSY
is a fast method. A number of methods have been proposed to improve the sta-
tistical signal elucidation such as CLASSY [89] which aims to identify clusters of
variables belonging to the same molecule, R-STOCSY [203] to use clustered groups
of variables to identify metabolic networks, iSTOCSY [90] which aims to deter-
mine the within- and between-metabolite relationships by iteratively performing
multiple 1D-STOCSY analyses, OR-STOCSY [204] which filters out orthogonal
variance prior to R-STOCSY, and RANSY [205] which uses the ratio between the
intensities of variables to show associations between variables. All methods use all
available data to calculate the correlation, covariance and/or ratio matrices.
Previous INTERMAP MWAS have shown it is not uncommon to find unknown
signals [39, 78, 79] which cannot be easily identified using STOCSY or other meth-
ods. Also, by studying differences in large populations, specific peaks may only be
present in a small subset of people. A STOCSY analysis of a non-abundant and
‘rare’ signal will be heavily influenced by the spectra without the peak, resulting
in the actual signal being obscured. Low intensity signals close to the baseline
are of considerable interest. Increasing use of higher frequency and thus higher
sensitivity NMR spectrometers mean that more of these low-intensity signals can
be distinguished from the baseline and noise [206]. However, the extreme variation
in gene-environmental exposure, typical of human populations, makes metabolite
identification challenging given the number of potential compounds present in hu-
man urine [13].
A new method is proposed here that aims to find an optimal subset of spectra
that contain a specific peak of interest. The similarity between each spectrum and
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a reference (set of spectral points) is evaluated and spectra with a high similarity
are further analysed using STOCSY. A STOCSY of such a subset may no longer
be obscured by noise and thus will provide a clearer description of the unknown
metabolite compared to a STOCSY on the full data set. SubseT Optimization by
Reference Matching (STORM) iteratively learns the true reference by repeating a
procedure to find the most highly correlated spectra and updating the reference
multiple times. It converges when a subset of samples has been found twice (stop
condition). By using only small parts of the spectrum in each iteration, the algo-
rithm is very fast. STORM aims to visualize low-intensity and rare signals close
to the baseline and distinguish these from noise. It does so by finding a subset of
spectra that contain the purest form of the unknown signal. Using that subset,
the J-coupled splitting multiplicity of the peak can be more clearly visualized to
aid in determining the identity.
I illustrate how STORM works and how it can be used for large data sets, where
the numbers of samples (n) have the same order of magnitude as the number
of variables (p). The resulting subset however, will contain much less samples,
hence the data matrix tends to be (very) wide (n  p). In data sets where
n  p often many significant correlations are found, of which some may be false
positive associations. To control for multiple testing, several approaches can be
used, among which the Bonferroni correction [111] and False Discovery Rate [112]
are the most commonly applied. In order to simplify the interpretation of a 2D-
STOCSY a different approach, statistical shrinkage of the covariance matrix [118],
can be used as it has been shown to limit the number of false positive associations
in Genome-Wide Association studies [120].
4.2 Materials and methods
4.2.1 NMR spectroscopy of INTERMAP samples
The urine specimens were prepared for, and analyzed with, high-resolution Nuclear
Magnetic Resonance (NMR) spectroscopy using a Bruker Avance III spectrome-
ter, operating at 600.29 MHz for 1H, equipped with a 5 mm, TCI, Z-gradient
Cryo-probe. 1H NMR spectra of urine were acquired using a standard 1D pulse
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sequence with water pre-saturation during both the relaxation delay (RD, 2s) and
the mixing time (tm, 150ms) [39, 207]. The 90
◦ pulse length was set to 10µs and a
total acquisition time of 2.73s was used. Per sample, 64 scans were collected into
32K data points using a spectral width of 20 ppm. FIDs were multiplied by an
exponential weighing function (corresponding to a line broadening of 0.3 Hz) prior
to Fourier transformation.
Confirmation of unknown signals was performed using a combination of a stan-
dard 1D 1H NMR pulse sequence with water peak pre-saturation (noesypresat), 2D
J-Resolved (J-Res), 2D 1H-13C Hetero-nuclear Single Quantum Coherence (HSQC)
and 1H-1H Total Correlation Spectroscopy (TOCSY) experiments. All experiments
were acquired using a Bruker AVANCE III spectrometer, operating at 600.29 MHz
for 1H, equipped with a 5 mm, TCI, Z-gradient CryoProbe. Two-dimensional (2D)
NMR analyses were performed on the urine sample with the highest quantity of
the unknown metabolite. Spectra were visualized using MestReNova (Mestrelab
Research S.L., Santiago de Compostela, Spain).
4.2.2 2D-J-Resolved spectroscopy
For the human urine sample with the highest level of the unknown, the 1H-1H
two-dimensional (2D) J-Res experiment was acquired using a pulse sequence to
detect the J-couplings in the second dimension [208], with suppression of the water
resonance. For the INTERMAP experiments, a total of 24 scans was collected over
a total of 40 increments into 16K data points. Spectral widths were set at 20 ppm
and 50 Hz for F2 and F1, respectively. A 2s RD and 0.68s acquisition time were
used.
4.2.3 2D-TOCSY spectroscopy
The 2D 1H-1H total correlation spectroscopy (TOCSY) NMR experiment was ac-
quired using a DIPSI-type pulse sequence [209]. A total of 32 scans over 256
increments was collected into 4K data points with a spectral width of 10 ppm for
each dimension. The data were multiplied with a Qsine-bell for a final number of
data points of 1K prior to Fourier transformation.
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4.2.4 1H-13C HSQC spectroscopy
A 2D 1H-13C Hetero-nuclear Single Quantum Coherence (HSQC) NMR spectrum
was acquired using a pulse sequence for hetero-nuclear one-bond scalar couplings
[210]. It was recorded with 310 scans at 4K resolution for F2 and 128 increments
for F1 using an RD of 1.5s between sequential scans. Spectral widths were set to
12 ppm for F2 and 170 ppm for F1. The spectral windows were centred at the
water signal for F2 and 75 ppm for F1.
4.2.5 Pre-treatment of INTERMAP NMR data
Free Induction Decays (FIDs) were Fourier transformed, referenced to an internal
standard (trimethylsilyl-[2H4]-propionate), baseline and phase corrected using in-
house software. The spectral regions containing water and urea (δ 6.4 to 4.5),
the internal standard (δ 0.2 to -0.2), δ 0.5 to 0.2, δ -0.2 to -4.5 and δ 15.5 to
9.5 were removed prior to normalization using median fold change [211]. The
remaining variables were binned to a total of 7100 variables using bin widths of
0.001 ppm. For quality control and analytical reproducibility, a separate study was
performed previously [37] where identification of split pairs was accurate (96%),
showing good analytical reproducibility of the data set. Metabolic outliers were
excluded from the data set using Hotelling’s T2 statistic [212] on the scores of
the principal component analysis. Metabolic outliers were defined as participants
whose scores, for either urine collection, mapped outside the Hotelling’s T2 95%
confidence interval [39].
4.2.6 Data analysis
Linear regression of Body Mass Index (BMI, defined as weight (in kg) divided by
height (in meters) squared) with the 1H NMR spectra was performed for both
urine-collections (‘visits’) of 1,880 non-diabetic US individuals (see Chapter 5.2).
Results were adjusted for potential confounding factors of age, sex and population
sample (field centres).
A spectral variable j is found to be significant if 1) its P -value (pj) is smaller
than 4×10−6, the MWSL [116] for an FWER of 1%, in both visits, 2) the regression
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coefficients (βj) from both visits are the same sign and 3) both of its adjacent
spectral points (j − 1 and j + 1) obey rules 1 and 2 as well. In order to represent
the variables, the ‘Manhattan’ representation (Equation 4.1) of the P -values was
used. Here Mj is the Manhattan index, p
1
j the P -value for urine collection 1, p
2
j
the P -value for urine collection 2, β1j the regression coefficient for urine collection
1 and β2j the regression coefficient for urine collection 2, all for variable j.
Mj = −
δ(β1j×β2j ),1 × β
1
j
|β1j |
log10
(
max
(
p1j , p
2
j
))
(4.1)
4.2.7 STORM algorithm
The algorithm consists of three steps that are repeated a number of times: subset
selection, STOCSY of subset, reference updating. There are three user-defined
parameters used in the algorithm: ns, b and q. ns is the expected number of
spectra with the hidden signal, the expected signal width (broadness) is indicated
with b, and q is a pre-defined P -value threshold for including the spectral variable
in the updated reference.
First, the algorithm calculates the Pearson correlation of each spectrum with
the reference. Next, the corresponding P -values are calculated by transforming the
correlation into the t-statistic with (n−2) degrees of freedom (see Equation 2.11).
At this point all spectra are in the subset. Then, spectra with a negative correlation
with the reference are excluded from the subset. From the remainder, the ns
spectra with the lowest P -values are chosen to be in the subset.
For the second step, a STOCSY is calculated using the spectra in the subset
only for a small number of variables, with the driver being the maximum intensity
of the previous reference. The variables that are included are limited by b, because
only variables in the vicinity of the driver are of immediate interest.
The third step is where the previous reference is updated using the STOCSY.
The new reference is defined as the set of spectral points of the STOCSY pseudo-
spectrum that are significantly correlated (based on q) with the driver. As a lower
number of samples are used for the STOCSY there is a higher chance of finding
higher correlations compared to using the full data set. Also the covariance is
more sensitive to abundant signals in the vicinity of the driver; in order to prevent
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including different metabolites in the new reference, b is used to limit the size (in
ppm) of the new reference. In theory, the ideal value for b is the full bandwidth
of the metabolite NMR peak. In practice, a value slightly wider than the first
reference was found to work best, as the full bandwidth is, like the hidden signal,
unknown. The new reference consists of all spectral points, within the broadness
window, that are significantly correlated to the driver. Hence, the previous driver
peak is always included in the new reference as its corresponding P -value will be
0, but it will not necessarily be the new driver. The new driver is defined as the
variable with the highest intensity in the new reference, i.e. b cannot be chosen to
be too wide or the reference may include other signals with higher intensity than
the unknown.
Next the updated (new) reference is fed back into the first step of the algorithm
and all spectra are used again to calculate the correlation to the new reference. This
procedure allows the algorithm to update the reference signal, using information
from previous iterations. STORM converges when a subset is found (at the end
of the first step) that is identical to any of previously found subsets. As STORM
uses small parts of all spectra at a time it is minimally memory intensive and very
fast. Pseudo-code is given in Algorithm 2. From this point forward, I will refer
to ‘STORM’ as the complete routine described above, the ‘subset’ as the spectra
with highest similarity to the reference before convergence, and to the STOCSY
of the subset to visualize the spectrum-wide correlations as the ‘relic’ (recovered
latent compound).
4.2.8 Additional STORM steps
Within STORM there is room for additional (optional) steps. For instance, in the
subset selection step where, instead of selecting ns spectra, one could also set a
P -value threshold (similar to, but different from, q) for inclusion to select at least
ns spectra. This step is particularly useful when the number of samples with the
signal is difficult to determine (as is often the case). This threshold needs be set
based on the number of samples, as the statistical power decreases with a lower
number of samples.
Also, as correlation is a scale-invariant measure, any type of initial reference can
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Algorithm 2 Pseudo code of STORM
1: k ← 1 % initialize number of iterations k
2: ind← (ppm ≡ ppmref ) % indices of ppmref
3: while sk−1 6= sh, where h ∈ {1, ..., (k − 2)} do
4: sk ← {1, ..., n}
5: Xr ← X1:n,ind
6: ri ← corr (Xri, ref) % correlation between object in Xr and ref
7: pi ← 2× tcdf
(
−
∣∣∣ri ×√#ind−21−r2i ∣∣∣ ,#ind− 2)
8: for i = 1 to n do
9: if ri > 0 then
10: sk 3 i % positively correlated spectra in subset
11: end if
12: end for
13: p← p (sk)
14: order ← sort p % sort p in ascending order
15: sk ← sk (order)
16: if ns < #sk then
17: sk ← sk(1 to ns)
18: end if
19: d← index max ref
20: d← ind(d) % index of driver signal
21: Xs ← Xsk,(d− b2+1):(d+ b2+1) % b is expected broadness of signal
22: D ← Xsk,d % driver
23: cj ← cov (Xsj, ref) % covariance between variable in Xs and D
24: rj ← corr (Xsj, ref) % correlation between variable in Xs and D
25: pj ← 2× tcdf
(
−
∣∣∣∣rj ×√ n−21−r2j
∣∣∣∣ , n− 2)
26: ref ← c(r > 0)
27: ref ← ref(p < q) % q is P -value threshold
28: ind← (c ≡ ref) % indices of ref
29: k ← k + 1
30: if k > niter then
31: break
32: end if
33: end while
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be chosen: for instance part of a spectrum, regression coefficients, LVs, covariance
of X and Y or the Manhattan representation of P -values. A possibility to more
accurately compare the reference with the spectra is to update the reference with
the mean of the ns most significant spectra in the first step and then recalculate
the correlation. Because the Pearson correlation is used (linear) and the reference
(e.g. Manhattan representation) may not scale linearly with the spectra, another
additional step can be to not include all spectral points significantly correlated
with the driver, but only the significant spectral points adjacent to the driver.
This will preserve a better ‘peak shape’ for the new reference as there will not be
any gaps.
4.2.9 Animal data
The Consortium for Metabonomic Toxicology (COMET) was a joint collaboration
between Imperial College London and six pharmaceutical companies in the early
2000s to access and predict drug toxicity in animals [213]. Urine, blood serum and
tissue samples from male Sprague-Dawley rats were collected over the course of
this study and measured with 1D and 2D NMR spectroscopy at Imperial College
London. Animal housing and analysis protocols are described elsewhere [213]. To
show the applicability of STORM for two dimensions 2D J-Res spectra, obtained
from blood serum samples, are used.
4.2.10 2D J-Res NMR and data pre-treatment
For the COMET samples a total of 16 scans were acquired per sample over 128
increments into 16K data points. Spectral widths were set at 12 ppm and 50 Hz
for F2 and F1, respectively, and a 1.5s RD and 4.56s acquisition time were used.
An unshifted sine-bell apodization function was applied to F2 and F1 of the J-Res
spectra prior to Fourier transformation. Data were tilted by 45◦ and symmetrized
to F1. Processed J-Res spectra were transferred to MATLAB using an in-house
MATLAB script followed by referencing the chemical shift to the highest intensity
(lactate, δ 1.317). Next, the spectra were interpolated in two dimensions (F2: δ
10.7080 to −1.1557, F1: 0.323 to −0.323 ppm (38.8 Hz)) to end up with spectra
of size [16384,127]. The spectra were cut between δ 4.65 and 0.75 to reduce the
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total number of variables and simultaneously exclude noisy regions and the water
peak.
4.3 Results
4.3.1 MWAS on body mass index
Part of the urinary metabolome-wide association for BMI is shown in Figure 4.1a.
Full results of the study elucidating the biochemistry of BMI are given in Chapter 5.
Figure 4.1 shows a section of the median 600 MHz 1H NMR spectrum of 1,880
individuals to illustrate difficulties in uncovering the identity of signals close to the
baseline/noise level. Signals significantly associated with BMI are shown in green.
STORM was applied to elucidate structural correlations of two unidentified
signals from the BMI MWAS. The signals resonate around δ 4.04 and δ 4.02
(Figure 4.1b) and their signals are close to the noise and baseline in the median
spectrum. The bottom section of Figure 4.1b shows the Manhattan representation
of the P -values obtained with linear regression. The Manhattan plot shows that
the unknown signals are positively associated with BMI. Based on the STOCSY
analysis of the most significant spectral points, they appear to be two different
metabolites mainly correlated with glucose signals (Figure 4.1c,d) as they are not
correlated with each other. The driver peaks of the STOCSYs are indicated by
the red arrows.
4.3.2 Application of STORM
The covariance of BMI with the significant spectral points around δ 4.04 was
used as initial reference for STORM. By using this set of adjacent spectral vari-
ables, noise has less of an influence compared to using a single spectral variable.
Figure 4.2 shows the STOCSY at each step, the new reference is the covariance
between the vertical red lines. The number of samples in each subset is shown in
the caption. Every time the reference is updated, the entire data set is used to
calculate the correlation with the new reference. Figure 4.2g shows the relic, where
it has become apparent that the significant signals at δ 4.04 and δ 4.02 actually
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belong to the same multiplet. This multiplet, possibly a doublet of doublets of
doublets (ddd), is strongly correlated to another multiplet signal at δ 3.74. The
multiplicity and possible structural correlation were not visible in the STOCSYs
of the entire data set (Figure 4.1c,d). The sample with the highest concentration
of the unknown metabolite from the final subset (n=33) was used for spectroscopic
experiments. The full data set and subset are shown in Figure 4.3, it also shows
many signals around δ 4.03 that are not the same as the relic.
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Figure 4.1: Graphic showing preliminary results from the MWAS on BMI and
illustrating problems identifying unknown signals. (a) Shows a small section of the
median spectrum 600 MHz 1H-NMR spectrum of urine from 1,880 non-diabetic US
INTERMAP participants. In green significant associations with BMI are shown
for this section. (b) Expanded region δ 4.05 to 4.00 from a. Top part shows
the median spectrum, bottom part shows the Manhattan representation of the
P -values. This shows both unknown signals have a positive association with BMI.
(c, d) STOCSY of δ 4.04 and δ 4.02 (most significant signals), respectively.
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Figure 4.2: Visualization of the subset, using STOCSY, after each iteration of
STORM to uncover the identity of a biomarker from the INTERMAP BMI study.
The boundaries of the updated reference are shown by two vertical red lines and
the driver of each STOCSY is indicated with an arrow. The driver is defined as
the highest intensity in the previous reference signal. (a) 193 samples. (b) 318
samples. (c) 359 samples. (d) 204 samples. (e) 86 samples. (f) 33 samples. Width
restricted by P -value threshold. (g) Shows the relic (same subset as f) with two
multiplet signals (δ 4.03 (ddd) of chiral CH and δ 3.74 (m) of CHH’OH) possibly
belonging to the same molecule.
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Figure 4.3: 1H NMR spectra from the first visit superimposed (a) All spectra
from the first urine collection plotted in the same figure. Shows the full data set
(n=1880). (b) Shows all spectra in the subset of STORM (n=33).
Using a Lorentzian function (Equation 4.2) centred at δ 4.0325 as reference,
a relic was extracted (Figure 4.4) that may have obscured the result of the data
analysis; it could be (one of) the cause(s) of the reduced significance around δ
4.03 as shown in Figure 4.1b. By selecting the optimal subset a clearer metabolic
signature of a possible obscuring compound can be extracted and, if required, it
can be removed from (selected) spectra by for instance STOCSY editing [214].
L(x) =
1
pi
1
2
γ
(x− x0)2 +
(
1
2
γ
)2 (4.2)
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Figure 4.4: The ascorbic acid relic and a possible obscuring signal. Top shows the
relic obtained with STORM in blue and the relic of a possible obscuring signal
(n=142) in red. The signal was obtained using a Lorentzian function (x0=4.0325,
γ=0.0001) as initial reference. Signal in red could possibly be one of the signals
suppressing the significance of ascorbic acid around δ 4.033. Bottom shows the
Manhattan representation (red represents positive association with BMI).
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Statistical shrinkage can reduce the number of significant correlations in a 2D
STOCSY when n  p to simplify the interpretation. Figure 4.5a shows part of
the 2D-STOCSY of the subset where a significant positive correlation is indicated
in red and negative correlations in blue. Despite the fact it shows only a small
part of the spectrum, it gives an indication of the considerable time that it would
take to fully interpret a 2D-STOCSY. Figure 4.5b shows the 2D-STOCSY with
its shrunken correlation matrix (λ=0.35) for the same data set.
Figure 4.5: Comparison of a pseudo 2D-spectrum with and without statistical
shrinkage. Cut-outs of a 2D-STOCSY (P -value threshold = 0.01) of the ascor-
bic acid subset (uncovered by STORM) from the INTERMAP non-diabetic U.S.
population (a) without shrinkage (b) with shrinkage. Shrinkage allows for easier
interpretation of a 2D-STOCSY.
The shrunken STOCSY show less residual variation compared to the non-
shrunken STOCSY and primarily shows structural correlations, which is beneficial
when interpreting a 2D-STOCSY for elucidating unknown spectroscopic signals. It
can be used instead of a correlation (or P -value) threshold, which can be somewhat
of an arbitrary choice [92] if not made data dependent. By shrinking the correlation
matrix spurious correlations can be removed from the data and this provides a more
reliable estimate of the true auto-correlation matrix. As STORM only uses a small
number of variables (p < n), there is no immediate need to use shrinkage until
STORM has converged and a (2D-)STOCSY is calculated for the selected subset.
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4.3.3 Identification of the relic
To validate the results of STORM and to uncover the peak multiplicity and struc-
tural correlations of the chemical shifts at δ 4.03 and 3.74, J-Res and TOCSY
experiments were performed (Figure 4.6a,b). The TOCSY spectrum shows struc-
tural correlations between δ 4.52, 4.03 and 3.74. The NMR spectrum of ascorbic
acid is known to have these chemical shifts. To confirm the identity, 1H-13C HSQC
and 1D 1H NMR spiking experiments were performed with and without the addi-
tion of authentic ascorbic acid. Figure 4.6c shows the 1H-13C HSQC of the urine
sample in red, overlaid with the ascorbic acid standard in blue. The 13C and 1H
chemical shifts of the standard match the chemical shifts of the relic in the urine
sample. To confirm the identification of ascorbic acid, a spike-in experiment was
performed (Figure 4.6d). The original urine 1H NMR spectrum is shown in red
and additions with 0.95 and 1.42 µmol ascorbic acid are shown in green and blue,
respectively. Last, a STOCSY was performed on the raw (including δ 6.4 to 4.5)
spectra of the subset to confirm the correlation between the different signals of
ascorbic acid (δ 4.52 (d), 4.03 (ddd) and 3.74 (m)) in the data (Figure 4.7).
Here it has been shown how the ascorbic acid concentration in the urine is
possibly associated with higher BMI (Figure 4.1b). This appears to contradict
previous results where ascorbic acid (vitamin C) was found to be negatively asso-
ciated with BMI in plasma [215]. In order to verify this observation, the correlation
of the intensity of the ascorbic acid 1H NMR signals from spectra in the subset
with various sources of vitamin C was calculated. Urinary ascorbic acid (n=33)
was found to be significantly correlated with the supplemental vitamin C intake
(r = 0.451, P = 0.013), as reported in the participant questionnaire data. It was
not significantly correlated to total vitamin C intake (P = 0.52) or fizzy drink
consumption (P = 0.27). It has been shown that the fractional urinary excretion
of ascorbic acid relative to the vitamin C supplement intake for healthy humans for
dosages well above the daily recommended amount is close to 100% [216], which
is what might be happening here. However, in order to determine if the reported
vitamin C intake is accurate, a separate experiment would have to be conducted
where dietary intake would be controlled, as is recommended for most profiling
studies [217].
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Figure 4.7: 1D-STOCSY of the subset using unprocessed data, the driver variable
is indicated by the red circular marker. Shows there is also correlation with the
ascorbic acid doublet at δ 4.52. Confirms findings obtained with the processed
data set.
4.3.4 Comparison of STORM with STOCSY and stability
selection
In the MWAS three signals, all inversely associated with BMI, were found that
belong to N -methyl nicotinate (NMNA), δ 9.13 (s), 8.84 (t) and 4.45 (s). However
the fourth NMNA signal (t), at δ 8.09, was not found to be significantly associated
with continuous BMI. To investigate whether the resonances indeed correspond to
NMNA, STORM was used to visualize the structural associations. The results
were compared with STOCSY in Figure 4.8a. Each coordinate on the scatterplot
is a combination of the correlation of a variable with the driver at δ 8.84 obtained
with STOCSY (x-axis) and STORM (y-axis). NMNA is shown in orange and the
variables from two other metabolites that highly correlate with NMNA are shown
in light blue (unknown metabolite) and green (hippuric acid). For clarity, each
metabolite peak is denoted by a different symbol, as shown in the legend. The δ
8.84 peak from the spectrum with the highest peak intensity was used as reference
for STORM. For each of the four groups, the fourth being the remainder of all
data point shown in dark blue, a kernel density estimate (KDE) was calculated
and shown on the top for STOCSY and on the right for STORM. The KDE shows
there is less overlap in the distributions of NMNA with the other metabolites
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when using STORM than with STOCSY, this means that the NMNA triplet at
δ 8.09 now has the same range of correlation coefficients as other NMNA signals.
The reduced significance of the triplet in the analysis is most likely caused by
the fact that it has a lower intensity (CH signal) and it is obscured by other
signals (residual variation) after visual inspection of the spectra. This shows how
STORM is able to more accurately visualize structural correlations in the data
set compared to STOCSY. As expected, the scatterplot in Figure 4.8a also shows
how, in general, auto-correlations calculated for the subset are higher compared
to the complete data set. If the need arises to reduce the number of correlations
statistical shrinkage, as described previously, can be employed.
As STORM uses extra information, the reference signal, to show structural as-
sociations, the relic should always be interpreted with some caution. The recently
proposed stability selection [93] does not rely on user input as it aims to find a
subset of samples using a resampling approach, for instance for regression its goal
is to find a resampled subset that has a more significant association with Y than
does the original data. This is a robust approach that ensures the problem is
not underestimated while retaining the same statistical power. Figure 4.8b shows
that there is a stronger linear relation between the correlation coefficients obtained
with STOCSY and stability selection, this suggests they both provide the simi-
lar information. When compared to Figure 4.8a it is clear that STORM, which
uses the multiplet structure to find the optimal subset, is able to show structural
associations more clearly.
However, stability selection was run 1,000,000 times using resampling with
replacement (bootstrapping) and in theory it should be able to find the same
subset as STORM if it were run long enough. STORM finished in seconds (<2s)
whereas stability selection took well over 10 minutes on a PC with a 3.4 GHz
CPU and 16 GB RAM. However, when comparing STORM with stability selection
for the NMNA example (Figure 4.8), it becomes clear that STORM outperforms
stability selection in terms of the end result as well as time-wise. It is worth to note
that when the sample size gets smaller, it will be become feasible to use stability
selection.
Another example, as shown in Figure 4.9, illustrates how STORM can help
to distinguish between structural and non-structural correlations, for instance be-
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tween highly correlated metabolites in the same pathway. It is known that the
urinary concentrations of 4-cresyl sulfate (4CS) and phenylacetylglutamine (PAG)
are highly correlated in humans due to their formation from proteins and aro-
matic amino acids by gut microbiota [78]. This can be seen in the 1D-STOCSY
of a PAG triplet at δ 2.27. Figure 4.9a,b show parts of the pseudo spectrum for
the aromatic (a) and aliphatic (b) region. The result of STORM is shown in Fig-
ure 4.9c,d. Using a subset of spectra that contain the PAG triplet (n=89) STORM
gives a clearer description of structural correlations and show less inter-molecular
correlations compared to a STOCSY using all available spectra (n=1880), showing
STORM is able to clearly differentiate PAG from 4CS.
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Figure 4.8: Comparison of STOCSY, STORM and stability selection (1,000,000
bootstrap resamplings) for the identification of N -methyl nicotinate (NMNA) sig-
nals in the INTERMAP BMI non-diabetic US data set. (a) Scatterplot of corre-
lations determined by STOCSY (x-axis, n=1,880) and STORM (y-axis, n=112)
using an NMNA peak at δ 8.84 as driver. (b) Scatterplot of correlations determined
by STOCSY (x-axis, n=1,880) and stability selection (y-axis, n=1,880) using an
NMNA peak at δ 8.84 as driver. For every axis the kernel density estimation of the
distribution of each class is shown in the same colour on the opposite side. NMNA
is shown in orange, hippuric acid in green, an unknown metabolite in light blue
and all other variables in dark blue. For each of the metabolites, each signal is
shown with a different symbol. For clarity, each distribution has been normalized
to the same total area. It shows that the density estimate of NMNA overlaps less
with others in STORM compared to STOCSY.
137
CHAPTER 4. STORM
Figure 4.9: Phenylacetylglutamine (PAG; signals shown here: m-CH (δ 7.42),
o-CH/p-CH (δ 7.36), CγH2 (δ 2.26), CβH2 (δ 2.11), CβH2 (δ 1.93)) relic shows
no influence of 4-cresyl sulfate (4CS; m-CH (δ 7.28), o-CH (δ 7.20), p-CH3 (δ
2.35)) in the INTERMAP non-diabetic US data set. Analysis of structural corre-
lations of PAG (driver peak = δ 2.27, P -value threshold = 10−10). (a) STOCSY
(n=1880) shown for aromatic region and (b) aliphatic region (driver indicated with
a red arrow). (c) Relic (n=89) shown for aromatic region and (d) aliphatic region
(driver indicated with a red arrow). Other well-known metabolites in these re-
gions include hippuric acid (Hip; o-CH (δ 7.84), p-CH (δ 7.64), m-CH (δ 7.55)),
4-hydroxyphenylacetic acid (HPA; o-CH (δ 7.16), m-CH (δ 6.85)) and succinic
acid (Succ; 2xCH2 (δ 2.41)).
4.3.5 Extension of STORM to two-dimensional data
A set of 203 J-Res NMR spectra from the COMET study [218] were used to
illustrate the applicability of STORM in two dimensions. Figure 4.10 illustrates
how STORM2 (see Algorithm 3 for pseudo code) is preferred over STOCSY to
give a clearer description of the structural associations. Figure 4.10a shows a J-
Res STOCSY analysis using F2 δ 3.55 and F1 -0.0046 ppm as driver peak. It
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shows many significant, based on a Bonferroni threshold, correlations with the
driver peak. To reduce the number of significant correlations a shrinkage-type
approach, recently applied to genomic data, was used: the correlation adjusted t
(cat)-scores [119]. CAT-scores are t-scores that have been de-correlated; in essence
each correlation is now independent of other tests (scaled down). Figure 4.10b
shows the effect of this using a P -value threshold of 0.05 for the STOCSY analysis;
it appears the signal of interest is a doublet. Figure 4.10c shows the pseudo-
spectrum obtained with STORM2. It shows two doublet of doublets at δ 3.55 and
3.65. In a previous study of COMET data it has been confirmed as glycerol [219].
Figure 4.10: Application and benefit of STORM compared to STOCSY for 2D
data. (a) Shows a STOCSY of a peak at F2 δ 3.55 and F1 -0.0046 ppm of 203 J-
Res NMR spectra of blood serum samples from the COMET study. The Bonferroni
threshold is P = 7.31×10−8. (b) STOCSY of the same signal as in a, using the
cat-scores to calculate the P -values. (c) Shows the relic (n=100) after application
of STORM with cat-scores. Relic shows two doublet of doublets at δ 3.65 and 3.55
that belong to glycerol.
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Algorithm 3 Pseudo code of STORM2
Require: X is an [p1,p2,n] matrix, ref is [p1,p2] and b is a binary matrix ([p1,p2])
indicating the variables of interest – where n is the number of samples, p1 the
first dimension of 2D data and p2 the second dimension
1: l←∑ b
2: Y ← ref(b) % vector sized [l, 1]
3: Y ← Y −
∑
Y
l
4: for k = 1 to n do
5: Xn← X:,:,k % matrix sized [p1, p2]
6: Xb← Xn(b) % vector sized [l, 1]
7: Xb← Xb−
∑
Xb
l
8: xXb ←
√∑l
j=1Xb
2
i
9: rk ← corr (Xb, Y )
10: pk = 2× tcdf
(
−
∣∣∣rk ×√ l−21−r2k ∣∣∣ , l − 2)
11: if rk > 0 then
12: s 3 k
13: end if
14: end for
15: p← p (s)
16: order ← sort p % sort p in ascending order
17: s← s (order)
18: if ns < #s then
19: s← s(1 to ns)
20: end if
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4.4 Discussion
Uncovering the identity of unknown spectroscopic signals is a critical step in large
MWAS and metabonomics studies. Established methods such as STOCSY can
fail to uncover the identity of rare low-concentration signals due to the large vari-
ability in human biofluid samples. It has been shown how subset selection can
improve visualization of structural correlations using STORM. Unlike currently
used statistical spectroscopy methods, STORM is not influenced by other signals
and noise as it iteratively learns not to include them in the subset. However, lo-
cal misalignments in spectra can lead to finding a smaller subset of samples than
those that contain the signal of interest. Aligning peaks beforehand can improve
results from statistical spectroscopy methods [220], this could possibly improve
STORMs ability to find the optimal subset. Alternatively, the relic can be used
as reference for alignment after the first run of STORM and the subsequent use of
STORM on the aligned data set may result in a subset with all spectra containing
the metabolite.
The choice of the initial reference and spectroscopic tool are very flexible, be-
cause STORM uses a scale-invariant similarity measure (correlation). The refer-
ence can thus be part of a single spectrum, regression coefficients or other parame-
ters that resemble a signal. Aside from recovering rare signals, it was demonstrated
how STORM also improves the visualization of more abundant signals. STORM
is an important advance in biomarker discovery as often there are 1H NMR signals
that remain unidentified due to their low concentration and/or natural occurrence.
STORMs applicability is not limited to 1D-NMR data, as it can more clearly ex-
tract structural information from 2D data was well. Thus STORM could be used
for any type of data where there is interpretable correlation present amongst vari-
ables, such as HPLC-UV and CE-UV, as well as 2D data such as two dimensional
NMR techniques (J-Res, TOCSY, COSY, and HSQC), LC-MS, GC-MS, CE-MS
and (other) MS/MS experiments.
STORM should, however, ideally be used to augment spectroscopic data inter-
polation to aid in the identification of structural unknowns in spectral data. Three
basic strategies can be followed to identify unknown metabolites:
1) The average 1H NMR spectrum of the data or regression coefficients can be
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used as reference for STORM and the iterative recovery procedure can be used to
obtain a subset if there is no information on the type of multiplet, as has been
described in Algorithm 2.
2) Alternatively, a (hierarchical) clustering algorithm (see section 2.1.10) can be
applied on data of a small region around the unidentified metabolite. Then a spe-
cific cut-off for the dendrogram can be determined using the modularity [174–176]
of the clustering tree (see section 2.4.5) and the average spectrum of each cluster
can be then used as reference for STORM. This is a fast and intuitive procedure,
that can also be automated, to select a reference signal that may be free of overlap
and thus provide a clearer spectroscopic signature.
3) If more information about the unidentified signal is available, for instance if re-
gression coefficients or STOCSY indicate a specific type of multiplet, a spectrum
containing the multiplet can be chosen (after visual inspection) as reference. Or
the multiplet can be generated from Lorentzian signals, see Equation 4.2. Then
a single iteration would suffice and the significance threshold for inclusion can be
a Bonferroni-corrected threshold [111] or alternatively one of the False Discovery
Rates [112, 114]. However, it is important to note that while in theory 1H NMR
signals have a Lorentzian peak shape, in practice the peaks are most likely not
perfectly Lorentzian, owing to acquisition and processing parameters and noise. A
solution for this, provided the shimming has been done properly, is to use the TSP
peak instead of a pure Lorentzian to generate a multiplet if the choice is made to
not use a single spectrum as reference.
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Metabolic Signatures of Human
Obesity in Two Western
Populations
Summary
Obesity is a major public health problem worldwide. Metabolic profiling by 1H
Nuclear Magnetic Resonance (NMR) spectroscopy and ion exchange chromatogra-
phy of 24hr urine samples is used to uncover metabolic biomarkers of obesity at the
systems level among 1,880 U.S. and 444 U.K. participants from the INTERMAP
epidemiologic study. Metabolic profiling of 24hr urine samples collected on average
three weeks apart show largely stable patterns of metabolite excretion associated
with obesity. Metabolome-wide analysis by 1H NMR of the U.S. samples identifies
20 urinary metabolites, clustered in inter-connecting metabolic pathways, signifi-
cantly associated (P = 5.9×10−7 to 2.0×10−36) with body mass index (BMI), 17
of which replicate in the U.K. samples. The majority of metabolic biomarkers are
novel with respect to discriminations of obesity phenotypes and include trimethy-
lamine and 4-cresyl sulfate (gut microbial co-metabolites), dimethylglycine (be-
taine oxidation pathway product), succinate and citrate (tricarboxylic acid cycle
intermediates), ketoleucine and the ketoleucine to leucine ratio (skeletal muscle mi-
tochondrial metabolism), and ethanolamine and 3-methylhistidine (skeletal muscle
turnover). Together, urinary metabolites account for up to 37% (U.S.) and 32%
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(U.K.) of population BMI variance. Multiple BMI-metabolite relationships are
mapped as part of an integrated systems network that describes the metabolic
disturbances and extensive homeostatic signature of human obesity. A level of
new systems complexity is revealed suggesting that the overwhelming BMI de-
terminants are the interactions of symbiotic microbial, dietary and other lifestyle
activities that extend the molecular view of obesity beyond what can be measured
using genetic studies in the general population.
5.1 Introduction
Rates of obesity and overweight have been rising worldwide in recent years and
now affect a large proportion of the adult population in the U.S.A., U.K. and many
other countries [58, 221, 222]. Obesity is associated with increased mortality from
heart disease, stroke, DM and cancer, contributing to nearly 3 million deaths per
year worldwide [58, 222]. Of the major non-communicable risk factors associated
with global disease burden, only the prevalence rates of obesity and fasting blood
glucose have not dropped in any country since the 1990s, indicating the appar-
ent failure of prevention strategies for public health [221]. Therefore, a better
understanding of the social, environmental, and genetic factors that influence obe-
sity, gene-environment interactions, together with the effects of obesity on human
metabolism, is needed to help control and prevent the obesity epidemic. Metabo-
nomics [12] offers a powerful means of capturing information at the systems level,
reflecting both genetic (host, microbial) and environmental influences to help un-
derstand the metabolic disturbances and pathways associated with chronic disease
[24, 223]. For example, the use of the MWAS approach is demonstrated to discover
novel molecular biomarkers associated with inter-individual blood pressure varia-
tion and cardiovascular disease risk [39]. Here, this approach is pursued further to
elucidate the metabolic signatures associated with BMI and obesity.
Specifically, a novel network model is constructed to help elucidate the con-
certed actions of multiple pathways and compartments, and their systemic inter-
connections with diet and gut microbial activities. The aim is to capture the
totality of metabolic information – whether on the causal pathway to, or as a
consequence of, obesity – to characterize the homeostatic metabolic signature of
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obesity. In this way the underlying metabolic disturbances, pathways and connec-
tivities associated with obesity are revealed by taking a systems level approach
which may give new insights into possible preventive approaches and treatments.
Untargeted urinary 1H NMR spectroscopy is used together with targeted anal-
yses of urinary amino acids by ion exchange chromatography, because of the known
importance of amino acids in obesity, especially the branched-chain amino acids
(BCAAs) [224–227]. The few previous metabolic phenotyping studies on human
obesity have mostly focused on serum or plasma metabolite profiles [225–229], but
here a unique population-based dataset of timed 24hr urine samples from the IN-
TERMAP epidemiologic study [73] is analysed. The use of 24hr urine samples has
the advantage of capturing the end-products of metabolism integrated over a 24hr
period.
Data on 1,880 individuals (962 men, 918 women) aged 40-59 years from the
eight U.S. INTERMAP population samples were used, with a replication dataset of
444 individuals (245 men, 199 women) aged 40-59 from the two U.K. INTERMAP
population samples [73] (Figure 5.1, Tables 5.1, 5.2 and 5.3). Two 24hr urine
samples were obtained per person, on average three weeks apart, giving data on
stability of metabolite excretion patterns over time. Height and weight measure-
ments and extensive covariate information including data on energy and nutrient
intakes (89 nutrients) based on four trained interviewer administered, multi-pass
24hr dietary recalls per person were also obtained [73].
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Table 5.1: Descriptive data on population samples and ethnicities for the
U.S. and U.K. INTERMAP study populations.
U.S. population a: Men Women Total
Population sample N (%) N (%) N (%)
Baltimore 121 (12.6) 103 (11.2) 224 (11.9)
Chicago 151 (15.7) 147 (16.0) 298 (15.9)
Corpus Christi, Hispanic 103 (10.7) 102 (11.1) 205 (10.9)
Corpus Christi, non-Hispanic 118 (12.3) 115 (12.5) 233 (12.4)
Honolulu 115 (12.0) 113 (12.3) 228 (12.1)
Jackson 117 (12.2) 114 (12.4) 231 (12.3)
Minneapolis 120 (12.5) 116 (12.6) 236 (12.6)
Pittsburgh 117 (12.2) 108 (11.8) 225 (12.0)
Ethnicity
White, non-Hispanic 564 (58.6) 493 (53.7) 1057 (56.2)
African-American 135 (14.0) 168 (18.3) 303 (16.1)
Japanese 115 (12.0) 115 (12.5) 230 (12.2)
Hispanic, white 62 (6.4) 70 (7.6) 132 (7.0)
Hispanic, non-white 47 (4.9) 40 (4.4) 87 (4.6)
Other 39 (4.1) 32 (3.5) 71 (3.8)
U.K. population b: Men Women Total
Population sample N (%) N (%) N (%)
Belfast 120 (49.0) 86 (43.2) 206 (46.4)
West Bromwich 125 (51.0) 113 (56.8) 238 (53.6)
Ethnicity
White, non-Hispanic 228 (93.1) 190 (95.5) 418 (94.1)
African-Caribbean 5 (2.0) 2 (1.0) 7 (1.6)
Indian (sub-continent) 12 (4.9) 6 (3.0) 18 (4.1)
Other Asian 0 (0) 1 (0.5) 1 (0.2)
aExcluding metabolic outliers based on Hotelling’s T2 test (n=132) and participants
with doctor-diagnosed DM (n=152).
bExcluding metabolic outliers based on Hotelling’s T2 test (n=47) and participants
with doctor-diagnosed DM (n=5).
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Table 5.2: Descriptive data of population, lifestyle and dietary variables for
962 men and 918 women in the U.S. INTERMAP study population.
U.S. population a: Men Women Total
Variables b Mean (SD) Mean (SD) Mean (SD)
Age, years 48.9 (5.4) 48.9 (5.4) 48.9 (5.4)
Body mass index, kg/m 28.9 (5.0) 28.3 (6.4) 28.6 (5.7)
Physical activity, hrs/day 3.5 (3.3) 3.0 (3.0) 3.2 (3.2)
Education, years 15.5 (3.1) 14.7 (2.9) 15.1 (3.0)
Total energy, kcal/day 2609.6 (695.8) 1869.1 (465.8) 2248.0 (700.4)
Animal protein, g/day 64.7 (24.7) 45.6 (16.9) 55.4 (23.3)
Vegetable protein, g/day 31.9 (11.5) 24.3 (8.3) 28.2 (10.8)
Cholesterol, mg/day 341.8 (169.4) 236.2 (114.5) 290.2 (154.5)
Total SFA, g/day 32.7 (13.4) 22.9 (9.2) 27.9 (12.6)
Total MFA, g/day 37.4 (14.0) 25.8 (9.9) 31.7 (13.5)
Total PFA, g/day 20.6 (8.4) 14.9 (6.4) 17.8 (8.0)
Total sugar, g/day 172.9 (72.0) 129.8 (47.7) 151.9 (65.0)
7-Day alcohol record, g/day 9.5 (14.5) 3.2 (6.6) 6.4 (11.8)
Starch, g/day 143.8 (47.0) 106.6 (32.6) 125.6 (44.6)
Calcium, mg/day 889.3 (400.7) 699.9 (316.4) 796.8 (374.1)
Phosphorus, mg/day 1486.2 (452.6) 1094.4 (329.6) 1294.9 (442.9)
Magnesium mg/day 363.4 (114.5) 272.6 (87.4) 319.1 (111.8)
Sodium, mg/day 4196.4 (1406.7) 3048.2 (931.5) 3635.7 (1328.6)
Potassium, mg/day 3310.8 (1050.1) 2514.3 (780.8) 2921.9 (1010.0)
Iron, mg/day 19.4 (8.1) 14.3 (5.1) 16.9 (7.2)
Urinary creatinine, mmol/24hr 16.4 (3.4) 10.5 (2.1) 13.5 (4.1)
N (%) N (%) N (%)
CVD history c 85 (8.8) 68 (7.4) 153 (8.1)
Medication for HBP 177 (18.4) 192 (20.9) 369 (19.6)
Lipid lowering drug use 72 (7.5) 45 (4.9) 117 (6.2)
NSAIDs use 88 (9.1) 107 (11.7) 195 (10.4)
Supplement use 464 (48.2) 521 (56.8) 985 (52.4)
Special diet 106 (11.0) 176 (19.2) 282 (15.0)
Smoking 170 (17.7) 120 (13.1) 290 (15.4)
Body mass index class d N (%) N (%) N (%)
Underweight 3 (0.3) 2 (0.2) 5 (0.3)
Normal weight 199 (20.7) 349 (38.0) 548 (29.1)
Overweight 430 (44.7) 269 (29.3) 699 (37.2)
Moderately obese 232 (24.1) 158 (17.2) 390 (20.7)
Severely obese 98 (10.2) 140 (15.3) 238 (12.7)
aExcluding metabolic outliers based on Hotelling’s T2 test (n=132) and participants
with doctor-diagnosed DM (n=152).
bMean of dietary recalls corresponding to both 24hr urine collections.
cDiagnosed heart disease/condition.
dDefined as underweight (BMI < 18.5 kg/m2), normal weight (18.5 ≤ BMI < 25.0
kg/m2), overweight (25.0 ≤ BMI < 30.0 kg/m2), moderately obese (30.0 ≤ BMI < 35.0
kg/m2) and severely obese (BMI ≥ 35.0 kg/m2).
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Table 5.3: Descriptive data of population, lifestyle and dietary variables for
245 men and 199 women in the U.K. INTERMAP study population.
U.K. population a: Men Women Total
Variables b Mean (SD) Mean (SD) Mean (SD)
Age, year 49.5 (5.6) 48.5 (5.6) 49.1 (5.6)
Body mass index, kg/m2 27.6 (3.9) 27 (5.3) 27.3 (4.5)
Physical activity, hours per day 2.4 (2.7) 2 (2.1) 2.2 (2.5)
Education, years 13.3 (3.1) 12.3 (3) 12.8 (3.1)
Total energy, kcal/day 2473.5 (610.3) 1840.3 (423.6) 2189.7 (620.2)
Animal protein, g/day 57.6 (23.2) 45.4 (15.6) 52.1 (21)
Vegetable protein, g/day 36.6 (10.8) 27.1 (6.9) 32.3 (10.4)
Cholesterol, mg/day 296.8 (140.1) 218.7 (102.1) 261.8 (130.3)
Total SFA, g/day 34.1 (14.1) 25.6 (10.5) 30.3 (13.3)
Total MFA, g/day 31.4 (10.9) 22.6 (8.2) 27.5 (10.8)
Total PFA, g/day 17.7 (7.3) 12.5 (4.9) 15.4 (6.8)
Total sugar, g/day 117.9 (44.6) 98.3 (37) 109.1 (42.5)
7-Day alcohol record, g/day 19.8 (21.9) 8.8 (11.8) 14.9 (18.8)
Starch, g/day 167.2 (50.2) 121.4 (30.4) 146.6 (48.2)
Calcium, mg/day 1014.5 (348.5) 853.8 (249.8) 942.4 (318.1)
Phosphorus, mg/day 1560.3 (434.7) 1224.2 (275.1) 1409.7 (407.3)
Magnesium mg/day 359.8 (95.6) 278.4 (64.5) 323.4 (92.4)
Sodium, mg/day 3848.6 (1208.9) 2923.3 (771.4) 3433.9 (1132.8)
Potassium, mg/day 3712.9 (910.6) 3021.8 (666.7) 3403.1 (879.6)
Iron, mg/day 14.8 (4.4) 11.2 (3) 13.2 (4.2)
Urinary creatinine, mmol/24hr 15 (2.8) 10.1 (2) 12.8 (3.5)
N (%) N (%) N (%)
CVD history c 24 (9.8) 18 (9.0) 42 (9.5)
Medication for HBP 34 (13.9) 23 (11.6) 57 (12.8)
Lipid lowering drug use 22 (9.0) 14 (7.0) 36 (8.1)
NSAIDs use 11 (4.5) 3 (1.5) 14 (3.2)
Supplement use 71 (29.0) 96 (48.2) 167 (37.6)
Special diet 43 (17.6) 43 (21.6) 86 (19.4)
Smoking 40 (16.3) 37 (18.6) 77 (17.3)
Body mass index class d N (%) N (%) N (%)
Underweight 0 (0) 1 (0.5) 1 (0.2)
Normal weight 56 (22.9) 78 (39.2) 134 (30.2)
Overweight 137 (55.9) 77 (38.7) 214 (48.2)
Moderately obese 40 (16.3) 26 (13.1) 66 (14.9)
Severely obese 12 (4.9) 17 (8.5) 29 (6.5)
aExcluding metabolic outliers based on Hotelling’s T2 test (n=47) and participants
with doctor-diagnosed DM (n=5).
bMean of dietary recalls corresponding to both 24hr urine collections.
cDiagnosed heart disease/condition.
dDefined as underweight (BMI < 18.5 kg/m2), normal weight (18.5 ≤ BMI < 25.0
kg/m2), overweight (25.0 ≤ BMI < 30.0 kg/m2), moderately obese (30.0 ≤ BMI < 35.0
kg/m2) and severely obese (BMI ≥ 35.0 kg/m2).
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5.2 Materials and methods
5.2.1 Study design
The results here relate to 1,880 of the 2,195 U.S. INTERMAP participants used
in the discovery phase and 444 of the 501 U.K. INTERMAP participants used in
the validation phase, the exclusions are outlined in Figure 5.1. See sections 4.2.1
and 4.2.5 for descriptions of the NMR acquisition parameters and pre-treatment
of the INTERMAP NMR data.
5.2.2 Data collection and pre-treatment (IEC)
Additionally, the urine samples of the first urine collection were analysed with
(Cat)Ion-Exchange Chromatography (IEC) to quantify the concentration of amino
acids and related compounds using the Biochrom 20+ and 30+ Amino Acid Anal-
ysers with Midas auto-samplers (Biochrom Ltd., Cambridge, U.K.). The amino
acids and related compounds were separated using mobile phases with different
pH and by varying temperature. Ninhydrin was used to derivatise the compounds
after separation, followed by measuring the absorbance at 570 nm of the coloured
complexes. EZChrom Elite (Agilent Technologies, Stockport, U.K.) was used to
integrate the peaks automatically and calculate the concentration using an internal
standard (2,4-diaminobutyrate) as a reference.
The robustness of the method was checked using quality control samples and
compounds were excluded where the variation in concentration was bigger than
±2.5 SD. Zeros in the data matrix were replaced by the lowest non-zero value in
each column prior to log-normalization.
5.2.3 Metabolite identification
STOCSY [38] and STORM [230] were used to identify structural correlations in
the data. A Bruker reference library was used to assign the chemical shifts to
metabolites. Confirmation of metabolite identification was done using a combina-
tion of strategies. Specimens containing the largest amount of each unidentified
metabolite were selected using an in-house MATLAB script and/or STORM. A
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catalogue of standard 1D 1H NMR pulse sequence with water peak pre-saturation
(noesypresat) and 2D NMR methods such as 2D J-Res, 2D 1H-13C HSQC, 1H-1H
COSY, 1H-1H TOCSY and diffusion-edited NMR experiments were applied to the
selected specimens to confirm the signals and their chemical shifts. Pre-treatment
of urine with Solid-Phase Extraction (SPE) methods was carried out for some
metabolites, to simplify urine specimens and isolate specific signals according to
their polarity and dissociation constant (pK). All SPE fractions were analysed by
1D NMR spectroscopy. Metabolites were confirmed by in situ spiking experiments
using authentic chemical standards. The strategy used for each identified metabo-
lite is shown in Table 5.4. Ascorbate has been omitted from the results, as the
main source of urinary ascorbate is supplemental vitamin C [230].
Table 5.4: Identification strategy for each 1H NMR-derived metabolite in-
cluding identified chemical shifts.
Metabolite δ (multiplicity) Confirmed by
Urinary glycoproteins 2.04 (s) Diffusion-edited 1H NMR
Tyrosine 3.06 (dd), 3.20 (dd), 3.94 (dd), 6.91 (d), 7.19 (d) STORM, SPE+1H NMR
4-Hydroxymandelate 4.93 (s), 6.91 (d), 7.30 (d) 1D&2D NMR, SPE+1H NMR, 1H NMR spike
Ketoleucine 0.94 (d), 2.10 (m), 2.62 (d) STOCSY, SPE + 1H NMR, HSQC, 1H NMR spike
Succinate 2.41 (s) STOCSY, HSQC, 1H NMR spike
N -acetyl neuraminate 2.06 (s) Diffusion-edited 1H NMR, 1H NMR spike
Hippurate 3.98 (d), 7.54 (t), 7.65 (t), 7.84 (d) STOCSY, 1D&2D NMR, SPE+1H NMR, LC-NMR
3-Methyl histidine 3.23 (dd), 3.31 (dd), 3.74 (s), 3.96 (dd), 7.14 (s), 8.07 (s) STORM, 1H NMR spike
Leucine 0.96 (2xd), 1.71 (m), 3.73 (t) 1D&2D NMR, SPE+1H NMR
Glutamine 2.14 (m), 2.46 (m), 3.77 (t) STORM, SPE+1H NMR
4-Cresyl sulfate 2.35 (s), 7.20 (d), 7.28 (d) STORM, 1D&2D NMR ,SPE+1H NMR
Pseudouridine 3.74 (dd), 3.85 (dd), 4.03 (m), 4.16 (t), 4.30 (t), 7.67 (s) STORM, SPE+1H NMR, 1H NMR spike
Creatinine 3.04 (s), 4.06 (s) STOCSY, 1D&2D NMR
2-Hydroxyisobutyrate 1.36 (s) STOCSY, 1H NMR spike
N -methyl nicotinate 4.45 (s), 8.09 (t), 8.84 (t), 9.13 (s) STOCSY, SPE+1H NMR, 2D NMR
Citrate 2.52 (d), 2.66 (d) STOCSY, STORM, 1D&2D NMR
Trimethylamine 2.88 (s) STORM, 1D&2D NMR
3-Hydroxymandelate 4.92 (s), 6.87 (ddd), 6.92 (t), 6.98 (d), 7.29 (t) STOCSY, STORM, HSQC, 1H NMR spike
Lysine 1.48 (m), 1.73 (q), 1.91 (m), 3.02 (t), 3.76 (t) STOCSY, 1H NMR spike , SPE+1H NMR
Ethanolamine 3.15 (t), 3.83 (t) STORM, 1H NMR spike
Dimethylglycine 2.93 (s) 1D&2D NMR
5.2.4 Statistical analysis
Regression models using the identified metabolites and amino acids and related
compounds were run using different sets of confounding variables. Model 1 ad-
justs for population descriptive factors age, gender and population sample. Model 2
for lifestyle factors cardiovascular disease history (heart disease/condition), mod-
erate to heavy physical activity (hours/day), medication for hypertension, pre-
scribed lipid lowering drugs, non-steroidal anti-inflammatory drug (NSAID) use,
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supplement use, special diet, smoking status and years of education. Model 3
for dietary factors total energy intake per day (kcal/day), dietary animal protein
(g/day), vegetable protein (g/day), cholesterol (mg/day), total saturated fatty
acids (g/day), total monounsaturated fatty acids (g/day), total polyunsaturated
fatty acids (g/day), total sugar (g/day), 7-day alcohol (g/day), starch (g/day), cal-
cium (mg/day), phosphorus (mg/day), magnesium (mg/day), sodium (mg/day),
potassium (mg/day) and iron (mg/day). Model 4 for 24hr urinary creatinine
(mmol/day).
For consistency, the results are presented as 25th to 75th centile difference in
BMI per unit change in metabolite. Using the U.S. population samples as the
discovery set, multiple linear regression is performed of individual BMI against
1) each 1H NMR detected spectral variable and 2) the urinary amino acids and
related compounds detected by IEC. Metabolite significance is determined using
different P -value thresholds for untargeted NMR discovery and targeted amino
acid analysis. For NMR, each metabolite has to be significant independently from
population and lifestyle factors (Model 1 and Model 2 ) and for both visits (also see
section 4.2.6). Metabolites that do not pass the thresholds for Model 1 and Model
2 are not included, unless stated otherwise. For IEC, a Bonferroni correction [111]
is used.
Bootstrap estimated 95% confidence intervals are listed for each test. Boot-
strap estimated 95% confidence intervals (CIs) of the BMI 25th to 75th centile
difference in metabolite levels (‘BMI change’) are estimated using 1,000 bootstrap
resamplings of the data and the reported P -value for the BMI change corresponds
to the minimum P -value for all signals corresponding to the identified metabolite.
Additionally, the gender-metabolite interaction with BMI is determined. The
significance of the gender interaction term was based on a Bonferroni correction
[111] for each data set.
The findings based on the U.S. population samples are replicated in the valida-
tion set comprising the two U.K. population samples, using a Benjamini-Hochberg
False Discovery Rate [112] of pFDR<0.05 to determine statistical significance.
Partial Spearman rank correlation, adjusted for Model 1, was used to investi-
gate the associations between the identified metabolites from NMR, amino acids
and related compounds from IEC, and the dietary intake of macro- and micro-
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nutrients. The dietary intake data were clustered with HCA using average linkage
(see section 2.1.10) and the optimal number of clusters was determined using
Equation 2.87. Partial Pearson rank correlation, adjusted for Model 1, was used
to investigate the associations between the identified NMR metabolites between
different visits.
To examine the proportion of BMI variance explained by the identified NMR
metabolites and amino acids and related compounds, a multiple linear regression
model with statistical shrinkage of regression coefficients [231] was constructed
containing all the (significantly associated) urinary metabolites plus the variables
in Model 1, 2 and 3, while ensuring each variable was represented only once in the
model.
5.2.5 Metabolic reaction network
Using MetaboNetworks [194], reactions that occur spontaneously or by means of
an enzyme linked to a human gene were identified in the Kyoto Encyclopaedia of
Genes and Genomes (KEGG) [179]. For each of the reactions, the main reaction
pairs were identified and an adjacency matrix was calculated for all compounds.
The shortest paths between all metabolites significantly associated with BMI were
calculated from the adjacency matrix and a network graph was drawn for all
compounds needed to connect all identified metabolites with the shortest paths.
Metabolites not listed in KEGG or metabolites not linked to other metabolites
using the human set of enzymes are shown by means of a dashed line to indicate
their closest related metabolite in the network. The labels next to the dashed lines
indicate whether it is a one-step reaction (‘1’) or if multiple steps are involved
(‘>1’) linking it to the closest related metabolite.
5.2.6 Metabolite fitting
The signals of 4-cresyl sulfate (4CS) and phenylacetylglutamine (PAG) are known
to overlap with acetaminophen, acetaminophen glucuronide, ibuprofen and hy-
droxyibuprofen [207]. In order to properly assess the BMI association of these two
microbial derivatives of tyrosine (4CS) and phenylalanine (PAG), the peaks from
these metabolites were fitted simultaneously with the NSAID peaks.
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First, a baseline was subtracted by fitting a cubic spline to a broader area
around the peaks using local minima. Then the metabolites are sorted in order
of decreased complexity (most complex multiplet first and singlets last) and si-
multaneously fit all signatures (multiplets) from a metabolite to the spectrum by
calculating the most probable chemical shift by maximizing the correlation of the
spectrum and each signature. When the optimal chemical shift is found, the sig-
natures are fitted to the spectrum while ensuring the fit cannot exceed the original
spectrum at any point (negative residuals are not allowed) while preserving the
ratio between multiple signals from the same metabolite (something that is not
implicitly done by other methods [232]). Next, the integrals of the fitted signatures
were calculated, the fit was subtracted from the spectrum and the next metabolite
is fit.
5.2.7 Validation dataset
Data from 444 U.K. participants were used to validate the findings in the U.S. pop-
ulation samples. The U.K. data were collected using the same sampling protocol
[73], descriptive data of the U.K. population factors are shown in Table 5.3. Linear
regression adjusting for Model 1, 2, 3 and 4 was performed and the Benjamini-
Hochberg False Discovery Rate (FDR) [112] was used to correct for multiple test-
ing. A metabolite was considered to be significantly associated with BMI if the
pFDR < 0.05 for at least Model 1 and Model 2. Only significantly associated
metabolites are included in the assessment of analytical stability and the metabolic
reaction network of the U.K. population samples.
5.3 Results
5.3.1 Untargeted 1H NMR discovery
A series of peaks of multiple metabolites were found to be significantly associated
with BMI as a continuous variable (Table 5.5, Figure 5.2a,b, see full page figure in
Appendix A; P = 5.9×10−7 to 2.0×10−36, first 24hr urine collection). The -log10
P -values and direction of association for the NMR detected metabolites are shown
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in the Manhattan plot (Figure 5.2b) and their correlations with dietary intake
nutrients in Figure 5.3 (abbreviations in Table 5.7 and full page figure in Ap-
pendix A). The significantly associated metabolites, size of associations with BMI
and P -values for the various models are shown in Tables 5.5, 5.8, 5.9 and 5.10; the
associations are not materially changed when dietary intake nutrients are added
to Model 1 and 2 (Table 5.9). The most significant biomarkers relate to a wide
range of biochemical pathways and physiological processes in multiple body com-
partments, as well as interactions between the products of symbiotic human and
microbial genomes.
Some of the urinary metabolites significantly associated with BMI are directly
correlated with dietary intakes. For example, most of the urinary amino acids
are correlated with dietary amino acids and animal protein (in contrast to the
ketoleucine to leucine ratio which is uncorrelated with dietary sources of amino
acids); 3-methylhistidine with fatty acid and animal protein intake, reflecting its
association with meat (muscle fibre) intake [233]; and the strong association of
N -methyl nicotinate, a biomarker of coffee drinking [234], with caffeine intake
(Figure 5.3). For some other metabolites, the observed 24hr urinary excretion
patterns may reflect intrinsic metabolic activity rather than direct correlations
with exogenous sources, given the absence of or largely inverse (for instance, glu-
tamine, pseudouridine, ethanolamine, glycine) associations with dietary intakes.
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Table 5.5: Structurally identified 1H NMR-derived urinary metabolites asso-
ciated significantly with body mass index (BMI) in 1,880 U.S. INTERMAP
participants, adjusted for Model 1.
Visit 1 Visit 2
Metabolite BMI change 95% CI P-value BMI change 95% CI P-value
Urinary glycoproteins 1.97 (1.62;2.32) 2.04×10−36 2.10 (1.79;2.40) 2.93×10−38
Tyrosine + 1.43 (1.14;1.71) 1.35×10−19 1.45 (1.14;1.76) 1.07×10−20
4-hydroxymandelate
Ketoleucine -1.25 (-1.49;-1.04) 2.22×10−19 -1.20 (-1.43;-1.00) 8.75×10−19
Succinate -1.03 (-1.25;-0.79) 3.22×10−18 -0.88 (-1.12;-0.68) 1.79×10−14
N -acetyl neuraminate 1.39 (1.11;1.70) 2.02×10−16 1.44 (1.14;1.75) 1.64×10−17
3-Methylhistidine 1.21 (0.97;1.47) 2.87×10−15 1.06 (0.79;1.39) 1.28×10−15
Hippurate -1.18 (-1.41;-0.96) 1.52×10−14 -1.33 (-1.59;-1.08) 3.14×10−16
Glutamine -1.08 (-1.34;-0.85) 2.64×10−14 -1.04 (-1.32;-0.81) 1.04×10−11
Creatinine 1.34 (1.03;1.64) 9.35×10−13 1.25 (0.94;1.58) 1.10×10−12
Leucine 1.21 (0.92;1.49) 1.16×10−12 1.32 (1.03;1.59) 5.06×10−15
Pseudouridine 1.29 (0.97;1.60) 2.10×10−12 1.35 (1.01;1.70) 9.22×10−13
N -methyl nicotinate -1.24 (-1.49;-0.99) 3.19×10−12 -1.12 (-1.36;-0.86) 7.66×10−11
Citrate -0.82 (-1.01;-0.64) 6.39×10−12 -0.76 (-0.98;-0.59) 7.13×10−12
2-Hydroxyisobutyrate 1.24 (0.68;1.52) 8.95×10−12 1.18 (0.71;1.39) 2.81×10−12
4-Cresyl sulfate -1.12 (-1.39;-0.84) 8.09×10−11 -1.28 (-1.55;-1.01) 2.05×10−13
Trimethylamine 0.82 (0.58;1.05) 2.04×10−09 0.83 (0.62;1.06) 2.06×10−09
Lysine 0.89 (0.63;1.14) 9.27×10−09 0.83 (0.54;1.20) 5.10×10−08
Ethanolamine 0.31 (0.21;0.53) 6.84×10−08 0.22 (0.16;0.39) 7.13×10−08
3-Hydroxymandelate -0.75 (-0.97;-0.53) 1.36×10−07 -0.89 (-1.11;-0.67) 2.17×10−09
Dimethylglycine 0.61 (0.43;0.82) 5.85×10−07 0.71 (0.51;0.96) 6.96×10−08
Table 5.6: Structurally unidentified 1H NMR-derived urinary signals associ-
ated significantly with body mass index (BMI) in 1,880 U.S. INTERMAP
participants, adjusted for Model 1.
Visit 1 Visit 2
δ (multiplicity) BMI change P-value BMI change P-value
1.17 (s) -0.47 2.0×10−06 -0.57 1.4×10−07
1.35 (s) 1.24 9.0×10−12 1.18 2.8×10−12
1.85 (s) -0.81 2.1×10−08 -0.81 4.0×10−08
1.98 (s) -1.04 1.9×10−13 -1.01 6.7×10−12
2.02 (s) -1.18 6.1×10−13 -1.10 1.0×10−09
2.08 (s) 1.28 1.8×10−13 1.40 1.1×10−15
3.34 (s) -0.62 2.6×10−09 -0.53 1.4×10−07
3.38 (s) 0.48 6.3×10−10 0.57 1.6×10−14
6.75 (u) 0.57 6.3×10−09 0.52 1.9×10−07
7.74 (d) 0.56 1.4×10−08 0.62 5.2×10−10
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Figure 5.2: Associations of body mass index (BMI) with urinary metabolites,
U.S. INTERMAP men and women (n=1,880), adjusted for Model 1. (a) Av-
erage 1H NMR spectrum of the first urine collection. Metabolites significantly
associated with BMI are, 1: ketoleucine, 2: leucine, 3: 2-hydroxyisobutyrate,
4: N -acetyl signals from urinary glycoproteins, 5: N -acetyl neuraminate, 6:
4-cresyl sulfate, 7: succinate, 8: glutamine, 9: citrate, 10: trimethylamine,
11: dimethylglycine, 12: lysine, 13: creatinine, 14: 3-methylhistidine, 15:
3-methylhistidine+pseudouridine+ascorbate, 16: ethanolamine, 17: hippurate,
18: ascorbate, 19: pseudouridine, 20: N -methyl nicotinate, 21: tyrosine+4-
hydroxymandelate, 22: 3-hydroxymandelate, U1-U10 unidentified metabolites (see
Table 5.6). (b) Manhattan plot showing for each variable the -log10(P) × sign of
BMI change. Statistically significant variables are coloured red if directly associ-
ated with BMI and blue if inversely associated.
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Figure 5.3: Associations of BMI-related urinary metabolites (Figure 5.2) with
dietary nutrients for the U.S. INTERMAP population, U.S. INTERMAP men and
women (n=1,880). Partial Spearman rank correlation between urinary metabolites
and dietary energy and nutrients, adjusted for Model 1. A Bonferroni threshold of
P < 1.3×10−05 denotes statistical significance. Dietary variables are ordered using
hierarchical cluster analysis of the auto-correlation matrix with average linkage.
The optimal number of clusters (maximal modularity) for the dendrogram was 3.
Labels are given in Table 5.7.
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Table 5.7: Abbreviations of urinary metabolites, urinary
amino acids and related compounds, and dietary nutri-
ents, as shown in Figures 5.3 and 5.4.
Variable name Abbreviation
1-Methyl histidine 1MHis
2-Hydroxyisobutyrate 2HIB
3-Hydroxymandelate 3HM
3-Methyl histidine 3MHis
4-Cresyl sulfate 4CS
4-Hydroxymandelate 4HM
Alanine Ala
Dietary animal protein Anim.Prot.
Arginine Arg
Asparagine Asn
Aspartic acid Asp
Dietary beta-carotene Bcar
Dietary calcium Ca
Dietary caffeine Caff
Carnosine Carn
Dietary cholesterol Chol
Citrate Cit
Creatinine Crea
Dietary copper Cu
Cystine Cys
Dimethylglycine DMG
Energy Energy
Ethanolamine Eta
Dietary alcohol EtOH
Dietary 7-day alcohol EtOH (7day)
Dietary iron Fe
Dietary heme iron Fe (heme)
Continued on next page
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Continued from previous page
Variable name Abbreviation
Dietary fructose FRUC
Dietary galactose GALA
Glutamine Gln
Glutamic acid Glu
Dietary glucose GLUC
Glycine Gly
Hippurate Hip
Histidine His
Isoleucine Ile
Dietary potassium K
Ketoleucine Kleu
Dietary lactose LACT
Dietary long chain omega-3 polyunsaturated fatty acid LC Omega3
Leucine Leu
Lysine Lys
Dietary maltose MALT
Methionine Met
Dietary myristoleic acid MFA 14:1
Dietary palmitoleic acid MFA 16:1
Dietary oleic acid MFA 18:1
Dietary gadoleic acid MFA 20:1
Dietary erucic acid MFA 22:1
Dietary magnesium Mg
Dietary sodium Na
(N -acetyls from) Urinary glycoproteins NAc GP
N -acetyl neuraminic acid NANA
N -methyl nicotinate NMNA
Dietary non-heme iron Nonheme
Dietary omega-3 polyunsaturated fatty acid Omega3
Dietary omega-6 polyunsaturated fatty acid Omega6
Continued on next page
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Continued from previous page
Variable name Abbreviation
Dietary phosphorus P
Dietary linoleic acid PFA 18:2
Dietary linolenic acid PFA 18:3
Dietary stearidonic acid PFA 18:4
Dietary arachidonic acid PFA 20:4
Dietary eicosapentaenoic acid PFA 20:5
Dietary docosapentaenoic acid PFA 22:5
Dietary docosahexaenoic acid PFA 22:6
Phenylalanine Phe
Proline Pro
Pseudouridine Psi
Dietary retinol Reti
Dietary selenium Se
Serine Ser
Dietary capric acid SFA 10:0
Dietary lauric acid SFA 12:0
Dietary myristic acid SFA 14:0
Dietary palmitic acid SFA 16:0
Dietary stearic acid SFA 18:0
Dietary arachidic acid SFA 20:0
Dietary behenic acid SFA 22:0
Dietary butyric acid SFA 4:0
Dietary caproic acid SFA 6:0
Dietary caprylic acid SFA 8:0
Dietary starch Starch
Succinate Succ
Dietary sucrose SUCR
Taurine Tau
Dietary trans-octadecenoic acid TFA 18:1
Dietary trans-octadecadienoic acid TFA 18:2
Continued on next page
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Continued from previous page
Variable name Abbreviation
Threonine Thr
Trimethylamine TMA
Dietary total fatty acids Tot. FA
Dietary total monosaturated fatty acid Tot. MFA
Dietary total polyunsaturated fatty acid Tot. PFA
Dietary total saturated fatty acid Tot. SFA
Dietary total trans-fatty acid Tot. TFA
Dietary total carbohydrate Tot.Carb.
Dietary total dietary fibre Tot.Fibre
Dietary total protein Tot.Prot.
Dietary estimated total sugars Tot.Sugar
Tryptophan Trp
Tyrosine Tyr
Valine Val
Dietary vegetable protein Veg.Prot.
Dietary vitamin A, international units VitA (IU)
Dietary vitamin A, retinol equivalents VitA (RE)
Dietary thiamin VitB1
Dietary vitamin B12 VitB12
Dietary riboflavin VitB2
Dietary niacin VitB3
Dietary pantothenic acid VitB5
Dietary vitamin B6 VitB6
Dietary folate VitB9
Dietary vitamin C VitC
Dietary vitamin E VitE
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Table 5.8: Estimated differences in body mass index (BMI) per 25th to 75th
centile difference in 1H NMR detected significant urinary metabolites of 1,880
U.S. INTERMAP participants adjusted for Model 1 and 2.
Visit 1 Visit 2
Metabolite BMI change 95% CI P-value BMI change 95% CI P-value
Urinary glycoproteins 1.74 (1.44;2.06) 4.61×10−31 1.79 (1.49;2.10) 1.81×10−29
Tyrosine + 1.33 (1.06;1.59) 1.67×10−18 1.37 (1.08;1.68) 3.96×10−20
4-hydroxymandelate
Ketoleucine -1.07 (-1.28;-0.88) 5.95×10−16 -1.03 (-1.23;-0.83) 1.77×10−15
Succinate -0.76 (-0.96;-0.57) 3.49×10−11 -0.65 (-0.86;-0.47) 3.55×10−09
N -acetyl neuraminate 1.37 (1.08;1.70) 3.04×10−16 1.31 (1.01;1.61) 7.00×10−15
3-Methylhistidine 1.06 (0.83;1.31) 3.77×10−13 0.92 (0.67;1.24) 2.47×10−13
Hippurate -0.95 (-1.18;-0.72) 1.28×10−10 -1.15 (-1.39;-0.90) 1.52×10−13
Glutamine -0.73 (-0.95;-0.53) 7.92×10−08 -0.68 (-0.92;-0.46) 4.37×10−06
Creatinine 1.29 (0.96;1.61) 5.91×10−13 1.23 (0.92;1.54) 2.87×10−13
Leucine 1.09 (0.80;1.36) 1.54×10−11 1.20 (0.92;1.47) 1.15×10−13
Pseudouridine 1.08 (0.80;1.40) 5.17×10−10 1.16 (0.85;1.47) 8.47×10−11
N -methyl nicotinate -1.00 (-1.24;-0.74) 8.94×10−09 -0.91 (-1.16;-0.66) 4.79×10−08
Citrate -0.64 (-0.81;-0.46) 1.84×10−08 -0.64 (-0.84;-0.50) 1.51×10−09
2-Hydroxyisobutyrate 0.67 (0.35;1.05) 6.44×10−06 0.65 (0.37;0.99) 6.02×10−06
4-Cresyl sulfate -1.11 (-1.39;-0.84) 9.74×10−12 -1.24 (-1.51;-0.98) 3.62×10−14
Trimethylamine 0.77 (0.54;1.00) 2.87×10−09 0.79 (0.59;1.01) 1.99×10−09
Lysine 0.77 (0.54;1.02) 1.93×10−07 0.78 (0.51;1.09) 6.10×10−08
Ethanolamine 0.28 (0.19;0.48) 2.39×10−07 0.19 (0.12;0.34) 2.05×10−06
3-Hydroxymandelate -0.63 (-0.83;-0.43) 3.11×10−06 -0.73 (-0.95;-0.52) 2.94×10−07
Dimethylglycine 0.57 (0.40;0.79) 5.28×10−07 0.70 (0.48;0.93) 2.68×10−08
Ketoleucine to leucine ratio -0.74 (-1.69;-0.42) 2.10×10−16 -1.60 (-1.82;-1.38) 5.82×10−33
Table 5.9: Estimated differences in body mass index (BMI) per 25th to 75th
centile difference in 1H NMR detected significant urinary metabolites of 1,880
U.S. INTERMAP participants adjusted for Model 1, 2 and 3.
Visit 1 Visit 2
Metabolite BMI change 95% CI P-value BMI change 95% CI P-value
Urinary glycoproteins 1.75 (1.44;2.06) 1.27×10−30 1.77 (1.47;2.08) 2.79×10−28
Tyrosine + 1.25 (1.00;1.52) 8.90×10−17 1.29 (0.94;1.52) 4.04×10−18
4-hydroxymandelate
Ketoleucine -1.20 (-1.42;-1.00) 4.79×10−20 -1.11 (-1.37;-0.96) 3.24×10−18
Succinate -0.66 (-0.84;-0.46) 1.38×10−08 -0.57 (-0.65;-0.28) 1.63×10−07
N -acetyl neuraminate 1.35 (1.06;1.72) 1.28×10−15 1.24 (0.96;1.55) 2.42×10−13
3-Methylhistidine 0.90 (0.65;1.13) 1.05×10−09 0.79 (0.41;0.99) 4.58×10−10
Hippurate -0.77 (-0.97;-0.53) 3.11×10−07 -0.99 (-1.07;-0.58) 1.86×10−10
Glutamine -0.67 (-0.89;-0.48) 6.52×10−07 -0.59 (-0.68;-0.25) 4.85×10−05
Creatinine 1.05 (0.73;1.36) 1.26×10−08 1.02 (0.57;1.19) 2.33×10−09
Leucine 0.84 (0.55;1.14) 3.53×10−07 0.97 (0.60;1.17) 2.94×10−09
Pseudouridine 0.89 (0.59;1.19) 4.11×10−07 1.01 (0.63;1.29) 1.60×10−08
N -methyl nicotinate -0.85 (-1.14;-0.57) 3.75×10−06 -0.82 (-0.92;-0.42) 2.15×10−06
Citrate -0.50 (-0.68;-0.34) 1.23×10−05 -0.53 (-0.58;-0.27) 7.24×10−07
2-Hydroxyisobutyrate 0.55 (0.21;0.93) 2.45×10−04 0.57 (0.27;0.84) 7.84×10−05
4-Cresyl sulfate -1.11 (-1.39;-0.86) 5.24×10−12 -1.25 (-1.54;-1.01) 1.17×10−14
Trimethylamine 0.58 (0.36;0.81) 8.34×10−06 0.61 (0.29;0.73) 4.59×10−06
Lysine 0.59 (0.36;0.82) 9.20×10−05 0.67 (0.38;0.93) 3.20×10−06
Ethanolamine 0.26 (0.17;0.45) 2.26×10−06 0.16 (0.08;0.30) 4.10×10−05
3-Hydroxymandelate -0.53 (-0.74;-0.32) 9.62×10−05 -0.61 (-0.75;-0.35) 2.65×10−05
Dimethylglycine 0.41 (0.22;0.62) 3.51×10−04 0.52 (0.25;0.68) 3.34×10−05
Ketoleucine to leucine ratio -0.69 (-1.62;-0.36) 9.30×10−15 -1.52 (-1.73;-1.27) 1.84×10−30
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Table 5.10: Estimated differences in body mass index (BMI) per 25th to 75th
centile difference in 1H NMR detected significant urinary metabolites of 1,880
U.S. INTERMAP participants adjusted for Model 1, 2, 3 and 4.
Visit 1 Visit 2
Metabolite BMI change 95% CI P-value BMI change 95% CI P-value
Urinary glycoproteins 1.56 (1.30;1.86) 8.08×10−30 1.54 (1.34;1.91) 2.32×10−26
Tyrosine + 0.99 (0.77;1.22) 4.56×10−13 1.07 (0.81;1.31) 1.73×10−15
4-hydroxymandelate
Ketoleucine -1.21 (-1.41;-1.02) 6.74×10−25 -1.10 (-1.35;-0.97) 7.18×10−22
Succinate -0.57 (-0.76;-0.38) 4.91×10−08 -0.46 (-0.59;-0.25) 3.04×10−06
N -acetyl neuraminate 1.30 (1.00;1.61) 1.84×10−17 1.13 (0.92;1.45) 1.30×10−13
3-Methylhistidine 0.57 (0.33;0.79) 2.37×10−05 0.49 (0.23;0.71) 2.62×10−05
Hippurate -0.57 (-0.76;-0.37) 3.20×10−05 -0.77 (-0.89;-0.46) 5.28×10−08
Glutamine -0.52 (-0.71;-0.35) 2.19×10−05 -0.49 (-0.58;-0.19) 1.72×10−04
Creatinine
Leucine 0.50 (0.24;0.73) 8.18×10−04 0.68 (0.41;0.95) 4.48×10−06
Pseudouridine 0.55 (0.28;0.81) 5.44×10−04 0.66 (0.38;0.95) 4.33×10−05
N -methyl nicotinate -0.64 (-0.88;-0.40) 1.05×10−04 -0.69 (-0.74;-0.28) 1.22×10−05
Citrate -0.43 (-0.59;-0.27) 4.35×10−05 -0.47 (-0.51;-0.22) 8.21×10−07
2-Hydroxyisobutyrate 0.43 (0.16;0.76) 1.53×10−03 0.48 (0.17;0.68) 2.38×10−04
4-Cresyl sulfate -0.95 (-1.21;-0.71) 7.60×10−11 -1.05 (-1.34;-0.84) 1.07×10−12
Trimethylamine 0.46 (0.28;0.66) 9.28×10−05 0.55 (0.17;0.56) 5.09×10−06
Lysine 0.39 (0.15;0.62) 4.43×10−03 0.52 (0.23;0.73) 6.15×10−05
Ethanolamine 0.24 (0.15;0.44) 1.10×10−06 0.13 (0.07;0.25) 2.23×10−04
3-Hydroxymandelate -0.39 (-0.58;-0.22) 1.48×10−03 -0.50 (-0.62;-0.26) 1.43×10−04
Dimethylglycine 0.20 (0.05;0.39) 5.06×10−02 0.35 (-0.07;0.43) 2.35×10−03
Ketoleucine to leucine ratio -0.60 (-1.47;-0.30) 8.21×10−14 -1.36 (-1.58;-1.16) 1.02×10−29
5.3.2 Gut microbial metabolism
Gut microbial disorders and microbe-host metabolic activities and signaling abnor-
malities have been implicated in the etiopathogenesis of several common chronic
diseases [20] and premorbid conditions including obesity [235, 236]. Specifically,
there is increasing evidence for a key role of the microbiota in the modulation
and control of immune response [20, 82, 237]. The products of three distinct
gut microbial-host co-metabolic pathways linked to BMI are observed in the U.S.
INTERMAP population.
The first concerns the action of the gut microbiota on dietary choline to produce
trimethylamine (TMA) via choline TMA-lyases [238]. TMA has been linked to the
development of atherosclerosis and cardiovascular disease via subsequent conver-
sion to trimethylamine N -oxide [239] by the flavin-containing monooxygenase-3
enzyme [240]. A higher urinary excretion of TMA (P = 2.0×10−9) with higher
BMI was found (Table 5.5, Figure 5.2a,b). Increased urinary TMA excretion has
been associated with steatosis, fatty liver and insulin resistance in animals fed high
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fat diets [241]. A previously unreported association with BMI (direct) of urinary
dimethylglycine (DMG) was found (P = 5.9×10−7), DMG is another product of
choline degradation and glycine-betaine oxidation [242].
The second pathway relates to distal colonic microbial protein putrefaction and
the metabolism of tyrosine and related compounds. A novel relationship (inverse)
with BMI of the host-gut microbial co-metabolite 4-cresyl sulfate was found (P =
8.1×10−11), which is a bacterial degradation product of tyrosine. Direct associa-
tions of BMI with tyrosine [225, 227, 228] and urinary 4-hydroxymandelic acid (P
= 1.4×10−19), another tyrosine metabolite, were also found. In addition, a pre-
viously unreported association (inverse) of BMI with urinary 3-hydroxymandelate
was found (P = 1.4×10−7). 3-Hydroxymandelate is a metabolite of p-synephrine
(bitter orange extract) [243], an α-adrenergic agonist.
The third pathway concerns production of benzoic acid from dietary polyphe-
nolics, flavenoids and related compounds in the proximal colon, which is phase 2
conjugated with glycine in the liver to form hippurate [244]; a strong inverse asso-
ciation of urinary hippurate across the range of BMI was found (P = 1.5×10−14)
and hippurate has previously been observed to be weakly inversely correlated only
in the morbidly obese [245] and in pre-diabetic individuals [246].
These findings complement evidence of differences in the gut microbial compo-
sition between obese and non-obese people [236] and indicate the important role
that symbiotic gut microbial-host co-metabolism may play in human obesity. In
humans, an increase in energy intake induces rapid changes in the composition of
the gut microbiota and concomitant changes in energy absorption and energy loss
in the stool [247]; this may be contributing to the associations observed of energy
intake overall and energy from animal protein, total and saturated fat with BMI
[248].
5.3.3 Branched-chain amino acid and energy metabolism
Blood levels of the BCAAs are markedly altered in obesity [224–229]. Direct asso-
ciations of BMI with urinary excretion of the BCAAs leucine, valine and isoleucine
are also observed in the U.S. INTERMAP population (Tables 5.5, 5.8 and 5.11).
The association (inverse) with BMI (P = 2.2×10−19) of ketoleucine, the first step
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metabolic product of leucine metabolism in skeletal muscle mitochondria (also
known as 2-oxoisocaproate), is reported for the first time here.
Table 5.11: Estimated differences in BMI per 25th to 75th centile difference in
variables (log10 values) on Ion Exchange Chromatography (IEC) for the first
urine collection of 1,880 U.S. INTERMAP participants adjusted for Model 1
and 2. Metabolites are ordered based on elution time.
Model 1 Model 2
Metabolite BMI change 95% CI P-value BMI change 95% CI P-value
Taurine 0.17 (-0.15;0.49) 3.68×10−01 0.08 (-0.24;0.36) 6.67×10−01
Threonine 1.17 (0.84;1.49) 4.44×10−11 1.11 (0.79;1.43) 4.88×10−11
Serine 0.34 (0.07;0.63) 3.06×10−02 0.41 (0.14;0.69) 6.22×10−03
Asparagine 0.04 (-0.26;0.35) 7.69×10−01 0.05 (-0.24;0.34) 7.31×10−01
Glutamine 0.81 (0.48;1.15) 1.29×10−05 0.97 (0.62;1.28) 5.31×10−08
Glycine -0.14 (-0.39;0.15) 3.98×10−01 0.12 (-0.11;0.37) 4.51×10−01
Alanine 1.56 (1.27;1.89) 4.85×10−18 1.44 (1.13;1.75) 5.75×10−17
Valine 0.97 (0.68;1.32) 6.87×10−16 0.86 (0.57;1.16) 2.48×10−14
Cystine 2.08 (1.72;2.50) 4.85×10−49 1.85 (1.49;2.26) 9.96×10−43
Methionine 0.34 (0.10;0.56) 1.06×10−02 0.28 (0.08;0.50) 2.61×10−02
Isoleucine 1.55 (1.01;2.11) 4.23×10−07 1.29 (0.79;1.81) 9.06×10−06
Leucine 0.87 (0.41;1.68) 3.66×10−04 0.67 (0.25;1.34) 4.03×10−03
Tyrosine 2.63 (2.25;3.08) 2.02×10−45 2.43 (2.02;2.85) 4.36×10−42
Phenylalanine 1.31 (0.96;1.63) 8.35×10−19 1.19 (0.89;1.51) 2.75×10−17
Ethanolamine 1.25 (1.00;1.54) 2.00×10−29 1.23 (0.98;1.49) 3.50×10−32
Lysine 2.03 (1.74;2.35) 4.64×10−33 1.86 (1.57;2.18) 6.90×10−31
1-Methyl histidine 0.94 (0.61;1.26) 9.47×10−07 0.75 (0.47;1.05) 3.68×10−05
Histidine 1.18 (0.82;1.52) 3.02×10−09 1.29 (0.94;1.62) 1.23×10−11
Tryptophan 0.67 (0.50;0.84) 4.49×10−11 0.62 (0.44;0.78) 1.75×10−10
3-Methyl histidine 4.28 (3.89;4.75) 8.28×10−80 3.80 (3.43;4.27) 1.79×10−67
Carnosine 1.21 (0.89;1.53) 7.16×10−15 1.11 (0.81;1.42) 4.23×10−14
Arginine 0.35 (0.16;0.54) 8.71×10−04 0.32 (0.14;0.48) 1.56×10−03
Furthermore, the association of the ketoleucine to leucine ratio with BMI is
even stronger (Table 5.8). Data in humans show increased utilization of leucine
and subsequent conversion to ketoleucine in muscle during exercise, as the leucine
aminotransferase enzyme (E.C. 2.6.1.6) is exercise inducible [249]. It is of note that
most of the enzymes connected with leucine metabolism and other biomarkers
detected here are not detected in large scale Genome-Wide Association Studies
(GWAS) of obesity [250] which may be related to the inability of GWAS approaches
to detect effects in inducible enzymes.
The hyperaminoacidemia associated with lack of exercise may contribute to
insulin resistance in obesity [224, 225]. The BCAA energy metabolism links into
various energy-related pathways including both the tricarboxylic acid (TCA) cycle
and a series of anaplerotic replenishment pathways to the TCA cycle (Figure 5.5).
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Associations (inverse) of BMI with the TCA cycle intermediates succinate (P =
3.2×10−18) and citrate (P = 6.4×10−12) are also shown here for the first time
(Table 5.5).
5.3.4 Skeletal muscle metabolism
The amino acid data shown here suggest a much broader involvement in multi-
ple pathways disturbed in obesity than the BCAAs alone (Figure 5.5). All the
urinary amino acids apart from asparagine, glycine, methionine, serine and tau-
rine significantly (Bonferroni-corrected P < 2.3×10−3) relate to BMI in at least
the Model 1 and Model 2 analyses (Table 5.11), with strongest association for
3-methylhistidine (P = 1.8×10−67, Model 2 ). Urinary 24hr creatinine excretion
is associated with BMI (P = 9.4×10−13, Table 5.5) reflecting increased muscle
turnover with higher BMI [251]; the association of BMI with 3-methylhistidine is
greatly attenuated after creatinine adjustment, since 3-methylhistidine is also a
marker of muscle turnover [233]. The highly significant association between BMI
and ethanolamine (P = 3.5×10−32) is similarly attenuated by creatinine adjust-
ment, as is evident by the high correlations between these metabolites when com-
paring the two urine collections (Figure 5.4a). However, unlike 3-methylhistidine,
ethanolamine is (largely) uncorrelated with nutrient intake, as already noted (Fig-
ure 5.3). Therefore, ethanolamine may be a novel intrinsic biomarker of skeletal
muscle turnover, reflecting its important structural role in skeletal muscle cell
membrane plasmalogens [252].
Both histidine and carnosine (beta-alanyl-histidine) were found to be positively
associated with BMI (Table 5.11) and the associations are not materially altered
when adjusted for the intake of dietary animal protein (Table 5.12), this is reflected
by a previous study on carnosine supplementation which showed that only 14% of
dietary carnosine is excreted in urine [253]. However, both carnosine and histidine
are no longer significant when corrected for urinary creatinine (Table 5.12) which
highlights their involvement in muscle turnover.
Alanine is another metabolite which is similarly attenuated after creatinine
adjustment and this suggests it is also related to muscle turnover. In the alanine-
glucose cycle, alanine is excreted from muscle to be taken up by the liver to make
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glucose (via deamination to pyruvate) which can then in turn be used as energy
source [254]. Potentially, in obese individuals this conversion is not required as
there are many other sources of energy available, for instance directly from the diet,
as the excretion of urinary alanine is only correlated to the dietary energy intake
(Figure 5.3). Alanine has previously been reported to be increased in plasma of
obese individuals [225, 227]. The association with BMI of threonine and arginine
are both similarly altered by the creatinine adjustment and they have been shown
to decrease with exercise [255].
Table 5.12: Estimated differences in BMI per 25th to 75th centile difference
in variables (log10 values) on IEC for the first urine collection of 1,880 U.S.
INTERMAP participants adjusted for Model 1, 2, 3 and 4.
Model 3 Model 4
Metabolite BMI change 95% CI P-value BMI change 95% CI P-value
Taurine -0.24 (-0.55;0.08) 1.94×10−01 -0.93 (-1.20;-0.64) 3.16×10−08
Threonine 0.88 (0.57;1.20) 2.89×10−07 -0.24 (-0.54;0.03) 1.41×10−01
Serine 0.20 (-0.08;0.49) 1.78×10−01 -0.82 (-1.09;-0.55) 1.57×10−08
Asparagine -0.05 (-0.35;0.24) 7.55×10−01 -0.64 (-0.88;-0.42) 1.59×10−06
Glutamine 0.77 (0.44;1.08) 1.72×10−05 -0.43 (-0.75;-0.12) 1.23×10−02
Glycine 0.02 (-0.22;0.27) 8.87×10−01 -0.66 (-0.94;-0.41) 2.80×10−06
Alanine 1.26 (0.94;1.58) 8.71×10−13 0.07 (-0.23;0.34) 6.79×10−01
Valine 0.73 (0.45;1.06) 1.26×10−10 0.24 (0.01;0.49) 2.24×10−02
Cystine 1.77 (1.42;2.17) 3.92×10−39 1.03 (0.77;1.32) 4.24×10−15
Methionine 0.15 (-0.07;0.37) 2.29×10−01 -0.20 (-0.39; 0.00) 8.11×10−02
Isoleucine 1.03 (0.54;1.53) 3.26×10−04 0.46 (-0.01;0.90) 7.93×10−02
Leucine 0.54 (0.14;1.14) 1.94×10−02 0.14 (-0.25;0.56) 4.89×10−01
Tyrosine 2.31 (1.93;2.72) 4.51×10−38 1.31 (0.99;1.66) 4.72×10−14
Phenylalanine 1.11 (0.81;1.41) 2.82×10−15 0.43 (0.21;0.67) 1.06×10−03
Ethanolamine 1.17 (0.94;1.44) 9.55×10−30 0.60 (0.41;0.79) 1.76×10−09
Lysine 1.71 (1.41;1.99) 4.20×10−25 0.81 (0.51;1.05) 3.51×10−07
1-Methyl histidine 0.55 (0.21;0.89) 5.15×10−03 -0.37 (-0.69;-0.07) 4.25×10−02
Histidine 1.12 (0.79;1.43) 4.40×10−09 0.04 (-0.25;0.34) 8.06×10−01
Tryptophan 0.57 (0.40;0.73) 2.59×10−09 0.33 (0.19;0.47) 1.24×10−04
3-Methyl histidine 4.03 (3.57;4.49) 1.10×10−61 1.62 (1.12;2.17) 1.12×10−07
Carnosine 0.96 (0.68;1.26) 8.39×10−11 0.12 (-0.14;0.38) 4.14×10−01
Arginine 0.28 (0.11;0.44) 5.49×10−03 0.14 (-0.01;0.29) 1.12×10−01
5.3.5 Other amino acids and related compounds
In contrast to all other metabolites reported here, asparagine and glycine and
novel relationships of serine and taurine with BMI (all inverse) are only apparent
after creatinine adjustment (Model 4, Table 5.12), implying they are independent
of muscle turnover. Higher plasma concentrations of asparagine have been linked
168
CHAPTER 5. METABOLIC SIGNATURES OF HUMAN OBESITY
to the activity of an enzyme that cleaves asparagine from N -acetyl glucosamine
compounds as the final step in the breakdown of glycoproteins in the lysosome
[256] and plasma asparagine concentrations were found to be weakly inversely
associated with BMI [227, 229]. However, higher concentrations of glycine have
been reported in plasma of lean individuals compared to obese [225, 227, 229] and
in urine [257]. Cystine (dicysteine) is found to be positively associated with BMI
(P = 1.0×10−42, Model 2 ) and animal and human data suggest an important role
of cystine in both glucose and lipid metabolism [258].
The aromatic amino acids (tyrosine, phenylalanine and tryptophan) are all
found to be positively associated with BMI in urine, which is consistent with ob-
servations in plasma for tyrosine [225–227, 229], phenylalanine [225, 227, 229] and
tryptophan [226]. The latter was also found higher in pre-diabetic individuals
[246]. Together with the aromatic gut microbial co-metabolites that were found
(4-cresyl sulfate, hippurate, 3- and 4-hydroxymandalate) this highlights the col-
lective importance of aromatic compounds and gut microbial degradation related
to BMI. Tyrosine and phenylalanine have direct associations with BMI and the
microbial degradation product of tyrosine [259], 4-cresyl sulfate, has an inverse
association with BMI. However, phenylacetylglutamine, the microbial degradation
product of phenylalanine [259], was not picked up in the NMR discovery analysis
(Model 1 ). It is known that NSAID use (acetaminophen, ibuprofen) can result
in overlap of phenylacetylglutamine with acetaminophen (glucuronide) and (hy-
droxy)ibuprofen [207]. Therefore, several metabolite signals were fitted simultane-
ously using the strategy described in section 5.2.6 and the association with BMI
re-evaluated (Table 5.13). However, phenylacetylglutamine still does not pass the
threshold for significance for NMR-derived metabolites. Also, the ratio between
the two metabolites is not more significant than 4-cresyl sulfate alone.
Hippurate, 4-cresyl sulfate and phenylacetylglutamine are the three most abun-
dant aromatic gut microbial metabolites in human urine [260]. The microbial
degradation products of tryptophan, indole compounds, are present in lower con-
centrations and the aromatic signals appear in the same region as hippurate, 4-
cresyl sulfate and phenylacetylglutamine and thus may be overlapped. While an
unknown NMR signal positively associated with obesity was found at δ 7.74 (dou-
blet signal) (Table 5.6), a chemical shift typically associated with CH signals in a
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benzene ring structure (such as indoles), it was not possible to uncover the identity
or even other structural correlations, possibly because of overlap with other com-
mon metabolites. Therefore, the predominant aromatic pathway associated with
obesity appears to be the microbial degradation of tyrosine to 4-cresol (which is
then sulfonated to form 4-cresyl sulfate).
Table 5.13: Association of BMI with gut-microbial co-metabolites 4-cresyl
sulfate and phenylacetylglutamine in 1,880 U.S. INTERMAP participants,
adjusted for Model 1. 4-Cresyl sulfate and phenylacetylglutamine signals
were fitted simultaneously with acetaminophen, acetaminophen glucuronide
and (hydroxy)ibuprofen, the most abundant metabolites that overlap with
4-cresyl sulfate and phenylacetylglutamine. Correlation of fitted 4-cresyl sul-
fate signal and the 4-cresyl sulfate 1H NMR variable (as in Table 5.5) is 0.94
(P < 9.88×10−324 ≈ 0).
Visit 1 Visit 2
Metabolite BMI change P-value BMI change P-value
4-Cresyl sulfate -1.12 3.46×10−10 -1.22 3.83×10−11
Phenylacetylglutamine -0.56 8.58×10−04 -0.45 5.48×10−03
4-Cresyl sulfate to phenylacetylglutamine ratio -1.08 1.24×10−08 -1.31 8.83×10−12
5.3.6 Other metabolite markers of obesity
A composite N -acetyl signal from urinary glycoproteins has the most significant as-
sociation with BMI (P = 2.0×10−36) (Table 5.5, Figure 5.2a,b). The association of
BMI with urinary glycoproteins likely reflects the known higher glomerular filtra-
tion rate associated with obesity and may provide an early non-invasive indicator
of the hyperfiltration process that is known to precede diabetes [261]. Addition-
ally, a direct association of BMI with N -acetyl neuraminate (NANA) was found (P
= 2.0×10−16). NANA is a hydrolytic breakdown product of urinary glycoproteins
with sialic acid sub-units [262] (Table 5.4).
Associations of BMI with urinary excretion of 2-hydroxyisobutyrate (P =
9.0×10−12) (direct) and N -methylnicotinate (P = 3.2×10−12) (inverse) are con-
sistent with previous observations in morbidly obese individuals [245]. However,
2-hydroxyisobutyrate is no longer significant when adjusted for several lifestyle
factors (Model 2, Table 5.8) and, as already noted, N -methylnicotinate is associ-
ated with coffee consumption [234, 263] (Figure 5.3), so these associations may be
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population dependent. The direct association of BMI with pseudouridine (P =
2.1×10−12) reflects increased whole body nucleic acid turnover with higher BMI.
5.3.7 Gender differences
Several differences in metabolic associations with BMI between men and women
were found (Tables 5.14, 5.15 and 5.16). For example, there is a greater associ-
ation of BMI with cystine in women than men (Table 5.16). Also associations
of BMI with carnosine, ethanolamine and 3-methylhistidine (all related to mus-
cle metabolism and turnover) are stronger in women than men (Tables 5.14, 5.15
and 5.16), consistent with higher muscle protein synthesis and turnover in women
[264], despite the fact that in the U.S. INTERMAP population men reported
greater moderate to heavy physical activity compared to women (P = 8.7×10−4).
In addition, N -acetyl neuraminate is also stronger in women compared to men
(Tables 5.14 and 5.15).
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Table 5.14: P -values for a gender-interaction term included in Model 1, 2, 3
and 4 for the first urine collection 1H NMR data for 1,880 U.S. INTERMAP
participants. Letters in parenthesis indicate the significantly associated gen-
der effect, (M) indicates more significant in men and (W) indicates a more
significant effect in women.
Model 1 Model 2 Model 3 Model 4
Urinary variable P-value P-value P-value P-value
Glycoproteins 3.89×10−02 3.15×10−02 3.83×10−02 8.82×10−03
Tyrosine + 2.39×10−01 1.35×10−01 1.47×10−01 2.16×10−02
4-hydroxymandelate
Ketoleucine 5.54×10−01 4.04×10−01 4.86×10−01 5.43×10−01
Succinate 9.96×10−02 1.79×10−01 1.75×10−01 1.57×10−02
N -acetyl neuraminate 7.10×10−08 (W) 4.59×10−07 (W) 6.18×10−07 (W) 1.18×10−05 (W)
3-Methyl histidine 1.23×10−01 3.81×10−01 5.20×10−01 7.71×10−02
Hippurate 5.90×10−03 1.49×10−02 2.07×10−02 6.81×10−04 (M)
Glutamine 7.79×10−01 7.43×10−01 6.68×10−01 1.47×10−01
Creatinine 6.87×10−04 (W) 3.01×10−03 3.65×10−03
Leucine 1.59×10−01 1.83×10−01 2.09×10−01 1.66×10−03
Pseudouridine 1.79×10−02 1.48×10−02 1.38×10−02 2.54×10−03
N -methyl nicotinate 6.74×10−04 (M) 2.26×10−03 (M) 3.34×10−03 4.95×10−05 (M)
Citrate 2.22×10−01 2.00×10−01 2.12×10−01 3.74×10−02
2-Hydroxyisobutyrate 5.85×10−05 (W) 3.11×10−03 1.36×10−02 3.62×10−04 (W)
4-Cresyl sulfate 1.28×10−01 1.56×10−01 2.47×10−01 4.66×10−01
Trimethylamine 5.19×10−02 1.13×10−01 2.74×10−01 9.33×10−02
Lysine 2.15×10−02 4.76×10−03 2.08×10−03 (W) 1.03×10−05 (W)
Ethanolamine 9.23×10−06 (W) 2.33×10−04 (W) 3.54×10−04 (W) 4.21×10−05 (W)
3-Hydroxymandelate 2.59×10−03 6.68×10−03 5.27×10−03 5.46×10−04 (W)
Dimethylglycine 2.37×10−02 7.64×10−02 1.10×10−01 2.42×10−03
Ketoleucine to leucine ratio 1.15×10−03 (W) 1.20×10−03 (W) 1.16×10−03 (W)
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Table 5.15: P -values for a gender-interaction term included in Model 1, 2,
3 and 4 for the second urine collection 1H NMR data for 1,880 U.S. IN-
TERMAP participants. Letters in parenthesis indicate the significantly asso-
ciated gender effect, (M) indicates more significant in men and (W) indicates
a more significant effect in women.
Model 1 Model 2 Model 3 Model 4
Urinary variable P-value P-value P-value P-value
Glycoproteins 2.97×10−02 1.00×10−02 1.89×10−02 8.90×10−03
Tyrosine + 2.53×10−01 6.75×10−02 8.00×10−02 3.61×10−02
4-hydroxymandelate
Ketoleucine 4.56×10−01 2.75×10−01 4.40×10−01 9.37×10−01
Succinate 1.10×10−01 2.43×10−01 1.41×10−01 1.06×10−01
N -acetyl neuraminate 4.57×10−06 (W) 1.38×10−05 (W) 2.27×10−05 (W) 7.74×10−04 (W)
3-Methyl histidine 2.11×10−04 (W) 3.20×10−03 5.05×10−03 1.15×10−03 (W)
Hippurate 7.20×10−02 4.98×10−02 5.56×10−02 8.58×10−03
Glutamine 2.46×10−01 3.91×10−01 2.98×10−01 1.54×10−01
Creatinine 3.09×10−03 3.95×10−03 3.98×10−03
Leucine 9.96×10−01 9.89×10−01 9.90×10−01 3.96×10−01
Pseudouridine 2.22×10−02 1.30×10−02 8.60×10−03 8.44×10−04 (W)
N -methyl nicotinate 2.14×10−02 7.11×10−02 8.80×10−02 7.21×10−03
Citrate 9.70×10−01 8.44×10−01 9.85×10−01 6.31×10−01
2-Hydroxyisobutyrate 1.74×10−01 4.96×10−01 5.61×10−01 2.59×10−01
4-Cresyl sulfate 1.32×10−01 2.31×10−01 3.21×10−01 4.28×10−01
Trimethylamine 2.17×10−01 3.42×10−01 2.88×10−01 1.87×10−01
Lysine 4.21×10−01 2.51×10−01 2.30×10−01 1.05×10−01
Ethanolamine 2.80×10−13 (W) 5.14×10−10 (W) 6.30×10−10 (W) 1.93×10−11 (W)
3-Hydroxymandelate 5.91×10−02 2.06×10−01 1.86×10−01 3.54×10−02
Dimethylglycine 2.85×10−03 1.58×10−02 1.83×10−02 1.83×10−03 (W)
Ketoleucine to leucine ratio 9.31×10−01 8.83×10−01 7.36×10−01
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Table 5.16: P -values for a gender-interaction term included in Model 1, 2,
3 and 4 for the first urine collection IEC data for 1,880 U.S. INTERMAP
participants. Letters in parenthesis indicate the significantly associated gen-
der effect, (M) indicates the metabolite is more significant in men and (W)
indicates a stronger effect in women.
Model 1 Model 2 Model 3 Model 4
Urinary variable P-value P-value P-value P-value
Taurine 2.76×10−01 2.77×10−01 1.73×10−01 4.24×10−05 (W)
Threonine 6.65×10−01 9.63×10−01 8.63×10−01 1.67×10−03 (W)
Serine 9.03×10−02 1.42×10−01 2.60×10−01 1.15×10−04 (W)
Asparagine 1.98×10−01 4.64×10−01 5.26×10−01 5.02×10−01
Glutamine 2.13×10−01 2.34×10−01 3.44×10−01 8.79×10−03
Glycine 9.39×10−02 7.06×10−02 1.20×10−01 6.49×10−01
Alanine 5.31×10−01 6.56×10−01 7.34×10−01 7.97×10−03
Valine 3.84×10−01 7.45×10−01 8.14×10−01 5.38×10−02
Cystine 3.05×10−05 (W) 5.25×10−05 (W) 1.94×10−04 (W) 1.63×10−06 (W)
Methionine 1.47×10−01 1.03×10−01 1.35×10−01 4.14×10−02
Isoleucine 3.91×10−02 3.90×10−02 8.88×10−02 1.81×10−02
Leucine 9.19×10−02 3.05×10−01 5.33×10−01 1.75×10−01
Tyrosine 4.16×10−02 4.04×10−03 3.24×10−03 5.79×10−06 (W)
Phenylalanine 6.31×10−01 1.52×10−01 2.01×10−01 3.74×10−03
Ethanolamine 1.25×10−07 (W) 2.94×10−09 (W) 1.62×10−09 (W) 3.53×10−08 (W)
Lysine 7.28×10−01 5.50×10−01 7.14×10−01 1.79×10−02
1-Methyl histidine 7.57×10−01 8.47×10−01 7.68×10−01 1.66×10−02
Histidine 1.67×10−02 3.53×10−02 3.97×10−02 2.34×10−01
Tryptophan 9.81×10−01 8.34×10−01 9.13×10−01 2.72×10−01
3-Methyl histidine 1.13×10−03 (W) 7.88×10−04 (W) 1.82×10−03 (W) 9.19×10−13 (W)
Carnosine 7.97×10−08 (W) 1.44×10−07 (W) 2.11×10−07 (W) 3.16×10−08 (W)
Arginine 2.19×10−01 2.95×10−01 5.74×10−01 4.58×10−01
5.3.8 Validation
The findings from the U.S. study were validated by investigating the association
with BMI of these metabolites in a U.K. cohort that was collected using the same
sample protocol as for the U.S. population [73]. Previously it has been shown that
these populations are metabolically similar [39], despite genetic and environmental
differences (Table 5.1). As described in section 5.2.4, the Benjamini-Hochberg FDR
[112] was used to adjust for multiple hypothesis testing. While most findings are
consistent across populations (Tables 5.17 and 5.18), some are not significantly
altered in the U.K. population which may be related to genetic or environmental
variation, different dietary patterns or statistical power (U.K. cohort is a quarter
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of the size of the U.S. cohort). Corrections of 1H NMR metabolite associations
with BMI for Model 3 and 4 are shown in Tables 5.19 and 5.20.
Table 5.17: Structurally identified 1H NMR-derived urinary metabolites as-
sociated significantly with BMI in the U.K. population, adjusted for Model
1. A Benjamini-Hochberg FDR correction was applied to the P -values.
Visit 1 Visit 2
Metabolite BMI change 95% CI pFDR BMI change 95% CI pFDR
Urinary glycoproteins 1.93 (1.38;2.48) 2.04×10−11 1.54 (1.05;2.08) 2.12×10−09
Tyrosine + 1.02 (0.56;1.49) 1.76×10−04 1.14 (0.66;1.55) 2.26×10−05
4-hydroxymandelate
Ketoleucine -0.87 (-1.19;-0.52) 4.97×10−04 -0.89 (-1.29;-0.52) 8.72×10−04
Succinate -0.54 (-0.82;-0.28) 4.37×10−03 -0.76 (-1.07;-0.51) 1.42×10−04
N -acetyl neuraminate 0.98 (0.57;1.48) 1.09×10−03 0.99 (0.57;1.43) 5.52×10−04
3-Methylhistidine 0.65 (0.16;1.18) 1.41×10−02 0.72 (0.30;1.19) 8.89×10−03
Hippurate -1.31 (-1.81;-0.87) 5.27×10−06 -1.16 (-1.59;-0.77) 2.26×10−05
Glutamine -0.80 (-1.28;-0.34) 4.37×10−03 -1.15 (-1.58;-0.75) 1.82×10−04
Creatinine 1.09 (0.50;1.71) 2.84×10−03 1.23 (0.70;1.80) 8.13×10−04
Leucine 0.64 (0.10;1.44) 1.99×10−02 0.59 (0.14;1.12) 1.73×10−02
Pseudouridine 0.90 (0.26;1.57) 8.48×10−03 0.31 (-0.27;0.92) 3.48×10−01
N -methyl nicotinate -0.17 (-0.52;0.18) 4.84×10−01 -0.41 (-0.77;-0.03) 1.28×10−01
Citrate -0.37 (-0.75;-0.04) 7.88×10−02 -0.85 (-1.21;-0.53) 4.82×10−04
4-Cresyl sulfate -0.98 (-1.41;-0.53) 1.09×10−03 -0.61 (0.85;1.93) 2.04×10−02
Trimethylamine 0.89 (0.48;1.38) 6.67×10−05 0.90 (-1.05;-0.21) 4.80×10−06
Lysine 0.32 (-0.07;0.79) 2.14×10−01 0.65 (0.56;1.29) 1.73×10−02
Ethanolamine 0.28 (-0.04;0.59) 1.17×10−01 0.22 (0.24;1.09) 2.39×10−01
3-Hydroxymandelate -0.31 (-0.60;0.01) 1.72×10−01 -0.26 (-0.10;0.67) 3.15×10−01
Dimethylglycine 0.67 (0.27;1.11) 1.36×10−03 0.77 (-0.61;0.10) 4.50×10−04
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Table 5.18: Structurally identified 1H NMR-derived urinary metabolites as-
sociated significantly with BMI in the U.K. population, adjusted for Model 1
and 2. A Benjamini-Hochberg FDR correction was applied to the P -values.
Visit 1 Visit 2
Metabolite BMI change 95% CI pFDR BMI change 95% CI pFDR
Urinary glycoproteins 1.79 (1.24;2.35) 6.53×10−10 1.44 (0.96;1.92) 2.82×10−08
Tyrosine + 1.00 (0.55;1.44) 1.40×10−04 1.08 (0.61;1.47) 5.81×10−05
4-hydroxymandelate
Ketoleucine -0.67 (-1.01;-0.32) 4.95×10−03 -0.74 (-1.10;-0.39) 5.23×10−03
Succinate -0.54 (-0.80;-0.27) 4.66×10−03 -0.70 (-0.99;-0.45) 4.66×10−04
N -acetyl neuraminate 0.94 (0.49;1.43) 2.11×10−03 0.97 (0.52;1.41) 1.03×10−03
3-Methylhistidine 0.60 (0.17;1.14) 2.03×10−02 0.79 (0.39;1.29) 3.45×10−03
Hippurate -1.20 (-1.70;-0.76) 3.40×10−05 -0.98 (-1.43;-0.54) 4.66×10−04
Glutamine -0.73 (-1.15;-0.27) 8.19×10−03 -1.05 (-1.50;-0.68) 4.66×10−04
Creatinine 1.23 (0.62;1.84) 9.63×10−04 1.15 (0.60;1.66) 1.66×10−03
Leucine 0.71 (0.16;1.60) 9.04×10−03 0.51 (0.10;1.10) 3.47×10−02
Pseudouridine 0.95 (0.35;1.54) 4.95×10−03 0.17 (-0.42;0.72) 6.14×10−01
N -methyl nicotinate -0.09 (-0.44;0.28) 7.22×10−01 -0.25 (-0.63;0.13) 3.46×10−01
Citrate -0.45 (-0.82;-0.13) 2.77×10−02 -0.86 (-1.21;-0.52) 4.66×10−04
4-Cresyl sulfate -0.96 (-1.41;-0.51) 1.44×10−03 -0.62 (-1.02;-0.22) 1.88×10−02
Trimethylamine 0.88 (0.50;1.26) 5.38×10−05 0.79 (0.46;1.17) 5.81×10−05
Lysine 0.35 (-0.06;0.76) 1.72×10−01 0.72 (0.31;1.13) 7.51×10−03
Ethanolamine 0.26 (-0.02;0.66) 1.26×10−01 0.20 (-0.10;0.59) 2.94×10−01
3-Hydroxymandelate -0.30 (-0.59;0.03) 1.72×10−01 -0.27 (-0.65;0.10) 2.94×10−01
Dimethylglycine 0.68 (0.25;1.18) 1.31×10−03 0.71 (0.26;1.29) 9.70×10−04
Ketoleucine to leucine ratio -1.26 (-1.79;-0.83) 2.70×10−08 -1.16 (-1.56;-0.73) 3.75×10−06
Table 5.19: Structurally identified 1H NMR-derived urinary metabolites as-
sociated significantly with BMI in the U.K. population, adjusted for Model 1,
2 and 3. A Benjamini-Hochberg FDR correction was applied to the P -values.
Visit 1 Visit 2
Metabolite BMI change 95% CI pFDR BMI change 95% CI pFDR
Urinary glycoproteins 1.96 (1.43;2.48) 8.88×10−11 1.51 (0.95;1.95) 7.65×10−09
Tyrosine + 1.06 (0.59;1.49) 1.00×10−04 1.11 (0.60;1.50) 5.29×10−05
4-hydroxymandelate
Ketoleucine -0.79 (-1.20;-0.40) 1.40×10−03 -0.72 (-1.27;-0.51) 5.70×10−03
Succinate -0.51 (-0.76;-0.24) 8.70×10−03 -0.68 (-0.94;-0.36) 7.81×10−04
N -acetyl neuraminate 0.90 (0.44;1.44) 4.61×10−03 0.97 (0.26;1.22) 1.88×10−03
3-Methylhistidine 0.56 (0.09;1.04) 3.46×10−02 0.76 (0.29;1.20) 5.70×10−03
Hippurate -1.07 (-1.48;-0.62) 3.71×10−04 -0.76 (-1.33;-0.47) 5.70×10−03
Glutamine -0.67 (-1.05;-0.22) 1.47×10−02 -0.97 (-1.37;-0.47) 1.52×10−03
Creatinine 1.22 (0.57;1.70) 1.20×10−03 1.04 (0.42;1.52) 5.70×10−03
Leucine 0.63 (0.07;1.52) 2.63×10−02 0.50 (0.03;1.02) 4.13×10−02
Pseudouridine 0.88 (0.29;1.42) 9.58×10−03 0.16 (-0.54;0.67) 6.70×10−01
N -methyl nicotinate 0.16 (-0.19;0.59) 5.46×10−01 0.00 (-0.41;0.36) 9.96×10−01
Citrate -0.40 (-0.79;-0.06) 5.62×10−02 -0.83 (-1.13;-0.40) 9.84×10−04
4-Cresyl sulfate -1.20 (-1.63;-0.74) 1.00×10−04 -0.87 (-1.07;-0.22) 1.52×10−03
Trimethylamine 0.84 (0.46;1.22) 1.39×10−04 0.79 (0.37;1.03) 8.17×10−05
Lysine 0.36 (-0.08;0.75) 1.84×10−01 0.75 (0.10;0.87) 5.70×10−03
Ethanolamine 0.21 (-0.13;0.55) 2.36×10−01 0.12 (-0.13;0.52) 5.79×10−01
3-Hydroxymandelate -0.13 (-0.44;0.25) 5.46×10−01 -0.14 (-0.54;0.23) 6.31×10−01
Dimethylglycine 0.62 (0.20;1.02) 3.48×10−03 0.67 (0.15;1.09) 2.55×10−03
Ketoleucine to leucine ratio -1.27 (-1.85;-0.82) 1.60×10−08 -1.12 (-1.60;-0.73) 8.51×10−06
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Table 5.20: Structurally identified 1H NMR-derived urinary metabolites as-
sociated significantly with BMI in the U.K. population, adjusted for Model
1, 2, 3 and 4. A Benjamini-Hochberg FDR correction was applied to the
P -values.
Visit 1 Visit 2
Metabolite BMI change 95% CI pFDR BMI change 95% CI pFDR
Urinary glycoproteins 1.88 (1.38;2.35) 2.40×10−11 1.35 (1.00;1.97) 6.99×10−08
Tyrosine + 0.89 (0.51;1.25) 4.49×10−04 1.01 (0.57;1.46) 7.96×10−05
4-hydroxymandelate
Ketoleucine -0.82 (-1.20;-0.45) 4.49×10−04 -0.74 (-1.24;-0.51) 3.51×10−03
Succinate -0.42 (-0.68;-0.15) 2.56×10−02 -0.62 (-0.84;-0.32) 7.91×10−04
N -acetyl neuraminate 0.88 (0.45;1.33) 3.35×10−03 0.85 (0.33;1.29) 3.51×10−03
3-Methylhistidine 0.23 (-0.23;0.74) 4.03×10−01 0.53 (0.09;0.94) 4.04×10−02
Hippurate -0.91 (-1.27;-0.48) 1.06×10−03 -0.76 (-1.39;-0.57) 3.62×10−03
Glutamine -0.65 (-1.06;-0.28) 1.44×10−02 -1.01 (-1.16;-0.37) 3.97×10−04
Creatinine
Leucine 0.31 (-0.16;1.03) 2.80×10−01 0.32 (0.01;0.94) 1.85×10−01
Pseudouridine 0.55 (-0.01;1.06) 1.05×10−01 0.04 (-0.53;0.60) 8.88×10−01
N -methyl nicotinate 0.05 (-0.24;0.46) 8.17×10−01 -0.05 (-0.46;0.25) 8.88×10−01
Citrate -0.32 (-0.66;-0.01) 1.21×10−01 -0.74 (-0.96;-0.30) 1.57×10−03
4-Cresyl sulfate -0.98 (-1.39;-0.52) 5.53×10−04 -0.74 (-0.92;-0.12) 3.51×10−03
Trimethylamine 0.82 (0.42;1.22) 8.93×10−05 0.74 (0.31;0.91) 7.96×10−05
Lysine 0.14 (-0.24;0.50) 5.99×10−01 0.59 (0.04;0.80) 2.07×10−02
Ethanolamine 0.27 (0.02;0.60) 1.27×10−01 0.17 (-0.10;0.61) 3.71×10−01
3-Hydroxymandelate -0.15 (-0.45;0.19) 5.16×10−01 -0.17 (-0.41;0.34) 4.98×10−01
Dimethylglycine 0.44 (0.05;0.78) 3.19×10−02 0.57 (0.14;0.96) 5.48×10−03
Ketoleucine to leucine ratio -1.09 (-1.59;-0.70) 2.69×10−06 -0.97 (-1.50;-0.69) 2.10×10−04
For instance, N -methyl nicotinate was found to be significantly associated (in-
verse) with BMI in the U.S. population (although related to coffee consump-
tion), but it is not associated with BMI in the U.K. population. Pseudouri-
dine was only found to be significantly associated in the first visit U.K. data,
but could not be replicated in the second urine specimens in the U.K. The last
NMR-detected metabolite that could not be reproduced in the U.K. cohort was 3-
hydroxymandelate. Lysine and ethanolamine could not be reproduced in the U.K.
cohort using the 1H NMR data, not surprisingly given the fact that these (espe-
cially ethanolamine) are not found in high concentrations. In the U.K. IEC data
both lysine and ethanolamine are significantly associated with BMI (Table 5.21).
Taurine, serine and asparagine, in the U.S. only found significant after creati-
nine adjustment (Model 4 ), are not found to be related to BMI in the U.K. cohort
when the same adjustment is made (Table 5.22). Furthermore, direct associations
of threonine, isoleucine and 1-methylhistidine could not be reproduced in the U.K.
cohort (Table 5.21). In terms of gender-related BMI-metabolite associations, only
the stronger association of cystine with BMI in women compared to men could be
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reproduced in the U.K. cohort (Tables 5.23, 5.24 and 5.25).
Table 5.21: Estimated differences in BMI per 25th to 75th centile difference
in variables on IEC (log10 values) for the first urine collection of 444 U.K.
INTERMAP participants, adjusted for Model 1 and 2.
Model 1 Model 2
Metabolite BMI change 95% CI pFDR BMI change 95% CI pFDR
Taurine -0.17 (-0.70;0.39) 6.86×10−01 -0.20 (-0.74;0.36) 5.96×10−01
Threonine 0.42 (-0.16;0.96) 2.38×10−01 0.47 (-0.07;0.99) 1.75×10−01
Serine 0.03 (-0.51;0.54) 9.61×10−01 0.13 (-0.33;0.63) 7.07×10−01
Asparagine -0.01 (-0.62;0.53) 9.73×10−01 0.06 (-0.48;0.60) 8.85×10−01
Glutamine 0.61 (-0.07;1.20) 8.04×10−02 0.71 (0.15;1.34) 3.44×10−02
Glycine -0.10 (-0.60;0.37) 7.91×10−01 -0.04 (-0.51;0.40) 8.85×10−01
Alanine 1.01 (0.43;1.60) 1.39×10−03 1.09 (0.54;1.69) 3.29×10−04
Valine 1.41 (0.88;1.99) 1.87×10−06 1.38 (0.90;1.94) 1.52×10−06
Cystine 1.62 (1.13;2.16) 2.94×10−11 1.51 (1.03;2.04) 1.16×10−10
Isoleucine 0.21 (-0.06;0.50) 2.28×10−01 0.22 (-0.05;0.54) 1.86×10−01
Leucine 1.69 (1.12;2.32) 1.28×10−07 1.69 (1.13;2.27) 5.15×10−08
Tyrosine 2.17 (1.54;2.81) 9.67×10−11 2.15 (1.57;2.78) 8.76×10−11
Phenylalanine 1.68 (1.09;2.33) 4.72×10−07 1.76 (1.17;2.34) 7.77×10−08
Ethanolamine 1.90 (1.30;2.47) 1.80×10−10 1.89 (1.28;2.48) 1.16×10−10
Lysine 1.37 (0.88;1.94) 4.49×10−07 1.31 (0.88;1.79) 6.65×10−07
1-Methyl histidine 0.88 (0.38;1.41) 1.44×10−02 0.65 (0.16;1.15) 7.30×10−02
Histidine 0.73 (0.18;1.26) 2.78×10−02 0.80 (0.28;1.32) 1.24×10−02
Tryptophan 1.26 (0.73;1.78) 2.15×10−05 1.22 (0.72;1.72) 2.41×10−05
3-Methyl histidine 2.49 (1.86;3.14) 1.80×10−10 2.38 (1.75;3.05) 6.06×10−10
Carnosine 0.93 (0.42;1.50) 1.64×10−03 1.05 (0.58;1.64) 2.42×10−04
Arginine 0.87 (0.49;1.31) 4.85×10−04 0.95 (0.58;1.38) 6.43×10−05
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Table 5.22: Estimated differences in BMI per 25th to 75th centile difference
in variables on IEC (log10 values) for the first urine collection of 444 U.K.
INTERMAP participants, adjusted for Model 1, 2, 3 and 4.
Model 3 Model 4
Metabolite BMI change 95% CI pFDR BMI change 95% CI pFDR
Taurine -0.30 (-0.85;0.30) 4.28×10−01 -0.58 (-1.08;-0.04) 9.15×10−02
Threonine 0.36 (-0.24;0.96) 3.59×10−01 -0.39 (-0.99;0.24) 2.88×10−01
Serine 0.10 (-0.46;0.61) 7.69×10−01 -0.53 (-1.11;-0.01) 9.15×10−02
Asparagine 0.03 (-0.56;0.58) 9.14×10−01 -0.41 (-0.98;0.11) 2.12×10−01
Glutamine 0.55 (-0.11;1.14) 1.30×10−01 -0.20 (-0.86;0.41) 6.11×10−01
Glycine -0.17 (-0.67;0.25) 6.01×10−01 -0.62 (-1.09;-0.17) 4.64×10−02
Alanine 1.11 (0.55;1.72) 6.42×10−04 0.41 (-0.16;0.99) 2.60×10−01
Valine 1.46 (0.87;2.08) 1.04×10−06 0.64 (-0.02;1.23) 8.23×10−02
Cystine 1.48 (1.01;2.01) 2.42×10−10 0.96 (0.51;1.45) 4.20×10−04
Isoleucine 0.13 (-0.18;0.45) 4.53×10−01 -0.14 (-0.41;0.15) 4.42×10−01
Leucine 1.69 (1.03;2.32) 4.41×10−07 0.72 (0.12;1.35) 8.23×10−02
Tyrosine 2.14 (1.50;2.72) 1.45×10−10 1.48 (0.92;2.01) 1.00×10−04
Phenylalanine 1.72 (1.11;2.37) 3.90×10−07 0.87 (0.27;1.49) 3.55×10−02
Ethanolamine 1.89 (1.29;2.42) 2.18×10−10 1.09 (0.46;1.65) 3.65×10−03
Lysine 1.22 (0.74;1.77) 6.97×10−06 0.68 (0.24;1.19) 3.46×10−02
1-Methyl histidine 0.79 (0.17;1.39) 5.24×10−02 0.15 (-0.52;0.79) 7.15×10−01
Histidine 0.69 (0.16;1.24) 4.25×10−02 0.02 (-0.54;0.53) 9.45×10−01
Tryptophan 1.16 (0.68;1.65) 8.02×10−05 0.68 (0.20;1.19) 3.91×10−02
3-Methyl histidine 3.08 (2.25;3.94) 1.45×10−10 1.55 (0.41;2.76) 3.14×10−02
Carnosine 1.00 (0.43;1.59) 1.10×10−03 0.13 (-0.46;0.69) 7.15×10−01
Arginine 0.83 (0.43;1.27) 6.42×10−04 0.39 (0.01;0.80) 1.31×10−01
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Table 5.23: P -values for a gender-interaction term included in Model 1, 2, 3
and 4 for the first urine collection 1H NMR data for 444 U.K. INTERMAP
participants. Letters in parenthesis indicate the significantly associated gen-
der effect, (M) indicates more significant in men and (W) indicates a more
significant effect in women.
Model 1 Model 2 Model 3 Model 4
Urinary variable P-value P-value P-value P-value
Glycoproteins 4.71×10−05 (W) 5.22×10−05 (W) 7.39×10−04 (W) 2.06×10−03 (W)
Tyrosine + 1.64×10−01 2.01×10−01 2.11×10−01 3.32×10−01
4-hydroxymandelate
Ketoleucine 7.10×10−01 8.01×10−01 5.45×10−01 4.96×10−01
Succinate 7.78×10−01 3.70×10−01 3.51×10−01 6.51×10−01
N -acetyl neuraminate 2.71×10−03 5.27×10−03 1.30×10−02 5.18×10−02
3-Methyl histidine 5.17×10−01 5.01×10−01 5.69×10−01 7.27×10−01
Hippurate 2.70×10−01 2.60×10−01 3.81×10−01 4.02×10−01
Glutamine 6.04×10−01 3.73×10−01 2.34×10−01 5.33×10−01
Creatinine 2.91×10−02 2.96×10−02 4.36×10−02
Leucine 6.62×10−01 5.78×10−01 9.05×10−01 7.67×10−01
Pseudouridine 3.24×10−02 9.60×10−02 2.73×10−01 2.56×10−01
N -methyl nicotinate 7.54×10−01 7.77×10−01 7.09×10−01 5.59×10−01
Citrate 6.59×10−01 4.19×10−01 2.58×10−01 6.84×10−01
4-Cresyl sulfate 3.53×10−02 3.10×10−02 9.19×10−02 1.07×10−01
Trimethylamine 1.38×10−03 (W) 3.19×10−03 5.83×10−03 1.28×10−02
Lysine 8.35×10−01 9.79×10−01 9.67×10−01 8.01×10−01
Ethanolamine 5.46×10−01 2.40×10−01 3.94×10−01 4.16×10−02
3-Hydroxymandelate 3.73×10−01 4.43×10−01 4.68×10−01 6.31×10−01
Dimethylglycine 1.24×10−02 2.34×10−03 (W) 7.14×10−03 1.72×10−02
Ketoleucine to leucine ratio 9.22×10−01 6.89×10−01 4.97×10−01
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Table 5.24: P -values for a gender-interaction term included in Model 1, 2, 3
and 4 for the second urine collection 1H NMR data for 444 U.K. INTERMAP
participants. Letters in parenthesis indicate the significantly associated gen-
der effect, (M) indicates more significant in men and (W) indicates a more
significant effect in women.
Model 1 Model 2 Model 3 Model 4
Urinary variable P-value P-value P-value P-value
Glycoproteins 2.53×10−02 6.65×10−02 1.19×10−01 9.88×10−02
Tyrosine + 1.27×10−01 1.44×10−01 1.24×10−01 2.36×10−01
4-hydroxymandelate
Ketoleucine 8.39×10−01 6.93×10−01 8.03×10−01 8.69×10−01
Succinate 9.59×10−01 7.90×10−01 9.98×10−01 9.00×10−01
N -acetyl neuraminate 5.98×10−01 6.21×10−01 7.83×10−01 7.77×10−01
3-Methyl histidine 2.57×10−01 2.85×10−01 3.12×10−01 2.36×10−01
Hippurate 3.15×10−02 2.06×10−02 8.48×10−03 2.65×10−02
Glutamine 2.41×10−02 2.26×10−02 2.22×10−02 5.00×10−02
Creatinine 2.01×10−02 1.85×10−02 4.10×10−02
Leucine 2.93×10−01 1.41×10−01 2.93×10−01 6.23×10−01
Pseudouridine 5.58×10−02 1.11×10−01 2.59×10−01 1.89×10−01
N -methyl nicotinate 6.13×10−01 7.85×10−01 9.19×10−01 8.89×10−01
Citrate 7.05×10−01 7.86×10−01 8.23×10−01 9.31×10−01
4-Cresyl sulfate 7.69×10−02 9.75×10−02 3.34×10−01 3.44×10−01
Trimethylamine 4.04×10−08 (W) 6.36×10−07 (W) 2.86×10−06 (W) 1.19×10−05 (W)
Lysine 6.25×10−01 5.37×10−01 5.49×10−01 9.45×10−01
Ethanolamine 6.95×10−01 9.58×10−01 8.59×10−01 7.33×10−01
3-Hydroxymandelate 1.15×10−01 9.57×10−02 1.40×10−01 5.87×10−01
Dimethylglycine 1.46×10−03 (W) 3.18×10−04 (W) 1.88×10−03 (W) 6.16×10−03
Ketoleucine to leucine ratio 4.10×10−01 6.59×10−01 9.00×10−01
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Table 5.25: P -values for a gender-interaction term included in Model 1, 2,
3 and 4 for the first urine collection IEC data for 444 U.K. INTERMAP
participants. Letters in parenthesis indicate the significantly associated gen-
der effect, (M) indicates the metabolite is more significant in men and (W)
indicates a stronger effect in women.
Model 1 Model 2 Model 3 Model 4
Urinary variable P-value P-value P-value P-value
Taurine 2.39×10−01 1.85×10−01 4.48×10−02 3.56×10−03
Threonine 4.73×10−01 5.54×10−01 5.48×10−01 9.02×10−01
Serine 3.21×10−01 3.22×10−01 3.00×10−01 9.24×10−01
Asparagine 9.53×10−01 8.90×10−01 8.79×10−01 9.64×10−01
Glutamine 5.41×10−01 4.70×10−01 3.56×10−01 7.48×10−01
Glycine 1.76×10−01 3.19×10−01 3.15×10−01 8.88×10−01
Alanine 8.20×10−01 6.96×10−01 4.78×10−01 7.00×10−01
Valine 3.70×10−01 4.79×10−01 6.97×10−01 5.13×10−01
Cystine 2.13×10−03 (W) 1.02×10−03 (W) 4.02×10−03 4.13×10−03
Isoleucine 7.04×10−01 6.45×10−01 8.18×10−01 8.33×10−01
Leucine 1.99×10−01 2.37×10−01 3.42×10−01 2.11×10−01
Tyrosine 2.08×10−01 2.83×10−01 4.19×10−01 3.27×10−01
Phenylalanine 1.44×10−01 2.86×10−01 3.72×10−01 2.86×10−01
Ethanolamine 6.65×10−01 9.61×10−01 8.94×10−01 6.87×10−01
Lysine 1.01×10−01 1.05×10−01 2.18×10−01 1.21×10−01
1-Methyl histidine 7.12×10−01 7.52×10−01 6.30×10−01 2.51×10−01
Histidine 4.22×10−01 3.68×10−01 3.37×10−01 6.61×10−01
Tryptophan 6.30×10−01 3.45×10−01 2.92×10−01 6.11×10−01
3-Methyl histidine 3.23×10−01 4.55×10−01 4.30×10−01 5.04×10−02
Carnosine 1.81×10−01 4.57×10−01 3.70×10−01 2.30×10−01
Arginine 2.82×10−01 4.24×10−01 6.75×10−01 4.72×10−01
5.3.9 Stability of urinary metabolite excretion patterns
The INTERMAP study used a serial sampling design with the two urine collec-
tions on average 3 weeks apart (see section 5.2.1). If the metabolites that were
found significantly associated with BMI in the two cohorts indeed reflect the un-
derlying obesogenic signature the urinary excretion should be highly consistent
between visits. This was tested by looking at the partial correlation between the
excretions in the first compared to the second visit, adjusted for Model 1. Fig-
ure 5.4a,b shows high inter-metabolite intra-visit correlations that highlight the
obesity-related homeostasis in metabolite excretion, with an added layer of com-
plexity in the U.S. samples – this could be due to the greater ethnic diversity
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(Table 5.1) or related to the cohort size. The data for both cohorts was adjusted
for multiple testing using similar Bonferroni corrections and there is an underpin-
ning inter-visit network of correlations common to both populations that highlights
the homeostasis. Some correlations are not symmetric between populations; these
may be caused by dietary, environmental, genetic and/or other reasons, or be-
cause of the difference in statistical power between the U.S. and U.K. data. On
the diagonal of Figure 5.4a,b the partial correlation of visit 1 and visit 2 is shown
for each metabolite and for each metabolite the highest correlation found is in-
deed the intra-metabolite concentration, as would be expected from this temporal
correlation matrix. The off-diagonal elements represent correlations of different
metabolites between visits, the correlation matrices were symmetrized as a corre-
lation would have to be commutative between visits. These patterns match the
auto-correlations of each visit as shown in Figure 5.4c,d.
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Figure 5.4: Inter- and intra-visit partial correlations of metabolites highlight the
obesity-related homeostasis in urinary 1H NMR metabolite excretion, adjusted for
Model 1. A Bonferroni threshold (P < 1.39×10−4 for U.S.) was used to correct for
multiple testing, with the threshold converted to a correlation threshold for the
U.K. data to allow for better comparison between the populations. Abbreviations
are spelled out in Table 5.6. (a) U.S. population (n=1,880). (b) U.K. popula-
tion (n=444). The smallest partial correlation is shown on the lower diagonal
for (a) and (b) and partial correlations are only shown if they exhibit symmetry
within population. (c) and (d) show the inter-visit correlations for the U.S. and
U.K. population samples, respectively, where the lower diagonal shows the auto-
correlations for the first urine collection data and the upper diagonal for the second
urine collection.
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5.3.10 Homeostatic metabolic network map of obesity
A novel minimally-structured metabolic map of the BMI biomarker data was con-
structed using the MetaboNetworks software (Chapter 3) to link together all these
observed biomarkers in an integrated metabolic reaction network [194]; this ef-
fectively summarizes the human systemic homeostatic signature of obesity (Fig-
ures 5.5 and 5.6).
The metabolic systems map (Figure 5.5), see full page figure in Appendix A,
reveals the diversity of underlying metabolic perturbations related to BMI, many
not observed previously, and the close connectivity between metabolites linked
to multiple human body compartments and gut microbial activities. The map
shows 1) the biomarkers significantly associated with BMI and the direction of
association (red: direct association, cyan: inverse association with BMI), and 2)
major metabolic function classified via a coloured overlay showing the class or
compartment associations of the metabolites (Figure 5.5 and Table 5.27). It in-
dicates links between muscle and BCAA energy metabolism and a dominantly
lipidic metabolism network. The gut microbial related biomarkers of BMI map
onto several pathways embedded in the host multi-compartment network, for in-
stance 4-cresyl sulfate and 3- and 4-hydroxymandelate to the aromatic amino acid
pathway cluster and trimethylamine to choline metabolism. Also hippurate (ben-
zoylglycine) production is linked to mitochondrial metabolism as all amino acid
conjugations require initiation via co-enzyme A adduct formation, which occurs
in the mitochondrial compartment [244]. The close connection of hippurate mod-
ulation with TCA cycle intermediates has been observed toxicologically where
mitochondrial activity has been compromised – metabolic connectivities are re-
lated to common compartmental location rather than simple enzymatic pathway
networks [265]. The reaction network therefore provides a systems overview of the
metabolic disturbances associated with obesity.
The metabolite associations are highly consistent between populations and by
including all metabolites significantly associated with BMI, as per Tables 5.17, 5.18
and 5.21, a network map was generated for the U.K. population (Figure 5.6), see
full page figure in Appendix A. Both networks are highly similar, highlighting the
consistency across populations of the homeostatic signature of obesity.
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Figure 5.5: Multi-compartmental metabolic reaction network illustrating the
human obesity-related homeostatic metabolic signature in the U.S. population
(n=1,880). Metabolites shown in red were found to be positively associated with
BMI, metabolites in cyan negatively associated with BMI and a green edge in-
dicates a stronger effect in women compared to men. The background shading
illustrates different types of metabolism: tricarboxylic acid (TCA) cycle (), TCA
anaplerotic (), mitochondrial (), muscle (), branched-chain amino acid (),
lipid, fatty acid and related (), gut microbial (), 1-carbon (), sugar, carbohy-
drate and related (), DNA and protein derivatives (), aromatic compounds ()
and sulfur () metabolism. Tables 5.26 and 5.27 list the full names, abbreviations
and closest affinity classifications for metabolites shown in this figure.
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Figure 5.6: Multi-compartmental metabolic reaction network illustrating the
human obesity-related homeostatic metabolic signature in the U.K. population
(n=444) using a Benjamini-Hochberg FDR adjustment of the P -values for mul-
tiple hypothesis testing (pFDR<0.05) (Tables 5.17, 5.18 and 5.21). Metabolites
shown in red were found to be positively associated with BMI, metabolites in
cyan negatively associated with BMI and a green edge indicates a stronger effect
in women compared to men. The background shading illustrates different types
of metabolism: tricarboxylic acid (TCA) cycle (), TCA anaplerotic (), mito-
chondrial (), muscle (), branched-chain amino acid (), lipid, fatty acid and
related (), gut microbial (), 1-carbon (), sugar, carbohydrate and related
(), DNA and protein derivatives (), aromatic compounds () and sulfur ()
metabolism. Tables 5.26 and 5.27 list the full names, abbreviations and closest
affinity classifications for metabolites shown in this figure.
Table 5.26: Full names and abbreviations of metabolites
in the metabolic reaction networks (Figures 5.5 and 5.6).
Full metabolite name Abbreviation
2-Ketovaline 2-Ketovaline
2-Methyl-1-hydroxybutyl thiamin 2Me-1OH-Bu-TPP
pyrophosphate
Continued on next page
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Continued from previous page
Full metabolite name Abbreviation
2-Methyl-1-hydroxypropyl thiamin 2Me-1OH-Pr-TPP
pyrophosphate
(S)-2-Methylbutanoyl co-enzyme A 2Me-Bt-CoA
S-(2-Methylbutanoyl)-dihydrolipoamide-E 2Me-Bt-DiH-LipE
S-(2-Methylpropanoyl)-dihydrolipoamide-E 2Me-Pp-DiH-LipE
2-Hydroxyethyl thiamin pyrophosphate 2OH-Et-TPP
2-Hydroxyisobutyrate 2OH-isobutyrate
2-Hydroxyphenylacetate 2OH-Ph-acetate
2-Oxoglutaramate 2-Oxoglutaramate
2-Oxoglutarate 2-Oxoglutarate
3-Carboxy-1-hydroxypropyl thiamin 3Cx-1OH-Pr-TPP
pyrophosphate
3-Fumarylpyruvate 3-Fumarylpyruvate
3-Iodo-L-tyrosine 3I-L-Tyr
3-Methyl-1-hydroxybutyl thiamin pyrophosphate 3Me-1OH-Bu-TPP
(S)-3-Methyl-2-oxopentanoate 3Me-2-oxopentanoate
S-(3-Methylbutanoyl)-dihydrolipoamide-E 3Me-Bt-DiH-LipE
3-Methyl histidine 3Me-His
L-Dopa 3OH-L-Tyr
3-Hydroxymandelate 3OH-mandelate
3-Oxopropanoate 3-Oxopropanoate
4-Cresyl sulfate 4-Cresyl sulfate
4-Maleylacetoacetate 4-Maleylacetoacetate
4-Hydroxymandelate 4OH-mandelate
4-Hydroxyphenylacetyl co-enzyme A 4OH-Ph-Ac-CoA
4-Hydroxyphenylacetylglycine 4OH-Ph-Ac-Gly
4-Hydroxyphenylpyruvate 4OH-Ph-pyruvate
4-Oxobutanoate 4-Oxobutanoate
5,10-Methenyl tetrahydrofolate 5,10-Methenyl-THF
5,10-Methylene-tetrahydrofolate 5,10-Methylene-THF
Continued on next page
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Full metabolite name Abbreviation
10-Formyl-tetrahydrofolate 10-Formyl-THF
10-Formyl-tetrahydrofolate-L-glutamate 10-Formyl-THF-L-Glu
Acetyl co-enzyme A Ac-CoA
Adenylosuccinate Adenylosuccinate
Arachidonylethanolamine AEA
Anserine Anserine
Arachidonate Arachidonate
Arachidonyl co-enzyme A Arachidonyl-CoA
beta-Alanine β-Ala
beta-Alanyl-L-arginine β-Ala-L-Arg
beta-Alanyl-L-lysine β-Ala-L-Lys
Betaine Betaine
Betaine aldehyde Betaine aldehyde
Carbamoyl phosphate Carbamoyl-P
Carnosine Carnosine
Cytidine diphosphate ethanolamine CDP-ethanolamine
Cephalin Cephalin
Choline Choline
Choloyl co-enzyme A Choloyl-CoA
Citrate Citrate
Cytidine monophosphate CMP
Cytidine monophosphate N -acetyl CMP-NANA
neuraminic acid
Co-enzyme A CoA
Creatine Creatine
Phosphocreatine Creatine-P
Creatinine Creatinine
Cysteinyldopa Cys-Dopa
Cysteinylglycine Cys-Gly
Dehydro-alanine Dehydro-Ala
Continued on next page
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Full metabolite name Abbreviation
D-Glucosamine phosphate D-Glca-P
Dihydrofolate DHF
Dihydrolipoamide-E DiH-LipE
Dimethylglycine DMG
Dopaquinone Dopaquinone
Ethanolamine Ethanolamine
Phosphoethanolamine Ethanolamine-P
Formate Formate
Fumarate Fumarate
Fumarylacetoacetate Fumarylacetoacetate
gamma-Aminobutyric acid GABA
gamma-Glutamyl-cysteine γ-Glu-Cys
Glycinamide ribonucleotide GAR
Glycine Gly
Glycocholate Glycocholate
Glutathionine GSH
Guanidinoacetate Guanidinoacetate
Hippurate Hippurate
Homocarnosine Homocarnosine
Homogentisate Homogentisate
Isobutyryl co-enzyme A IsoBt-CoA
Isocitrate Isocitrate
Ketoleucine Ketoleucine
L-Alanine L-Ala
L-Arginine L-Arg
L-Arginine-succinate L-Arg-succinate
L-Asparagine L-Asn
L-Aspartate L-Asp
L-Cystine L-Cys
L-Cystathionine L-Cystathionine
Continued on next page
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Full metabolite name Abbreviation
L-Formylkynurenine L-Formylkynurenine
L-Glutamine L-Gln
L-Glutamine L-Glu
L-Histidine L-His
L-Homocysteine L-homo-Cys
L-Isoleucine L-Ile
Lipoamide-E LipE
L-Leucine L-Leu
L-Lysine L-Lys
L-Phenylalanine L-Phe
L-Serine L-Ser
Leukotriene A4 LTA4
Leukotriene C4 LTC4
L-Threonine L-Thr
L-Tryptophan L-Trp
L-Tyrosine L-Tyr
L-Valine L-Val
Malate Malate
Malonyl co-enzyme A Malonyl-CoA
Methanal Methanal
(N -acetyls from) Urinary glycoproteins NAc GP
N -acetyl-D-glucosamine 6-phosphate NAc-D-Glca 6-P
N -acetyl-D-mannosamine NAc-D-Mana
N -acetyl glucosamine NAc-Glca
N -acetyl neuraminic acid NANA
N -carbamoyl-L-aspartate N-Carbamoyl-L-Asp
N -formyl-L-asparate N-Formyl-L-Asp
N -methyl nicotinate NMNA
O-succinylhomoserine O-Suc-hSer
Oxaloacetate Oxaloacetate
Continued on next page
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Full metabolite name Abbreviation
Phenylacetyl co-enzyme A PhAc-CoA
Phenylacetaldehyde Ph-acetaldehyde
Phenylacetate Ph-acetate
Phenethylamine PhEt-amine
Phenylpyruvate Ph-pyruvate
Plasmenylcholine Pl-choline
Plasmenylethanolamine Pl-ethanolamine
Pseudouridine Pseudouridine
Phosphatidylserine Ptd-Ser
Pyruvate Pyruvate
5-Phosphoribosylamine Riba-5P
Saccharopine Saccharopine
S -acetyldihydrolipoamide-E Sac-DiH-LipE
1-(5’-Phosphoribosyl)- SAICAR
4-(N -succinocarboxamide)-5-aminoimidazole
Sarcosine Sarcosine
S -succinyldihydrolipoamide-E S-Succinyl-DiH-LipE
Succinate Succinate
Succinyl co-enzyme A Succinyl-CoA
Taurine Taurine
Tetrahydrofolate THF
Trimethylamine TMA
Thiamin pyrophosphate TPP
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Table 5.27: Abbreviations and closest affinity classifica-
tions of metabolites in the metabolic reaction networks
(Figures 5.5 and 5.6). An X indicates an affinity to a
specific class.
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2-Ketovaline X
2Me-1OH-Bu-TPP X
2Me-1OH-Pr-TPP X
2Me-Bt-CoA X X
2Me-Bt-DiH-LipE X
2Me-Pp-DiH-LipE X
2OH-Et-TPP X
2OH-isobutyrate X
2OH-Ph-acetate X
2-Oxoglutaramate X
2-Oxoglutarate X
3Cx-1OH-Pr-TPP X
3-Fumarylpyruvate X
Continued on next page
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3I-L-Tyr X
3Me-1OH-Bu-TPP X
3Me-2-oxopentanoate X
3Me-Bt-DiH-LipE X
3Me-His X
3OH-L-Tyr X
3OH-mandelate X X
3-Oxopropanoate X
4-Cresyl sulfate X X
4-Maleylacetoacetate X
4OH-mandelate X X
4OH-Ph-Ac-CoA X X
4OH-Ph-Ac-Gly X X
4OH-Ph-pyruvate X
4-Oxobutanoate X
5,10-Methenyl-THF X
5,10-Methylene-THF X
Continued on next page
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10-Formyl-THF X
10-Formyl-THF-L-Glu X X
Ac-CoA X
Adenylosuccinate X
AEA X
Anserine X
Arachidonate X
Arachidonyl-CoA X X
β-Ala
β-Ala-L-Arg
β-Ala-L-Lys
Betaine X
Betaine aldehyde X X
Carbamoyl-P X
Carnosine X
CDP-ethanolamine X
Cephalin X
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Choline X
Choloyl-CoA X X
Citrate X
CMP X
CMP-NANA X
CoA X
Creatine X
Creatine-P X
Creatinine X
Cys-Dopa X X
Cys-Gly X
Dehydro-Ala
D-Glca-P X
DHF X
DiH-LipE X
DMG X
Dopaquinone X
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Ethanolamine X
Ethanolamine-P X
Formate X X
Fumarate X
Fumarylacetoacetate X
GABA
γ-Glu-Cys X
GAR
Gly
Glycocholate X X
GSH X
Guanidinoacetate X
Hippurate X X
Homocarnosine X
Homogentisate X
IsoBt-CoA X X
Isocitrate X
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Ketoleucine X X
L-Ala X
L-Arg
L-Arg-succinate X
L-Asn X
L-Asp X
L-Cys X
L-Cystathionine X
L-Formylkynurenine X
L-Gln X
L-Glu X
L-His X
L-homo-Cys X
L-Ile X
LipE X
L-Leu X X
L-Lys
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L-Phe X
L-Ser
LTA4 X
LTC4 X
L-Thr
L-Trp
L-Tyr X
L-Val X
Malate X
Malonyl-CoA X
Methanal X
NAc GP X
NAc-D-Glca 6-P X
NAc-D-Mana X
NAc-Glca X
NANA X
N-Carbamoyl-L-Asp X
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N-Formyl-L-Asp X X
NMNA
O-Suc-hSer
Oxaloacetate X
PhAc-CoA X X
Ph-acetaldehyde X
Ph-acetate X
PhEt-amine X
Ph-pyruvate X
Pl-choline X
Pl-ethanolamine X
Pseudouridine X
Ptd-Ser X
Pyruvate X
Riba-5P X
Saccharopine X
Sac-DiH-LipE X
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SAICAR X
Sarcosine X
S-Succinyl-DiH-LipE X
Succinate X
Succinyl-CoA X X
Taurine X
THF X
TMA X
TPP X
5.3.11 Population BMI variance
In order to investigate the collective importance of metabolism, environment, diet
and lifestyle in the ongoing obesity epidemic a multiple linear regression model was
calculated using the covariates from Model 1, 2 and 3, and the metabolic variables
(NMR, IEC) that were significantly associated with BMI, ensuring each metabolite
was only included once. Together the models explain 49% (U.S.) and 45% (U.K.)
201
CHAPTER 5. METABOLIC SIGNATURES OF HUMAN OBESITY
of the population BMI variance (Tables 5.28 and 5.29). The urinary metabolites
alone account for 37% (U.S.) and 32% (U.K.) of the BMI variance (Table 5.30).
These results are in stark contrast with a mere 1.45% of BMI variance explained by
the combination of all known common genetic variants for BMI [250], suggesting
metabolism, environment, diet and lifestyle play a far larger role in obesity than
genetics/hereditary factors.
Model 1 covariates (population structure) account for 3.27% (U.S.) and 3.31%
(U.K.) of the BMI variance, Model 2 (lifestyle factors) for 6.57% (U.S.) and 6.75%
(U.K.) and Model 3 (dietary variables) for 2.09% (U.S.) and 3.27% (U.K.). For the
metabolite contribution, all metabolites associated with (skeletal) muscle turnover
(creatinine, 3-methylhistidine, ethanolamine, ketoleucine to leucine ratio, histi-
dine, carnosine, 1-methylhistidine (U.S. only)) together explain 14.57% (U.S.) and
9.72% (U.K.) of the BMI variance which is the largest proportion of any of the
metabolite groups (Table 5.30). Urinary glycoproteins and N -acetyl neuraminate
explain 5.80% (U.S.) and 7.19% (U.K.) of the BMI variance highlighting the un-
derlying aspect of renal function and obesity [261] which, given that participants
with known diabetes were excluded, may indicate damage to the glomerular barrier
[266] preceding diabetes. It is already well known that amino acids, in particular
the BCAAs leucine, isoleucine and valine, play a huge role in obesity [224, 225,
227]. In this study the amino acids collectively explain 9.19% in the U.S. cohort
and 8.55% of BMI variance in the U.K. cohort (Table 5.30). However, it is of note
that the aromatic amino acids (tyrosine, phenylalanine, tryptophan) explain close
to half of the amino acid related BMI variance, 4.14% (U.S.) and 3.46% (U.K.).
Cystine, on its own, explains 3.53% and 3.00% of the BMI variance in the U.S.
and U.K., respectively. TCA cycle intermediates citrate and succinate explain
1.20% (U.S.) and 0.74% (U.K.) of the total BMI variance with succinate being
the most important of the two (Tables 5.28 and 5.29), this may be caused by the
fact that the chemical shifts of citrate are highly affected by pH differences. Last,
gut microbial co-metabolites collectively explain 1.53% (U.S.) and 3.92% (U.K.) of
the population BMI variance. This is reflected by the known association between
obesity and the microbiome in humans [245, 247, 267–269].
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Table 5.28: Multiple linear regression with statistical
shrinkage of regression coefficients of BMI against uri-
nary metabolites and population, lifestyle and dietary
factors for 1,880 U.S. INTERMAP participants; R2 of
the model is 0.49 with the correlation shrinkage param-
eter λ=0.014. Metabolites were included on the basis of
being significant in Model 1 and 2 or in Model 4, see Ta-
bles 5.5, 5.8 and 5.11. The most significant was included
for variables that were measured by both 1H NMR and
IEC. All dietary variables are also included. 7 binary
variables were created for 8 centres. Gender is coded as
0 for men and 1 for women.
Variable Sign BMI R2 explained
Gender + 1.66%
Age + 0.08%
Sample 1 − 0.04%
Sample 2 − 0.65%
Sample 3 − 0.23%
Sample 4 − 0.01%
Sample 5 − 0.03%
Sample 6 + 0.55%
Sample 7 − 0.02%
Diagnosed heart condition/disease + 0.06%
Physical activity − 0.04%
Medication for hypertension + 4.28%
Prescribed lipid lowering drugs + 0.04%
NSAIDs use + 0.23%
Supplement use − 0.32%
Special diet + 0.40%
Smoker − 0.16%
Education − 1.03%
Continued on next page
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Continued from previous page
Variable Sign BMI R2 explained
Total energy intake + 0.01%
Dietary animal protein + 0.27%
Dietary vegetable protein − 0.01%
Dietary cholesterol + 0.38%
Dietary total SFA + 0.10%
Dietary total MFA + 0.45%
Dietary total PFA + 0.03%
Estimated total sugar + 0.00%
Alcohol 7-day record − 0.19%
Dietary starch − 0.12%
Dietary calcium + 0.10%
Dietary phosphorus + 0.00%
Dietary magnesium − 0.09%
Dietary sodium + 0.11%
Dietary potassium − 0.04%
Dietary iron − 0.18%
Urinary creatinine (mmol/24hr) + 7.25%
Urinary glycoproteins + 4.87%
Urinary succinate − 0.87%
Urinary N -acetyl neuraminate + 0.93%
Urinary hippurate − 0.35%
Urinary glutamine − 1.51%
Urinary pseudouridine + 0.35%
Urinary N -methyl nicotinate − 0.69%
Urinary citrate − 0.33%
Urinary 4-cresyl sulfate − 0.63%
Urinary trimethylamine + 0.17%
Urinary 3-hydroxymandelate − 0.33%
Urinary dimethylglycine + 0.05%
Urinary ketoleucine to leucine ratio − 1.09%
Continued on next page
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Continued from previous page
Variable Sign BMI R2 explained
Urinary taurine − 0.60%
Urinary threonine + 0.07%
Urinary serine − 0.32%
Urinary asparagine − 1.09%
Urinary glycine − 0.16%
Urinary alanine + 0.32%
Urinary valine + 0.40%
Urinary cystine + 2.93%
Urinary isoleucine + 0.03%
Urinary tyrosine + 3.66%
Urinary phenylalanine + 0.40%
Urinary ethanolamine + 1.72%
Urinary lysine + 1.12%
Urinary 1-methyl histidine + 0.07%
Urinary histidine − 0.01%
Urinary tryptophan + 0.08%
Urinary 3-methyl histidine + 4.34%
Urinary carnosine + 0.10%
Urinary arginine − 0.01%
205
CHAPTER 5. METABOLIC SIGNATURES OF HUMAN OBESITY
Table 5.29: Multiple linear regression with statistical
shrinkage of regression coefficients of BMI against urinary
metabolites and population, lifestyle and dietary factors
for 444 U.K. INTERMAP participants; R2 of the model
is 0.45 with the correlation shrinkage parameter λ=0.040.
Metabolites were included on the basis of being signifi-
cant in Model 1 and 2 or in Model 4, see Tables 5.17, 5.18
and 5.21. The most significant was included for variables
that were measured by both 1H NMR and IEC. All di-
etary variables are also included. 1 binary variable was
created for 2 centres. Gender is coded as 0 for men and
1 for women.
Variable Sign BMI R2 explained
Gender + 1.75%
Age + 1.27%
Sample − 0.30%
Diagnosed heart condition/disease + 0.14%
Physical activity − 0.33%
Medication for hypertension + 2.37%
Prescribed lipid lowering drugs + 1.45%
NSAIDs use + 0.07%
Supplement use − 0.07%
Special diet + 1.15%
Smoker − 0.03%
Education − 1.13%
Total energy intake + 0.08%
Dietary animal protein + 0.01%
Dietary vegetable protein − 0.30%
Dietary cholesterol − 0.00%
Dietary total SFA + 0.00%
Dietary total MFA + 0.45%
Continued on next page
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Continued from previous page
Variable Sign BMI R2 explained
Dietary total PFA − 0.23%
Estimated total sugar − 0.22%
Alcohol 7-day record − 0.00%
Dietary starch − 0.00%
Dietary calcium − 0.02%
Dietary phosphorus − 0.05%
Dietary magnesium − 0.35%
Dietary sodium + 0.86%
Dietary potassium + 0.00%
Dietary iron + 0.69%
Urinary creatinine (mmol/24hr) + 2.71%
Urinary glycoproteins + 6.91%
Urinary succinate − 0.73%
Urinary N -acetyl neuraminate + 0.28%
Urinary hippurate − 1.39%
Urinary glutamine − 1.90%
Urinary citrate + 0.01%
Urinary 4-cresyl sulfate − 0.46%
Urinary trimethylamine + 1.57%
Urinary dimethylglycine + 0.50%
Urinary ketoleucine to leucine ratio − 1.88%
Urinary glycine − 0.92%
Urinary alanine + 0.18%
Urinary valine + 0.27%
Urinary cystine + 3.00%
Urinary tyrosine + 3.10%
Urinary phenylalanine + 0.23%
Urinary ethanolamine + 2.50%
Urinary lysine + 0.62%
Urinary histidine − 1.03%
Continued on next page
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Continued from previous page
Variable Sign BMI R2 explained
Urinary tryptophan + 0.12%
Urinary 3-methyl histidine + 1.51%
Urinary carnosine + 0.09%
Urinary arginine + 0.17%
Table 5.30: Variance contribution of different components in the multiple
linear regression model with statistical shrinkage of regression coefficients of
BMI against urinary metabolites and population, lifestyle and dietary factors.
Component Variables included U.S. U.K.
Full model Model 1, 2 and 3, urinary metabolites 48.79% 45.42%
Population structure Model 1 3.27% 3.31%
Lifestyle factors Model 2 6.57% 6.75%
Dietary variables Model 3 2.09% 3.27%
Urinary metabolites All urinary metabolites 36.86% 32.09%
Creatinine, 3-methylhistidine, ethanolamine,
Muscle metabolites ketoleucine/leucine-ratio, histidine, carnosine, 14.57% 9.72%
1-methylhistidine (U.S. only)
Gut microbial co-metabolites Hippurate, 4-cresyl sulfate, trimethylamine, 1.53% 3.92%
and related 3-hydroxymandelate (U.S. only), dimethylglycine
Renal function metabolites Glycoproteins, N -acetyl neuraminate 5.80% 7.19%
TCA cycle metabolites Citrate, succinate 1.20% 0.74%
Alanine, asparagine (U.S. only), glutamine, glycine,
Amino acids histidine, isoleucine (U.S. only), lysine, phenylalanine, 9.19% 8.55%
serine (U.S. only), threonine (U.S. only), tryptophan,
tyrosine, valine
Aromatic amino acids Phenylalanine, tryptophan, tyrosine 4.14% 3.46%
Amino acid related Taurine (U.S. only), cysteine 3.53% 3.00%
(sulfur metabolism)
Other urinary metabolites Pseudouridine (U.S. only), 1.04% N/A
N -methyl nicotinate (U.S. only)
5.4 Discussion
The 24hr urinary metabotypes are the daily end-products of the body’s biochem-
ical activities and renal homeostatic regulation to maintain plasma composition
and are highly consistent between visits and populations in the cross-sectional
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study design (Figures 5.4, 5.5 and 5.6). In order to explain the highly com-
plex multi-compartmental systemic interactions in obesogenesis no single ‘close
the loop’ experiment is possible, thus it is unlikely that manipulation of a single
pathway affected by obesity will be able to differentiate cause from consequence.
Nevertheless, some targeted experiments may shed more light on different aspects
identified here, such as investigating the biological role of specific gut microbiota
involved in these pathways (for instance tyrosine to 4-cresyl sulfate) and assess
differences related to the possible introduction of certain probiotics [270], as it has
been shown here these pathways are significantly perturbed in obesity.
A previous animal study has shown that gut microbiota modulate the endo-
cannabinoid system, the endocannabinoid system in turn regulates gut perme-
ability and that cannabinoids cause adipogenesis in mice [271]. In this study
ethanolamine, a phospholipid and major component of the endocannabinoid sys-
tem [252], was found increased with higher BMI and associated with skeletal muscle
metabolism, whereas most microbial metabolites were found inversely associated
with BMI, with the exception of trimethylamine and dimethylglycine (which can
have a mammalian as well as microbial source). It may be interesting in future
to investigate whether the same gut microbiota that are involved in modulation
of the endocannabinoid system are also responsible for the excretion of some gut
microbial co-metabolites positively associated with BMI. Also how the relative
abundance of microbiota involved in production of, for instance, hippurate and
4-cresyl sulfate are in relation to the endocannabinoid-related microbiota.
600 MHz 1H NMR spectroscopy is well suited to measure 100s of metabolites
simultaneously, however this comes at the price of overlap between metabolites,
and thus increased variance of variables, which may cause regression dilution in
the analyses described here. However, in contrast to other studies on obesity, in
plasma [225–229, 245, 246] and spot urine [246], the use of 24hr urine samples
as biological reporter matrix gives an integrated value over 24hr, and the serial
sampling design of the study shows the stability of metabolite excretion patterns
in the data presented here (Figure 5.4). Moreover, 24hr urine gives a homeostatic
signature of all metabolic processes in a biological system, whereas the plasma
biological matrix holds information on physiological status at the specific sampling
time [223]. Compared to the other studies studying the metabolome in relation to
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obesity [225–229, 245, 246], this study has by far the largest cohort and investigates
metabolic disturbances related to continuous BMI opposed to looking at differences
between lean and (severely) obese individuals. The results in the U.S. and U.K.
are largely in accordance, however these results cannot be extrapolated to Asian
populations (such as the Chinese and Japanese INTERMAP cohorts) as obesity
is known to manifest differently in Asian populations [272–274].
In conclusion, the relationships shown here between the 24hr urinary metabo-
type and BMI delineate the homeostatic metabolic signature associated with the
modern obesity epidemic in two western populations. They reveal multiple con-
nections between metabolic compartments, and provide possible starting points for
new approaches to prevention and treatment. One such an approach may be the
introduction of specific probiotics to replace ‘pro-obesogenic gut microbes’ with
‘healthy ones’ [270], as it has been shown that specific groups of microbiota taken
from human faecal samples influence weight gain in mice [275, 276]. Or by taking a
diametrically opposed approach by identifying changes in microbial compositions
related to specific dietary habits and change as much of the diet needed to alter
‘pro-obesogenic’ gut microbes [247, 267]. Given that the proportion of the total
body mass that is skeletal muscle mass is on average 30% in women and 38% in men
[277], the high level of resting energy consumption and even higher level of energy
expenditure during exercise, where up to 90% of the whole body oxygen uptake is
used by the skeletal muscles [278], it is not surprising that muscle markers, such as
for instance 3-methylhistidine, creatinine and ethanolamine, explain a large pro-
portion of the BMI variance (Table 5.30). In addition, the new observation that
the ketoleucine to leucine ratio correlates strongly with BMI is related to the uti-
lization of BCAAs in muscle metabolism. More specifically, because it is the first
step in the catabolism of leucine and under control of an exercise inducible enzyme
[249] it indicates that the physical inactivity associated with obesity constrains the
ability to use such pathways for energy expenditure. This further confounds the
‘calorific burden’ of non-exercise, thus favouring obesogenesis. Therefore lifestyle
changes such as regular exercise should be made collectively with changes in diet
and other aspects [279], or else the upward trends in obesity-related morbidity and
mortality in the U.S., U.K. and other countries [221] may cause the costs of the
healthcare system to ‘grow out of proportions’.
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Chapter 6
Optimized Biomarker Discovery
and Confounder Elimination via
Covariate-Adjusted Orthogonal
Projections to Latent Structures
Summary
Metabolism is influenced by genetics, diet, disease status and other environmental
factors. Attributing differences in metabolic profile to one or more of these factors
ideally should to be done while controlling for the potential metabolic influence
of the other factors. I describe here Covariate-Adjusted Orthogonal Projections
to Latent Structures (CA-OPLS), a novel method and framework to adjust mul-
tivariate data for confounding factors. Firstly, using simulated data, I show that
CA-OPLS finds similar numbers of true positive associations with significantly less
false positives compared to other methods. Secondly, CA-OPLS is exemplified in
this chapter using a large-scale metabolic phenotyping study of two Chinese popu-
lations at different risks for adult cardiovascular diseases. Compared to a previous
study on the same population, CA-OPLS finds that a number of previously re-
ported biomarkers are associated with external factors rather than the difference
between populations. In addition, a number of previously unreported biomarkers
linked to different metabolic pathways are found and discussed. CA-OPLS and
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the data analysis framework can be applied to any type of multivariate data where
confounding may be an issue, moreover the confounder adjustment procedure is
easily translatable to other multivariate regression techniques as well.
6.1 Introduction
The human metabolic phenotype is influenced by many different factors, such as
dietary, environmental, genetic and microbial variation, [20, 39, 280–282] and re-
flects the health status of an individual [223]. It can be studied with metabonomics
[12] which involves using multivariate statistical methods to find which changes in
metabolite profiles are related to an outcome/response. For metabonomics stud-
ies urine is the most desirable biofluids, followed by plasma/serum, as it can be
relatively non-invasively obtained and they are not likely to be volume limited
in man [13]. Urine gives a homeostatic signature of all metabolic processes in a
biological system, including genetic, diet and gut microbial activity, and thus the
variation in the urinary metabolic profile can be attributed to many factors other
than disease risk, whereas the plasma/serum biological matrix holds information
on physiological status at the specific sampling time [223].
Measurement of the metabolome by NMR and/or MS yields data sets/matrices
(‘X’) with thousands to ten-thousands of variables, with often a much lower num-
ber of samples (‘n’) than the number of variables (‘p’). This wealth of information
comes at a price: there are likely to be spurious findings which will need to be
controlled for (multiple testing), as well as findings possibly attributable to other
factors (confounding) rather than the response variable (‘Y’). In molecular epi-
demiology studies there often is a wealth of meta-data available and the data of
population, metabolic and lifestyle risk factors are often gathered at the same time
as sample collection [283] and using this information confounders can be identified
and corrected for.
Controlling for confounding factors is an important aspect in epidemiological
research; however it is not common practice in metabonomics. In order to model
possibly confounding factors, three approaches have been used in metabonomic
studies.
First, multiple linear regression has been used [284–286] to regress Y on a
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matrix of the confounders (‘C’) and a single variable ‘i’ from the data set (‘Xi’) at
a time. This adjusts the contribution of Xi on Y as C is also included in the same
model. However, this approach is univariate for X, thus this regression has to be
done for each variable in X.
Second, different multivariate methods have been used to regress each con-
founder on X and then compare the significant metabolites with those found when
regressing Y on X [287–290].
Third, in metabonomics OPLS [95] is used to remove variation orthogonal to
Y from X before calculating the regression coefficients. OPLS has been claimed
to possibly correct for confounders [291–293], however confounders are not nec-
essarily orthogonal to the response and thus this method will not correct for all
confounders. Nevertheless, the OPLS method is popular in metabonomics due
to its ability to deal with large number of variables, a high degree of collinear-
ity in the data and only requiring one parameter to be estimated (the number of
(orthogonal) components).
The na¨ıve approach of concatenating matrices C and X and regressing Y on this
concatenated matrix (size [n,(p+c)], where c indicates the number of confounders)
using multivariate methods, to deal with n < p data, will most likely not properly
adjust for confounders as the number of variables in X will dominate the model.
Regularization approaches such as the lasso [149] can be used to circumvent this
problem in forcing the majority of regression coefficients (β) to 0 (uninteresting
variables). However, the lasso model can contain at most n non-zero coefficients
and is known to perform poorly when the data set consists of many correlated
variables (as is the case with metabonomics data) as lasso only includes a single
variable from a correlated set of variables. Therefore, the inclusion (non-zero
coefficient) of a variable from X in the lasso model does not necessarily mean it is
not associated with a confounder. The elastic net [152] on the other hand is able to
regularize coefficients while simultaneously including groups of correlated variables,
thus making a joint model of confounders and variables, however attributing which
variables are associated with a confounder still poses a problem.
In gene expression and proteomic literature there are methods that aim to sep-
arate covariations in the data [294–296]. In gene expression and GWAS there are
methods that aim to correct for unknown confounders by adjusting the model pre-
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dictions if the residual X data is still correlated to Y (unknown unmodelled effect)
[297–299] and methods that aim to adjust for both known (batch and population
structure) and unknown confounding factors [300, 301]. However, there are impor-
tant differences between the analysis of genomic/proteomic data and metabonomic
data. For the former, the data analysis is often done univariate for each variable
in X: each single-nucleotide polymorphism-gene combination is modelled individ-
ually. For the latter, the data is often analysed using multivariate methods as
these are able to capture interesting metabolite-metabolite interactions associated
with Y. These metabolite-metabolite interactions can be part of a perturbed path-
way associated with Y. Therefore, the methods commonly used in genomics and
proteomics are not easily applied to metabonomics data and a different approach
must be taken.
6.2 Materials and methods
6.2.1 INTERMAP
In this study, data from the three Chinese population samples were included to
study differences within the Chinese INTERMAP population. These three samples
(all rural) are from two geographical locations in PRC, two from the north (Pinggu
county in Beijing and Yu county in Shanxi) and one from the south (Wuming
county in Guangxi). See sections 4.2.1 and 4.2.5 for descriptions of the NMR
acquisition parameters and pre-treatment of the INTERMAP NMR data.
6.2.2 Identification of metabolites
STORM [230] was used to identify metabolites making use of the correlation struc-
ture of 1H NMR data. Localized clustering of small spectral regions was used to
selected reference spectra for STORM (see section 4.4). Additionally, a Bruker
compound library and internal databases were used to identify metabolites.
Confirmation of unknown signals was performed using a combination of stan-
dard 1D 1H NMR pulse sequence with water peak pre-saturation, 2D J-Resolved
(JRES), 1H-1H Correlation Spectroscopy (COSY), 1H-1H Total Correlation Spec-
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troscopy (TOCSY) and 2D 1H-13C Hetero-nuclear Single Quantum Coherence
(HSQC) experiments. All experiments used for identification purposes were ac-
quired using a Bruker AVANCE II spectrometer, operating at 800.32 MHz for 1H,
equipped with a 5 mm, TCI, Z-gradient CryoProbe.
6.2.3 PLS algorithm
To avoid the computationally expensive inflating step in non-iterative partial least
squares [94] (NIPALS) (see section 2.3.9), a modified version of the original SIM-
PLS algorithm [141] can be used to deal with a data matrix (X) where n < p
(Algorithm 4). The modification is regarding the first step in the original SIMPLS
(proposed for n > p) which, in the case of n < p, would result in a square matrix
of order p. In the modified algorithm, a sample-sample association matrix (A) is
defined as A = XXT , a square matrix of order n, and both X and Y are assumed
to be centered and, if required, scaled. It is repeated until a stop criterion (speci-
fied number of components or the maximum number of n components) is reached
(Algorithm 4). The algorithm gives the same results as the NIPALS algorithm for
a univariate response, however with a significant time gain [141]. Same as for NI-
PALS, this algorithm can also be used to do OPLS (see section 2.3.10), for which
the data matrix X is replaced by the orthogonal signal corrected [143] matrix Xosc.
Algorithm 4 SIMPLS [141] pseudo-code for X matrices with size n < p
1: A← XXT % association matrix
2: Y0 ← Y
3: k ← 1 % initialize k
4: while k ≤ n do
5: Rk ← Y Y TAY % weighted response
6: t← ARk % scores
7: Tk ← t√tT t
√
n− 1 % update score matrix
8: P ← XTT % loadings
9: Ck ← ATk % covariance-contribution of scores
10: Y ← Y − Tk
TTk Ck
CTk Y % update Y
11: βk ←
(
(R(( n−1
CTR
)◦Ik))
T
X
)T
TTT
T TY0 % ◦ denotes Hadamard product
12: k ← k + 1 % update k
13: end while
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6.2.4 Assessment of model fit and predictive ability
Two common statistics are often used to assess the fit and predictive ability of a
model, the goodness of fit (R2y) (Equation 2.53) and goodness of prediction (Q
2
y)
(Equation 2.54) [302]. The predictions (Yˆ ) of the (O)PLS algorithm are (roughly)
in the same range as the scaled response Y˜ .
For a sample, say Yi = 1, Equation 2.54 would penalize Yˆi = 1.2 the same
as Yˆi = 0.8 as the squared error is used. However, Yˆi = 1.2 is further from the
other class, say Y = −1, than Yˆi = 0.8 is. In other words, there is more certainty
that Yˆi = 1.2 is class Y = 1 than for Yˆi = 0.8. In order to avoid penalizing
this ‘error’, if for a response of two classes, the predicted value is bigger (in the
absolute sense) than its true value, the prediction is replaced with its true value
[137] (Equation 6.1) before calculating R2y and Q
2
y using Equations 2.53 and 2.54.
Yˆi =
{
Yi : sign(Yˆi − Yi) = sign(Yi)
Yˆi : otherwise
(6.1)
In this sense, this adjusted Q2y has also been termed the discriminant Q
2 [303].
Determining whether a model generalizes well is often done by judging whether
or not the Q2y is high enough and is a positive value. However, the definition of
high is subjective. Therefore it is better to look at it in relation to the R2y. The
robustness of cross-validation (RCV) is defined as the ratio between the two (Equa-
tion 6.2). The RCV can be seen as a measure of how well the model generalizes
(Q2y) with respect to the optimal fit (R
2
y).
RCV =
Q2y
R2y
(6.2)
A permutation scheme can be used to determine whether the value for RCV is
robust. For instance, Y can be permuted multiple times to obtain an acceptable
lower bound for the RCV of the model. However, permutation tests with Y can
result in negative Q2y and it should be avoided that these contribute to the lower
bound of the RCV. A soft threshold for the RCV can be determined for each
model. I consider an RCV > 0.25 to be reasonably robust, with RCV’s > 0.9
(provided the Q2y is not too low) to be indicative of highly robust models (see also
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section 6.3).
6.2.5 Variable significance
The variable significance is shown in plots similarly to the Manhattan plot
(Equation 6.3).
Sj = −
δ(β1j×β2j ),1 × β
1
j
|β1j |
log10
(
max
(
q1j , q
2
j
))
(6.3)
Defining Sj as the significance, β
a
j as the regression coefficient for visit ‘a’ and
qaj as the q-value (Storey-Tibshirani FDR [114]) for visit ‘a’, all for variable j.
Because of the uniqueness of the INTERMAP data, another constraint is placed
on the significance of a variable, as there are two urine collections of the same
individuals: a variable has to be significant in both models as well as having the
same sign in both.
6.2.6 Generation of the metabolic reaction network
Using metabolites significantly associated with the Chinese populations of two ge-
ographical regions a metabolic reaction network is constructed to highlight the
differential excretion of metabolites linked to different pathways and to show the
metabolite-metabolite relationships. In the network an edge exists between two
metabolites if a reaction, with these metabolites as main reactant pairs, is listed in
KEGG [179] that can occur in Homo sapiens (solid lines, Figure 6.12) or the most
abundant endosymbionts (dotted lines, Figure 6.12) which make up 99% of the
phylotypes found in the human gut [17]: the phyla Firmicutes, Bacteroidetes,
Proteobacteria (alphaproteobacteria, betaproteobacteria, gammaproteobacteria,
deltaproteobacteria) and Actinobacteria.
6.2.7 Simulated data
In order to compare confounder-adjusted OPLS (CA-OPLS) to standard PLS and
OPLS, 100 data sets were simulated with 50 case (Y = 1) and 50 control (Y =
0) objects. In the data generation two confounding effects were added, one which
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was non-orthogonal to Y (r = ±0.36) and another which was almost orthogonal
to Y (r = ±0.04). The Pearson correlation between the two confounders was r =
±0.2.
Each data set consists of 2000 variables sampled from normal distributions with
unit variance (σ2 = σ = 1), see Equation 2.3. 10% of the variables were sampled
using a different mean for one class to induce class separation. These 10% are
considered to be the ‘true positives’. Both confounders also affect 10% of the
variables, with the addition that there is 25% overlap between the 200 variables
affected by Y and the variables affected by each of the confounders. The difference
in mean (effect size, es) between the distributions of the two classes was 1 (≈61%
overlap of distributions) and 1.645 (≈41% overlap) for the first 50 and the second
50 simulated data sets, respectively.
In total there are 8 (23) unique types of samples, and the class of each object
i is coded as a 3-tuple Si with 3 elements x, y and z : where x indicates whether
the sample is case or control, y whether it is affected by confounder 1 and z for
confounder 2.
The same goes for the variables, each variable (j ) has a 3-tuple code Vj with
3 elements x, y and z that indicate whether or not the variable is affected by the
case/control status, confounder 1 and/or confounder 2, respectively. Additionally,
the effect of each factor (Y, confounder 1, confounder 2) was assigned a sign for
each variable at random, where for variable j, aj, bj and cj are the signs for Y,
confounder 1 and confounder 2, respectively. This results in a total of 27 (33)
unique types of variables.
6.2.8 Generation of simulated data
The data for each variable is drawn from specific normal distributions (with σ2 =
σ = 1) depending on the sample class, effect size (es) and effect signs (aj, bj and
cj). For a variable j unaffected by any of the covariates (Vj = (0, 0, 0)) data for
object i is simply drawn from a standard normal distribution, Xij = φ(0, 1). Data
for variables that only contain information of case/control status are calculated
according to Xij = δSi,1bc×φ(aj×es, 1)+δSi,0bc×φ(0, 1). Here, only one Kronecker
Delta has a value of 1, depending on object i’s 3-tuple and the 3-tuple values for
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the confounders (b, c) are not important as the variable is not affected by the
confounders. The same goes for variables which only contain information from
confounder 1 (Xij = δSi,a1c × φ(bj × es, 1) + δSi,a0c × φ(0, 1)) or confounder 2
(Xij = δSi,ab1×φ(cj× es, 1) + δSi,ab0×φ(0, 1)), where the a in the Kronecker Delta
indicates that the value for the case/control status has no effect for this variable.
The equations are expanded when multiple effects play a rule for a variable.
Data for object i for variables with information on Y and confounder 1 is generated
by Xij = δSi,11c×(φ(aj×es, 1)+φ(bj×es, 1))+δSi,10c×φ(aj×es, 1)+δSi,01c×φ(bj×
es, 1) + δSi,00c × φ(0, 1). Note that again only one Kronecker Delta has a value of
1 in this equation. The same goes for variables affected by Y and confounder 2:
Xij = δSi,1b1 × (φ(aj × es, 1) + φ(cj × es, 1)) + δSi,1b0 × φ(aj × es, 1) + δSi,0b1 ×
φ(cj × es, 1) + δSi,0b0 × φ(0, 1) and for variables where Y plays no role, but both
confounder 1 and 2 play a role: Xij = δSi,a11 × (φ(bj × es, 1) + φ(cj × es, 1)) +
δSi,a10 × φ(bj × es, 1) + δSi,a01 × φ(cj × es, 1) + δSi,a00 × φ(0, 1).
Last, the data for variables affected by Y, confounder 1 and confounder 2 is
drawn from normal distributions using Xij = δSi,111×(φ(aj×es, 1)+φ(bj×es, 1)+
φ(cj × es, 1)) + δSi,110 × (φ(aj × es, 1) + φ(bj × es, 1)) + δSi,101 × (φ(aj × es, 1) +
φ(cj × es, 1)) + δSi,011 × (φ(bj × es, 1) + φ(cj × es, 1)) + δSi,100 × φ(aj × es, 1) +
δSi,010 × φ(bj × es, 1) + δSi,001 × φ(cj × es, 1) + δSi,000 × φ(0, 1)
All of these individual equations can be combined into a single equation to
generate the data. Only one Kronecker Delta for the variable j and one Kronecker
Delta for the object i have a value of 1, hence ultimately only a few values are
used to generate the data Xij = δVj ,000×φ(0, 1) + δVj ,100× (δSi,1bc×φ(aj × es, 1) +
δSi,0bc×φ(0, 1))+δVj ,010×(δSi,a1c×φ(bj×es, 1)+δSi,a0c×φ(0, 1))+δVj ,001×(δSi,ab1×
φ(cj × es, 1) + δSi,ab0× φ(0, 1)) + δVj ,110× (δSi,11c× (φ(aj × es, 1) + φ(bj × es, 1)) +
δSi,10c× φ(aj × es, 1) + δSi,01c× φ(bj × es, 1) + δSi,00c× φ(0, 1)) + δVj ,101× (δSi,1b1×
(φ(aj×es, 1)+φ(cj×es, 1))+δSi,1b0×φ(aj×es, 1)+δSi,0b1×φ(cj×es, 1)+δSi,0b0×
φ(0, 1)) + δVj ,011× (δSi,a11× (φ(bj × es, 1) + φ(cj × es, 1)) + δSi,a10× φ(bj × es, 1) +
δSi,a01× φ(cj × es, 1) + δSi,a00× φ(0, 1)) + δVj ,111× (δSi,111× (φ(aj × es, 1) + φ(bj ×
es, 1) + φ(cj × es, 1)) + δSi,110 × (φ(aj × es, 1) + φ(bj × es, 1)) + δSi,101 × (φ(aj ×
es, 1)+φ(cj×es, 1))+δSi,011×(φ(bj×es, 1)+φ(cj×es, 1))+δSi,100×φ(aj×es, 1)+
δSi,010 × φ(bj × es, 1) + δSi,001 × φ(cj × es, 1) + δSi,000 × φ(0, 1)). Figure 6.1 shows
an example of the multivariate data structure of the simulated data sets shown by
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PCA.
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Figure 6.1: Principal Component Analysis pairs plot of the first 5 components of
an auto-scaled simulated data set with 62% overlap between variables. The R2X
shows the variance of X explained by each component. Labels: (•) S000, (•) S010,
(•) S001, (•) S011, (•) S100, (•) S110, (•) S101 and (•) S111.
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If a variable with 3-tuple of type V1yz is found to be significant it is consid-
ered a true positive (TP) finding, as these variables contain information of the
case/control status. All other variables (V0yz) are considered to be false positives
(FP) if they are found to be significantly contributing to the models. In order
to compare CA-OPLS with PLS and OPLS for the simulated data sets, the same
seed for the random number generator was used, to ensure the random sampling
was performed exactly the same for all methods.
6.3 Multivariate confounder adjustment frame-
work
It is of interest to relate differences in metabolic profiles to an outcome [12], yet
different factors can alter processes in the body as well, resulting in alterations
of the metabolic profiles. By including confounding variables in an MLR (sec-
tion 2.2.2) model, the confounders are used to ‘counterweight’ X and not Y [304].
Therefore, I translated this into a multivariate data analysis framework and adjust
X for each confounder and then regress Y on the adjusted X matrix (see Figure 6.2
and Algorithm 5).
The framework (Figure 6.2) is designed to minimize the effect of sampling- and
selection-bias and to avoid over-fitting of the models. Therefore the calculations are
performed in an MCCV [135] (section 2.3.4) procedure – specifically, for this study
1000 iterations of the MCCV procedure were performed for both the simulation
study (section 6.4.1) and the study of a real data set – distinguishing northern and
southern Chinese INTERMAP participants (section 6.4.3). In each iteration, the
data set is randomly partitioned in a model (M) and validation (V) set, for this
study 1/7th of the data was used for the test set in each iteration. V is completely
set aside and is not used in the scaling, parameter estimation or modelling in any
way to avoid bias in model prediction.
The next step is to find the optimal parameter setting (P) to model each
confounder on X. This is determined using CMV [139] (section 2.3.8) on M. The
model set is split (again any partitioning can be chosen, 1/7th was used) in training
(Mtr) and test sets (Mte), ensuring each object in M is only in Mte once. In every
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iteration Mtr is centered and scaled. This can be done for instance using mean-
centering, auto-scaling or pareto-scaling (see section 2.3.1). Here, auto-scaling
was used for both the simulation and real data sets. Mte is then scaled using the
parameters (mean, standard deviation) from Mtr to avoid bias. Ci is auto-scaled by
default to ensure the regression coefficients for the different confounders are on the
same scale. Next, Ci is regressed on Mtr using different parameters, for instance
different λ for ridge regression [145] or number of (orthogonal) components for
(O)PLS. Here, OPLS (see section 2.3.10) was used due to its popularity within
metabonomics [305] and the fact that it was used in a previous study on the same
data [78].
223

CHAPTER 6. CA-OPLS
When each sample has been in Mte once, the cross-validated error of prediction
(Q2) is calculated (see section 2.3.5). The number of components that gives the
lowest error is chosen as optimal parameter. However, in the case where there are
multiple local optima for Q2, the local optimum with the lowest number of compo-
nents is chosen to avoid over-fitting. The next step involves scaling M, regressing
Ci on M using OPLS with P − 1 orthogonal components and one predictive com-
ponent [144], and saving the regression coefficients in the i th column of B for each
confounder (where 1 ≤ i ≤ c).
However, not all confounders may be modelled properly by the data. It is
recommended to test if each confounder can be modelled accurately before includ-
ing them in the adjustment. To avoid adjusting for confounders that cannot be
modelled properly, some constraints can be placed on which confounders are to be
adjusted for. First, I used here a (hard) threshold for the RCV (see section 6.2.4)
of the confounder of 0.25 to ensure the models generalize well. Second, a lower
threshold of 0.1 for the Q2 of the confounder is used to avoid models with (very)
poor predictive ability. Only confounders that pass both thresholds (Q2 ≥ 0.1 and
RCV ≥ 0.25) are adjusted for.
After regression coefficients are obtained for all confounders, M is split into Mtr
and Mte in a cross-validation setting to find the optimal number of components
for modelling Y. Mtr and Mte are scaled as before. Prior to regressing Y on Mtr,
Mtr is adjusted for confounders using Algorithm 5. As the individual confounders
may be correlated, the resulting regression coefficients will also be correlated and
thus non-orthogonal. Regression coefficients of the confounders must therefore
be adjusted (see Algorithm 5) for their auto-correlation (rB, size [c,c]) prior to
adjusting the data. In this procedure, a Jacobian matrix is numerically computed
using random matrix theory [306] using rB. Then the number of uncorrelated
components (u) is defined as the number of eigenvalues from the decomposition of
rB that are larger than the largest eigenvalue from the Jacobian matrix. Once u
is known, B is de-correlated and a new set of de-correlated regression coefficients
(D) is obtained by decomposing the covariance of the regression coefficients (ΣB,
size [c,c]). Of the decomposed covariance matrix, the eigenvectors and eigenvalues
that explain at least 95% of the total variance are retained (subject to there being
at least u components that are retained). Next, u components that span the space
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Algorithm 5 Confounder-adjustment procedure pseudo-code
1: rB ← corr(B) % [c,c]
2: ΣB ← cov(B) % [c,c]
3: J ← RMT(rB) % [ c(c+1)2 , c(c+1)2 ]
4: λB ← eig(rB) % [c,1]
5: u← #λB > maxci=1(Jii)
6: V, λ← eig(ΣB) % [c,d], [d,1] where u ≤ d ≤ c
7: D ← B
(
V
(√
λ
)−1)
% [p,d]
8: d← rank(D)
9: W ← 0d,u % [d,u]
10: for k = 1 to u do
11: for j = 1 to d do
12: wj ∼ φ(0, 1) % [d,1]
13: end for
14: w ← w −WW Tw
15: w ← w‖w‖
16: w0 ← 2w
17: while
√
(w ± w0)2 >  do
18: w0 ← w
19: w ← DT (Dw)◦3 % ◦3 denotes element-wise cube
20: w ← w −WW Tw
21: w ← w‖w‖
22: end while
23: Wk ← w
24: end for
25: W ←
(
V
(√
λ
)−1)
W % [c,u]
26: W ← W (
√
W TW ◦ I)−1 % ◦ denotes Hadamard product
27: U ← BW % [p,u]
28: T ← XU % [n,u]
29: P ← XTT
TTT
% [p,u]
30: Xadj ← X − TP T % [n,p]
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of D (where u ≤ rank(D) ≤ c) are sought in an iterative process and are saved
in subsequent columns of W. W is then transformed to span the space of B and
normalized. This results in finding a set of uncorrelated regression coefficients (U).
U is used to adjust the data matrix (represented as ‘X’ in Algorithm 5) for the
confounders.
Y is then regressed on the adjusted Mtr and the model is used to predict Mte
(after Mte is adjusted for the confounders). Note that U can be used to do this,
it need only be calculated once. Then, based on the Q2y for Mte, the optimal
number of components for predicting Y is found. At this point Y is regressed on a
scaled and confounder-adjusted M to obtain the regression coefficients for Y (βY ).
V is then scaled with the same parameters as M, adjusted for confounders and
predicted using βY . βY is saved for all models of the MCCV.
In order to determine which variables are contributing to the model, Y and M
are bootstrapped [131], β is recalculated a number of times – this was done 25 times
for each iteration in the MCCV – and each of these bootstrapped β’s (βboot) is saved
in a separate matrix. At the end of the MCCV procedure two matrices are obtained
with regression coefficients, those of each model (1,000) and those of the bootstrap
models (25,000). The mean of the models and the variance of the bootstrap
models are calculated and from these a t-score (and subsequently a P -value) can
be calculated for each variable in the multivariate model [116]. The obtained
P -values are corrected for multiple testing by calculating the q-values using the
Storey-Tibshirani False Discovery Rate [114]. In order to correct for multiple
testing in this context, 5% false discoveries are allowed. Only variables whose
regression coefficient is the same sign in all models and q < 0.05 are considered
to be consistently and similarly contributing (‘significant’) in all models of the
MCCV.
The confounder-adjustment procedure in conjunction with OPLS and the data
analysis framework is named Confounder-Adjusted Orthogonal Projection to La-
tent Structures (CA-OPLS). The potential of CA-OPLS is demonstrated using
simulated data sets (see section 6.2.8) and a data set from the INTERMAP study
[73]. Previous studies have shown that the northern and southern Chinese IN-
TERMAP populations are at different risks for cardiovascular disease [307] and
that the metabolic profiles of these rural populations are also different, with the two
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northern Chinese populations (see section 6.2.1) more similar to each other than
to the southern sample [39]. However, it is unclear whether some external factors
may have caused the difference in metabolic profile [78] between the two popula-
tions instead of genetic differences [308]. Therefore several population, lifestyle and
dietary factors, that are found to be significantly different between the two popu-
lations, are adjusted for using the multivariate confounder-adjustment framework,
so that metabolites consistently contributing to the models can be explored.
6.4 Results
6.4.1 Method comparison using simulated data
In order to exemplify what type of corrections CA-OPLS makes, it is compared
with PLS and OPLS, two commonly used methods in metabonomics [305], using
the simulated data sets (see section 6.2.8). In this example, CA-OPLS adjusts
either for covariate 1 (non-orthogonal to Y) or for covariate 2 (almost orthogonal
to Y). Table 6.1 shows the percentages of TP and FP findings and shows how well
the methods performed in finding consistently contributing variables associated
with the case/control status for the data set with 61% overlap (see section 6.2.8)
of the distributions for the two classes.
All methods find between 97 and 99% of the true positives (V1yz) in the 50
simulated data sets. However, the differences are observed in the results for the
amount of false positive findings. It is clear that CA-OPLS (correcting for covariate
1) finds a much lower number of false positives compared to the other methods. As
expected OPLS and CA-OPLS (for covariate 2) perform similarly. PLS tends to
have a lower FP rate than OPLS/CA-OPLS (covariate 2), which may be surprising.
However, when looking at what 3-tuples are falsely associated (Table 6.1), notice
that OPLS finds a much higher percentage of 3-tuples V01z significant (correlated
to case/control status), whereas PLS finds the highest percentages of V001 and
V000, both un-correlated to the case/control status thus these findings are spurious
(noise, random variation). Similar, but less pronounced, results are found for the
data set with less (41%) overlap between groups (Table 6.2).
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Table 6.1: Full results table showing the mean percentage of significant as-
sociations for the simulated data using an effect size of 1 (≈61% overlap of
sampling distributions). The 95% confidence intervals are given in parenthe-
ses. Type of variable is shown as Vx,y,z, where x, y and z are the influence
of the response variable, confounder 1 and confounder 2, respectively. The
value for x, y and z indicate the type of variable and how each factor in-
fluences the generated variable, for instance ±V1,0,1 indicates the variable is
influenced by the response variable and confounder 2 and that the contri-
bution of both has the same sign, and ±V1,−1,0 means that the variable is
influenced by both the response variable and the first confounder, however
the sign of both is inverse.
3-Tuple PLSDA OPLSDA C1A-OPLS C2A-OPLS
±V1,0,0 99.43 99.42 98.06 99.42
(99.24 − 99.62) (99.24 − 99.60) (97.57 − 98.54) (99.24 − 99.60)
±V1,0,1 98.96 99.64 94.10 99.37
(98.50 − 99.43) (99.36 − 99.91) (92.69 − 95.52) (99.03 − 99.72)
±V1,0,−1 99.20 99.22 97.67 99.39
(98.77 − 99.63) (98.78 − 99.66) (96.86 − 98.49) (98.98 − 99.79)
±V1,1,0 97.73 91.38 98.21 91.50
(96.68 − 98.79) (88.32 − 94.44) (97.47 − 98.95) (88.45 − 94.54)
±V1,−1,0 97.95 91.44 98.29 91.74
(97.11 − 98.79) (88.67 − 94.21) (97.60 − 98.99) (89.03 − 94.46)
±V1,1,1 96.36 91.60 91.63 88.99
(93.16 − 99.55) (87.52 − 95.68) (87.14 − 96.12) (84.33 − 93.64)
±V1,1,−1 97.19 86.83 97.25 90.01
(95.06 − 99.31) (81.56 − 92.11) (95.42 − 99.08) (85.14 − 94.88)
±V1,−1,1 95.89 92.51 94.64 90.61
(93.42 − 98.37) (88.32 − 96.70) (91.67 − 97.61) (86.08 − 95.15)
±V1,−1,−1 96.33 85.95 98.12 90.70
(93.93 − 98.72) (80.22 − 91.68) (96.52 − 99.72) (85.98 − 95.42)
±V0,1,0 4.08 30.86 0.39 28.51
(3.69 − 4.46) (28.33 − 33.39) (0.27 − 0.51) (26.22 − 30.80)
±V0,1,1 2.89 26.03 0 26.36
(1.82 − 3.96) (22.46 − 29.60) (0 − 0) (22.89 − 29.84)
±V0,1,−1 4.14 28.29 0 29.23
(2.75 − 5.53) (24.51 − 32.07) (0 − 0) (25.46 − 32.99)
±V0,0,1 0.93 0.63 0.07 0.58
(0.76 − 1.10) (0.47 − 0.78) (0.02 − 0.12) (0.44 − 0.72)
J0,0,0 1.12 0.61 0.33 0.59
(1.03 − 1.21) (0.54 − 0.68) (0.28 − 0.38) (0.51 − 0.66)
±V1,y,z 98.85 97.27 97.54 97.34
(98.58 − 99.13) (96.76 − 97.78) (96.98 − 98.10) (96.83 − 97.86)
±V0,y,z 1.35 3.09 0.31 2.91
(1.26 − 1.44) (2.92 − 3.26) (0.26 − 0.36) (2.75 − 3.06)
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Table 6.2: Full results table showing the mean percentage of significant as-
sociations for the simulated data using an effect size of 1.645 (≈41% overlap
of sampling distributions). The 95% confidence intervals are given in paren-
theses.
3-Tuple PLSDA OPLSDA C1A-OPLS C2A-OPLS
±V1,0,0 100 100 100 100
(100 − 100) (100 − 100) (100 − 100) (100 − 100)
±V1,0,1 100 100 99.89 100
(100 − 100) (100 − 100) (99.68 − 100) (100 − 100)
±V1,0,−1 100 100 100 100
(100 − 100) (100 − 100) (100 − 100) (100 − 100)
±V1,1,0 100 98.83 100 98.95
(100 − 100) (98.19 − 99.48) (100 − 100) (98.25 − 99.65)
±V1,−1,0 100 98.13 100 98.32
(100 − 100) (97.13 − 99.12) (100 − 100) (97.43 − 99.21)
±V1,1,1 100 98.33 100 95.67
(100 − 100) (96.42 − 100) (100 − 100) (91.12 − 100)
±V1,1,−1 100 93.61 100 97.15
(100 − 100) (88.11 − 99.11) (100 − 100) (92.86 − 100)
±V1,−1,1 100 100 100 100
(100 − 100) (100 − 100) (100 − 100) (100 − 100)
±V1,−1,−1 100 96.28 100 96.81
(100 − 100) (91.44 − 100) (100 − 100) (92.06 − 100)
±V0,1,0 4.10 42.99 0.11 39.34
(3.60 − 4.60) (41.84 − 44.13) (0.03 − 0.18) (38.15 − 40.53)
±V0,1,1 3.00 36.59 0 37.42
(1.33 − 4.67) (31.73 − 41.46) (0 − 0) (33.06 − 41.77)
±V0,1,−1 3.26 38.32 0 39.83
(1.42 − 5.09) (33.10 − 43.54) (0 − 0) (34.26 − 45.41)
±V0,0,1 0.81 0.44 0 0.39
(0.58 − 1.03) (0.27 − 0.61) (0 − 0) (0.25 − 0.54)
J0,0,0 0.81 0.33 0.14 0.3
(0.73 − 0.88) (0.28 − 0.38) (0.11 − 0.17) (0.26 − 0.35)
±V1,y,z 100 99.56 99.99 99.64
(100 − 100) (99.43 − 99.69) (99.97 − 100) (99.51 − 99.77)
±V0,y,z 1.07 3.83 0.13 3.55
(0.99 − 1.16) (3.72 − 3.95) (0.10 − 0.15) (3.43 − 3.67)
6.4.2 Difference in risk factors between the northern and
southern Chinese populations
It has been shown that the prevalence of CVD in general, and systolic (SBP) and
diastolic blood pressure (DBP) specifically, is higher in the north of PRC com-
pared to the south [307, 309, 310] and that northern and southern Han Chinese
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are genetically different [308]. A number of significant differences are found be-
tween the northern and southern Chinese INTERMAP populations for a number
of population, metabolic, lifestyle and dietary risk factors for CVD. These factors
may play a role in the previously found differences in metabolic profiles between
these two populations [78]. Tables 6.3 and 6.4 show this for data from the first and
second visit to the clinical centres, respectively. The two northern populations are
grouped as they are much more similar to each other than to the southern popula-
tion [39]. Based on these results, a number of significantly different factors (BMI,
(on medication for) HBP, smoking status, physical activity, Na:K ratio and total
intake of fats) and population structure variables (age, gender) were chosen to cor-
rect for using CA-OPLS (see section 6.4.4). The choice between HBP/meds status
and individual measurements of SBP or DBP was made as both the SBP and DBP
are lowered by medication while there still may be an underlying condition.
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Table 6.3: Descriptive statistics of the Chinese INTERMAP population for
the first visit. Shows mean (σ) or percentage for each factor with the P -value
calculated using a two-sample t-test or χ2 test, as appropriate. Significance
is indicated by a † and based on a Bonferroni threshold of P < 7.7×10−04
for both visits.
North South
Participants n=523 n=244
Mean (σ) or % Mean (σ) or % P-value
Gender (% men) 49.14 47.13 6.04×10−01
Age (years) 48.81 (5.86) 48.91 (5.64) 8.23×10−01
Education (years) 5.40 (2.96) 5.47 (2.70) 7.40×10−01
SBP (mmHg) 124.83 (19.63) 116.98 (14.95) 1.79×10−09 †
DBP (mmHg) 75.60 (11.34) 69.09 (8.99) 9.04×10−17 †
Hypertension, HBP 8.99 0.41 4.93×10−06 †
HBP or HBP medication (%) 22.75 5.33 2.61×10−09 †
Body mass index (kg/m2) 23.79 (3.49) 21.77 (2.57) 2.23×10−18 †
Diabetes Mellitus, DM (%) 1.15 0 9.30×10−02
Diagnosed heart disease (%) 7.65 1.23 3.19×10−04 †
CVD/HBP/DM/lipid meds. (%) 12.62 2.87 1.82×10−05 †
Smoking (%) 41.87 22.54 1.95×10−07 †
Physical activity (hours/day) 4.55 (3.57) 8.85 (2.03) 7.07×10−78 †
Alcohol drinking (%) 56.41 52.87 3.59×10−01
Energy intake (kcal/day) 2131.33 (675.86) 1980.82 (620.17) 2.48×10−03
Na (mg/1000kcal) 2323.45 (823.26) 1361.66 (609.41) 3.03×10−59 †
K (mg/1000kcal) 900.77 (222.97) 1034.33 (287.57) 4.23×10−10 †
Na/K-ratio 2.69 (1.06) 1.37 (0.65) 6.17×10−78 †
Cholesterol intake (mg/1000kcal) 84.04 (112.11) 96.51 (77.70) 7.46×10−02
Total fat intake (%kcal) 18.83 (6.81) 22.87 (6.91) 1.96×10−13 †
Alcohol intake (%kcal) 2.22 (5.35) 2.87 (6.88) 1.92×10−01
Fibre intake (g/1000kcal) 14.23 (4.20) 14.17 (5.14) 8.54×10−01
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Table 6.4: Descriptive statistics of the Chinese INTERMAP population for
the second visit. Shows mean (σ) or percentage for each factor with the
P -value calculated using a two-sample t-test or χ2 test, as appropriate. Sig-
nificance is indicated by a † and based on a Bonferroni threshold of P <
7.7×10−04 for both visits.
North South
Participants n=523 n=244
Mean (σ) or % Mean (σ) or % P-value
Gender (% men) 49.14 47.13 6.04×10−01
Age (years) 48.81 (5.86) 48.91 (5.64) 8.23×10−01
Education (years) 5.40 (2.96) 5.47 (2.70) 7.40×10−01
SBP (mmHg) 122.71 (18.78) 113.73 (12.75) 3.35×10−14 †
DBP (mmHg) 75.42 (10.77) 67.27 (7.48) 1.11×10−30 †
Hypertension, HBP 8.99 0.41 4.93×10−06 †
HBP or HBP medication (%) 22.75 5.33 2.61×10−09 †
Body Mass Index (kg/m2) 23.79 (3.49) 21.77 (2.57) 2.23×10−18 †
Diabetes Mellitus, DM (%) 1.15 0 9.30×10−02
Diagnosed heart disease (%) 7.65 1.23 3.19×10−04 †
CVD/HBP/DM/lipid meds. (%) 12.62 2.87 1.82×10−05 †
Smoking (%) 41.87 22.54 1.95×10−07 †
Physical activity (hours/day) 4.55 (3.57) 8.85 (2.03) 7.07×10−78 †
Alcohol drinking (%) 56.41 52.87 3.59×10−01
Energy intake (kcal/day) 2028.05 (607.81) 1943.36 (617.23) 7.60×10−02
Na (mg/1000kcal) 2313.50 (782.81) 1217.47 (550.87) 3.27×10−82 †
K (mg/1000kcal) 873.03 (172.57) 951.69 (203.07) 2.66×10−07 †
Na/K-ratio 2.72 (0.98) 1.32 (0.60) 4.18×10−96 †
Cholesterol intake (mg/1000kcal) 84.46 (114.85) 89.00 (70.88) 5.02×10−01
Total fat intake (%kcal) 18.64 (6.88) 22.32 (7.01) 2.92×10−11 †
Alcohol intake (%kcal) 2.13 (5.46) 2.90 (7.20) 1.38×10−01
Fibre intake (g/1000kcal) 14.50 (4.20) 13.55 (5.22) 1.33×10−02
6.4.3 Unadjusted data analysis
First, I compare the results from the previous study that used OPLS and t-tests
to test the significance of each 1H NMR variable [78] with results obtained using
the new framework and assessment of variable contribution to the models. Fig-
ure 6.3 shows the resulting Monte Carlo cross-validated score plot of the mean
predictions of each sample and Figure 6.4 shows the NMR spectrum with consis-
tently contributing metabolites coloured in red (higher in north) and cyan (higher
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in south), see full page figure in Appendix A. The lower panel of Figure 6.4 shows
the variable significance with the consistently contributing metabolites that were
identified listed in Table 6.5. For model 1 the R2y is 0.72 with the Q
2
y being 0.68,
resulting in an RCV of 0.95, and for model 2 the R2y, Q
2
y and RCV are 0.71, 0.67
and 0.95, respectively. This highlights the overall quality of the models. In order
to indicate the spread of the mean predictions, the kernel density estimate (KDE)
of the predicted values for each class is included on the top of the score plots in
Figure 6.3. To obtain the KDE, for each sample the mean and standard deviation
of its prediction (when it was part of the test set) in the MCCV are calculated.
Then for each sample the probability density function is calculated using Equa-
tion 2.3. Summing the density functions of each sample per class then yields the
KDE as shown.
To analyse the sensitivity of the models, each model was used to predict the
data set from the other urine collection, resulting in goodness of external pre-
dictions of 0.61 for model 1 (predicting urine collection 2) and 0.64 for model 2
(predicting urine collection 1) (Figure 6.5). While both data sets do consist of the
same individuals, the similarity between spectra from the same individual across
urine collections is not high, indicated by an Rv-coefficient [311] of 0.31, where an
Rv of 1 would indicate perfect similarity and 0 indicates dissimilarity.
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Figure 6.3: (a) Score (prediction) plot of the unadjusted model of urine collection
1. (b) Score (prediction) plot of the unadjusted model of urine collection 2. North
Chinese individuals (Beijing and Shanxi) are shown as red circles and south Chi-
nese (Guangxi) as cyan crosses. The prediction accuracy and robustness of both
models was good (R2y=0.72/0.71 and Q
2
y=0.68/0.67, for model 1/2, respectively).
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Figure 6.4: Top shows the average 1H NMR spectrum from the first urine collection
samples. The bottom shows the contribution of each variable. In red, metabolites
are shown that are significantly higher in the north (compared to the south), and
in cyan metabolites significantly lower in the north are shown. For each variable
the highest q-value across both models is shown. Labels, 1: fatty acids (C5 - C10),
2: 2-oxoisocaproate, 3: leucine, 4: valine, 5: isoleucine, 6: unknown (1.15 (s), 3.49
(d), 3.61 (d), 3.67 (m), 3.83 (m)), 7: ethanol, 8: ethyl glucuronide, 9: lactate, 10:
2-hydroxyisobutyrate, 11: unknown (1.42 (d), 1.46 (d), 1.51 (d)), 12: alanine, 13:
lysine, 14: unknown (1.82 (m), 3.52 (s)), 15: phenylacetylglutamine, 16: S -acetyl-
1-propenyl sulfoxide, 17: N -acetyl neuraminate, 18: glutamine, 19: acetone, 20:
prolinebetaine, 21: unknown (2.32 (d), 2.34 (d), 2.38 (d), 2.40 (d), 3.52 (m)),
22: 4-cresyl sulfate, 23: succinate, 24: citrate, 25: beta-aminoisobutyrate, 26:
dimethylamine, 27: sarcosine, 28: unknown methiin metabolite (2.76 (s)), 29: N -
acetyl-S -methyl-L-cysteine sulfoxide, 30: unknown methiin metabolite (2.81 (s)),
31: S -methyl-L-cysteine sulfoxide (methiin), 32: trimethylamine, 33: dimethyl-
glycine, 34: unknown (1.84 (m), 2.78 (m), 2.95 (s), 3.36 (m), 3.59 (m), 3.62
(m)), 35: creatine, 36: creatinine, 37: N6,N6,N6 -trimethyllysine, 38: dimethylsul-
fone, 39: O-acetylcarnitine, 40: choline, 41: carnitine, 42: histidine, 43: taurine,
44: scyllo-inositol, 45: trans-aconitate, 46: 4-hydroxyphenylacetate, 47: glucose,
48: glycine, 49: 1-methylhistidine, 50: 3-methylhistidine, 51: guanidinoacetate,
52: 4-hydroxyhippurate, 53: unknown (3.96 (d), 7.30 (t), 7.42 (t)), 54: hippu-
rate, 55: N -methyl nicotinate, 56: N -methyl nicotinamide, 57: tyrosine, 58: 3-
hydroxymandelate, 59: tryptophan/tryptamine, 60: pseudouridine, 61: N -methyl-
2-pyridone-5-carboxamide, 62: formate.
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Figure 6.5: (a) Score (prediction) plot of urine collection 2 predicted by the unad-
justed model of urine collection 1. (b) Score (prediction) plot of urine collection 1
predicted by the unadjusted model of urine collection 2. North Chinese samples
(Beijing and Shanxi) are shown as red circles and South Chinese (Guangxi) as
cyan crosses. The prediction accuracy and robustness of both models was good
(R2y=0.72/0.71 and Q
2
y=0.68/0.67) and the external validation closely matched the
internal (unbiased) validation, Q2y,ext of 0.61 and 0.64 for models 1 and 2, respec-
tively.
6.4.4 Confounder adjusted modelling
The CA-OPLS algorithm determines, as described, which confounders are mod-
elled accurately to be included in the confounder adjustment. After the adjust-
ment procedure the geographical location (north versus south) was modelled and
the resulting score plot (Figure 6.6) of the MCCV predictions still shows good sep-
aration, however they are lower compared to the unadjusted model, with Q2y values
of 0.50 and 0.60 for urine collection 1 and 2, respectively. The resulting RCV are
0.92 and 0.93, which indicates the validation procedure is robust. Again, this is
also demonstrated by predicting the other urine collection using the models, with
goodness of external predictions of 0.46 for model 1 (predicting urine collection
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2) and 0.57 for model 2 (predicting urine collection 1) (Figure 6.7). Figure 6.8
shows the significant metabolites that consistently contribute to the models, see
full page figure in Appendix A, and unidentified metabolites are only included if
their STORM [230] pseudo-spectrum showed a clear interpretable pattern of NMR
peaks (Figure 6.9).
Figure 6.6: Score plots of models adjusted for age, gender, BMI, (on medication
for) HBP, smoking status, physical activity, Na:K ratio and total intake of fats.(a)
Score (prediction) plot of covariate adjusted model of urine collection 1. (b) Score
(prediction) plot of covariate adjusted model of urine collection 2. North Chinese
samples (Beijing and Shanxi) are shown as red circles and South Chinese (Guangxi)
as cyan crosses. The prediction accuracy and robustness of both models decreased
compared to the unadjusted models, however the cross validation robustness is
still good (R2y=0.54/0.64 and Q
2
y=0.50/0.60, each for model 1/2, respectively).
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Figure 6.7: Score plots of models adjusted for age, gender, BMI, (on medication
for) HBP, smoking status, physical activity, Na:K ratio and total intake of fats.
(a) Score (prediction) plot of urine collection 2 predicted by the covariate adjusted
model of urine collection 1. (b) Score (prediction) plot of urine collection 1 pre-
dicted by the covariate adjusted model of urine collection 2. North Chinese samples
(Beijing and Shanxi) are shown as red circles and South Chinese (Guangxi) as cyan
crosses. The prediction accuracy and robustness of both models decreased com-
pared to the unadjusted models, however the cross validation robustness is still
good (R2y=0.54/0.64 and Q
2
y=0.50/0.60, for model 1/2) and the external valida-
tion closely matched the internal (unbiased) validation, Q2y,ext of 0.46 and 0.57 for
models 1 and 2, respectively.
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Figure 6.8: Top shows the average 1H NMR spectrum from the first urine collection
samples. The bottom panels show the variable contribution across the MCCV
models. This model was adjusted for age, gender, HBP (meds), BMI, physical
activity, smoking status, Na:K ratio and total fat intake. Compared to Figure 6.5
a number of metabolites are no longer significant, however 29 remain significant.
Labels, 1: 2-oxoisocaproate, 2: leucine, 3: valine , 4: unknown (1.15 (s), 3.49
(d), 3.61 (d), 3.67 (m), 3.83 (m)), 5: ethyl glucuronide, 6: 2-hydroxyisobutyrate,
7: unknown (1.42 (d), 1.46 (d), 1.51 (d)), 8: unknown (1.82 (m), 3.52 (s)), 9:
S -acetyl-1-propenyl sulfoxide, 10: glutamine, 11: acetone, 12: unknown (2.32
(d), 2.34 (d), 2.38 (d), 2.40 (d), 3.52 (m)), 13: prolinebetaine, 14: sarcosine,
15: dimethylglycine, 16: unknown (1.84 (m), 2.78 (m), 2.95 (s), 3.36 (m), 3.59
(m), 3.62 (m)), 17: creatine, 18: N6,N6,N6 -trimethyllysine, 19: dimethylsulfone,
20: O-acetylcarnitine, 21: carnitine, 22: taurine, 23: 4-hydroxyhippurate, 24: 1-
methylhistidine, 25: histidine, 26: tyrosine, 27: pseudouridine, 28: formate, 29:
N -methyl nicotinate.
In every iteration of the MCCV the confounders are modelled and only included
if the models were sufficiently predictive. In theory this is dependent on sampling
of training and test sets, however in practice there is a high consistency in which
confounders could be accurately modelled. For the Chinese population, gender
and smoking status were modelled accurately for all MCCV iterations and Na:K-
ratio in 94.4% and 100% of the models for urine collection 1 and 2, respectively.
From the other possible covariates, age, fat intake and HBP/meds could not be
modelled accurately, and BMI and physical activity were only included in 4-11%
of the covariate adjusted models.
In order to give a rough estimate of the association of metabolites, that are no
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longer significant after covariate adjustment, with the confounders, a correlation
network was calculated, displayed in Figure 6.10. The correlations were adjusted
for multiple testing using a Bonferroni correction of P < 1.9×10−04 for both urine
collections. In addition, the correlations had to be more significant than the most
significant correlations with the metabolites of the three factors that were not
modelled accurately (age, fat intake, HBP/meds).
From Figure 6.10 it becomes clear that the dietary Na:K-ratio has a large
number of correlations, which in general seem to have the inverse sign of the
correlations of physical activity with the metabolite levels. The reason for this
appears to be that Na:K-ratio and physical activity are inversely associated. In
general, south Chinese individuals are physically more active and consume more
potassium and less sodium (Tables 6.3 and 6.4). Individuals who are physically
active have a lower Na:K-ratio (Figure 6.11), which means they consume relatively
more potassium and less sodium than physically less active individuals.
6.4.5 Discriminatory metabolites
As can be seen in Table 6.5 the unadjusted model finds the same metabolites as
reported by Yap et al. [78], plus a large number of new associations not previously
found (2-oxoisocaproate, ethanol, ethyl glucuronide, lysine, S -acetyl-1-propanoyl
sulfoxide, glutamine, acetone, citrate, beta-aminoisobutyrate, dimethylamine, sar-
cosine, methiin, N -acetyl methiin, trimethylamine, N6,N6,N6 -trimethyllysine, his-
tidine, dimethylsulfone, O-acetylcarnitine, choline, carnitine, taurine, 4-hydroxy-
phenylacetate, glucose, glycine, 1-methylhistidine, 3-methylhistidine, guanidinoac-
etate, 4-hydroxyhippurate, creatinine, N -methyl nicotinate, N -methyl nicotinam-
ide, N -methyl-2-pyridone-5-carboxamide, 3-hydroxymandelate, tyrosine, pseudo-
uridine, tryptophan/tryptamine, formate). The adjusted model shows how a
number of these metabolites are no longer significant after adjusting for con-
founders/covariates (see Table 6.5).
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Table 6.5: Metabolites that differ significantly between northern (‘N’) and southern
(‘S’) Chinese individuals for the study by Yap et al. [78], the unadjusted OPLSDA
model and the CA-OPLSDA model. Differences between the unadjusted and ad-
justed model are due to the covariate adjustment. The letters ‘N’ and ‘S’ indicate
in what the group higher relative concentrations were found.
Metabolite δ (multiplicity) Y
a
p
e
t
a
l.
U
n
a
d
ju
st
e
d
A
d
ju
st
e
d
Fatty acids C5-C10 (0.88 (m), 1.31 (m), 1.56 (m), 2.19 (m)) N N
2-Oxoisocaproate (0.94 (d)) N N
Leucine (0.97 (2d)) N N N
Valine (0.99 (d), 1.05 (d)) N N N
Isoleucine (1.01 (d)) N N
UNK (1.15 (s), 3.49 (d), 3.61 (d), 3.67 (m), 3.83 (m)) N N
Ethanol (1.19 (t), 3.67 (q)) S
Ethyl glucuronide (1.23 (t)) S S
Lactate (1.33 (d)) N N
2-Hydroxyisobutyrate (1.36 (s)) S S S
UNK (1.42 (d), 1.46 (d)) N N
Alanine (1.48 (d)) N N
Lysine (1.48 (m), 1.73 (m), 1.91 (m), 3.03 (t)) S
UNK (1.82 (m), 3.52 (s)) N N N
Phenylacetylglutamine (1.92 (m), 2.11 (m), 2.27 (m), S S
3.67 (m), 4.19 (m), 7.36 (t), 7.43 (t))
N -acetyl glycoproteins (1.95-2.04) N
S -acetyl-1-propenyl sulfoxide (1.96 (dd), 2.03 (s), N N
6.49 (dq), 6.65 (dq))
N -acetyl neuraminic acid (2.06 (s)) N N
Glutamine (2.14 (m), 2.46 (m)) N N
Acetone (2.24 (s)) S S
Continued on next page
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Continued from previous page
Metabolite δ (multiplicity) Y
a
p
e
t
a
l.
U
n
a
d
ju
st
e
d
A
d
ju
st
e
d
Proline betaine (2.30 (m), 2.51 (m), 3.11 (s), 3.30 (s), S S S
3.55 (m), 4.08 (m))
UNK (2.32 (d), 2.34 (d), 2.38 (d), 2.40 (d), 3.52 (m)) N N
4-Cresyl sulfate (2.35 (s), 7.21 (d), 7.29 (d)) S S
Succinate (2.41 (s)) S S
Citrate (2.54 (d), 2.68 (d)) S
beta-Aminoisobutyrate (1.20 (d), 2.61 (m), 3.04 (2d), S
3.11 (2d))
Dimethylamine (2.72 (s)) S
Sarcosine (2.74 (s), 3.61 (s)) N N
UNK methiin metabolite (2.76 (s)) N
N -acetyl-S -methyl-L-cysteine sulfoxide (2.78 (s)) N
UNK methiin metabolite (2.81 (s)) N
S -methyl-L-cysteine sulfoxide (methiin) (2.84 (s)) N N
Trimethylamine (2.88 (s)) N
Dimethylglycine (2.93 (s)) N N N
UNK (1.84 (ddd?), 2.78 (t?), 2.95 (s, 2xCH3), N N
3.36 (dd, 2xCH), 3.59 (m), 3.62 (m))
Creatine (3.04 (s), 3.93 (s)) S S S
Creatinine (3.06 (s), 4.06 (s)) S
N6,N6,N6 -Trimethyllysine (3.12 (s)) S S
Histidine (3.14 (dd), 3.25 (dd), 4.00 (dd), 7.09 (s), 7.84 (s)) N N
Dimethylsulfone (3.15 (s)) N N
O-acetylcarnitine (2.15 (s), 3.19 (s)) S S
Choline (3.20 (s), 3.52 (m), 4.07 (m)) N
Carnitine (2.44 (dd), 3.23 (s), 3.43 (m)) S S
Taurine (3.26 (t), 3.42 (t)) S S
Continued on next page
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Continued from previous page
Metabolite δ (multiplicity) Y
a
p
e
t
a
l.
U
n
a
d
ju
st
e
d
A
d
ju
st
e
d
scyllo-Inositol (3.34 (s)) S S
trans-Aconitate (3.45 (s), 6.59 (s)) S S
4-Hydroxyphenylacetate (3.45 (s), 6.87 (d), 7.17 (d)) S
Glucose (3.25 (dd), 3.42 (m), 3.49 (m), 3.54 (dd), 3.74 (m), N
3.84 (m), 3.91 (dd))
Glycine (3.57 (s)) N
1-Methylhistidine (3.21 (2d), 3.29 (2d), 3.69 (s), 3.92 (t), S S
7.02 (s), 7.85 (s))
3-Methylhistidine (3.17 (2d), 3.25 (2d), 3.69 (s), 7.00 (s), S
7.62 (s))
Guanidinoacetate (3.80 (s)) S
4-Hydroxyhippurate (3.95 (s), 6.97 (d), 7.76 (d)) S S
UNK (3.96 (d), 7.30 (t), 7.42 (t)) S
Hippurate (3.98 (d), 7.56 (t), 7.64 (t), 7.84 (d)) S S
N -methyl nicotinate (4.40 (s), 8.09 (t), 8.84 (t), 9.12 (s)) N N
N -methyl nicotinamide (4.48 (s), 8.19 (t), 8.90 (d), 8.97 (d), S
9.28 (s))
3-Hydroxymandelate (6.85 (d), 6.92 (t), 6.99 (d), 7.31 (t)) S
Tyrosine (6.90 (d), 7.19 (d)) N N
Trypophan/tryptamine (7.21 (t), 7.28 (t), 7.36 (s), 7.51 (d), S
7.71 (d))
Pseudouridine (7.67 (s)) S S
N -methyl-2-pyridone-5-carboxamide (3.65 (d), 6.67 (d), S
7.83 (dd), 8.34 (d)) S
Formate (8.46 (s)) N N
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Figure 6.9: Statistical pseudo-spectra obtained with STORM for significant
metabolites with multiple visible peaks in the NMR spectrum. From top to
bottom, left to right: 2-oxoisocaproate, leucine, valine, unknown (1.15 (s), 3.49
(d), 3.61 (d), 3.67 (m), 3.83 (m)), ethyl glucuronide, unknown (1.42 (d), 1.46
(d), unknown 1.82 (m), 3.52 (s)), S -acetyl-1-propenyl sulfoxide (1.97 (dd) 2.03
(s)), S -acetyl-1-propenyl sulfoxide (6.49 (dq) 6.65 (dq)), glutamine, proline be-
taine, unknown (2.32 (d), 2.34 (d), 2.38 (d), 2.40 (d), 3.52 (m)), sarcosine, un-
known (1.84 (ddd?), 2.78 (t?), 2.95 (s, 2xCH3), 3.36 (dd, 2xCH), 3.59 (m), 3.62
(m)), creatine, histidine, dimethyl sulfone, O-acetylcarnitine, carnitine, taurine,
1-methylhistidine, 4-hydroxyhippurate, N -methyl nicotinate and tyrosine.
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Figure 6.10: Correlation network of urinary metabolites associated with the dif-
ference between north and south Chinese individuals and the confounding factors.
Metabolites listed here are no longer significant after covariate adjustment, and the
correlations here may indicate which confounders are associated with the metabo-
lites. The confounding factors are shown in grey. The average Spearman rank
correlations of both urine collections is only shown if it had the same sign for both
urine collections and both urine collections passed the multiple testing Bonferroni
threshold of P < 1.9×10−04.
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Figure 6.11: Dietary sodium-to-potassium ratio for both visits plotted against
the physical activity level, defined as the number of self-reported hours a day of
moderate-to-heavy physical activity. Both figures show that physical activity and
Na:K-ratio are anti-correlated and different between northern (red circle = Beijing,
red cross = Shanxi) and southern (cyan asterisk) Chinese individuals.
6.4.6 Metabolic reaction network
Using the biomarkers significantly different between northern and southern Chinese
a condensed multi-compartmental metabolic reaction network was constructed us-
ing MetaboNetworks [194]. It shows the shortest paths between the metabolites
in terms of number of reactions, only considering reactions that can occur in the
Homo sapiens supra-organism (see section 6.2.6). Figure 6.12 shows the resulting
metabolic reaction network of the homeostatic urinary signature of the differences
between northern and southern Chinese, see full page figure in Appendix A. The
links between metabolites are indicated by a solid line for reactions that occur
spontaneous or due to human enzymes and by dotted lines for reactions that oc-
cur only due to gut microbial enzymes. The background colours indicate pathways
and specific types of metabolism, and metabolites were assigned to the class to
which they show the closest affinity. Metabolites that were not assigned to one
of the classes are either involved in many different processes or did not fit in any
particular class. Figure 6.12 highlights the interconnectivity between many of the
metabolites found to be differentially expressed between northern and southern
Chinese INTERMAP participants.
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Figure 6.12: Perturbations to a living system often instigate changes to multi-
ple pathways simultaneously; shown here is a condensed multi-compartmental
metabolic reaction network of the homeostatic urinary signature of differences
between north and south Chinese individuals for the human supra-organism, cre-
ated using the MetaboNetworks software [194]. Metabolites shown in red have
been found in higher concentrations after covariate adjustment in north Chinese
individuals and metabolites in cyan were found higher in south Chinese individ-
uals, both in a slightly larger font size to distinguish them from the metabolites
no longer significant after covariate adjustment, those are still shown in red and
cyan, except in a lighter shade and the same font size as the rest of the network.
Metabolites not connected in the network, and those not listed in KEGG, were
connected to the closest related metabolite in the network, indicated by a dashed
line. The background shading illustrates different types of metabolism based on
the closest affinity with some overlap between groups: tricarboxylic acid (TCA)
cycle (); TCA anaplerotic metabolism (); coenzyme A metabolism (); lipid
and fatty acid related metabolism (); branch-chain amino acid metabolism ();
bile acid metabolism (); aromatic compounds (); sulphur metabolism (); gly-
colysis and amino sugar metabolism (); 1-carbon and related metabolism ();
purine and pyrimidine metabolism (); muscle metabolism (); various vitamin
B’s metabolites (); lysine metabolism (); urea cycle metabolites (); and ke-
tone bodies (). Full names for the abbreviated metabolite names can be found
in Table 6.6.
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Table 6.6: List of abbreviations and full names for
metabolites in the network shown in Figure 6.12.
(Abbreviated) name Full metabolite name
(3S)-Cit-CoA (3S)-Cityl coenzyme A
1,2-Propanediol 1,2-Propanediol
1Me-His 1-Methylhistidine
2(OH-Et)TPP 2-Hydroxyethyl thiamin
pyrophosphate
2,3,4,5-TetraH-dipicolinate 2,3,4,5-Tetrahydrodipicolinate
2,3-DiH-2,3-diOH-benzoyl-CoA 2,3-Dihydro-2,3-dihydroxybenzoyl
coenzyme A
2,3-DiOH-3Me-valerate 2,3-Dihydroxy-3-methylvalerate
2,3-DiOH-isovalerate 2,3-Dihydroxyisovalerate
2,4-DiOH-hept-2-enedioate 2,4-Dihydroxy-hept-2-enedioate
2,5-Dioxopentanoate 2,5-Dioxopentanoate
2,6-DiAm-pimelate 2,6-Diaminopimelate
2-Aceto-2OH-butanoate 2-Aceto-2-hydroxybutanoate
2-Acetolactate 2-Acetolactate
2Am-6-oxohexanoate 2-Amino-6-oxohexanoate
2Am-6-oxopimelate 2-Amino-6-oxopimelate
2Am-adipate 2-Aminoadipate
2Am-malonate semialdehyde 2-Aminomalonate semialdehyde
2-Butenoyl-CoA 2-Butenoyl coenzyme A
2DeH-3deO-galactonate 6P 2-Dehydro-3-deoxy-galactonate
6-phosphate
2DeH-pantoate 2-Dehydro-pantoate
2DeO-ribose 5P 2-Deoxyribose 5-phosphate
2HIB 2-Hydroxyisobutyrate
2Me-1(OH-Bu)TPP 2-Methyl-1-hydroxybutyl
thiamin pyrophosphate
2Me-1(OH-Pr)TPP 2-Methyl-1-hydroxypropyl
Continued on next page
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Continued from previous page
(Abbreviated) name Full metabolite name
thiamin pyrophosphate
2Me-Bt-CoA 2-Methylbutanoyl coenzyme A
2Me-citrate 2-Methylcitrate
2OH-glutarate 2-Hydroxyglutarate
2-oxo-3deO-gluconate 2-Oxo-3-deoxy-gluconate
2-oxo-3deO-gluconate 6P 2-Oxo-3-deoxy-gluconate
6-phosphate
2-Oxoadipate 2-Oxoadipate
2-Oxobutyrate 2-Oxobutyrate
2-Oxoglutaramate 2-Oxoglutaramate
2-Oxoglutarate 2-Oxoglutarate
2-Oxoisocaproate 2-Oxoisocaproate
2-oxoisovalerate 2-Oxoisovalerate
2Ph-acetamide 2-Phenylacetamide
3(Me-Bt)CoA 3-Methylbutanoyl coenzyme A
3,4-diHPA 3,4-Dihydroxyphenylacetate
3,4-diOH-benzoate 3,4-Dihydroxybenzoate
3,4-diOH-Ph-acetaldehyde 3,4-Dihydroxyphenylacetaldehyde
3-Amino-isobutyrate 3-Amino-isobutyrate
3Cx-1(OH-Pr)TPP 3-Carboxy-1-hydroxypropyl
thiamin pyrophosphate
3DeH-sphinganine 3-Dehydrosphinganine
3HM 3-Hydroxymandelate
3IsoPr-malate 3-Isopropylmalate
3Me-1(OH-Bu)TPP 3-Methyl-1-hydroxybutyl
thiamin pyrophosphate
3Me-2-oxopentanoate 3-Methyl-2-oxopentanoate
3Me-His 3-Methylhistidine
3OH-3Me-2-oxopentanoate 3-Hydroxy-3-methyl-2-oxopentanoate
3OH-Bt-CoA 3-Hydroxybutanoyl coenzyme A
Continued on next page
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(Abbreviated) name Full metabolite name
3-Oxopropanoate 3-Oxopropanoate
3-Ureidopropionate 3-Ureidopropionate
4Am-butyrate 4-Aminobutyrate
4-Cresol 4-Cresol
4CS 4-Cresyl sulfate
4-Guanidinobutanoate 4-Guanidinobutanoate
4HPA 4-Hydroxyphenylacetate
4-Imidazolone-5-propanoate 4-Imidazolone-5-propanoate
4OH-2-oxoglutarate 4-Hydroxy-2-oxoglutarate
4OH-2-oxohexanoate 4-Hydroxy-2-oxohexanoate
4OH-2-oxopimelate 4-Hydroxy-2-oxopimelate
4OH-benzaldehyde 4-Hydroxybenzaldehyde
4OH-benzoate 4-Hydroxybenzoate
4OH-benzoyl-CoA 4-Hydroxybenzoyl coenzyme A
4OH-cinnamate 4-Hydroxycinnamate
4OH-cinnamoyl-CoA 4-Hydroxycinnamoyl coenzyme A
4OH-hippurate 4-Hydroxyhippurate
4OH-Ph-acetaldehyde 4-Hydroxyphenylacetaldehyde
4OH-phenacyl alcohol 4-Hydroxyphenacyl alcohol
4-Oxobutanoate 4-Oxobutanoate
5,10-Methylene-tetraH- 5,10-Methylene-
methanopterin tetrahydromethanopterin
5,10-Methylene-THF 5,10-Methylene-tetrahydrofolate
5-Adenylyl-2Am-adipate 5-Adenylyl-2-aminoadipate
5DeH-4deO-glucarate 5-Dehydro-4-deoxyglucarate
5Me-barbiturate 5-Methylbarbiturate
5Me-H4MPT 5-Methyl-
5,6,7,8-tetrahydromethanopterin
5Me-THF 5-Methyltetrahydrofolate
6DeO-5-oxofructose 1P 6-Deoxy-5-oxofructose 1-phosphate
Continued on next page
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(Abbreviated) name Full metabolite name
Ac-adenylate Acetyladenylate
Ac-choline Acetylcholine
Ac-CoA Acetyl coenzyme A
Acetate Acetate
Acetoacetate Acetoacetate
Acetoacetyl-CoA Acetoacetyl coenzyme A
Acetone Acetone
AcP Acetylphosphate
Ac-phenol Acetylphenol
Adenylosuccinate Adenylosuccinate
ADMA Asymmetric dimethylarginine
ADP Adenosine 5-diphosphate
ADP-glucose Adenosine 5-diphosphate glucose
Adrenaline Epinephrine
Ala Alanine
Allothreonine Allothreonine
α-Glucose 6P alpha-Glucose 6-phosphate
αIsoPr-malate alpha-Isopropylmalate
α-Linolenoyl-CoA alpha-Linolenoyl coenzyme A
Am-acetaldehyde Aminoacetaldehyde
Am-adip.-S alpha-Aminoadipoyl-S -acyl enzyme
AMP Adenosine 5-phosphate
Anserine Anserine
APS Adenosine 5-phosphosulfate
Arabino-hex-3-ulose 6P Arabino-hex-3-ulose 6-phosphate
Arachidonate Arachidonate
Arachidonyl-CoA Arachidonyl coenzyme A
Arg Arginine
Arg-succinate Argininosuccinate
Arterenol Norepinephrine
Continued on next page
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(Abbreviated) name Full metabolite name
Asp Aspartate
Benzoate Benzoate
Benzoyl-CoA Benzoyl coenzyme A
Betaine Betaine
βAla beta-Alanine
βAla-Arg beta-Alanylarginine
βAla-Lys beta-Alanyllysine
β-Fructose 6P beta-Fructose 6-phosphate
βMe-Mal-CoA beta-Methylmalyl coenzyme A
Biocytin N6 -Biotinyl-lysine
Biotin Biotin
Biotinyl-5-AMP Biotinyl 5-adenosine 5-phosphate
Carbamoyl P Carbamoyl phosphate
Carnitine Carnitine
Carnosine Carnosine
Ceramide N -acylsphingosine
Chenodiol Chenodeoxycholate
Cholate Cholate
Choline Choline
Choline P Choline phosphate
Choloyl-CoA Choloyl coenzyme A
Chorismate Chorismate
Citrate Citrate
Citrulline Citrulline
CMP Cytidine 5-phosphate
CMP-NANA Cytidine 5-phosphate
N -acetyl neuraminate
CoA Coenzyme A
Creatine Creatine
Creatinine Creatinine
Continued on next page
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(Abbreviated) name Full metabolite name
Cys Cysteine
CysGly Cysteinylglycine
Cystathionine Cystathionine
Cysteate Cysteate
Cytidine Cytidine
Deoxycholate Deoxycholate
DeP-CoA Dephospho coenzyme A
DHF Dihydrofolate
DiH-ceramide Dihydroceramide
DiH-LipE Dihydrolipoamide E
DiMe sulfone Dimethylsulfone
DKHP 2-Deoxy-5-ketogluconic acid
6-phosphate
DMA Dimethylamine
DMF Dimethylformamamide
DMG Dimethylglycine
Dopamine 3,4-Dihydroxyphenethylamine
Ethanal Ethanal
Ethanol Ethanol
Ethyl glucuronide Ethyl glucuronide
FA Fatty acid
FA C5 Valeric acid
FA C6 Caproic acid
FA C7 Enanthic acid
FA C8 Caprylic acid
FA C9 Pelargonic acid
FA C10 Capric acid
Farnesyl PP Farnesyl pyrophosphate
For-kynurenine Formylkynurenine
Formamide Formamide
Continued on next page
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(Abbreviated) name Full metabolite name
Formate Formate
Fructose 1P Fructose 1-phosphate
Fructose 6P Fructose 6-phosphate
Fuculose 1P Fuculose 1-phosphate
Fum-acetoacetate Fumarylacetoacetate
Fumarate Fumarate
γGluCys gamma-Glutamylcysteine
GAR Glycinamide ribonucleotide
Glca Glucosamine
Glca P Glucosamine phosphate
GlcNAc N -acetylglucosamine
Gln Glutamine
Glu Glutamine
Gluconate Gluconate
Gluconate 6P Gluconate 6-phosphate
Glucono-1,5-lactone 6P Glucono-1,5-lactone 6-phosphate
Gluconolactone Gluconolactone
Glucose Glucose
Glucose 1P Glucose 1-phosphate
Glucose 6P Glucose 6-phosphate
Glucosylceramide Glucosyl-N -acylsphingosine
Glutaryl-CoA Glutaryl coenzyme A
Gly Glycine
Glyceraldehyde 3P Glyceraldehyde 3-phosphate
Glycerone P Glycerone phosphate
Glycochenodeoxycholate Glycochenodeoxycholate
Glycocholate Glycocholate
Glycodeoxycholate Glycodeoxycholate
Glyoxylate Glyoxylate
GM3 (N -acetylneuraminyl)galactosyl-
Continued on next page
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(Abbreviated) name Full metabolite name
glucosyl-N -acylsphingosine
GSH Glutathione
Guanidinoacetate Guanidinoacetate
Hippurate Hippurate
His Histidine
HMG-CoA Hydroxymethylglutaryl coenzyme A
Homocarnosine Homocarnosine
Homocitrate Homocitrate
HTPA (2S,4S)-4-Hydroxy-
2,3,4,5-tetrahydrodipicolinate
Hydrouracil Hydrouracil
Ile Isoleucine
Indole-3-acetamide Indole-3-acetamide
Indoleacetaldehyde Indoleacetaldehyde
Indoleacetate Indoleacetate
Indoleglycerol P Indoleglycerol phosphate
IsoBt-CoA Isobutanoyl coenzyme A
Isocitrate Isocitrate
IsoPe PP Isopentenyl pyrophosphate
LacCer Lactosylceramide
Lactaldehyde Lactaldehyde
Lactate Lactate
Lactose Lactose
Lecithin Phosphatidylcholine
Leu Leucine
Levulose Levulose
Linoleate Linoleate
Linolenate Linolenate
Linoleoyl-CoA Linoleoyl coenzyme A
LipE Lipoamide E
Continued on next page
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(Abbreviated) name Full metabolite name
Lys Lysine
Malate Malate
Mal-CoA Malyl coenzyme A
Malonyl-CoA Malonyl coenzyme A
Me-CoM Methylcoenzyme M
Me-corrinoid Methylcorrinoid
Me-glyoxal Methylglyoxal
Me-isocitrate Methylisocitrate
Me-malonate Methylmalonate
Me-malonate semialdehyde Methylmalonate semialdehyde
Me-malonyl-CoA Methylmalonyl coenzyme A
meso-2,6-DiAm-pimelate meso-2,6-Diaminopimelate
Methanal Methanal
Methanol Methanol
Methiin S -methyl-L-cysteine sulfoxide
MMA Methylamine
N2Cit-N6Ac-N6OH-Lys N2 -cityl-N6 -acetyl-N6 -hydroxylysine
N6,N6,N6-TriMe-Lys N6,N6,N6 -trimethyllysine
N6-[(Indol-3-yl)Ac]-Lys N6 -[(indol-3-yl)acetyl]-lysine
N6Ac-2,6-diAm-pimelate N6 -acetyl-2,6-diaminopimelate
N6Ac-N6OH-Lys N6 -acetyl-N6 -hydroxylysine
N6OH-Lys N6 -hydroxylysine
NA Nicotinamide
NA ribonucleotide Niconamide ribonucleotide
NAc-Asp N -acetylaspartate
NAc-citrulline N -acetylcitrulline
NAc-glca 6P N -acetylglucosamine 6-phosphate
NAc-mana N -acetylmannosamine
NAc-mana 6P N -acetylmannosamine 6-phosphate
NAc-Methiin N -acetyl-S -methyl-L-cysteine sulfoxide
Continued on next page
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(Abbreviated) name Full metabolite name
NAD Nicotinamide adenine dinucleotide
NANA N -acetyl neuraminic acid
NANA 9P N -acetyl neuraminic acid 9-phosphate
N-Carbamoyl-Asp N -carbamoylaspartate
N-For-Asp N -formylaspartate
N-For-Glu N -formylglutamate
N-Formimino-Glu N -formiminoglutamate
NM2P5C N -methyl-2-pyridone-5-carboxamide
NMNA N -methyl nicotinate
NMND N -methyl nicotinamide
Nonaprenyl-4OH-benzoate Nonaprenyl-4-hydroxybenzoate
Nopaline N2 -(1,3-dicarboxypropyl) arginine
N-Ribosyl-NA N -ribosylnicotinamide
N-Suc-2,6-diAm-pimelate N -succinyl-2,6-diaminopimelate
N-Suc-Glu N -succinylglutamate
OAc-carnitine O-acetylcarnitine
O-Suc-hSer O-succinylhomoserine
Oxaloacetate Oxaloacetate
PAG Phenylacetylglutamine
Palmitoylcarnitine Palmitoylcarnitine
Palmitoyl-CoA Palmitoyl coenzyme A
Pantoate Pantoate
Pantothenate Pantothenate
PAP Phosphoadenosine phosphate
PhAc Phenylacetate
PhAc-CoA Phenylacetyl coenzyme A
Phe Phenylalanine
Phenol Phenol
Pp-adenylate Propanoyladenylate
Proline betaine Proline betaine
Continued on next page
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(Abbreviated) name Full metabolite name
Propanal Propanal
Propanoyl-CoA Propanoyl coenzyme A
PRPP 5-Phosphoribosyl 1-pyrophosphate
Psi Pseudouridine
Psi 5P Pseudouridine 5-phosphate
PtdSer Phosphatidylserine
Pyridoxal 5P Pyridoxal 5-phosphate
Pyruvate Pyruvate
Rhamnulose 1P Rhamnulose 1-phosphate
Riba 5P Ribosylamine 5-phosphate
Ribose Ribose
Ribose 5P Ribose 5-phosphate
Ribulose 5P Ribulose 5-phosphate
S-(OHMe)GSH S -(hydroxymethyl)glutathione
S-2(Me-Bt)-DiH-LipE S -(2-Methylbutanoyl)-
dihydrolipoamide E
S-2(Me-Pp)-DiH-LipE S -(2-Methylpropanoyl)-
dihydrolipoamide E
S-3(Me-Bt)-DiH-LipE S -(3-Methylbutanoyl)-
dihydrolipoamide E
SA1PSO S -acetyl-1-propenyl sulfoxide
Saccharopine Saccharopine
Sarcosine Sarcosine
scyllo-Inositol scyllo-Inositol
Seleno-Cys Selenocysteine
Selenocystathionine Selenocystathionine
Ser Serine
S-For-GSH S -formylglutathione
Solanesyl PP Solanesyl pyrophosphate
Sphinganine Sphinganine
Continued on next page
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(Abbreviated) name Full metabolite name
Sphingomyelin Sphingomyelin
S-Suc-DiH-LipE S -succinyl-dihydrolipoamide E
S-Suc-GSH S -succinylglutathione
Succinate Succinate
Suc-CoA Succinyl coenzyme A
Sucrose Sucrose
Sulfite Sulfite
SulfoAc-CoA Sulfoacetyl coenzyme A
Sulfoacetaldehyde Sulfoacetaldehyde
Taurine Taurine
Taurochenodeoxycholate Taurochenodeoxycholate
Taurocholate Taurocholate
Taurodeoxycholate Taurodeoxycholate
TCE Trichloroethylene
TCE epoxide Trichloroethylene epoxide
Thr Threonine
TMA Trimethylamine
TPP Thiamin pyrophosphate
trans-Aconitate trans-Aconitate
Trehalose 6P Trehalose 6-phosphate
Trp Tryptophan
Tryptamine Tryptamine
Tyr Tyrosine
Tyramine Tyramine
UDP Uridine 5-diphosphate
UDP-Ara4FN Uridine 5-diphosphate 4-deoxy-
4-formamido-beta-arabinopyranose
UDP-galactose Uridine 5-diphosphate galactose
UDP-glucose Uridine 5-diphosphate glucose
UDP-NAc-glca Uridine 5-diphosphate
Continued on next page
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(Abbreviated) name Full metabolite name
N -acetyl-glucosamine
UMP Uridine 5-monophosphate
Undecaprenyl P Undecaprenyl phosphate
Undecaprenyl P α-Ara4FN Undecaprenyl phosphate 4-deoxy-
4-formamido-alpha-arabinopyranose
Undecaprenyl PP Undecaprenyl pyrophosphate
Uracil Uracil
Urea Urea
Urocanate Urocanate
Val Valine
Vanillate 4-Hydroxy-3-methoxybenzoate
BCAAs (leucine, valine) and derivatives (2-oxoisocaproate) are found higher in
the north compared to the south after covariate adjustment, which may indicate
a difference in energy metabolism, something also reflected by the tricarboxylic
acid (TCA) cycle intermediates citrate and succinate that are found in higher con-
centrations in southern Chinese and BCAA isoleucine found higher in the north
before covariate adjustment. Aside from the BCAAs, amino acids histidine, tyro-
sine and glutamine are also found higher in the north after covariate adjustment.
Glutamine is involved in TCA anaplerotic metabolism and histidine in muscle
metabolism. While tyrosine partly links into the TCA anaplerotic metabolism
via a microbial conversion to pyruvate, it is an aromatic amino acid which is
found higher in the north both before and after covariate adjustment. Other
aromatic compounds, all related to gut-microbial metabolism, were found to be
higher in the south before covariate adjustment (4-cresyl sulfate, phenylacetylglu-
tamine, hippurate, 4-hydroxyphenylacetate and 3-hydroxymandelate). The fact
that phenylacetylglutamine, 4-cresyl sulfate and hippurate are no longer signifi-
cant after the adjustment may be related to gender and body weight differences
[260] (also see Figure 6.10). The only other aromatic compound (besides tyrosine)
found in both models is 4-hydroxyhippurate, which has been linked to the intake
of citrus fruits [312] and its urinary excretion is higher in the south. The most
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common biomarker of citrus fruit intake [312], proline betaine, was also found in
higher concentrations in southern Chinese individuals supporting this association.
scyllo-Inositol, also a potentially citrus-related metabolite, is only found higher in
the south before covariate adjustment. Aside from being a biomarker for citrus
fruit intake, proline betaine is also considered an osmoprotectant, as are carnitine
and trimethyllysine, both of which are also found in higher concentrations in the
south. Also, the intra-cellular concentration of both scyllo-inositol and taurine
(also found higher in the south after adjustment) increases when the extra-cellular
fluid is hypertonic [313], this may indicate that southern Chinese individuals, be-
cause they consume less sodium and more potassium (see Tables 6.3 and 6.4, and
Figure 6.11), are under less osmotic stress which may be reflected by the excretion
of these metabolites. It should be noted however that the excretion of carnitine
and O-acetylcarnitine has also been linked to meat intake [281] and that, aside
from being osmoprotective, taurine is also a major metabolite in the conjugation
of bile acids (as is glycine), this it may be related to the higher intake of fats in
the southern Chinese, indicating a difference in lipid and fatty acid metabolism
between the different regions. Urinary excretion of taurine may also be indica-
tive of cataplerosis [314]. Acetone is a by-product of breakdown of lipids and fatty
acids for energy release. Furthermore, it has been noted that incomplete fatty acid
oxidation, and possible fat excess in skeletal muscle tissue, can perturb the energy
anaplerosis and possibly cause DM [315], one of the risk factors for CVD. How-
ever, doctor-diagnosed DM is not significantly different between the populations
(Tables 6.3 and 6.4).
Aside from taurine (and 4-cresyl sulfate), a number of other sulfur contain-
ing metabolites have been found, with dimethyl sulfone and S -acetyl-1-propenyl
sulfoxide remaining significant after the adjustment. Dimethyl sulfone has been
found to be related to onion intake [316], which may also be the case for S -acetyl-
1-propenyl sulfoxide which shows a structural similarity to isoalliin (the lachry-
matory factor in onions). However, the formation of S -acetyl-1-propenyl sulfoxide
from isoalliin does not follow any of the known isoalliin degradation pathways
[317]. 1-Propenesulfenic acid may get acetylated through an acetyl-CoA conjuga-
tion mechanism to form S -acetyl-1-propenyl sulfoxide.
Another metabolite possibly linked to dietary intake is ethyl glucuronide, which
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is a long-term marker of alcohol consumption and a component of rice wine [318].
N -methyl nicotinate (trigonelline) is a metabolite linked to many different sources,
among which is coffee consumption [234, 263], but it is also a major metabolite of
niacin (vitamin B3). Two other metabolites related to nicotinamide metabolism,
N -methyl nicotinamide and N -methyl-2-pyridone-5-carboxamide, were found to be
consistently contributing in the unadjusted model only. In the metabolic network
(Figure 6.12), there are multiple domains related to different B vitamins, such as
thiamin (B1), panthothenate (B5), pyridoxal (B6), biotin (B7), folate (B9) and
cobalamin (B12). These play a role in many processes, including lipid metabolism
which appears to be different between these populations.
Closely linked to the lipidic domain through choline metabolism (choline, di-
methylamine and trimethylamine are significant in the unadjusted model) are for-
mate, dimethylglycine and sarcosine. These were all found higher in the north and
part of 1-carbon metabolism. Sarcosine is also linked to creatine and urea for-
mation via a microbial link. Creatine is, among many other processes, related to
muscle metabolism and, like 1-methylhistidine, it is found higher in the south and
this may reflect a difference in muscle metabolism between the populations, which
could possibly be a long-term effect from being more physically active (Tables 6.3
and 6.4). 2-Hydroxyisobutyrate is also found higher in the south which may be
the product of n-butyrate producing bacteria, the same bacterium (Faecalibac-
terium prausnitzii) is also associated with higher levels of beta-aminoisobutyrate,
taurine and dimethylamine, and lower levels of lactate and glycine [319]. These
metabolites are similarly expressed in the southern Chinese, indicating a possible
difference in n-butyrate producing bacteria between the northern and southern
Chinese. Last, pseudouridine, a marker of tRNA turnover, is found higher in the
south.
6.5 Discussion
CA-OPLS finds a lower number of false positive associations compared to other
commonly used methods in metabonomics (PLS, OPLS), while the number of true
positive associations remains the same. Adjusting the data for confounding factors
may lead to a (seemingly) less predictive model (lower Q2y), however the numbers
263
CHAPTER 6. CA-OPLS
of spurious findings are reduced, thus this greatly improves the interpretability of
the results. Therefore, the CA-OPLS framework leads to finding a more robust
set of biomarkers and more accurate predictions by:
1) reducing sampling bias by random sampling, independent scaling of model and
validation sets and MCCV [135],
2) optimizing the number of (orthogonal) components using CMV [139],
3) removing specific layers of confounding information from the data and
4) evaluating the variable significance across all models instead of calculating one
global model as by Cloarec et al. [144].
If a covariate (confounder) cannot be accurately modelled (i.e. no measurable
effect in X) it is not included in the adjustment procedure and therefore does not
influence the model. If this is the case for all covariates, by definition CA-OPLS
defaults to OPLS. I would like to stress that while many factors can be adjusted
for simultaneously, this will ultimately lead to loss of power (as many layers of
information are removed), regardless of the method (multivariate or univariate).
However, including many highly (anti-)correlated covariates does not pose a prob-
lem for CA-OPLS as it finds an orthonormal set of factors from the confounder
models to adjust the data.
Different factors differentially expressed between northern and southern Chi-
nese individuals influence metabolite associations. Using CA-OPLS some previ-
ously found associations are found to be primarily associated with potentially con-
founding factors as they were no longer consistently contributing to the model after
covariate adjustment and they also correlate with the confounders. The metabo-
lites that are significant after adjustment highlight underlying processes, most
noticeably lipid, energy and gut-microbial metabolism, are potentially of interest
in determining what may be causing the difference in prevalence of cardiovascular
disease between northern and southern Chinese.
However, also a number of metabolites associated with dietary intakes were
found to be different between the populations, among which the novel metabolite
S -acetyl-1-propenyl sulfoxide. The structure of the previously unreported metabo-
lite S -acetyl-1-propenyl sulfoxide was determined using a collection of NMR ex-
periments on a freeze-dried sample of overnight urine from a volunteer who con-
sumed 900 grams of white and red onions during dinner. From those experiments
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another potentially onion related metabolite with a similar structure to S -acetyl-1-
propenyl sulfoxide was witnessed (Figure 6.12). This was only weakly observed in
some INTERMAP spectra of people with very high amounts of S -acetyl-1-propenyl
sulfoxide, it could potentially be 1-propenesulfenic acid, however, the identity of
the unknown metabolite is not of interest here as it was not found to be signif-
icantly different between the two populations. As the chemical shift of the CH3
groups (δ 3.16, singlet) from dimethyl sulfone appears in a region where there
are many compounds, S -acetyl-1-propenyl sulfoxide may be a better biomarker
of onion consumption as its chemicals shifts are more pronounced and appear in
regions where there is little overlap. A proper nutritional intervention study will
have to be conducted to confirm whether this is indeed the case [217].
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Chapter 7
General Conclusions and Future
Directions
The common theme of this thesis is the evaluation and subsequent improvement of
standard practice in data analysis, exploration and visualization of metabonomics
and molecular epidemiology studies. For this purpose, I developed 3 new methods
to improve the data modelling, identification of unknown metabolites in 1H NMR
data and visualization of metabolic reaction networks. In addition I proposed two
data analysis frameworks that aim to minimize the amount of bias in modelling
data of MWAS.
7.1 MetaboNetworks
In Chapter 3 I described the MATLAB application MetaboNetworks that can be
used to construct metabolic reaction networks using a completely new method-
ology. Namely, the inclusion of data from multiple organisms to create a multi-
compartmental network map of systems biochemistry is what makes it different
from other methods. Compared to other software packages and applications it
has a number of other advantages, such as that all computations and network
modelling is done in one software program, in which the resulting network can
be changed, edited and explored interactively. MetaboNetworks is publically and
freely available from the MATLAB File-Exchange as open source software under
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a BSD 2-clause license (MATLAB File-Exchange entry 42684). MetaboNetworks
was demonstrated using an example from the COMET study [218] on hydrazine
toxicity and has also been used in Chapters 5 and 6 of this thesis. In addition,
it has been used to illustrate the coverage of the breast milk metabolome by two
new analytical methods [320].
7.2 STORM
Low intensity NMR signals close to the baseline are of considerable interest. In-
creasing use of higher frequency and thus higher sensitivity NMR spectrometers
mean that more of these low-intensity signals can be distinguished from the base-
line and noise [206]. However, the extreme variation in gene-environmental ex-
posure, typical of human populations, makes metabolite identification challenging
given the number of potential compounds present in human urine [13]. Especially
for 1H NMR where signals from many of these metabolites can overlap making both
analytical and statistical identification of metabolite signals challenging. STORM
takes a new approach to tackling this problem using a reference signal that resem-
bles the unknown metabolite pattern and finds all spectra that contain this signal
and exclude all others, opposed to other methods such as STOCSY [38] which
use all spectra. In Chapter 4 I have shown how STORM outperforms available
methods such as STOCSY [38] and stability selection [93], and STORM has been
used extensively in identifying metabolites for the studies presented in Chapters 5
and 6 of this thesis. Different groups have picked up on STORM as well [321–
324] and the theory behind the subset selection in STORM has recently spawned
an OPLSDA offspring called Statistical HOmogenous Cluster SpectroscopY [325]
(SHOCSY), also see discussion in section 7.4.
7.3 Metabolic Signatures of Human Obesity
Obesity is a major worldwide contributor to mortality, disease and disability [58].
Aside from the well-known ‘contributions’ of lack of exercise and poor diet, the
molecular mechanisms are still poorly understood. Chapter 5 described the untar-
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geted and targeted analysis of the urinary metabolome in relation to BMI, as an
indicator of obesity, in eight U.S. INTERMAP population samples with a total of
1880 participants. 35 unique urinary metabolites from untargeted 1H NMR spec-
troscopy and targeted ion-exchange chromatography are associated with BMI after
adjustment for several covariates including age, gender, population sample, CVD
history and (reported) physical activity. 27 of these were validated in an indepen-
dent and smaller (n=444) cohort of two U.K. INTERMAP population samples.
A combined regression model of population covariates, dietary energy sources and
urinary metabolites (35 for U.S. and 27 for U.K.) explains 49% and 45% of the
population BMI variance in the U.S. and U.K., respectively. In these models the
metabolites collectively explain 37% and 32% for the U.S. and U.K., respectively.
This is in stark contrast to the largest genomic study on obesity-related genetic
variation [250] which was only able to explain 1.45% of the total BMI variance.
However, this is not completely surprising as some of the novel relations can-
not be picked up by GWAS. For instance, the enzyme related to deamination of
leucine to ketoleucine is exercise induced [249] and multiple metabolites associated
with BMI are related to gut microbial activities. The close connectivities between
metabolites linked to multiple human body compartments and three distinct gut
microbial-host co-metabolic pathways have not been observed previously, although
it is well known that gut microbes play an important role in obesity [235, 236, 247,
276, 326]. However, in order to explain the highly complex multi-compartmental
systems interactions in obesogenesis no single ‘close the loop’ experiment is pos-
sible. Although in some cases, such as 4-cresyl sulfate, whose association with
BMI is unaffected by the different adjustment models, investigating which specific
microbiota play a role in the conversion from tyrosine to 4-cresol may give new
insights in gut microbial co-metabolism and obesity. However, the results also
clearly show that the most important contributors to BMI variance are metabo-
lites related to muscle metabolism, hence the age old ‘regular exercise reduces
overweight’ still stands.
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7.4 CA-OPLS
In Chapter 5 I performed the regression analyses using MLR to adjust for con-
founding factors and other covariates, as is standard in epidemiological studies.
While most reported findings in literature are univariate, and can thus be inde-
pendently verified, especially in the omic-sciences there can be multivariate rela-
tionships that cannot be captured in the same way. The multivariate relationships
can be modelled using methods such as PCA, PLS and ridge regression and may
provide more insight in the underlying biochemistry, and for 1H NMR data, the
former two are very popular due to the fact they can capture multiple independent
multivariate relationships between variables associated with a response variable.
However, multivariate methods cannot correct for confounding factors the same
way univariate methods, such as MLR, can.
Therefore I developed a new algorithm which is described in Chapter 6, CA-
OPLS. There, also a data analysis framework is outlined to adjust the multivariate
data for confounders and perform the overall data analysis with as little bias as
possible. I have shown the advantage of CAOPLS over PLS and its extension
OPLS in modelling simulated data, of which the variable relationships with ex-
ternal factors were known a priori, and how CA-OPLS reduces the number of
false positive associations. I then applied CA-OPLS on data from a previous
study which investigated the differences between northern and southern Chinese
individuals, two populations at different risks for CVD and also metabolically dif-
ferent [39]. I found that a large number of the previously reported findings [78]
were no longer significant when several covariates, among which gender, smoking
status and physical activity, were taken into account in modelling the metabolic
phenotype associated with the difference between these populations.
In most studies using (O)PLS the number of components is chosen by cross-
validation, and then a full model is calculated using all data [144]. However, in this
approach all data is used to calculate the full model and is therefore not validated
independently. To circumvent this issue, I designed the framework in two loops, in
the inner loop CMV [139] to determine the optimal number of components based
on the training data alone, and the outer loop is an MCCV [135] procedure to
avoid sampling bias.
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This has two advantages, the first being that the scaling of the data, selection of
number of components and construction of the prediction model are all performed
without using the test data, therefore this test set is an independent set and can be
used for proper validation. The second is that because random sampling of training
and test can also introduce bias especially if a regular selection pattern [134] is used,
the cross-validation procedure is repeated many times to avoid this and to obtain
both a reliable estimate of the regression coefficients as well as for the predicted
responses. In order to determine the variation of the regression coefficients a
number of bootstrap resamplings are made of the training samples and using the
regression coefficients from these models the variance of each regression coefficient
is calculated. This is a more robust procedure than by simply calculating the
correlation between the scores from the full model and the original data [144].
These advantages are substantial compared to the disadvantage of the increased
computational time it takes to calculate the models using MCCV compared to
k -fold CV.
The SHOCSY method, proposed by Zou et al. [325], uses subset selection of the
samples (like STORM) in an OPLSDA model to give a better separation between
groups to find biomarkers. Zou et al. choose to exclude samples that are predicted
to be part of the other group as these are claimed to be known non-responders
(idiosyncratic) to the treatment (response). Instead of excluding these samples
from the model, using CA-OPLSDA this information could have been taken into
account in modelling, thus retaining all samples and not losing statistical power
using a subset for classification.
7.5 Opportunities for extending this work and
future directions
The work presented in this thesis spans a broad range of tools that can be used
in the omic-sciences, but especially CA-OPLS has potential to be applied in other
fields than molecular epidemiology studies due to its capability to deal with con-
founders in collinear multivariate data such as other ‘omics’ technologies, drug
discovery, ecology and potentially finance. In molecular epidemiology studies it
271
CHAPTER 7. GENERAL CONCLUSIONS AND FUTURE DIRECTIONS
could potentially also be used to correct for batch effects. 1H NMR data typically
is very reproducible [36, 37], so correcting for batch effects may be particularly
useful for the analysis of large MS data sets which are known to have batch effects
[28].
The multivariate confounder adjustment framework described in Figure 6.2
and Algorithm 5 is translatable to other multivariate regression techniques such
as PCR, ridge regression, lasso and the elastic net, as it only needs regression
coefficients for each confounder to adjust the data. However, the sparsity of the
regression coefficients from lasso and elastic nets may require the confounder ad-
justment procedure (Algorithm 5) to be slightly altered to account for this.
The covariate-adjustment procedure relies on establishing a priori a set of po-
tential confounders, whereas other methods, for instance surrogate variable anal-
ysis [297], focus on unknown confounders and correct the model for potential
confounders a posteriori. Combining these two approaches (known and unknown
confounders) in a multivariate framework will be an interesting avenue to pursue,
especially if the transparency of the model predictors (importance of variables)
is retained, as it has been shown for GWAS that such an approach outperforms
correcting for only known or only unknown factors for analysing data univariately
[300], how this holds for multivariate analyses remains to be seen. For instance,
merging the covariate-adjustment procedure to correct for known confounders a
priori, then using the surrogate variable approach to identify possible unknown
confounding factors a posteriori and subsequently adjust not only the predictive
model but also the variable contributions (regression coefficients) will be a partic-
ular interesting challenge. In order for this combination to work, ideally the same
method that is used for the modelling and covariate-adjustment should also be
used for defining the surrogate variables.
MetaboNetworks uses KEGG data to generate a database of metabolic re-
actions as it contains the highest amount of genomes of all the databases (see
section 3.1). However, it is well-known that databases may be incomplete [327]
and that the overlap between multiple human metabolic network databases is poor
[200]. Therefore, integration of multiple databases may help to create a consen-
sus database, because Aristotle’s “the whole is greater than the sum of its parts”
certainly applies here as well. However, the different databases use different nota-
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tions which further complicates integrating them [200] and thus requires extensive
manual curation [183, 187].
The underlying algorithms and graphical user interface of MetaboNetworks can
also be used to calculate, plot and explore correlation networks (see for instance
Figure 6.10). For this type of network, where a priori each node can have an edge
to another node, different graph theoretical algorithms can be used to find interest-
ing structures in the network, such as finding cliques or modules with soft (fuzzy)
instead of ‘hard’ bounds [328] or by applying different weights to each module
to give a better representation of the structure of the network in the case where
the data may be heterogeneous [329]. Correlation network analysis is especially
popular in gene expression studies to explore gene-gene interactions [330–332], but
may be equally useful for metabonomics studies to highlight metabolite-metabolite
interactions [85, 333].
The rationale behind STORM can be used in many other fields as well, such
as by finding clusters of samples with specific gene expression patterns or in com-
bination with other statistical spectroscopy techniques (see review in [91]), such
as iSTOCSY [90], for improved information recovery. iSTOCSY is an extension of
STOCSY which sequentially performs multiple STOCSYs on signals that are cor-
related to the initial driver and then defines clusters of highly correlating peaks, an
approach which has also been used by methods such as CLASSY [89] and statisti-
cal recoupling of variables [203]. However, in iSTOCSY the sequential STOCSYs
on potentially different metabolites are still performed on the entire data ma-
trix. Using an optimized subset of spectra, as shown in Chapter 4, it is easier to
determine which signals are related to the same metabolite and which to other
metabolites. Moreover, using different subsets for the different comparisons will
result in a potentially better description of the subsequent analyses. This idea
(‘iSTORM’) would resemble the idea of bi-clustering [331, 334], also known as
co-clustering [335] in the chemometrics literature, in that it can be used to clus-
ter both variables as well as samples. A correlation network can be constructed
using the novel inter-metabolite relationships (correlations) between the variables
obtained using this approach. However, in iSTOCSY a ‘hard’ correlation thresh-
old is used to determine whether a variable is correlated to the driver, instead I
would personally opt for an FDR-type procedure to adjust for multiple testing as
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this is data dependent and it is likely that the STORM subsets consist of different
number of samples.
Another potential application of STORM has to do with improving the data
quality of NMR spectra as certain peaks may not be aligned to the same chem-
ical shift due to differences in pH or other sample conditions (‘biological matrix
effect’). Using STORM, multiple reference signatures (‘relics’) can be extracted,
these can then be used as input for alignment algorithms such as correlation op-
timized warping [336], fast Fourier transform cross-correlation alignment [337] or
recursive segment-wise peak alignment [220] to align specific parts of the spectrum.
Alternatively, the STORM relic can also be used to fit metabolite peaks. However,
unless the data is aligned beforehand local chemical shift variation must be taken
into account. This may improve the fitting of metabolite signals using actual peak
shapes opposed to using theoretical pure Lorentzian peaks to generate multiplet
signals to fit the data with [232, 338].
The work on the obesity-related homeostatic urinary metabolic signature was
done using data of two western populations (U.S. and U.K.). For a long time,
obesity was mainly a public health problem in western populations, however is has
become a global problem in the past two decades [58]. The INTERMAP study
also has data of four Japanese and three Chinese population samples; however
these data were not included in the study presented in Chapter 5 as it is well
known that obesity and cardiovascular disease manifest in different ways in Asian
populations [272–274, 339]. Therefore, the results described in Chapter 5 may not
generalize well in Asian populations due to potential genetic differences, whereas
they might in other populations where obesity follows similar trends to the U.S.
and U.K. such as other European and Middle Eastern populations [58, 340, 341].
In addition, the results in Chapter 5 show that there are a number of gut
microbial co-metabolites associated with obesity, and it is already known that
some gut microbiota are associated with BMI at the phylum level [236]. Therefore,
investigating which specific gut microbiota are related to the excretion of the
BMI-related microbial metabolites and how the composition of the microbiota is
affected by changes in the diet, may provide even more insights into the microbial
component of BMI variation.
Previously it has been shown that hippurate is also (inversely) related to blood
274
CHAPTER 7. GENERAL CONCLUSIONS AND FUTURE DIRECTIONS
pressure, even after adjustment for BMI [39], this illustrates that metabolites can
be associated with multiple risk factors independently. Thus studying the simi-
larities and differences between the BMI metabolic phenotype and metabolic phe-
notypes associated with other risk factors such as blood pressure, but also for
instance for smoking and DM, can be particularly interesting to study population-
wide grouping. The predictions of the models can studied simultaneously by, for
instance, hierarchical model fusion [342]. This is a new approach in which the
results of multiple outcomes can be combined in one full model. This may give
rise to the discovery of interesting clusters of participants with specific metabolic
phenotypes associated with a combination of different risk factors.
Preliminary analyses of the data in Chapter 5 have shown that most of the
metabolites associated with BMI are also correlated with dietary patterns and
nutrient intake. Therefore, uncovering relationships between food and nutrient in-
take on one hand, and the metabolic profile on the other hand, may provide useful
insights on which diet-metabolite relationships are associated with disease or other
factors [343]. Comparing whole metabolic profiles instead of individual metabo-
lites may be the best strategy, because not all food/nutrient-metabolite associa-
tions will be as clear as proline betaine with citrus fruits [263, 312], (N -acetyl)-S -
methyl-cysteine sulfoxide excretion with cruciferous vegetable consumption [344]
and trimethylamine N -oxide excretion with fish consumption [345]. However, MS
techniques will give more metabolic coverage than 1H NMR data alone, in addition
to the increased sensitivity in MS compared to NMR which may be required to
detect metabolites present in low concentrations [217]. Also, more and different
metabolites can be measured with mass spectrometry compared to 1H NMR spec-
troscopy, thus in addition to finding new dietary biomarkers it may also result in
finding new metabolite-BMI associations. However, Bouatra et al. have shown
that as a platform for metabolic profiling of urine, 1H NMR spectroscopy detects
more unique and a higher total number of metabolites compared to each MS tech-
nique individually [25]. Combined, however, the MS methods cover a bigger part
of the urinary metabolome than 1H NMR does. Despite many recent advances in
sample preparation, automated measurements and methodologies for mass spec-
trometry based metabolic profiling [29–35], the downside of mass spectrometry is
that its reproducibility is still far from that of 1H NMR [36, 37] among other issues
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in data treatment [346, 347]. However, mass spectrometry is rapidly catching up
[348] and the combined use of both 1H NMR spectroscopy and mass spectrome-
try may be particularly useful in future, and more practical, if the differences in
sample preparation are minimal [349].
Important to take into account is that the data generated by 1H NMR spec-
troscopy and mass spectrometry is different. Where 1H NMR data is highly
collinear, MS data is sparse after pre-processing. This requires different data
analysis strategies. Information from MS can complement 1H NMR data, and vice
versa, however care must be taken in linking the two data types.
The combined analysis of two or more data sets is referred to as ‘data fusion’
and multiple different types of fusion exist, see review in [350]. The three main
strategies of data fusion are called data-, feature- and decision-level fusion. De-
cision level fusion involves constructing separate predictive models for each data
set and then merging the individual models to result in a single predictive model.
Data-level fusion involves concatenating two data sets and constructing a single
predictive model using all data. Feature-level fusion is an intermediate approach
between data- and decision-level fusion, in that variable selection methods are used
to select a set of features (variables) from each set and these selected variables are
then merged (after scaling of the individual variables) to obtain a single predictive
model. Different strategies have been used for the fusion of different omics data
sets [351].
Given that data from 1H NMR and MS platforms are different and thus may
require different statistical methods to model, decision- and feature-level fusion
may be preferred over data-level fusion for the combined analysis of these types
of data. With the continued developments in chromatographic MS for improved
reproducibility and high-throughput analysis I foresee that it will become more
common that studies have data from both complementary platforms, which would
give more information of the biological system under study that can then be used
in modelling. Also, the availability of data for different biofluids, which would
require different data treatment strategies [342], would result in a potentially more
accurate description of the system.
One of the definitions of systems biology is that it aims to provide a sys-
temic overview of ‘everything that occurs’ in a biological system in response to
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(possible) external perturbations using a combination of experimental and com-
putational methods [1]. With high-throughput analysis and better reproducibility
thereof, and the reduction of costs, it will become more common to have studies
with data of potentially all omics. This will allow a joint model of genes, tran-
scripts, proteins and metabolites. However more research must be focussed on
how to obtain such a fused model and what type of fusion is best suited for this
task. One possibility is decomposing the data from multiple sources and use the
part that co-varies between all sources [352]. While this does give a transparent
model in terms of variable contributions, it does not consider that not all data
may be suited to be analysed with the same statistical method. A feature-level
fusion approach may therefore be the ‘best of both worlds’, and may be able to
capture complex multivariate phenotypic relationships across the different plat-
forms that would otherwise not be uncovered. For instance, jointly modelling the
‘static’ genes (both mammalian and microbial) and the ‘dynamic’ metabolites,
possibly supplemented with transcriptomics and/or proteomics data, could lead
to uncovering the role of genes with unknown functions in relation to metabolic
phenotype variations. This goes both ways, as this may also result in being able
to infer causality from variations in the metabolic profile through the less ‘vari-
able’, or more ‘stable’, descriptors. This is the goal of metabolic quantitative trait
loci mapping to study disease etiology by linking gene function with metabolic
phenotypes [353]. When these gene-transcript-protein-metabolite interactions are
carefully modelled in a population-wide context, by jointly modelling the envi-
ronmental factors and adjusting for confounders, accurate descriptions of different
disease phenotypes may ultimately lead to personalized medical treatments.
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ABSTRACT
Summary: MetaboNetworks is a tool to create custom sub-networks
in Matlab using main reaction pairs as defined by the Kyoto
Encyclopaedia of Genes and Genomes and can be used to explore
transgenomic interactions, for example mammalian and bacterial as-
sociations. It calculates the shortest path between a set of metabolites
(e.g. biomarkers from a metabonomic study) and plots the connectivity
between metabolites as links in a network graph. The resulting graph
can be edited and explored interactively. Furthermore, nodes and
edges in the graph are linked to the Kyoto Encyclopaedia of Genes
and Genomes compound and reaction pair web pages.
Availability and implementation: MetaboNetworks is available from
http://www.mathworks.com/matlabcentral/fileexchange/42684.
Contact: jmp111@ic.ac.uk or j.nicholson@imperial.ac.uk
Supplementary information: Supplementary data are available at
Bioinformatics online.
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1 INTRODUCTION
Investigating the dynamic metabolic responses in living systems
because of external perturbations gives complementary informa-
tion to genomic and/or proteomic approaches. This field is
known as metabonomics (Nicholson et al., 1999) and provides
a ‘top-down’ view of the living system to show global changes
instead of cell-specific interactions between genes, proteins and/
or metabolites. Metabolic pathway information can aid the in-
terpretation of biological changes indicated by significant differ-
ences in metabolite concentration identified in metabonomic
studies. The effective transformation of metabolic spectroscopy
data to biological knowledge presents a significant bioinfor-
matics challenge. In particular, the increased interest in clinical
applications of metabolic phenotyping makes practical data
visualization in a biological/medical framework of great
importance.
The Kyoto Encyclopaedia of Genes and Genomes (KEGG)
(Kanehisa and Goto, 2000) is an online resource where the inter-
action information of genes, proteins and metabolites is inte-
grated and it can be used to investigate molecular networks in
specific organisms or for all (Kanehisa et al., 2012). KEGG pro-
vides many static pathways and metabolic reaction networks as
well as a global metabolic map. The standalone application
NeAT (Faust et al., 2010) can be used to draw custom metabolic
reaction sub-networks for a specific organism. However, it is
useful to have the ability to edit graphs, as can be done for
pathways e.g. using KEGGParser (Arakelyan and Nersisyan,
2013) in Matlab. MetaboNetworks aims to fill this gap for meta-
bolic reaction networks and combine the ability to draw custom
maps and being able to edit them.
Rarely do metabolic networks and programs consider that the
typical mammal is not a single organism, but a system compris-
ing of a combination of mammalian, bacterial and potential
parasitic organisms. Specifically, there is symbiosis between a
host organism and its gut microbiota, and that gut microbes
have functions and enzymes that are not found in mammalian
organisms (Gill et al., 2006; Nicholson et al., 2012). Therefore, it
is important to be able to combine metabolic reaction networks
for different organisms. MetaboNetworks has the option to in-
clude data from multiple organisms and investigates if reactions
can occur in any of the selected organisms. In the present study,
we have illustrated the new approach using an NMR-based toxi-
cological biomarker input dataset. This is an area of particular
importance as metabolic phenotyping has shown to be particu-
larly useful for studying toxicological processes as models for
human disease (Nicholson and Wilson, 2003; Nicholson et al.,
2002).
MetaboNetworks only requires the basic version of Matlab
(The Mathworks, Natick, MA, USA) and does not require any
additional toolbox. Although the MatlabBGL toolbox (Gleich,
2006) has a number of graph layout algorithms in mex/cþþ code
that can be used to speed up the calculation of large graphs in
MetaboNetworks, all MetaboNetworks’ functionalities are im-
plemented using a simple graphical user interface and Matlab
code.
2 METHODS AND FEATURES
First, the appropriate data from KEGG has to be imported toMatlab. In
MetaboNetworks this is done using a function that uses the KEGG
REST-API to calculate a metabolite adjacency matrix that can later be
used to draw the graphs. The user can select one or multiple organisms
for which complete genomes are available in KEGG; for these organisms
a list of enzymes (with E.C. numbers) that are associated with a gene from
any of the organisms is determined. Using this enzyme list, all reactions
are queried and enzymes involved in the reactions are matched against the
enzyme list. Only reactions that require an enzyme from the list or that
are listed as ‘non-enzymatic’ or ‘spontaneous’ are used to find their main*To whom correspondence should be addressed.
 The Author 2013. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which
permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
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reaction pairs. The compounds from these reaction pairs are considered
adjacent. Each row/column in the adjacency matrix indicates a specific
compound (with a KEGG compound ID) and a list of all names for these
compounds are found from the KEGG compound database. A reaction
database has previously been collected using a similar approach (Ma and
Zeng, 2003) to MetaboNetworks, however, that database includes reac-
tions from all species, whereas MetaboNetworks focusses on organisms
of interest as not all reactions can occur in all organisms.
Second, when the data collection is complete, MetaboNetworks can be
used to create and explore custom networks. A list of metabolites, e.g.
biomarkers arising from a metabonomic experiment, can be passed to
MetaboNetworks and it searches for the shortest path between each of
these metabolites using the breadth-first search algorithm. All com-
pounds that are a part of a shortest path between any of the metabolites
are included in the network. By default, MetaboNetworks plots the net-
work as a circular graph. Other graph layouts include a spring-embedded
layout, high-dimensional embedding and two types of uniform edge-
length layouts, the last aim to place nodes with as little overlap as pos-
sible. If the Matlab statistical toolbox is installed, multidimensional scal-
ing can also be used.
Last, when the initial network layout is satisfactory the graph layout
can be manually adjusted. Supported adjustments include node position,
node/edge removal, highlighting nodes (see green edges of nodes in Fig.
1), and shortest paths (orange edges in Fig. 1), node text and nodes/edge/
text properties (font, width, size, etc.). If additional data is supplied, the
association of the metabolites with a response variable can be shown as
node colour (see Fig. 1). Furthermore, the network can be exported as a
tif, png, pdf, eps or other image formats, the network can always be reset
to the original graph (all changes are lost). Another option is to click on a
node to open a web browser showing the compound entry in KEGG or
show reactions pairs in KEGG of selected nodes. The Supplementary
Information includes a full walkthrough of the software and all the
capabilities.
3 DISCUSSION
MetaboNetworks can be used to investigate and modify complex
metabolic reaction networks. It improves the visual interpret-
ation of metabonomic experiments with coverage across dispar-
ate metabolic pathways. The network should ideally be viewed as
a connected network of probabilistic events (reactions) (Wilson
and Nicholson, 2003) that lie on the shortest path between two
metabolites. The database can be tailored to the study by includ-
ing specific organisms, as we have done for the hydrazine toxicity
network by including all bacteroidetes and firmicutes species, as
it has been shown that germ-free rats react differently to hydra-
zine (Swann et al., 2009). MetaboNetworks can possibly also be
used for identifying unknown metabolites by generating a net-
work of metabolites correlated to the unknown metabolite. The
unknown can be part of the shortest path between the known
metabolites as the correlation can be due to a similarity in
structure.
Note that use of the KEGG-API is free for academic use;
however, non-academic users should ask for permission (see
http://www.pathway.jp/).
Fig. 1. Shows the graphical user-interface of MetaboNetworks with a custom network drawn for significant metabolites from a hydrazine toxicity study
in rats (Nicholls et al., 2001). Metabolites higher in hydrazine-dosed rats compared with controls are shown in red, and metabolites lower in hydrazine-
dosed rats are shown in blue. The white nodes are part of shortest paths between the coloured nodes. The edges shown in orange are part of the shortest
path (four reactions) between taurine and glycine. Aside from the rat, all bacteroidetes and firmicutes species were included in the database
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ABSTRACT: We describe a new multivariate statistical approach to recover
metabolite structure information from multiple 1H NMR spectra in popula-
tion sample sets. Subset optimization by reference matching (STORM) was
developed to select subsets of 1H NMR spectra that contain speciﬁc spectro-
scopic signatures of biomarkers diﬀerentiating between diﬀerent human
populations. STORM aims to improve the visualization of structural cor-
relations in spectroscopic data by using these reduced spectral subsets con-
taining smaller numbers of samples than the number of variables (n ≪ p).
We have used statistical shrinkage to limit the number of false positive
associations and to simplify the overall interpretation of the autocorrelation
matrix. The STORM approach has been applied to ﬁndings from an ongoing human metabolome-wide association study on body
mass index to identify a biomarker metabolite present in a subset of the population. Moreover, we have shown how STORM
improves the visualization of more abundant NMR peaks compared to a previously published method (statistical total correlation
spectroscopy, STOCSY). STORM is a useful new tool for biomarker discovery in the “omic” sciences that has widespread
applicability. It can be applied to any type of data, provided that there is interpretable correlation among variables, and can also
be applied to data with more than one dimension (e.g., 2D NMR spectra).
Metabolome-wide association (MWA) studies1 are a power-ful means to ﬁnd connections between disease risk factors
and metabolic phenotypes in large populations.2 Advancements
in automated reproducible measurements of samples by 1H
nuclear magnetic resonance (1H NMR) spectroscopy3 have given
rise to increasingly large data sets such those available from the
INTERMAP1,4 study. INTERMAP combines measurements of
blood pressure, extensive dietary information, questionnaire data,
and urinary metabolite excretion data from 1H NMR spectro-
scopic analysis of 24-h urine collections,1.4 Statistical analyses of
large data sets such as INTERMAP yields many “nominally”
signiﬁcant associations of a risk factor with spectroscopic signals that
can be assigned to speciﬁc metabolites after structural elucidation.
1H NMR peak intensities are intrinsically highly correlated stoichio-
metrically with peaks from the same molecule; however peaks
from diﬀerent compounds can overlap, reducing the correlation.
Therefore, two-dimensional (2D) experiments are often needed
for structure elucidation.5
Identiﬁcation of 1H NMR spectroscopic signals by statis-
tical methods is an important aspect in MWA studies, as it
uses the data that have been modeled to more accurately recover
information about possible biomarkers without requiring addi-
tional spectroscopic experiments, which has obvious advantages
in terms of eﬃciency and in usage of samples where volume is
limited.6 A widely used statistical spectroscopy tool in NMR-
based metabonomics7 is statistical total correlation spectroscopy
(STOCSY), developed by Cloarec et al.,8 which is related to
generalized 2D correlation theory as used for IR and Raman
spectroscopy.9 In the case of 1H NMR spectra, STOCSY can
generate a pseudoselective one-dimensioal (1D) TOCSY spectrum,
based on the correlation with the intensity of a given peak (driver),
or a 2D autocorrelation matrix to show all spectrumwide asso-
ciations in the data. A related method, covariance NMR, uses
the covariance matrix as a substitute for a second Fourier
transformation in 2D NMR spectroscopy.10
Over the past few years, STOCSY and its variants have
proven to be a valuable tool in identiﬁcation of spectroscopic
signals, as they can visualize both structural associations and
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nonstructural (e.g., metabolic pathway) interactions.11 STOCSY
makes use of the covariance and correlation between variables, and
as these are simple to calculate (eq 1), STOCSY is a fast method.
In eq 1, X̅ and X̅d denote the mean-centered data matrix
(n samples, p variables) and driver (n samples, one variable),
respectively, which are used to calculate spectralwide cor-
relations in the form of a pseudoselective 1D total correlation
spectroscopy (TOCSY) spectrum.
= ̅ × ̅
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where d ∈ {1, ..., p}.
In the past few years, a number of methods have been pro-
posed to improve the statistical signal elucidation such as
CLASSY,12 which aims to identify clusters of variables
belonging to the same molecule; R-STOCSY,13 to use clustered
groups of variables to identify metabolic networks; iSTOCSY,14
which aims to determine the within- and between-metabolite
relationships by iteratively performing multiple 1D STOCSY
analyses; and OR-STOCSY,15 which ﬁlters out orthogonal
variance prior to R-STOCSY. All methods use all available data
to calculate the correlation and covariance matrices. Previous
MWA INTERMAP studies have shown it is not uncommon to
ﬁnd unknown signals1,16 that cannot be easily identiﬁed by
STOCSY or other methods. Also, by studying diﬀerences in
large populations, speciﬁc peaks may be present only in a small
subset of people. A STOCSY analysis of a rare signal will be
heavily inﬂuenced by the spectra without the peak, resulting in
the actual signal being obscured. Low-intensity signals close to
the baseline are of considerable interest. Increasing use of higher
frequency and thus higher sensitivity NMR spectrometers mean
that more of these low-intensity signals can be distinguished
from the baseline and noise.17 However, the extreme variation
in gene-environmental exposure, typical of human populations,
makes metabolite identiﬁcation challenging, given the number
of potential compounds present in human urine.
We propose here a new method that aims to ﬁnd an optimal
subset of spectra that contain a speciﬁc peak of interest. The
similarity between each spectrum and a reference (set of spectral
points) is evaluated, and spectra with a high similarity are further
analyzed by STOCSY. A STOCSY of such a subset may no
longer be obscured by noise and thus will provide a clearer
description of the unknown metabolite compared to a STOCSY
on the full data set. Our method, subset optimization by reference
matching (STORM), iteratively learns the true reference by
repeating a procedure to ﬁnd the most highly correlated spectra
and updating the reference multiple times. It converges when a
subset of samples has been found twice. Because it uses only
small parts of the spectrum in each iteration, the algorithm is
very fast. STORM aims to visualize low-intensity and rare signals
close to the baseline and distinguish these from noise. It does so
by ﬁnding a subset of spectra that contain the purest form of
the unknown signal. By use of that subset, the J-coupled splitting
multiplicity of the peak can be more clearly visualized to aid in
determining the identity.
We illustrate how STORM works and how it can be used for
large data sets, where the numbers of samples (n) has the same
order of magnitude as the number of variables (p). The resulting
subset, however, will contain less samples, hence the data matrix
tends to be wide (n≪ p). In data sets where n≪ p, often many
signiﬁcant correlations are found, of which some may be false
positive associations. To control for multiple testing, several
approaches can be used, among which the Bonferroni correc-
tion and false discovery rate18 are the most commonly applied.
We have used a diﬀerent approach to simplify the interpretation
of 2D-STOCSY: statistical shrinkage of the covariance matrix,19
which has been shown to limit the number of false positive
associations in genome-wide association studies.20
■ MATERIALS AND METHODS
Human Data. The international study of macro- and
micronutrients and blood pressure (INTERMAP) study is
investigating dietary and other factors associated with blood
pressure,4 one of the major risk factors underlying the worldwide
epidemic of cardiovascular diseases.21 As well as eight blood
pressure measurements, data obtained include four 24-h dietary
recalls, measurements of height and weight, questionnaire
information, and two timed 24-h urine collections, for each of
4680 men and women aged 40−59 from 17 ﬁeld centers in four
countries (People’s Republic of China, Japan, United Kingdom,
and United States).
NMR Spectroscopy. The urine samples were prepared
for, and analyzed with, high-resolution 600 MHz 1H NMR
spectroscopy.22 Data on urinary metabolite excretion were available
from both urine collections for 4630 individuals. Conﬁrmation of
unknown signals was performed by a combination of a standard
1D 1H NMR pulse sequence with water peak presaturation
(noesypresat), 2D J-resolved (JRES), 2D 1H−13C hetero-
nuclear single quantum coherence (HSQC) and 1H−1H total
correlation spectroscopy (TOCSY) experiments. All experi-
ments were performed on a Bruker Avance III spectrometer,
operating at 600.29 MHz for 1H, equipped with a 5 mm, TCI,
Z-gradient cryoprobe. Two-dimensional (2D) NMR analyses
were performed on the urine sample with the highest quantity
of the unknown metabolite. Experimental protocols are described
in section 1 of the Supporting Information. Spectra were visualized
by use of MestReNova (version 7.0.2, Mestrelab Research S.L.,
Santiago de Compostela, Spain).
Data Pretreatment of 1H NMR Spectroscopic Sets.
Free induction decays (FIDs) were Fourier-transformed,
referenced to an internal standard (trimethylsilyl propionate,
TSP), and baseline- and phase-corrected by use of in-house
software. The spectral regions containing water and urea (δ 6.4
to 4.5), the internal standard (δ 0.2 to −0.2), and regions δ 0.5
to 0.2, δ −0.2 to −4.5, and δ 15.5 to 9.5 were removed prior to
normalization via the mean fold change method.23 The
remaining variables were binned to 7100 variables with bin
widths of 0.001 ppm. Metabolic outliers were excluded from
the data set by use of Hotelling’s T2 statistic24 on the scores of
the principal component analysis. Metabolic outliers were deﬁned1
as participants whose scores, for either urine collection, mapped
outside the Hotelling’s T2 ellipse (CI = 0.95).
Data Analysis. Linear regression of body mass index [BMI,
deﬁned as weight (in kilograms) divided by height (in meters)
squared] with the 1H NMR spectra was performed for both
urine collections (“visits”) of 1880 nondiabetic U.S. individuals.
Results were adjusted for potential confounding factors of age,
sex, and population sample (ﬁeld center). A spectral variable i is
found to be signiﬁcant if (1) its p-value (pi) is smaller than 4 ×
10−6, the metabolome-wide signiﬁcance level25 (MWSL) for a
familywise error rate of 1%, in both visits; (2) the regression
coeﬃcients (βi) from both visits have the same sign; and
(3) both of its adjacent spectral points (i − 1 and i + 1) obey
rules 1 and 2 as well. In order to represent the variables we have
used the “Manhattan” representation (eq 2) of the p-values.
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Here Mi is the Manhattan index, pi is the p-value, and βi is the
regression coeﬃcient, all for variable i:
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■ SUBSET OPTIMIZATION BY REFERENCE
MATCHING (STORM)
The algorithm consists of three steps that are repeated a number
of times: subset selection, STOCSY of subset, and reference
updating. There are three user-deﬁned parameters used in the
algorithm: ns, b, and q. ns is the expected number of spectra with
the hidden signal, the expected signal width (broadness) is
indicated with b, and q is a predeﬁned p-value threshold for
including the spectral variable in the updated reference.
First the algorithm calculates the Pearson correlation of each
spectrum with the reference. Next the corresponding p-values
are calculated by transforming the correlation into the t-statistic
with n − 2 degrees of freedom. At this point all spectra are in
the subset. Then spectra that have a negative correlation with
the reference are excluded from the subset. From the remainder,
the ns spectra with the lowest p-values are chosen to be in the
subset.
For the second step, a STOCSY is calculated for the spectra
in the subset only for a small number of variables, with the
driver being the maximum intensity of the previous reference.
The variables that are included are limited by the broadness
parameter, because we are only interested in variables in the
vicinity of the driver.
The third step is where the previous reference is updated by
use of the STOCSY. The new reference is deﬁned as the set of
spectral points of the STOCSY pseudospectrum that are
signiﬁcantly correlated (based on q) with the driver. As we are
using a lower number of samples for the STOCSY, there is
a higher chance of ﬁnding higher correlations compared to
using the full data set. Also, the covariance is more sensitive to
abundant signals in the vicinity of the driver; in order to
prevent inclusion of diﬀerent metabolites in the new reference,
we use the parameter b to limit the size of the new reference. In
theory, the ideal value for b is the full bandwidth of the
metabolite NMR peak. In practice, a value slightly wider than
the ﬁrst reference has been found to work best, as the full
bandwidth is, like the hidden signal, unknown. The new reference
consists of all spectral points, within the broadness window,
that are signiﬁcantly correlated with the driver. Hence, the
previous driver peak is always included in the new reference, as
its corresponding p-value will be 0, but it will not necessarily be
the new driver. The new driver is deﬁned as the variable with
the highest intensity in the new reference; that is, b cannot be
Figure 1. Graphic showing preliminary results from the MWA study on body mass index (BMI) and illustrating problems identifying unknown
signals. (a) Small section of the median 600 MHz 1H NMR spectrum of urine from 1880 nondiabetic U.S. INTERMAP participants. Full results of
the study elucidating the biochemistry of BMI will be published elsewhere. Signiﬁcant associations with BMI are shown in green for this section.
(b) Expanded region δ 4.05 to 4.00 from panel a. Top part shows the median spectrum; bottom part shows the Manhattan representation of the
p-values. This shows both unknown signals have a positive association with BMI. (c, d) STOCSY of δ 4.04 and 4.02 (most signiﬁcant signals),
respectively.
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chosen to be too wide or the reference may include other
signals with higher intensity than the unknown.
Next the updated (new) reference is fed back into the ﬁrst
step of the algorithm and all spectra are used again to calculate
the correlation with the new reference. This procedure allows
the algorithm to update the reference signal, using information
from previous iterations. STORM converges when a subset is
found (at the end of the ﬁrst step) that is identical to any of
the previously found subsets. As STORM uses small parts of all
spectra at a time, it is minimally memory-intensive and very fast.
Pseudocode is given in Figure 1 of the Supporting Information.
From this point forward, “STORM” will denote the complete
routine described above, the “subset” is the spectra with highest
similarity to the reference before convergence, and the STOCSY
of the subset to visualize the spectrumwide correlations will be
known as the “relic” (recovered latent compound). Additional
steps within the STORM algorithm and information on statistical
shrinkage are given in sections 2 and 3 of the Supporting
Information. All calculations were performed in MATLAB
(R2011a, The Mathworks, Natick, MA).
■ RESULTS AND DISCUSSION
Metabolome-Wide Association Study on Body Mass
Index. Part of the urinary metabolome-wide association for
BMI is shown in Figure 1a. Full results of the study elucidating
the biochemistry of BMI will be published elsewhere. The
ﬁgure shows a section of the median 600 MHz 1H NMR spec-
trum of 1880 individuals. Signals signiﬁcantly associated with
BMI are shown in green. STORM was applied to elucidate
structural correlations of two unidentiﬁed signals from the
MWA BMI study. The signals resonate around δ 4.04 and 4.02
(Figure 1b), and their signals are close to the noise and baseline
in the median spectrum. The bottom section of Figure 1 b
shows the Manhattan representation of the p-values obtained
Figure 2. Visualization of the subset, using STOCSY, after each iteration of STORM to uncover the identity of a biomarker from the INTERMAP
BMI study. The boundaries of the updated reference are shown by two vertical red lines, and the driver of each STOCSY is indicated with an arrow.
The driver is deﬁned as the highest intensity in the previous reference signal. (a) 193 samples; (b) 318 samples; (c) 359 samples; (d) 204 samples;
(e) 86 samples; (f) 33 samples. Width was restricted by the p-value threshold. (g) The relic (same subset as panel f) with two multiplet signals
[δ 4.03 (ddd) of chiral CH and δ 3.74 (m) of CHH′OH], possibly belonging to the same molecule.
Analytical Chemistry Article
dx.doi.org/10.1021/ac302360v | Anal. Chem. 2012, 84, 10694−1070110697
with linear regression. The Manhattan plot shows that the un-
known signals are positively associated with BMI. On the basis
of STOCSY analysis of the most signiﬁcant spectral points, they
appear to be two diﬀerent metabolites mainly correlated with
glucose signals (Figure 1c,d) as they do not correlate with each
other. The driver peaks of the STOCSYs are indicated with red
arrows.
Application of STORM. The covariance of BMI with the
signiﬁcant spectral points around δ 4.04 was used as initial
reference for STORM. By using this set of adjacent spectral
variables, noise has less of an inﬂuence compared to using a
single spectral variable. Figure 2 shows the STOCSY at each
step; the new reference is the covariance between the vertical
red lines. The number of samples in each subset is shown in the
caption. Every time the reference is updated, the entire data set
is used to calculate the correlation with the new reference.
Figure 2g shows the relic, where we see that the signiﬁcant
signals at δ 4.04 and 4.02 actually belong to the same multiplet.
This multiplet, possibly a doublet of doublets of doublets, is
strongly correlated with another multiplet signal at δ 3.74. The
multiplicity and possible structural correlation were not visible
in the STOCSYs of the entire data set (Figure 1c,d). The
sample with the highest concentration of unknown metabolite
from the ﬁnal subset (n = 33) was used for spectroscopic
experiments. The full data set and subset are shown in Figure 2
of the Supporting Information; it also shows many signals
around δ 4.03 that are not the same as the relic. Section 4 of the
Supporting Information describes how a diﬀerent signal with
resonances around δ 4.03 (Figure 3 of the Supporting Information)
can be extracted by use of STORM. This signal may have
obscured the result of the data analysis; it could be (one of the)
cause(s) of the reduced signiﬁcance around δ 4.03 as shown in
Figure 1b. By selecting the optimal subset, a clearer metabolic
signature of a possible obscuring compound can be extracted
and more accurately removed from (selected) spectra, for
example, by STOCSY editing.26 Statistical shrinkage can reduce
the number of signiﬁcant correlations in a 2D STOCSY when
n≪ p to simplify the interpretation (Figure 4 of the Supporting
Information).
Identiﬁcation of the Relic. To validate the results of
STORM and to uncover the peak multiplicity and structural
correlations of the chemical shifts at δ 4.03 and 3.74, JRES and
Figure 3. Experiments performed on the urine sample with the highest amount of unknown metabolite. (a) Untilted JRES spectrum (δ 4.75 to 3.63)
shows the multiplicity of the signals at δ 4.03 (ddd) and 3.74 (m). (b) 1H−1H TOCSY spectrum (δ 4.75 to 3.63) shows structural correlation
between δ 4.03, 3.74, and 4.52 (d). (c) 1H−13C HSQC spectra (F1, δ 87.5 to 32.5; F2, δ 4.75 to 3.63) of (red) urine sample and (blue) ascorbic acid
standard. (d) 1H NMR spectra of spike-in experiments on the urine sample, zoomed in on each signal of ascorbic acid (multiplicity shown
underneath). The urine sample spectrum is shown in red, and spectra with added 0.95 and 1.42 μmol of ascorbic acid are shown in green and blue,
respectively. Key: d, doublet; ddd, doublet of doublets of doublets; m, multiplet.
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TOCSY experiments were performed (Figure 3a,b). The TOCSY
spectrum shows structural correlations between δ 4.52, 4.03, and
3.74. The NMR spectrum of ascorbic acid is known to have
these chemical shifts. To conﬁrm the identity, 1H−13C HSQC
and 1D 1H NMR experiments were performed with and
without the addition of authentic ascorbic acid. Figure 3c shows
the 1H−13C HSQC of the urine sample in red, overlaid with the
ascorbic acid standard in blue. The 13C and 1H chemical shifts
of the standard match the chemical shifts of the relic in the
urine sample. To conﬁrm the identiﬁcation of ascorbic acid, a
spike-in experiment was performed (Figure 3d). The original
urine 1H NMR spectrum is shown in red, and additions with
0.95 and 1.42 μmol of ascorbic acid are shown in green and
blue, respectively. Finally, a STOCSY was performed on the
raw (including δ 6.4 to 4.5) spectra of the subset (Figure 5 of
the Supporting Information) to conﬁrm the correlation between
the diﬀerent signals of ascorbic acid [δ 4.52 (d), 4.03 (ddd), and
3.74 (m)] in the data.
Here we have shown how the ascorbic acid concentration in
the urine is possibly associated with higher BMI (Figure 1b).
This contradicts previous results where ascorbic acid (vitamin
C) was found to be negatively associated with BMI.27 In order
to verify our ﬁndings, we correlated the intensity of the ascorbic
acid 1H NMR signals from spectra in the subset with various
sources of vitamin C. We found urinary ascorbic acid (n = 33)
to be signiﬁcantly correlated with vitamin C supplement intake
(r = 0.451, p = 0.013) as reported in the participant questionnaire
data, whereas it was not signiﬁcantly correlated with total vitamin
C intake (p = 0.52) or ﬁzzy drink consumption (p = 0.27). It has
been shown that the fractional urinary excretion of ascorbic acid
relative to the vitamin C supplement intake for healthy humans
for dosages well above the daily recommended amount is close
to 100%,28 which is what we might be seeing here. However, in
order to determine if the reported vitamin C intake is accurate,
a separate experiment would have to be conducted where dietary
intake would be controlled, as is recommended for most proﬁling
studies.
Comparison of STORM with STOCSY. In our analysis we
found three signals (negatively) associated with BMI that are
from N-methylnicotinic acid (NMNA): δ 9.13 (s), 8.84 (t), and
4.45 (s). However, we did not ﬁnd the fourth NMNA signal (t)
at δ 8.09 signiﬁcant. To investigate whether our resonances
correspond with NMNA, we have used STORM to visualize
the structural associations. We have compared our results with
STOCSY in Figure 4. Each coordinate on the scatterplot is a
combination of the correlation of a variable with the driver at δ
8.84 obtained with STOCSY (x-axis) and STORM (y-axis).
Aside from NMNA (shown in orange), we have labeled signals
from two other metabolites that highly correlate with NMNA
in light blue (unknown metabolite) and green (hippuric acid);
each metabolite peak is denoted by a diﬀerent symbol as shown
in the ﬁgure legend. The δ 8.84 peak from the spectrum with
the highest peak intensity was used as reference for STORM.
For each of the four groups, the fourth being the remainder of
all data points shown in dark blue, we calculated kernel density
estimates (KDE), shown on the top for STOCSY and on the
right for STORM. The KDE shows there is less overlap in the
distributions of NMNA with the other metabolites when using
STORM than with STOCSY, this means that the NMNA triplet
at δ 8.09 now has the same range of correlation coeﬃcients as
other NMNA signals. The reduced signiﬁcance of the triplet in
our analysis is most likely caused by the fact that it has a lower
intensity and is obscured by other signals (residual variation)
when inspecting the spectra (not shown). This shows how
STORM is able to more accurately visualize structural correla-
tions in the data set. The recently proposed iSTOCSY aims to
distinguish structural from nonstructural correlations;14 how-
ever, it starts from a driver peak and from the initial STOCSY,
multiple STOCSY analyses of the signiﬁcantly correlated spectral
points are performed iteratively on the entire data set.
As STORM uses extra information, the reference signal, to
show structural associations, the relic should always be
interpreted with some caution. The recently proposed stability
selection29 does not rely on user input as it aims to ﬁnd a subset
of samples using a resampling approach; for example, for regres-
sion its goal is to ﬁnd a resampled subset that has a more
signiﬁcant association with Y than does the original data. This is
a robust approach that ensures the problem is not underestima-
ted while retaining the same statistical power. However, when
comparing STORM with stability selection for the NMNA
example (Figure 4), we found that STORM outperforms stability
selection in terms of the end result (Figure 6 of the Supporting
Information) as well as timewise for 1 000 000 permutations of
stability selection. However, when the sample size gets smaller, it
will be faster to use stability selection.
Another example to show how STORM can help to
distinguish between structural and nonstructural correlations,
for example, highly correlated metabolites in the same pathway,
is shown in Figure 5. It has been shown that the urinary con-
centrations of 4-cresyl sulfate (4CS) and phenylacetylglutamine
(PAG) are highly correlated in humans due to their formation
Figure 4. Comparison of STOCSY and STORM for the identiﬁcation
of N-methylnicotinic acid signals in the INTERMAP BMI nondiabetic
U.S. data set. Scatterplot of correlations determined by STOCSY
(x-axis, n = 1880) and by STORM (y-axis, n = 112), using an
N-methylnicotinic acid (NMNA) peak at δ 8.84 as driver, is shown.
For each axis the kernel density estimation of the distribution of each
class is shown in the same color on the opposite side. NMNA is shown
in orange, hippuric acid in green, an unknown metabolite in light blue,
and all other variables in dark blue. For each of the metabolites, each
signal is shown with a diﬀerent symbol. For clarity, each distribution
has been normalized to the same total area. It shows that the density
estimate of NMNA overlaps less with others in STORM compared to
STOCSY.
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from proteins and aromatic amino acids by gut microbiota.16
This can be seen in the 1D STOCSY of a PAG triplet at δ 2.27.
Figure 5a,b shows parts of the pseudospectrum for (a) aromatic
and (b) aliphatic regions. The result of STORM is shown in
Figure 5c,d. Here we see that using a subset of spectra that
contain the PAG triplet (n = 89) gives a clearer description of
structural correlations and less confusion caused by intermolecular
correlations compared to the STOCSY using all available spectra
(n = 1880), thereby clearly diﬀerentiating PAG from 4CS.
■ CONCLUSION
Uncovering the identity of unknown spectroscopic signals is a
critical step in large MWA and metabonomic studies. Esta-
blished methods such as STOCSY can fail to uncover the identity
of rare low-concentration signals due to the large variability in
human bioﬂuid samples. We have shown how subset selection can
improve visualization of structural correlations using our new
method, STORM. Unlike currently used statistical spectroscopy
methods, STORM is not inﬂuenced by other signals and noise as
it iteratively learns not to include them in the subset. However,
local misalignments in spectra can lead to ﬁnding a smaller subset
of samples than those that contain the signal of interest. Aligning
peaks beforehand can possibly improve STORMʼs ability to ﬁnd
the optimal subset;30 additionally, the relic can be used as
reference for alignment afterward, and performing STORM on
the aligned data set will result in a subset with all spectra with
the unknown. The choice of the initial reference and spectro-
scopic tool are very ﬂexible, because STORM uses a scale-
invariant similarity measure (correlation). The reference can
thus be part of a single spectrum, regression coeﬃcients, or
other parameters that resemble a signal. Aside from recovering
rare signals, we have demonstrated how STORM also improves
the visualization of more abundant signals. STORM is an
important advance in biomarker discovery, as often peaks
remain unidentiﬁed due to their low concentration and/or
natural occurrence; however, its applicability is not limited to
1D NMR data, as we have also shown how it can more clearly
extract structural information compared to STOCSY from 2D
data (see section 5 and Figures 7 and 8 of the Supporting
Information). Thus STORM could be used for any type of data
where there is interpretable correlation present among variables,
such as HPLC-UV and CE-UV, as well as 2D data such as two-
dimensional NMR techniques (JRES, TOCSY, COSY, and
HSQC), LC/MS, GC/MS, CE/MS, and other MS/MS experi-
ments. STORM should, however, ideally be used to augment
spectroscopic data interpolation to aid in the identiﬁcation of
structural unknowns in spectral data.
■ ASSOCIATED CONTENT
*S Supporting Information
Eight ﬁgures and additional text and equations describing
experimental protocols, additional steps in the STORM algorithm,
Figure 5. Phenylacetylglutamine [PAG; signals shown here are m-CH (δ 7.42), o-CH/p-CH (δ 7.36), CγH2 (δ 2.26), CβH2
(δ 2.11), and CβH2 (δ 1.93)] relic shows no inﬂuence of 4-cresyl sulfate (4CS; signals m-CH (δ 7.28), o-CH (δ 7.20), and p-CH3 (δ 2.35)] in
the INTERMAP nondiabetic U.S. data set. Analysis of structural correlations of PAG (driver peak = δ 2.27, p-value threshold = 10−10): STOCSY
(n = 1880) for (a) aromatic region and (b) aliphatic region (driver indicated with a red arrow), and relic (n = 89) for (c) aromatic region and (d)
aliphatic region (driver indicated with a red arrow). Other well-known metabolites in these regions include hippuric acid [Hip; o-CH (δ 7.84), p-CH
(δ 7.64), and m-CH (δ 7.55)], 4-hydroxyphenylacetic acid [HPA; o-CH (δ 7.16) and m-CH (δ 6.85)], and succinic acid [Succ; 2×CH2 (δ 2.41)].
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statistical shrinkage, extraction of obscuring compounds, and a 2D
NMR example of STORM. This material is available free of charge
via the Internet at http://pubs.acs.org.
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Abstract Because cerebrospinal fluid (CSF) is the biofluid
which interacts most closely with the central nervous sys-
tem, it holds promise as a reporter of neurological disease,
for example multiple sclerosis (MScl). To characterize the
metabolomics profile of neuroinflammatory aspects of this
disease we studied an animal model of MScl—experimental
autoimmune/allergic encephalomyelitis (EAE). Because
CSF also exchanges metabolites with blood via the blood–
brain barrier, malfunctions occurring in the CNS may be
reflected in the biochemical composition of blood plasma.
The combination of blood plasma and CSF provides more
complete information about the disease. Both biofluids can
be studied by use of NMR spectroscopy. It is then necessary
to perform combined analysis of the two different datasets.
Mid-level data fusion was therefore applied to blood plasma
and CSF datasets. First, relevant information was extracted
from each biofluid dataset by use of linear support vector
machine recursive feature elimination. The selected varia-
bles from each dataset were concatenated for joint analysis
by partial least squares discriminant analysis (PLS-DA). The
combined metabolomics information from plasma and CSF
enables more efficient and reliable discrimination of the
onset of EAE. Second, we introduced hierarchical models
fusion, in which previously developed PLS-DA models are
hierarchically combined. We show that this approach ena-
bles neuroinflamed rats (even on the day of onset) to be
distinguished from either healthy or peripherally inflamed
rats. Moreover, progression of EAE can be investigated
because the model separates the onset and peak of the
disease.
Keywords EAE .Multiple sclerosis . Metabolomics . Data
fusion . Classification . Variable selection
Introduction
Multiple sclerosis (MScl) is an inflammatory, presumably
autoimmune, disease of the central nervous system (CNS) in
which the fatty myelin sheaths which surround the axons of
the brain and spinal cord are damaged, leading to demyeli-
zation [1]. MScl is one of the most common neurological
diseases affecting young adults and has enormous effect on
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the health system and economy of many countries.
Although the cause of MScl is still elusive, it is believed
to be a combination of genetic and environmental factors
with a possible infectious origin. Signs of MScl can be
observed not only in CNS but also in the peripheral nervous
system (PNS) [2].
Diagnosis of MScl is still challenging, especially in its
early stage. Currently, diagnosis of MScl is mostly based on
clinical evidence complemented with laboratory investiga-
tions, for example presence of lesions in the brain and/or
spinal cord (visualized by magnetic resonance imaging,
MRI). However, lesions have been found in other neurolog-
ical diseases, for example Guillain–Barré syndrome [3], and
in non-neurological diseases, for example systematic vascu-
litis [4] or sarcoidosis [5]. Furthermore, brain lesions have
been found in healthy individuals [6]. Therefore, brain
lesions are not sufficiently specific for proper, early diagno-
sis. To improve diagnosis of MScl it is necessary to combine
information from cerebrospinal fluid analysis, MRI results,
and all clinical symptoms.
To fingerprint MScl at the molecular level, biological
samples must be analyzed. Because CSF is the biofluid in
direct contact with the brain and spinal cord, it is the most
suitable choice for fingerprinting MScl. Investigation of the
biochemical composition of CSF may reveal abnormal sta-
tus of the brain. CSF is absorbed into the blood via a semi-
permeable membrane, the blood–brain barrier (BBB).
Therefore, effects of CNS diseases can potentially also be
seen in the biochemical composition of blood plasma.
Obviously, cross-over effects from the plasma to the CSF
may also cause changes in the biochemical composition of
the CSF. In MScl, the BBB is often damaged, causing
“leakage” [7]. This suggests that plasma may contain pre-
dictive information about the disease. Therefore we propose
to study the metabolic profiles of both CSF and plasma.
These types of sample are relatively difficult to obtain from
humans and interesting information is very often obscured
by other factors, for example genetic, environmental, and
dietetic background. Thus we opt for the possibility of using
samples from designed and controlled experiments in
rodents.
The animal model of MScl, the experimental autoim-
mune/allergic encephalomyelitis (EAE) model has become
an important tool in studies of neuroinflammatory aspects of
MScl [8, 9]. EAE is a cell-mediated experimental autoim-
mune disorder of the CNS and shares its clinical expression
and pathological picture with that of MScl. EAE is used as a
pre-clinical model of a single episode of MScl. Similar to
MScl, in EAE a strong increase in infiltration of the BBB
occurs, which leads to increased exchange between CSF and
plasma.
In this study we extracted CSF and plasma samples at
two time points during progression of the disease, namely at
the onset and the peak; these samples were obtained from
healthy, immune booster (a group of animals injected with
complete Freund adjuvant emulsion, CFA), and EAE
(resembling MScl) Lewis rats. The metabolic profile of the
CSF and plasma was measured using the untargeted and
unbiased technique of high-field 1D proton nuclear magnetic
resonance (1H NMR). This method enables analysis of both
biofluids with a very similar measurement procedure. The 1H
NMR data of each biofluid can be analyzed separately or the
two complementary NMR data sets can be combined (fused)
in the analysis. In this work, CSF and blood plasma NMR
spectra were used in a mid-level data fusion. The metabolite
information extracted for each biofluid can be directly con-
verted into relative concentrations for each biofluid and
compared.
To obtain such information from the individual or com-
bined data sets several analytical challenges must be solved.
First, the disease must be distinguished from the healthy
condition but also from other diseases, for example periph-
eral inflammation. This means we must construct a multi-
class classifier. Second, even if well controlled the experi-
ment still carries additional variances unrelated to the study,
i.e. biological and experimental variations. Third, the num-
ber of variables recorded by NMR is much larger than the
number of samples, which implies specific statistical prob-
lems. Moreover most of these variables are probably unre-
lated to the studied problem or are redundant. To solve these
problems we propose the following architecture for the data
analysis. Linear support vector machine recursive feature
elimination (SVM-RFE) is used as variable-selection tech-
nique for both data sets. The selected variables are fused and
analyzed using either one multi-class partial least-squares
discriminant analysis (PLS2-DA) model or multiple two
classes PLS-DA models, the latter using a novel approach
in which a hierarchical structure enables introduction of
prior knowledge. We introduce this method as hierarchical
models fusion (HMF). We show that by using HMF, EAE-
affected rats can be distinguished from either healthy or
peripherally inflamed rats on the day of onset (when no
physical symptoms of neuroinflammation are present) with
100% correct classification. In addition, the progression of
EAE can be described. In summary, HMF enables simulta-
neous characterization of all the groups studied without
applying multiclass classifier.
Materials and methods
Experimental design of EAE models
Experimental autoimmune/allergic encephalomyelitis
(EAE) is the animal model commonly used for studying
neuroinflammatory aspects of the autoimmune disease
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multiple sclerosis (MScl). The experimental arrangement
was as previously described by Smolinska et al. and/or
Hendricks [10, 11]. Here, we briefly summarize the main
points. Three sets of male Lewis rats (Harlan Laboratories,
the Netherlands) were inoculated on Day 0. First, a set of 30
animals was injected with guinea pig myelin basic protein
(MBP), complete Freund adjuvant H37 RA (CFA, Difco
Laboratories, Detroit, MI, USA) and Mycobacterium tuber-
culosis type H37RA (Difco). Another group of 30 animals
was injected with CFA only. Next to these MBP and CFA
challenged rats, referred to as the EAE and peripherally
inflamed groups, respectively, a healthy group undergoing
anaesthesia only (healthy control) was included. In each
group, half of the animals were sacrificed to collect both
CSF and plasma on Day 10 (onset of disease in the EAE
group) and the other half on Day 14 (peak of disease in the
EAE group). Typical progression of the disease is shown in
Fig. S1 in the Electronic Supplementary Material, and
details of the design of the EAE experiment are summarized
in Table 1.
CSF and plasma sampling, sample preparation, and data
acquisition
On Days 10 and 14, animals were euthanized with CO2/O2,
and blood and CSF were collected. Sampling, sample prep-
aration, and acquisition of CSF NMR spectral data were as
described elsewhere [11]. Blood was sampled intravenously
by use of a heparin-treated syringe. Next, every blood
sample was centrifuged for 10 min at 4 °C with a relative
centrifugal force of 2,000g to separate the plasma. After
centrifugation, samples of the supernatant were stored at
−80 °C for further analysis.
For the NMR measurements, stored frozen plasma
(50 μL) was left at room temperature to thaw. Next, the
plasma sample was diluted with 200 μL water and the
proteins were then removed by centrifugation for 30 min
at 2,000g (filter 10 kDa Centrisart I 13239-E; Sigma–
Aldrich, St Louis, MO, USA) [12]. After protein removal,
the supernatant was lyophilized. Before NMR measure-
ments the lyophilized plasma samples were re-dissolved in
50 μL of water, after which 550 μL buffer solution was
added to furnish a volume sufficient for NMR measurement.
The buffer solution consisted of 2.85 mmol L−1 TSP-d4
(sodium 3-(trimethylsilyl)propionate-2,2,3,3-d4) (99 atom%
D), 6.92 mmol L−1 sodium azide (NaN3), 42.08 mmol L
−1
dibasic sodium phosphate dehydrate (Na2HPO4.2H2O), and
7.30 mmol L−1 HCl solvated in a H2O–D2O (99.96 atom%D)
mixture (7.93:1). The final TSP concentration in each plasma
sample was 2.61 mmol L−1.
1H NMR spectra of 86 plasma samples were acquired on
an Avance III (Bruker BioSpin, Bruker, Billerica, MA,
USA) 500-MHz system equipped 5-mm cryoprobes,
CPTCI (1H-13C/15N/2H + Z-gradients) (Bruker BioSpin).
Water suppression was achieved by pre-saturation. For each
1D 1H NMR spectrum 256 scans were accumulated with a
spectral width of 10,273 Hz resulting in a total of 18 K
points. The acquisition time for each scan was 3.2 s.
Between scans, a 4-s relaxation delay was used. Before
spectral analysis, all acquired free induction decays (FIDs)
were zero-filled to 32 K data points, multiplied with a
0.3 Hz line-broadening function, Fourier transformed, man-
ually phased, and the TSP internal reference peak was set to
0 ppm by use of ACD/SpecManager software version 12.0
[13]. All 86 rat CSF spectra were acquired and preprocessed
as described elsewhere [11]. However, because of high line
broadening of the internal standard (TSP) four spectra from
CSF and plasma were not included in the spectral analysis.
Ultimately, 82 CSF spectra and 86 plasma spectra were
transferred to Matlab (version 7.9; Mathworks, Natick,
MA, USA) for further analysis. Overlap between both CSF
and plasma spectra was observed for 82 of these samples
(Table 1).
Preprocessing of CSF and plasma NMR spectra
The 1H NMR spectral data was preprocessed in Matlab; this
typically involved baseline correction, alignment, binning,
normalization, and scaling. For four samples (out of the 86)
only plasma 1H NMR spectra were available. Therefore
these four spectra were not used in the pre-processing and
analysis process. Baseline correction of NMR spectra was
performed by applying the asymmetric least-squares method
[14]. Fluctuations in chemical shift were removed by
applying improved parametric time warping (I-PTW)
[15]. Each CSF and plasma spectrum was normalized
Table 1 Experimental design of EAE model
Group Inflammation type Day 10 Day 14
Healthy None C10 C14
n015 n015
p014 p014
CFA Peripheral P10 P14
n015 n015
p014 p015
CFA+MBP Peripheral & neuroinflammation N10 N14
n015a n015b
p014 p011
“n” indicates the number of rats; “p” indicates the number of common
samples between CSF and plasma
a One CSF sample was discarded because of blood contamination and
one from blood plasma because of sampling
b Three CSF samples were discarded because of blood contamination
and two from blood plasma because of sampling and preparation
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to a total area-under-curve (AUC) of 1, to correct for potential
differences in sample concentration. To reduce the high
dimensionality of the data, binning was performed by means
of adaptive intelligent binning [16]. This procedure led to 409
bins for CSF and 478 for plasma, which can be regarded as
relative metabolites concentrations. Absolute quantification of
metabolites in CSF and plasma samples was not performed
and used. Data analysis was performed on binned data, i.e. on
relative metabolite concentrations. The final step of prepro-
cessing consisted of autoscaling.
Data analysis
Explorative analysis by means of robust principal-component
analysis (R-PCA) was first used to control the presence of
outliers in both datasets [17]. The strategy for supervised data
analysis consisted of data division into a training set (75% of
samples per class) and an independent test set (25% of samples
per class) by using the Duplex algorithm [18], variable selec-
tion by support vector machine recursive feature elimination
(SVM-RFE) for linear kernels [19] performed on each dataset
(CSF and plasma) separately, and discriminant analysis by
PLS-DA [20] performed on both individual and fused data-
sets. For data fusion, so-called mid-level data fusion architec-
ture was used [21]. In this approach the two data sources are
first pre-processed and analyzed separately to extract relevant
information; next they are fused and analyzed as a unique
dataset. We used this method because it was shown to
eliminate redundancy of variables. Particular steps of
this type of data fusion are described in the sections
“SVM-RFE” and “Classification of individual and fused
plasma and CSF datasets”. In this fusion approach every
data source is treated separately for pre-processing, scal-
ing, and variable selection. Next, the optimum set of
variables is combined into a single set and analyzed by
PLS-DA. In the last step of data analysis the approach for
cumulative fusion by means of hierarchical models fusion
(HMF) was carried out. This method, proposed for the first
time in this paper, is described in detail in the section
“Hierarchical models fusion”. The results of this method are
compared with those from PLS2-DA, a variation of PLS-DA
which enables more than two groups to be analyzed simulta-
neously (see the section “Hierarchical models fusion”).
SVM-RFE
SVM-RFE was originally proposed by Guyon et al. [19] and
applied to a microarray dataset in a cancer study. The
method is based on the binary classification method SVM.
This technique first maps objects into a feature space by use
of kernel transformation and then tries to find a hyperplane
which separates the data into two classes [22]. From all the
separating hyperplanes, SVM looks for the one that gives
the biggest separation between the borderline training sam-
ples of the two classes. The borderline training samples are
called support vectors. All support vectors have an alpha
value, indicating how supporting this object is for the posi-
tion of the hyperplane. Non-supporting objects have an
alpha value equal to 0 whereas alpha equal to 1 indicates
the highest support. RFE is a backward-elimination algo-
rithm which ranks features on the basis of the weights of
linear SVM. The algorithm starts with a full training set to
train a linear SVM. Next, the variables are ranked by sort-
ing, in descending order, the square of the SVM’s weights
{wj
2}:
wj
2 ¼
X
i¼8aiyixij
 2
ð1Þ
where 8 contains the indexes of support vectors, αi are alpha
values and yi are the class labels. A variable with smallest
weight wj is then removed. Indeed, the smaller the weight of a
variable, the less it contributes to the size of the margin
between classes. The remaining variables are used to train
another linear SVM and the entire process is repeated
until all variables have been eliminated. In the work
described in this paper, one variable was removed in
each iteration.
We used a leave-one-out (LOO) cross-validation (CV)
approach to select the optimum set of variables per data set.
In this procedure one sample from the training set is left out
and a variables ranking is obtained on the basis of the remain-
ing objects. The procedure is repeated until every object is left
once. The final ranking was obtained by sorting the variables
on the basis of the number of times it was selected in the
LOOCV procedure. The variables selected median + 1 times
made up the optimum set. The complete scheme for LOOCV
can be found in the Electronic supplementary material.
Classification of individual and fused plasma and CSF
datasets
After selecting the optimum set of variables, the features of
both data sets were concatenated and autoscaled.
Subsequently, the variables of the fused sets were ranked
by SVM-RFE. Classification of fused sets was performed by
PLS-DA, a well-known method used in many omics fields
[20, 23]. PLS-DA uses group information to maximize the
separation between groups of observations. It is currently
widely used in metabolomics because of its ability to cope
with high correlations between variables. In PLS-DA a
linear model is constructed in accordance with Eq. (2):
y ¼ Xbþ r ð2Þ
where X is a dataset matrix, y a vector of group member-
ships, b a vector of regression coefficients (i.e. weights of
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individual variable), and r a vector of model residuals. The
regression coefficients reflect the relative importance of the
variables in the PLS-DA model. PLS2-DA is a variation of
PLS-DA, where the response “y” is not a vector but a
matrix, which enables more than two groups to be analyzed
simultaneously.
The optimum complexity (i.e. number of latent variables,
LV) for all individual and fused models was determined by
LOOCV performed on training sets. The optimum number of
LVwas selected on the basis of the minimum error of the root-
mean-square error of cross-validation (RMSECV). For all
individual and fused models the optimum model complexity
was determined to be 1LV. All PLS-DA models were validat-
ed with an independent test set. A PLS-DA model is consid-
ered statistically valid if it has good prediction ability. After
validation, a final model is then reconstructed using all avail-
able samples. The model can be visualized in a score plot. The
importance of all variables on the predictive model can be
investigated by means of the regression coefficients [24].
After the individual two-class (binary) models have been
are optimized they can be used for HMF.
Hierarchical models fusion
In this paper, we propose a new approach, hierarchical
models fusion (HMF), which uses hierarchically multiple
simple two-class classification models to represent individ-
ually specific parts of the inter-class variation. This ap-
proach uses, as any supervised method, a-priori knowledge
of the classes (for instance, type of inflammation) and estab-
lishes commonalities between them.
The use of simple two-class models makes the results
easier to interpret. The objective of the method proposed
here is to describe the relevant differences gradually instead
of explaining all variation from all classes at once. This
gradual process becomes possible by applying statistically
optimized binary models to the data at each step and then
combining the outcomes. Because it fuses the outcome of all
earlier optimized models it describes and shows all the
relevant differences in the data. By using this approach it
is possible to visualize separation between studied classes
and the relationship between objects without applying mul-
ticlass classification models (for example PLS2-DA or lin-
ear discriminant analysis, LDA).
To demonstrate the HMF approach, let us consider a
dataset with three classes: non-effect (i.e. healthy), effect 1
(e.g. peripheral inflammation), and effect 2 (e.g. neuroin-
flammation). First, individual binary PLS-DA models of
interest have to be optimized (i.e. models 1 and 2 from
Fig. 1). A graphical representation of HMF is shown in
Fig. 1. These models can then be hierarchically applied to
the data in accordance with a-priori knowledge (here exper-
imental design). For example having data containing three
classes, i.e. effect 1, effect 2, and non-effect, it is possible to
use HMF to separate all three classes. In the first step, model
1 (effect 1 versus non-effect) is used to obtain a new score
for all samples in data matrix X. This new score (here called
Xscore) separates non-effect objects from objects belonging
to group effect 1 and group effect 2. In the next step, another
model (model 2: effect 1 versus effect 2) can be applied to
matrix X to assess and distinguish these two effects. In that
way a second score is obtained for all samples in data matrix
Fig. 1 A graphical representation of hierarchical models fusion
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X (here called Yscore). At each step, a new score is obtained
by multiplying data matrix X with PLS-DA weights. These
two new scores (Xscore and Yscore) can then be combined
and used to visualize the relationship between studied
groups. When the new scores are orthogonal they can be
represented as usual (i.e. with perpendicular axis).
Because HMF is based on a hierarchical structure, the
complexity of the studied problem is reduced by describing
every difference on a different level (i.e. step). It decom-
poses the difficulty of multi-class separation into simpler,
solvable two-class problems. Indeed, the representation of
HMF as a decision tree (Fig. 1) is similar to the classifica-
tion and regression trees (CART) [25]. However, in HMF at
each step (node) not a single variable but a PLS-DA model
is used to separate objects. To represent the usefulness of
HMF for analyzing multiple classes, simulated data were
created. The results are shown in the Electronic supplementary
material.
Obviously, the presented method can be used not just for
visualization of relationships between samples but also for
prediction of new samples (e.g. from an extra experiment).
Moreover, information about variables significant for dis-
crimination is associated with PLS-DA weights. Therefore
biological interpretation is feasible also.
Any results obtained by predictive methods must be
validated before drawing any conclusions. In HMF the
validation is twofold. First, all the individual PLS-DA mod-
els are validated using independent test sets. Second, the
complete HMF structure is also validated. Moreover to
reduce the possibility of random classification we performed
a permutation test for HMF.
Metabolite identification
Metabolite identification of the most relevant set of varia-
bles was carried out by using the 800 MHz library (for CSF)
and the 500 MHz library (for plasma) of metabolite NMR
spectra from the Chenomx NMR Suite 7.0 (Chenomx,
Edmonton (AD), Canada). The libraries of metabolite spec-
tra were obtained on the basis of a database of pure com-
pound spectra acquired by use of a particular pulse sequence
and acquisition conditions, namely, the NOESY-
presaturation pulse sequence with 4 s acquisition time and
1 s recycle delay [26]. The Chenomx NMR Suite software
fits the spectral signatures (singlets, doublets, triplets etc), i.
e. the peak shapes, of a compound from an internal database
of reference spectra to the experimental NMR spectrum.
Results
Explorative analysis of the CSF and plasma datasets
The 82 sets of NMR data of plasma and the 82 sets of NMR
data of CSF were each pre-processed as described in the
“Materials and methods” section. Examples of plasma and
CSF spectra are shown in Fig. 2. It is apparent the intensities
of many metabolites (normalized to the TSP signal, for
Fig. 2 Section of the 800 MHz 1H NMR spectrum of CSF (blue) and the 1H 500 MHz NMR spectrum of plasma (red)
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visualization purposes only), for example alanine and argi-
nine, are higher in the plasma spectrum than in that from the
CSF. Most metabolites present in CSF can be observed in
plasma. A few volatile metabolites are not visible in plasma,
because of lyophilisation. Some metabolites, for example
glutamate and phenylalanine, are detected in plasma only.
This is mostly because of the low concentration of these
metabolites in CSF. The NMR spectra of CSF were divided
into 409 bins, which contain resonances of 33 identified
metabolites and some unidentified signals. For plasma, the
NMR spectra were divided into 478 bins, which correspond
to resonances of 50 identified metabolites and some uniden-
tified signals.
After pre-processing, explorative analysis was performed
by means of R-PCA and PCA. Initially, R-PCAwas applied
to the autoscaled spectra of 82 rat CSF and plasma samples,
to check for outliers. No outliers were detected. Figure 3a
and b show the PCA score plots of the plasma and CSF
NMR spectra, respectively. These figures show that samples
belonging to group “N14” are clearly separated from the
other samples along PC2 for plasma data and along PC4 for
CSF data. In both situations PC1, which is the main source
of variance, does not show any group information. This
indicates that a large source of the variance in the data does
not correspond to the available groups. No clear grouping is
present because most of the groups overlap. It is important
to mention that further PCs did not show groupings either.
Supervised analysis
The most straightforward approach for separating the six groups
present in CSF and plasma data simultaneously is to apply a
multi-class method, for example PLS2-DA. The two datasets
can be analyzed separately by PLS2-DA. Alternatively, the CSF
and plasma data can be fused and PLS2-DA can be applied to
the fused data. However, PLS2-DA has to describe all group-
related variations at the same time. This might lead, on the one
hand, to worse results in comparison with multiple binary PLS-
DA models and on the other hand, to difficulties in biological
interpretation. One can apply binary PLS-DA models to handle
individual biological samples (CSF and plasma) and the (mid-
level) fused data sets. This implies that for a full description
many binary PLS-DA models have to be constructed and opti-
mized. Therefore, we propose and present a new approach,
namely HMF. In HMF, a limited number of multiple binary
PLS-DA models are used to still fully describe the fused CSF
and plasma data. The fusionwas achieved by using the approach
described in the “Materials and methods” section (subsections
“SVM-RFE” and “Classification of individual and fused plasma
and CSF datasets”). Binary PLS-DAmodels were applied to the
fused datasets to extract information about the metabolic effects
of the different group treatments shown in Table 1 and
to establish the significance of the variables. All opti-
mum binary PLS-DA models were constructed using
1LV only. Next these optimized binary PLS-DA models
are used in HMF. Below, we first present the results of
PLS2-DA, then the binary PLS-DA models, and finally
those of HMF. The outcomes of HMF are compared
with PLS2-DA of the fused datasets.
PLS2-DA—complete EAE model for plasma data, CSF data
and fused sets
We applied PLS2-DA to separate simultaneously all six
groups of the CSF dataset and of the plasma dataset. The
variables included in the PLS2-DA model are selected by
linear SVM-RFE. The number of LVs in the PLS2-DA model
was optimized by cross-validation. Correct classification for
Fig. 3 PCA score plot of: a plasma NMR spectra; b CSF NMR spectra
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an independent test set was 57.1% for the plasma data and
56% for the CSF (correct classification per class is included in
Table S1 in the Electronic Supplementary Material). It is
interesting to note that better results are obtained for the binary
PLS-DA models (at least for the binary PLS-DA models
considered) than for PLS2-DA. However, it is important to
mention that PLS2-DA has a more difficult problem to solve
(i.e. separate six classes at once) than PLS-DA.
A similar situation is encountered for fused datasets.
Correct classification for an independent test set is 65%
for PLS2-DA (correct classification per class can be found
in the Electronic Supplementary Material, Table S1). This
result is much worse than for multiple PLS-DA models.
PLS2-DA performance (64% classification) is in turn still
much better than a random classifier (correct classification
17%) but still insufficient for proper diagnosis. However,
one should notice that some groups are classified completely
correctly (100%, e.g. “C10”), whereas others are totally
misclassified.
PLS-DA models for plasma data, CSF data, and for mid-level
fused sets: the onset of neuroinflammation
We present the results of PLS-DA obtained for the group
“P10” versus “N10”, because this represents the interesting
case of early onset of neuroinflammation. Binary PLS-DA
models were derived for the separate CSF and plasma data
sets and for mid-level fused data sets. The predictive models
for the problem “P10” vs. “N10” are displayed as PLS-DA
score plots in Fig. 4a, b, and c. These 1LV score plots are
presented as the density distribution of the entire group. The
PLS-DA model of CSF is constructed on the basis of 87
variables. The PLS-DA model of CSF alone has no predic-
tion ability, as follows from the 50% correct classification
Fig. 4 Density distribution of PLS-DA scores of: a “P10” vs. “N10”
for CSF data; the amount of y variance for 1LVis equal to 77.5%; b “P10”
vs. “N10” for plasma data; the amount of y variance for 1LV is equal to
63.5%; c “P10” vs. “N10” for fused data; the amount of y variance for
1LV is equal to 61.3%; d Regression coefficients for fused PLS-DA
model
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for an independent test set. Accordingly the groups “P10”
and “N10” (for CSF) are not separated in Fig. 4a. For
plasma, the PLS-DA model separates the classes somewhat
better, as follows from the classification for independent test
sets of 75%. However, there is still quite some overlap and
the groups of points are still mixed, as can be seen on the
horizontal axis of Fig. 4b.
Because the individual analysis did not furnish satisfac-
tory results, we decided to fuse the selected variables from
plasma and CSF data. The SVM-RFE conducted on the
fused sets, led to 11 variables (of the 112 initially selected
variables). The resulting PLS-DA model of fused datasets is
shown in Fig. 4c. Correct classification for the independent
test set is 100%, demonstrating the statistical adequacy of
this model. As can be seen from Fig. 4c, there is clear
separation. Figure 4d shows the regression coefficients of
this PLS-DA model. Interestingly, the fusion model
consists of six CSF and five plasma variables. This
suggests that both biofluids contribute significantly to
the group separation.
Table 2 summarizes the results of the PLS-DA models for
“P10” versus “N10”, and for two other pairs of groups,
namely “C10” vs. “P10”, and “N10” vs. “N14”. These
models were used in the HMF. Table 2 lists, with the degree
of correct classification for independent test sets, the number
of variables selected by RFE-SVM used in PLS-DA models
for the fused data. We find that the binary PLS-DA model
for “P10 vs. N10” (early onset of neuroinflammation)
results in 100% correct classification. The same is true for
“N10” vs. “N14” (progression of neuroinflammation),
whereas for “C10” vs. “P10” 93% correct classification is
achieved. The score plots and regression coefficients of mod-
els “C10” vs. “P10” and “N10” vs. “N14” are shown in
Figs. S5a–S5d in the Electronic Supplementary Material.
In Table 2 only a few of many possible pairs of groups for
PLS-DA have been presented. Nevertheless, in Table S2 in
the Electronic Supplementary Material correct classification
for the independent test set obtained for individual analysis
of plasma data, CSF data, and fused datasets by PLS-DA for
different pairs of groups can be found. To achieve full or
nearly full description of the fused data set, without having
to use all pairs of groups, we apply hierarchical data models
fusion, HMF, in the next section.
Hierarchical models fusion
The predictive power of the individual PLS-DA models is,
by itself, already satisfactory (as is apparent from Table 2
and Table S2 in the Electronic Supplementary Material). At
this point one could stop the analysis and start biological
interpretation of the results. However each PLS-DA model
only looks at two groups at a time and is, therefore, not able
to predict the results for a completely unknown sample.
Thus, it is necessary to combine the different models. The
idea of HMF is to join them in a meaningful order. To
perform HMF on the CSF and plasma datasets, we used
the PLS-DA models of “C10” vs. “P10”, “P10” vs. “N10”,
and “N10” vs. “N14” (Table 2). These characterize, respec-
tively, the effect of peripheral inflammation, neuroinflam-
mation, and progress of neuroinflammation. They are,
therefore, consistent with the experimental design shown
in Table 1. The HMF approach used in this paper is repre-
sented in Fig. 5. Note that we present here HMF on the
fusion of two datasets but the same principle could be
applied to a single dataset. As explained in the “Materials
and methods section”, HMF is validated in two ways. First,
all individual PLS-DA models were statistically validated
with independent test sets. Second, the complete scheme of
HMF was validated with a set including all test sets used in
the binary PLS-DA models from Table 2 and, additionally,
some samples belonging to classes “C14” (four samples in
test set and ten in training set) and “P14” (five samples in
test set and ten in training set). The graphical representation
of HMF for training and test set samples is shown in the
Electronic Supplementary Material in Fig. S5. It is apparent
all test samples are predicted correctly. The permutation test
was also performed for all six classes, as an extra check. The
p-value for 40,000 permutations was equal to 0.0006.
We started with the PLS-DA model of peripheral inflam-
mation, i.e. “C10” vs. “P10” (shown in Fig. 5 as step 1).
This enables one to separate healthy objects, i.e. those
without any type of inflammation (Table 1) from all those
with peripheral inflammation. The latter also includes
groups which have undergone neuroinflammation, because,
in accordance with the experimental design shown in
Table 1, these groups were injected with CFA. This step
enables creation of a first new score (i.e. Xscore) for all
Table 2 Correct classification
for an independent test set
obtained for fused datasets,
number of variables from plasma
and CSF used in a PLS-DA
model, and number of samples
in training set and test set
PLS-DA model Correct classification No. of variables in PLS-DA model No. of samples
Plasma CSF Training Test
C10 vs. P10 93% 4 13 20 8
P10 vs. N10 100% 5 6 20 8
N10 vs. N14 100% 8 3 18 7
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samples in the data. In other words, this model separates the
healthy groups from those with any form of inflammation
(neuro or peripheral).
In a second step, we used a PLS-DA model of “P10” vs.
“N10”, shown in Fig. 4d. This model distinguishes periph-
eral inflammation from neuroinflammation at the onset of
EAE. Therefore, by using this model we are able to separate
neuroinflamed animals from animals that were only periph-
erally inflamed (i.e. “P10” and “P14”; shown in Fig. 5 as
step 2). Similar to step 1, a second score is generated, the
Yscore. At this level, we have separated samples belonging
to groups with peripheral inflammation (i.e. “P10” and
“P14”) from the neuroinflamed groups (“N10” and “N14”).
The last step (number 3) considers the separation of the
onset of the disease from the peak of EAE. To achieve this
separation, we applied the PLS-DA model of “N10” vs.
“N14”, i.e. the model describing the severity of neuroin-
flammation. At this level, a third new score is created, the
Zscore. After iterative application of these simple 1LV mod-
els to fused plasma and CSF datasets, we can integrate the
three new scores, i.e. Xscore, Yscore, and Zscore. They are
then used to visualize the outcome. They represent the
relationship between the groups and their separation. The
corresponding graph is shown in Fig. 6. As can be observed,
full separation of the different groups is achieved. It is worth
mentioning that samples belonging to healthy groups “C10”
and “C14” mostly overlap. However, a small shift along the
x-axis is observable, probably because of sampling time
(Day 10 vs. Day 14). As can be noticed, samples belonging
to group “P14” overlap with healthy groups, which is in
agreement with our previous finding that peripheral inflam-
mation has vanished by day 14 [11].
Discussion
By using a mid-level fusion architecture we were able to
identify a set of metabolites that revealed significant
changes in the plasma and CSF of neuroinflamed animals.
Based on the regression coefficients of the PLS-DA model
of fused datasets (for example Fig. 4d and Electronic
supplementary material) the importance of the individual
metabolites in each PLS-DA model and a direction of
elevation/reduction of concentration can be evaluated.
On the basis of this information, biological interpreta-
tion of these metabolites and their connection to EAE,
neural inflammation, and/or MScl can be performed.
Therefore, the first aspect to be discussed is the nature
of the selected metabolites. It should be mentioned that
the main objective of this paper is not to provide a
biological explanation, but to present the methodology
Fig. 5 Representation of
hierarchical models fusion for
fused plasma and CSF NMR
datasets. Asterisk, note that
“P14” is classified as control
(the inflammation has gone, see
section below)
Fig. 6 Graphical representation of HMF applied to fused data from
plasma and CSF
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for fusion and analysis of 1H NMR metabolomics data-
sets. Therefore biological conclusions are not stressed.
One can notice that many (mostly neutral) amino acids
were found to be discriminatory for EAE groups and, there-
fore, we focus on these. Transport of neutral amino acids
through the BBB is significant for overall regulation of
cerebral metabolism and neurotransmitter production [27].
BBB amino acid transport is important in regulation of
several pathways of brain amino acid metabolism. It is
known that EAE affects the BBB. It causes disruption of
the BBB and affects the saturable transport system of sub-
stances involved in the disease process [28]. Injection of
CFA can itself lead to increased BBB permeability to small
molecules and even specific serum proteins [29].
We found that tyrosine concentration is reduced in plas-
ma of groups “P10”, “N10”, and “N14”. It has been reported
previously that tyrosine has a role in BBB permeability [30].
In accordance with our results Monaco et al. detected a
reduced level of plasma tyrosine in MScl [31]. Another
neutral amino acid related to EAE groups is alanine. This
metabolite was found as a relevant metabolite in both plas-
ma and CSF. Its concentration is reduced in the CSF and
plasma of EAE groups in comparison with healthy controls
and peripheral inflamed group “P10”. Alanine is associated
with energy metabolism and is known to be used as a source
for pyruvate for energy metabolism and for macromolecules
within neural and immune cells [11]. Similarly, lysine con-
centration was elevated in CSF and plasma from neuroin-
flamed groups “N10” and “N14”. Qureshi and co-workers
in a study on the role of neurotransmitter amino acids in
CSF of MScl patients reported increased levels of lysine in
CSF and plasma of MScl patients [32].
We found the combination of glutamate and proline
signals in plasma decreased in the EAE groups compared
with the other groups. In a previous study a change of
glutamate concentration in CSF was reported in a clinical
study of MScl [33]. Glutamate is a very important neuro-
transmitter and the most abundant free amino acid in the
brain. A metabolite closely interconnected with glutamate is
glutamine. This metabolite was found in plasma as discrim-
inatory for groups injected with immune booster (i.e., “P10”
and “N10”) when compared with the healthy groups, and its
concentration was elevated in these groups. It was also
found as discriminatory when comparing “P10” and
“N10” groups. In CSF, its level was found to be down
regulated in group “P10” in comparison with healthy con-
trols. This metabolite is involved in energy metabolism. It
has been shown that glutamine is a necessary nutrient for
cell proliferation, serving as a specific fuel for inflammatory
cells and enterocytes and, when present in appropriate con-
centrations, enhancing cell function [34]. The last amino
acid that is discussed here is phenylalanine. This metabolite,
which was diminished in EAE groups, is the precursor to
tyrosine and is needed for function of the catecholamine
neurotransmitters epinephrine, norepinephrine, dopamine,
and tyramine. In a previous study by Monoco et al. a
reduced level of phenylalanine was found in MScl [31].
One aspect which has not been emphasized is the impor-
tance of a proper preprocessing. Here the use of AI binning
ensures that one bin corresponds to one peak, thus prevent-
ing signals from different metabolites being mixed within
one bin. Normalization is the second important preprocess-
ing aspect. We compared the effect of classical total area
normalization with that of probabilistic quantum normaliza-
tion. No strong differences were observed (data not shown)
therefore we decided to use the simplest approach. However
one should be aware that total area normalization could be
suboptimum, because of the large effect of highly abundant
multiplets (e.g. glucose).
The third aspect to be discussed is connected with the
data analysis strategy used in this manuscript, i.e. mid-level
data fusion and HMF. First, the approach of mid-level data
fusion performed here enabled individual variable selection
and thus discard of irrelevant information. Second, the HMF
method, shown in this paper, is a novel, simple strategy for
multi-class analysis. Each PLS-DA model only looks at two
groups at a time and, therefore, a single model cannot
predict a completely unknown sample. This is a minor
advantage of HMF over multiple PLS-DA models. One
should keep in mind that the outputs of this method are
statistically accurate, because they are based on validated
binary predictive models. Moreover, the complete scheme
of HMF was also validated. The output of HMF (i.e. new
scores) can be used for visualization or prediction of new
samples. However, it is good practice to check if these new
scores are orthogonal.
When comparing HMF and PLS2-DA, it is important to
mention that it is possible that if some groups do not behave
in accordance with the experimental design, the optimum
solution for class separation can be flipped. In other words,
if one or more groups cannot be distinguished, PLS2-DA
still tries to separate them, which may affect the solution for
the whole PLS2-DA model. In the case of EAE datasets,
there are two groups (i.e. “N10” and “P14”) that are char-
acterized by behaviour different than was assumed by ex-
perimental design. For the “N10” group we have previously
shown that animals are heterogeneous regarding disease
response [11]. Further, the second group “P14” was not (or
no longer) peripherally inflamed on day 14. This causes the
results obtained by PLS2-DA to be sub-optimum for groups
“N10”, “C14”, and “P14”. In the method proposed here,
HMF, the situation described for PLS2-DA cannot happen.
HMF leads to the optimum solution, because it includes
relevant sources of variance between groups individually
rather than all at the same time. This suggests that if two
groups are not separable this can be easily detected during
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the HMF and does not affect the separation between other
groups.
In our study the HMF was shown for fused plasma
and CSF NMR datasets. However this approach can be
also used for one type of sample (as shown in the Electronic
supplementary material). Obviously, the individual PLS-DA
models can be developed for any type of sample and then
HMF can be applied.
Conclusions
In this study we have demonstrated the feasibility of fusion
of metabolomics 1H NMR datasets from different biofluids.
From the perspective of data analysis multiple challenges
had to be addressed. One was concerned with the biological
variation usually encountered in omics experiments.
Another issue was linked to the number of variables
recorded by NMR, which is, first, much greater than to the
number of samples and, second, most are probably unrelated
to the studied problem or redundant. We successfully solved
these problems using a new architecture for data fusion in
which SVM-RFE is used as variable selection method and
PLS-DA to focus on the information of interest through a
training procedure.
We analyzed CSF and plasma metabolomics data of the
EAE model for MScl using mid-level data fusion. The proce-
dure was represented by constructing a predictive model for
neuroinflamed group “N10”, i.e. before physical symptoms
have appeared, versus a peripherally inflamed group “P10”.
Prediction models based on either CSF or plasma metabolo-
mics data alone could not separate the immune booster and
EAE groups at day 10, whereas the predictive model using a
fused set of variables from CSF and plasma managed to
separate the two groups with 100% correct classification for
the independent test set. One should be aware that these results
do not imply that all new samples will be always correctly
classified. However validation with the independent test set
and the permutation test set indicates the results are meaning-
ful. This shows that by using bio-molecular information
(metabolomic data), a diagnosis can be made before physical
symptoms arise. Our results also demonstrate that plasma can
be of significant importance in the diagnosis of neuroinflam-
mation. Therefore, we believe that plasma should be consid-
ered when investigating neuroinflammation.
Finally, we have introduced a new multi-class method,
HMF, which describes relevant sources of variance
connected with groups’ description by fusing individual
binary models. We have shown that by using HMF we are
able to separate groups in our data by using simple, easily
interpretable, one-component predictive models.
From a biological perspective, the selected metabolites
seem to be relevant, because the metabolites described in
this study were previously found to be related to EAE and/or
MScl. Therefore, they provide biological validation for the
fusion of data from two different biofluids.
Further research will focus on deeper interpretation and
absolute quantification of newly detected metabolites in
plasma and CSF and their relationship to BBB. These two
steps are time-consuming but would give more insight into
the mechanism of the disease. The pattern and concentra-
tions defined by these variables could also be studied by
themselves and put into a systems biology context. Absolute
quantification would be crucial for obtaining advanced bio-
logical conclusions and conformation using a completely
different analytical method (e.g. mass spectrometry).
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ABSTRACT: The prevalence of renal stone disease is
increasing, although it remains higher in men than in women
when matched for age. While still somewhat controversial, several
studies have reported an association between renal stone disease
and hypertension, but this may be confounded by a shared link
with obesity. However, independent of obesity, hyperoxaluria has
been shown to be associated with hypertension in stone-formers,
and the most common type of renal stone is composed of
calcium oxalate. The chloride−oxalate exchanger slc26a6 (also
known as CFEX or PAT-1), located in the renal proximal tubule,
was originally thought to have an important role in sodium
homeostasis and thereby blood pressure control, but it has
recently been shown to have a key function in oxalate balance by
mediating oxalate secretion in the gut. We have applied two orthogonal analytical platforms (NMR spectroscopy and capillary
electrophoresis with UV detection) in parallel to characterize the urinary metabolic signatures related to the loss of the renal chloride−
oxalate exchanger in slc26a6 null mice. Clear metabolic diﬀerentiation between the urinary proﬁles of the slc26a6 null and the wild type
mice were observed using both methods, with the combination of NMR and CE-UV providing extensive coverage of the urinary
metabolome. Key discriminating metabolites included oxalate, m-hydroxyphenylpropionylsulfate (m-HPPS), trimethylamine-N-oxide,
glycolate and scyllo-inositol (higher in slc26a6 null mice) and hippurate, taurine, trimethylamine, and citrate (lower in slc26a6 null
mice). In addition to the reduced eﬃciency of anion transport, several of these metabolites (hippurate, m-HPPS, methylamines) reﬂect
alteration in gut microbial cometabolic activities. Gender-related metabotypes were also observed in both wild type and slc26a6 null
groups. Urinary metabolites that showed a sex-speciﬁc pattern included trimethylamine, trimethylamine-N-oxide, citrate, spermidine,
guanidinoacetate, and 2-oxoisocaproate. The gender-dependent metabolic expression of the consequences of slc26a6 deletion might
have relevance to the diﬀerence in prevalence of renal stone formation in men and women. The diﬀerent composition of microbial
metabolites in the slc26a6 null mice is consistent with the fact that the slc26a6 transporter is found in a range of tissues, including the
kidney and intestine, and provides further evidence for the “long reach” of the microbiota in physiological and pathological processes.
KEYWORDS: oxalate, slc26a6, CFEX, NMR spectroscopy, metabolic proﬁling, capillary electrophoresis
■ INTRODUCTION
There is an epidemiological association between renal stone
formation and other disorders such as hypertension,1,2 type 2
diabetes, and obesity. However, the mechanistic and aeitopatho-
genic links between these apparently diverse conditions are not
fully understood.1 The most common stone type is composed of
calcium oxalate, and for this reason, there has always been
interest in oxalate metabolism and excretion in renal stone
disease. An animal model that has shed light on the importance
of altered oxalate balance in renal stone formation is the slc26a6
(CFEX, PAT-1) null mouse, originally produced because of
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the expression of this chloride−oxalate (formate) exchanger
in the renal proximal tubule, and a postulated role in renal
sodium reabsorption and thus blood pressure control.3,4
Moreover, a large-scale metabolome-wide association study
found an inverse correlation between urinary formate levels
and diastolic blood pressure.5 However, to date there is no
clear evidence for a direct link between the function of this
exchanger and blood pressure. Indeed, slc26a6 has a broad
speciﬁcity, and in addition to oxalate and formate, it can also
transport chloride, sulfate and bicarbonate; transport is also
inhibited by p-aminohippurate.7 This transporter is not found
exclusively in the kidney, but it is also present in the gut (small
intestine, cecum, and proximal colon), pancreas, skeletal
muscle, and heart.3 However, its highest aﬃnity is for oxalate,
which has been the main focus of recent attention, prompted by the
serendipitous ﬁnding of calcium oxalate renal stone formation in
slc26a6 null mice due to signiﬁcant hyperoxaluria secondary to
reduced gut secretion of oxalate, leading to increased circulating
levels.3
A dual metabolic proﬁling strategy, combining NMR spec-
troscopy with CE-UV of the same urine sample, has been applied
in order to comprehensively describe the urinary metabolic
phenotype of the slc26a6-null mouse model. Both technologies
have been widely applied in the metabolic ﬁngerprinting of
various diseases, including hypertension, type 2 diabetes, and
inﬂammatory conditions, and together oﬀer complementary
information. While NMR generates comprehensive and robust
proﬁles of a broad range of low molecular weight molecules,
CE-UV can provide quantitative data on ionic species including
chloride and nitrates. Here we show the direct relationship
between urinary oxalate and a range of urinary metabolites and
show clear sex-dependent slc26a6-related diﬀerences in
metabolism.
■ MATERIALS AND METHODS
Sample Collection
Urine samples were provided by the Department of Internal
Medicine, Yale University School of Medicine. Wild type control
and slc26a6 null mice were bred continuously on a 129S6/SvEv
genetic background. The urine samples were obtained from the
mice at 6 weeks old. Protocols for use of experimental animals
were approved by the Yale Institutional Animal Care and Use
Committee. Animal handling and generation of slc26a6 null mice is
detailed elsewhere.4
Chemicals
Sodium tetraborate decahydrate (STD), β-cyclodextrin
sulfated (analytical grade, Sβ-CD) and methanol were
purchased from Sigma-Aldrich (Steinheim, Germany),
sodium dodecyl sulfate (SDS) and sodium hydroxide from
Panreac Quiḿica S.A.U. (Barcelona, Spain), and hydrochloric
acid from Fluka (Buchs, Switzerland). Reverse osmosed deionized
water (Milli-Q Synthesis from Millipore, Bedford, MA, USA) was
used for standard solution and electrolyte preparations. All the
standards used for peak identiﬁcation were obtained from Sigma
Aldrich.
1H NMR Sample Treatment and Instrument Conditions
Urine samples were prepared with pH 7.4 phosphate buﬀer as
described previously.8 1H NMR spectroscopy was performed at
300 K on a Bruker 800 MHz spectrometer (Bruker Biospin,
Karlsruhe, Germany) using the following standard one-dimen-
sional pulse sequence with saturation of the water resonance:
Relaxation delay (RD)-90°-t1-90°-tm-90°-acquire free induction
decay (FID), where 90° represents the applied 90° radio fre-
quency (rf) pulse, t1 is an interpulse delay set to a ﬁxed interval of
3 ms, RD was 2 s and tm (mixing time) was 100 ms. Water sup-
pression was achieved through irradiation of the water signal
during RD and tm. Each urine spectrum was acquired using 8
dummy scans, 256 scans, 64 000 time domain points with a
spectral width of 20 000 Hz. Prior to Fourier transformation, the
FIDs were multiplied by an exponential function corresponding
to a line broadening of 0.3 Hz.
CE-UV Sample Treatment and Instrumental Conditions
Metabolic ﬁngerprinting was performed using two diﬀerent
separation modes:9,10 a capillary zone electrophoresis method in
reverse polarity (CZE-RP) that detectsmainly anions, and amicellar
electrokinetic chromatography method in normal polarity
(MEKC-NP) that detects cations and neutral compounds.
CE experiments were carried out on a P/ACE MDQ system
(Beckman Instruments, Fullerton, CA, USA) equipped with
diode array UV-absorbance detection (190−600 nm), a
temperature-controlled (liquid cooled) capillary compartment
and an autosampler. Electrophoretic data were acquired and
analyzed with 32 Karat software (P/ACE MDQ instrument).
Separations achieved with reverse polarity were performed
using a capillary (Beckman Coulter, Buckinghamshire, England)
coated with polyacrylamide (PAG) 60 cm in total length, 50 cm
eﬀective length and 50 μm internal diameter. On ﬁrst use, the
capillary was conditioned by a pressure ﬂush of 0.1 MHCl (1 min),
electrophoretic buﬀer (BGE1) (10 min) and an electrokinetic ﬂush
of electrolyte with 0.5 kV/cm (10 min). Between runs, the capillary
was ﬂushed under pressure with deionized water (2min) and BGE1
(2min). All experiments were performed at 25 °Cusing a separation
potential of−20 kV. Samples were injected at the cathode, with 0.5
psi (3447 Pa) pressure applied for 10 s. The compounds were
detected at the anode. BGE1 was prepared with 0.2 M phosphoric
acid, adjusted to pH 6.10 with NaOH, and 10% (v/v) methanol
added (the current observed under these conditions was 70 μA).
Data were collected at a frequency of 4 Hz.
Separations achieved with normal polarity were performed in a
fused silica capillary, 50 cm total, 40 cm eﬀective length (50 μm
internal diameter) (Composite Metal Services, Hallow, Wor-
cester, U.K.). New capillaries were conditioned for 30 min at
25 °Cwith 1MNaOH, followed by 0.1 MNaOH for 20 min and
deionized water for 10 min. Before each analysis, the capillaries
used were washed with 0.1MHCl and deionized water for 1 min,
and then 2 min with the run buﬀer. The running buﬀer (BGE2)
comprised 25 mM sodium borate, 75 mM SDS and 6.25 mM
sulfated β-cyclodextrin. The pH was adjusted to pH 9.50 with
1 M NaOH, after addition of SDS and cyclodextrin. Buﬀer
solutions were ﬁltered through a 45 μm ﬁlter before use. The
capillary was maintained at 20 °C, with 18 kV applied voltage and
5 s hydrodynamic injection.
All the samples were initially run in CZE-RP method using an
acidiﬁed urine sample. Afterwards, the same samples were mixed
with 5 μL of BGE2 and 40 μL of water for MEKC-NP method.
Peak identiﬁcation was the main drawback of CE-UV due to
the selectivity of the UV detector. We were also limited by the
small amount of sample. Peak assignment was performed by
spiking the sample with standards and comparing migration
times and spectral absorption.
Preprocessing and Data Analysis
1H NMR Spectroscopy. The spectra were automatically
phased, baseline corrected and referenced to 3-(trimethylsilyl)
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propionate-2,2,3,3-d4 (TSP; δ 0.0) using an in-house routine
written in MATLAB (The MathWorks, Natick, Massachusetts).
Spectral regions corresponding to water and urea resonances
(δ 4.5−6.5) were removed, and spectra were normalized using
the probabilistic quotient method.11
The NMR peak assignments were based on published
literature chemical shifts.12,13 Chemical shifts belonging to the
same metabolite were assigned by statistical total correlation
spectroscopy (STOCSY) using an in-house Matlab script.14
CE-UV. Raw proﬁles from both polarities were treated with an
in-house program developed in Matlab 7.0. First they were
baseline corrected and aligned separately using the correlation
optimized warping (COW)method previously described;15 later
both polarities were joined, ﬁrst the signals from MEKC-NP
mode followed by signals from CZE-RP proﬁle. The maximum
value for hippurate, a signal that appears in both proﬁles, was
obtained, and the ratio between both hippurate signals was used for
scaling. Subsequently all the data were normalized to the
probabilistic quotient,11 and the resultant matrix was submitted to
multivariate data analysis with SIMCA P+ 12.0.
NMR-CE. Raw data from NMR and CE were combined in a
single matrix after baseline correction, normalization and
multialignment had been independently achieved. Both data
sets were scaled to the highest peak in the proﬁle to give equal
weight to all signals.
Principal component analysis (PCA) was performed with the
combined data set (1H NMR, CE-UV and NMR-CE) in order to
generate metabolic proﬁling data. Moreover, partial least square
discriminant analysis (PLS-DA) and orthogonal partial least
square discriminant analysis (OPLS-DA)16 were also carried out
to characterize the metabolic consequences of slc26a6 deletion in
mice.
Every model was built using pareto scaling,17 and the quality of
the models was assessed by the cumulative R2 value, and the
predictive ability by cumulative Q2 extracted according to the
internal 7-fold cross-validation18 default method of Umetrics
SIMCA-P+12.0.1 software. The signiﬁcance of the discrim-
inatory metabolites was validated using a combination of cross
validation and jackknife intervals.
Furthermore for NMR-CE, a program developed in Matlab
based on the Pearson correlation coeﬃcient, known as capillary
electrophoresis−nuclear magnetic resonance statistical hetero-
analytical correlation spectroscopy (CE−NMR-SHY), was
applied in order to establish and plot single linear correlations
among variables deriving from the two diﬀerent techniques.19
These correlations were driven from selected identiﬁed
metabolite signals in the NMR or CE proﬁles that diﬀerentiated
the slc26a6-null mice from the wild type. They were further
analyzed to aid peak identiﬁcation and to establish possible
pathway associations with other metabolites. As in previous
studies,19 correlations greater than a threshold θ of 0.3 for this
CE−NMR-SHY, corresponding to high sensitivity and a high
probability of detecting structural correlations, were plotted.
■ RESULTS AND DISCUSSION
Metabolic Phenotyping of the slc26a6 Null Mouse Model
Clearmetabolic diﬀerentiationwas found between slc26a6 null mice
and wild type control mice for both analytical techniques, namely
NMR spectroscopy (Figure 1A,B) and CE-UV (Figure 2A,B). The
CE-UV data presented are the result of the combination of two
modes of CE separation in which the total proﬁle contains cations,
anions and neutral compounds.20,21 A strong metabolic signature
discriminating male and female mice was also apparent in both data
sets. Several of the strain dependent metabolic diﬀerences were
found to correlate with urinary oxalate.
Characterization of the Metabolic Phenotype of
slc26a6 Null Mice Using 1H NMR Spectroscopy. Signiﬁcant
changes were observed in the global 1H NMR metabolic
ﬁngerprint of the SLC26A6-null mice urine, showing the
strong impact of genetic modulation on the urine composition
(Figure 1A,B). These diﬀerences manifest in the PCA scores
plot as driving the variation in the second component (t2)
(Figure 3A). The ﬁrst component (t1) was dominated by
variation relating to sex diﬀerences speciﬁcally: trimethylamine
(TMA 2.88 (s)) and spermine (3.12 (m), 2.138 (m)) were
higher in concentration in male mice and glycerate (4.09 (dd)),
formate (8.46 (s)) and citrate (2.68 (d), 2.54 (d)) were higher in
female mice. Regardless of sex diﬀerences, the slc26a6-null
phenotype was dominated by higher urinary concentrations of
(m-HPPS) (7.38 (t), 7.21 (m), 2.91 (t), 2.51 (t), 7.16 (dd)) and
lower urinary hippurate signals (7.84 (d), 7.64 (t), 7.56 (t), 3.97
(d)) in comparison with the wild type mice (Figure 1D). The
PCA model coeﬃcients also indicated higher urinary levels of
trimethylamine-N-oxide (TMAO) and creatine were associated
with slc26a6 null mice with respect to the wild type mice.
OPLS-DA models were built to compensate for the eﬀect of
gender on the model in order to obtain a more direct proﬁle of
the slc26a6-related inﬂuence. In addition to the diﬀerential slc26a6
related metabolites identiﬁed from the PCA models, OPLS-DA
also ranked scyllo-inositol, lactate and alanine as signiﬁcantly
higher in the urine of slc26a6 mice, whereas urinary excretion of
hippurate, taurine and TMA was lower in the slc26a6 group.
Characterization of the Metabolic Phenotype of
slc26a6 Null Mice Using CE-UV. The CE-UV derived
metabolic phenotype of slc26a6 null mice was stronger than
the NMR derived phenotype (Figure 2A,B), with separation of
slc26a6 null and wild type control mice dominating the ﬁrst
component of the PCA model and sex diﬀerences inﬂuencing
the second component (Figure 3B). Most metabolites were
structurally identiﬁed, but some signiﬁcantly discriminatory
signals could not be assigned to known metabolites since the
identity of metabolites from CE-UV analysis is reliant on com-
parison of migration time and spectral absorbance of the pure
standard; this is only achieved by careful spiking of samples. As
can be seen from Figure 2C, slc26a6 null mice showed higher
levels ofm-HPPS (Var_6718), oxalate (Var_5727) and allantoin
(Var_2122). On the other hand, hippurate levels (Var_2220 in
normal polarity and Var_9726 in reverse polarity) were con-
sistently higher in wild type control mice.
The diﬀerence between the two analytical techniques in terms
of the contribution of genetic background and gender to the
overall variance sources of variance can be attributed to the
diﬀerential capacity of each analytical technique to visualize
diﬀerent types of compounds within a biological sample. For
example, oxalate and nitrate are observable in the CE-UV but not
the 1H NMR spectra, whereas taurine and the methylamines are
more readily observable in the NMR proﬁles. However, both
techniques contribute information on diﬀerent metabolites to the
total metabolic proﬁle and together extend the coverage of the
metabolome. Moreover, the metabolites that are detected by both
techniques provide conﬁrmation of the models, and thus the two
analytical technologies are highly complementary.
Themain discriminatory features of slc26a6 deletion inmice in
the CE-UV PCA model were higher concentrations of m-HPPS
and oxalate and lower concentrations of hippurate in comparison
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with the wild type group. The OPLS-DA model was able to
identify further discriminatory features including higher
excretion of allantoin and chlorides, whereas citrate was
positively associated with the wild type control.
Characterization of the Metabolic Phenotype of
slc26a6 Null Mice Combining Two Analytical Platforms:
1H NMR Spectroscopy and CE-UV. Statistical integration of
nuclear magnetic resonance (NMR) spectroscopy and capillary
electrophoresis (CE) data has been previously demonstrated in a
mouse model based on urinary metabolite proﬁles19 with a view
to combining their diﬀerent strengths and advantages, with
regard to the ability to diﬀerentiate between diﬀerent biological
conditions and to identify potential metabolic pathways of
response.
This data integration strategy was applied to the metabolic
characterization of slc26a null mice compared to wild type
control using a combination of high resolution 1H NMR
spectroscopy and CE with ultraviolet detection (UV) in order to
achieve a more complete global metabolic proﬁle in which
oxalate is included.
PCA score plots derived from the combined data set (Figure 3C)
showed grouping of samples according to gender along the ﬁrst
component (t1) as well as clear separation between wild type
control and slc26a6 null mice along the second component (t2), in-
dicating that themetabolic characteristics of the groups aremarkedly
diﬀerent. The combination of both analytical techniques allowed
visualization of a broader range of metabolites in the same proﬁle.
Moreover, the enhanced quality of the model built using the
combined data set over the PCA models generated from individual
analytical methods can be measured by the increase in predictive
capability of the models (Q2), which increased from 0.34 (CE) and
0.39 (NMR) to 0.45 for the combined NMR-CE (Figure 3).
The OPLS-DA model, used as before to reduce the inﬂuence
of gender on the model, found clear separation between the
slc26a6 null and wild type groups along the predictive com-
ponent on the OPLS-DA cross-validated scores plots (Figure 4A)
of theNMR-CE combineddata set. Variableswith higher covariance
on the predictive OPLS-DA component were identiﬁed from the
S-plots. Higher levels of m-HPPS, oxalate, scyllo-inositol, TMAO,
creatine, lactate, alanine, chlorides, allantoin and glycolate were
characteristic of slc26a6 null mice, while higher urinary levels of
hippurate, taurine, TMA, succinate, methionine, citrate were
features of wild type mice. The signiﬁcance of these metabolites
as characteristic of the genetic strain was conﬁrmed using the
jack-knife interval (Figure 4B, Supporting Information Table S1).
When the interval includes zero value, the covariance is not
signiﬁcant and the compound should not be considered as a
potential biomarker. For this reason, creatinine, although
apparently discriminatory in the OPLS-DA models was excluded
from the Supporting Information Table S1, which summarizes the
potential candidate biomarkers indicated by the plot and lists the
discriminant metabolites obtained individually by each techni-
que. Spearman rank correlation between variables intensity and
Figure 1.Typical 800MHz 1HNMR spectra of urine obtained from amale wild type mouse (A) and a male null-SLC26A6mouse (B). Fragments of the
NMR spectra (data aligned and normalized) showing diﬀerences in some of the discriminant metabolites according to the gender (C) and knockout
condition (D). 1. Hippurate [δ 7.84 (d), 7.64 (t), 7.56 (t), 3.97 (d)]; 2. Taurine [δ 3.43 (t), 3.27 (t)]; 3. TrimthylamineN-oxide (TMAO) [δ 3.27 (s)];
4. Trimethylamine (TMA) [δ 2.88 (s)]; 5. Scyllo inositol [δ 3.36 (s)]; 6. Creatinine [δ 4.05 (s), 3.045 (s)]; 7. Creatine [δ 3.93 (s), 3.04 (s)];
8. Glycerophosphoryl choline [δ 3.23 (s)]; 9. Dimethylamine [δ 2.72 (s)]; 10. Glycerate [δ 4.09 (dd), 3.83 (dd), 3.72 (dd)]; 11. α-Ketoisocaproate
[δ 2.62 (d), 0.94 (d)]; 12. Lactate [δ 4.11(q), 1.33 (d)]; 13.m-HPPA sulfate (m-HPPS) [δ 7.38 (t), 7.21 (m), 7.16 (dd), 2.91 (t), 2.51 (t)]; 14. Alanine
[δ 3.79 (qt), 1.48 (d)].
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group for metabolites found to be signiﬁcant using OPLSDA and
jack-kniﬁng is also provided in Supporting Information Table S1.
The discrete distribution of the classes, slc26a6 null (n = 11) and
wild type (n = 8), also causes a discrete distribution in the rank
correlation. In this study, the highest absolute rank correlation
(fully separated groups) that can be achieved is 0.856 with a
corresponding p-value of 2.89 × 10−6, because of the discrete
group levels indicating a true and marked diﬀerence in the
metabolism of the SLC26A6 null mice. Finally, using the p-values
determined with the Spearman correlation, we have calculated
the corresponding q-values using the false discovery rate22
(FDR) using the R-package fdrtool.23 We chose to allow 5% false
discoveries (q≤ 0.05) for our ﬁndings. Themetabolites that remain
positively associated with slc26a6 deletion, after FDR, are
m-HPPA, lactate, glycerolphosphorylcholine and oxalate. Hippurate
remains negatively associated with slc26a6 deletion.
Inﬂuence of Gender on the Metabolic Phenotype of
slc26a6NullMice.On the basis of the results obtained from the
PCAmodel, OPLS-DAmodels were performed in order to study
the inﬂuence of gender and to determine if the metabolic features
of slc26a6 mice were consistent for male and female animals.
Clear clustering in both the PCA and the OPLS-DA scores plots
due to gender was also observed. Discriminant metabolites for
female mice were identiﬁed by NMR and CE separately. Higher
urinary concentrations of TMAO, creatine, 2-oxoisocaproate,
3-methyl-2-oxovalerate, m-HPPS, citrate and glycerate were
associated with female mice in the NMR proﬁles. Conversely,
TMA, methionine, spermine and alanine were positively associated
with male mice. Further gender dimorphic metabolites extracted
from the more OPLS-DA models of the CE-UV data were uridine
(higher in females) and urea, penylalanine and allantoin (higher in
males). As before, the statistical signiﬁcance of the metabolites was
conﬁrmed by jack-knife interval (Figure 5A,B).
Supporting Information Table S2 shows the Spearman rank
correlation (RHO correlation) between male (n = 11) and
female (n = 8) mice. These result in the same discrete possible
rank correlations as in the slc26a6 null versus wild type com-
parison in Supporting Information Table S1. Of the metabolites
manifesting sex diﬀerences in urinary concentration in the current
experiment, guanidinoacetate, creatine, creatinine, spermine, TMA
and trimethylamine-N-oxide (TMAO) have previously been
reported in mice.1 Sex diﬀerences for urinary creatine and citrate
concentrations have also previously been reported for humans with
higher excretion in females,2 consistent with the observations in the
current study. Guanidinoacetate, also excreted in higher concen-
trations in female urine, is converted into creatine in the liver using
S-adenosylmethionine as the methyl donor,3 and therefore it is
possible that this pathway is up-regulated in females.
Higher levels of TMAO have been reported in female Han
Wistar rats than in male rats.24 Hippurate, succinate, 2-oxogluta-
rate and dimethylglycine were elevated in the urine of females.25
Of the metabolites strongly correlated with gender, creatine, uric
acid, trimethylamine, methionine, alanine and TMAO were also
correlated with the slc26a6 null group and thus deconvolution
of the gender versus slc26a6 transporter deletion eﬀects is
complicated.
Figure 2. CE-UV metabolic ﬁngerprinting of urine corresponding to male wild type mouse (A) and male SLC26A6-null mouse (B). Diﬀerent levels
observed in some metabolites according to the knockout condition (C). 1. Urea; 2. Creatinine; 3. Creatine; 4. Histidine; 5. Phenylalanine; 6.
Methyluridine; 7. PAG; 8. Allantoin; 9. Hippurate; 10. Uridine; 11. Uric/Inosine; 12. Benzoate; 13. Chlorides; 14. Nitrate; 15. Oxalate; 16. Fumarate;
17. Oxoglutarate; 18. Succinate; 19. Isocitrate; 20. Glutarate; 21. Citrate; 22.m-HPPA sulfate (theorical); 23. Glycolate (coelutes); 24. Acetoacetate; 25.
Lactate; 26. Ketosiovalerate; 27. Glycerate/Benzoate; 28. α-Ketoisocaproate; 29. Phenylpyruvate; 30. Phenyllactate; 31. Glutamate; 32. Hippurate/
Vanillate 33. Ascorbate. Wild type control highlighted in blue. SLC26A6-null mice highlighted in red.
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Although the main source of TMA is the bacterial breakdown
of choline in the intestine, this metabolite may have a wider role
in physiology andmay act as a signaling molecule. Methylamines,
particularly TMA, have been shown to be present in higher
concentrations in the urine of male mice and are lower in castrated
mice.26,27 Trace amine-associated receptors are thought to act as
pheromone receptors in the nose,28 a hypothesis that is supported
by the fact that several of these trace amines such as TMA and
isoamylamine can speed up puberty in female mice. Conversely,
urinary concentrations of TMAO are higher in female mice.
TMAO can be generated from the oxidation of TMA via hepatic
ﬂavin monooxygenase enzymes, predominantly FMO3,27 which is
derived from dietary constituents such as choline. However
TMAO can also be directly absorbed from food. For example,
cold water dwelling ﬁsh typically contain high levels of this
metabolite, as it has antifreeze functions.
m-HPPS excretion has been shown both in the current study
and previous studies to be inﬂuenced by gender. In the present
study, it is also highly correlated with the slc26a6-null group.
Stanley et al. reported higher concentrations of m-HPPS sulfate
in male rat urine samples, which reﬂects the higher sulfation
activity of male sulfotransferase enzymes in rats.30 Sex diﬀerences
in sulfation are well documented with four times higher cytosolic
sulfation in male rat liver compared with females. However, this
sex-related diﬀerence was reversed in mice, with female mice
showing the higher sulfating activity, which ﬁts with the higher
levels of HPPS observed in female mice in the current study.31
As for the slc26a6 deletion ﬁndings, we have calculated the
corresponding q-values using FDR with respect to sex diﬀer-
ences. For the gender comparison TMA, alanine, PAG and sper-
mine remain positively associated with male mice after exclusion
based on q-values. m-HPPA, formate, TMAO, creatine, creatinine,
2-oxoisocaproate, 3-methyl-2-oxoisovalerate, glycerate, guanidinoacetate
and methylmalonate remain positively associated with female mice.29
Identiﬁcation of Statistical Correlation between the Two
Main Phenotypic Characteristics, Oxalate and m-HPPS with
the Global Urine Proﬁles
Bidirectional correlation analysis of the combined data set
(NMR-CE) was applied in order to establish pairwise corre-
lations structures. It was also used for metabolic or functional
correlations either within or between NMR and CE data,19 such
as those between molecules related by pathway or shared res-
ponse to the slc26a6 deletion.
Since oxalate (Var_5727, p-value <0.05), a molecule that
can be exchanged by slc26a6 and plays a key role in the
characterization of slc26a6 deletion, is NMR invisible, a
correlation matrix was calculated for the combined CE-UV and
NMR detected signals using the oxalate signal in the CE-UV
trace as the driver. A univariate Pearson correlation matrix
encompassing all NMR and CE data was used with the oxalate
signal with a cutoﬀ level of p < 0.05. Signals that covaried across
the NMR-CE data set are colored in red (Figure 6) and indicate a
signiﬁcant correlation (p < 0.05) with the oxalate signal. These
signals included m-HPPS (signals on NMR; triplet δ 7.38 (r)
0.497, multiplet δ 7.21 (r) 0.559, triplet δ 2.91 (r) 0.561, triplet
Figure 3. Scores plots from the PCA model derived from the NMR (A), CE (B), and NMR_CE combined data set (C) using pareto scaling (red
triangle, knockout female; blue triangle, knockout male; green box, wild type female; orange box, wild type male).
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δ 2.51 (r) 0.563, doublets of doublets δ 7.16 (r) 6.00, and in CE;
Var_6718 (r) 0.886), TMAO (singlet δ 3.27 (r) 0.600), lactate
(doublet δ1.33 (r) 0.610), chlorides (Var_5164 (r) 0.549), nitrate
(Var_5228 (r) 0.718), fumarate (Var_6168 0.580), 2-oxoglutarate
Figure 5. (A) Scores plot from the OPLS-DA model derived from the NMR_CE data showing separation according to gender (B) Covariance for
discriminant variables in female and male mice including jack-knife interval (p > 95%).
Figure 4. (A) Scores plot fromOPLS-DAmodel derived from the NMR_CE data showing separation according to slc26a6-null and wild type mice. (B)
Covariance for discriminant variables in the wild type and slc26a6-null mice including jack-knife interval (p > 95%); green bars show no statistical
signiﬁcance as determined by the interval which includes zero value.
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(Var_6308 (r) 0.619), glutamate (Var_6528 (r) 0.730), citrate
(Var_6628 (r) 0.757), glycolate (Var_7038 (r) 0.825),
benzoate/glycerate (Var_8968 (r) 0.640), which also revealed
positive correlation with oxalate. Moreover, hippurate (signals on
NMR; doublet δ 7.84 (r)−0.599, triplet δ 7.64 (r)−0.595, triplet
δ 7.56 (r) −0.596, doublet δ 3.97 (r) −0.600, and on CE;
Var_2220 (r) −0.761, Var_9726 (r) −0.701), and taurine
(triplet δ 3.43 (r) −0.490, triplet δ 3.27 (r) −0.516) were
signiﬁcantly anticorrelated with oxalate (Figure 6); p-values and
correlation coeﬃcients, corresponding to the signals for
metabolites that statistically correlate with oxalate, can be
seen in Supporting Information Table S3.
The general assumption would be that metabolites that are
strongly signiﬁcantly correlated are more likely to be related to
each other either mechanistically, e.g., in a shared perturbed
metabolic pathway, or undergoing a similar metabolic response
to the genetic modiﬁcation. Thus oxalate was most strongly
associated with m-HPPS, glycolate, citrate, nitrate (all positive)
and hippurate (negative). The association between oxalate and
nitrate simply reﬂects the capacity of the transporter for carrying
multiple anions.8 Chloride was positively correlated to oxalate,
but as it was added to every sample in order to ensure the
complete oxalate solubility in the urine, its biological signiﬁcance
was not considered in the correlations. Glycolate is one of the
precursors for oxalate, together with glycine, hydroxyproline and
glyoxalate;9 the other precursors were not indicated as
discriminatory of the slc26a6 null model, nor were they
signiﬁcantly correlated with oxalate.
One of the strongest metabolic correlations with oxalate, and
indeed one of the strongest metabolites characterizing the
metabolic phenotype of the slc26a6 mouse, was m-HPPS. The
correlation matrix driven from m-HPPS showed correlations
with hippurate (negative) creatinine, methylmalonate, creatine
and TMAO (positive). Here the picture is confounded slightly
sincem-HPPS, although highly discriminatory for the slc26a6-
null class, is also consistently higher in female mice over males.
Thus, some of the metabolites that were correlated to
m-HPPS, such as creatinine and TMA, may be reﬂective of
sex-related diﬀerences in metabolism rather than the genetic
modiﬁcation.
m-HPPS was found to be strongly discriminant for slc26a6
deletion in both the combined and gender stratiﬁed models, but
was also modestly discriminant for gender. Since this metabolite
was one of the most inﬂuential in characterizing the slc26a6
phenotype, a correlation network was also calculated in order to
explore potential pathway connections.
A correlation matrix was calculated for the triplet δ 2.91,
p-value = 1.93 × 10−5 of m-HPPS, as this was the signal with the
highest signiﬁcance in discriminating the slc26a6 null group and
that also occurs in a spectral region with minimal spectral overlap
from other metabolite resonances. As can be seen in Figure 7,
TMAO (singlet δ 3.27 (r) 0.629), creatine (singlet δ 3.04 (r)
Figure 6. Correlation structure obtained after selecting oxalate in CE and applying a p = 0.05 signiﬁcance criterion. Signals positively and highly
correlated to oxalate signal can be seen highlighted in red on the top hemisphere of the ﬁgure, such asm-HPPS [signals onNMR; triplet δ 7.38 (r) 0.497,
multiplet δ 7.21 (r) 0.559, triplet δ 2.91 (r) 0.561, triplet δ 2.51 (r) 0.563, doublets of doublets δ 7.16 (r) 6.00, and on CE; Var_6718 (r) 0.886], TMAO
[singlet δ 3.27 (r) 0.600], lactate [doublet δ1.33 (r) 0.610], chlorides [Var_5164 (r) 0.549], nitrate [Var_5228 (r) 0.718], fumarate [Var_6168 0.580],
2-oxoglutarate [Var_6308 (r) 0.619], glutamate [Var_6528 (r) 0.730], citrate [Var_6628 (r) 0.757], glycolate [Var_7038 (r) 0.825], benzoate/
glycerate [Var_8968 (r) 0.640]. Signals highly but negatively correlated to oxalate signal can be seen at the bottom hemisphere of the ﬁgure, also
highlighted in red, hippurate [signals on NMR; doublet δ 7.84 (r)−0.599, triplet δ 7.64 (r)−0.595, triplet δ 7.56 (r)−0.596, doublet δ 3.97 (r)−0.600,
and on CE; Var_2220 (r) −0.761, Var_9726 (r) −0.701], taurine [triplet δ 3.43 (r) −0.490, triplet δ 3.27 (r) −0.516].
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0.687, singlet δ 3.93 (r) 0.573), creatinine (singlet δ 3.045 (r)
0.738, singlet δ 4.05 (r) 0.753), scyllo-inositol (singlet δ 3.37 (r)
0.492), 2-oxoisocaproate (doublet δ 0.94 (r) 0.535, doublet δ
2.62 (r) 0.655), methyl malonate (doublet δ 1.25 (r) 0.734),
3-methyl-2-oxovalerate (doublet δ 1.11 (r) 0.573), indoxylsulfate
(doublet δ 7.71 (r) 0.661, doublet δ 7.50 (r) 0.673, singlet δ 7.36
(r) 0.576), chlorides (Var_5164 (r) 0.178) and oxalate (Var_5727
(r) 0.483), were positively and highly correlated to m-HPPS signal.
In the same way, signals corresponding to hippurate (signals
on NMR; doublet δ 7.84 (r) −0.693, triplet δ 7.64 (r) −0.669,
triplet δ 7.56 (r) −0.666, doublet δ 3.97 (r) −0.592, and on
CE; Var_2220 (r) −0.739, Var_9726 (r) −0.760), TMA
(singlet δ 2.88 (r) −0.642) and methionine (singlet δ 2.14 (r)
−0.564), were strongly negatively correlated to m-HPPS.
Supporting Information Table S4 shows p-values and
correlation coeﬃcients of these metabolites.
The use of correlation matrices can provide additional
information to that extracted from the multivariate models. For
example, nitrate falls below the signiﬁcance level set for the
multivariatemodels generated for theCE-UVdata but is highlighted
as a correlate of oxalate using the Pearson correlation statistic.
Likewise the correlation matrix calculated for m-HPPS identiﬁes
indoxylsulfate and several other gut microbial metabolites (TMA,
TMAO, hippurate and other phenolics) as strong correlates, thereby
further supporting the metabolic signature of gut microbial
metabolites, although indoxyl sulfate is not in itself identiﬁed as a
discriminatory feature of the OPLS-DA models.
Diﬀerential Expression of Gut Microbial Metabolites in the
slc26a6 Null Mouse
The use of transgenic models of altered intestinal transport can
also probe the interactions between dietary substrates and the gut
microbiota. There is increasing interest in the gut microbiome
and the symbiotic relationship with its host, more speciﬁcally the
inﬂuence it may have on host immunity and metabolism.13
However, an aspect that has not been considered yet in any detail
is whether alterations in intestinal nutrient transport can in turn
aﬀect metabolism by changing the gut microbes or their meta-
bolism. Intestinal bacteria have their own metabolic pathways
and metabolites, which may integrate with those of the host.13
Although the slc26a6 urine model was created to explore the
relationship between renal anion exchange and sodium
regulation, it is known that this anion exchange transporter is
ubiquitously found throughout the intestine and other tissues,
such as heart, kidney, and liver.3 The strong diﬀerences in
m-HPPS and hippurate suggest that themetabolic phenotype of this
knockout is related at least partially to altered intestinal microbial
presence or activity, which may be more closely associated with
eﬀects arising from the expression of this transporter in the
intestine. m-HPPS is a metabolite product from the metabolism
of caﬀeic acid (CA), ferulic acid (FA) and chlorogenic acid,
Figure 7. Correlation structure obtained after selecting m-HPPS on NMR and applying a p = 0.05 signiﬁcance criterion. Signals positively and highly
correlated to oxalate signal can be seen highlighted in red on the top hemisphere of the ﬁgure, such as TMAO [singlet δ 3.27 (r) 0.629], creatine [singlet
δ 3.04 (r) 0.687, singlet δ 3.93 (r) 0.573], creatinine [singlet δ 3.045 (r) 0.738, singlet δ 4.05 (r) 0.753], scyllo-inositol [singlet δ 3.37 (r) 0.492], α-
ketoisocaproate [doublet δ 0.94 (r) 0.535, doublet δ 2.62 (r) 0.655], methyl malonate [doublet δ 1.25 (r) 0.734], α-keto-β-methyl-N-valerate [doublet δ
1.11 (r) 0.573], indoxylsulfate [doublet δ 7.71 (r) 0.661, doublet δ 7.50 (r) 0.673, singlet δ 7.36 (r) 0.576], chlorides [Var_5164 (r) 0.178] and oxalate
[Var_5727 (r) 0.483]. Signals highly but negatively correlated to oxalate signal, such as hippurate [signals on NMR; doublet δ 7.84 (r) −0.693, triplet δ
7.64 (r)−0.669, triplet δ 7.56 (r)−0.666, doublet δ 3.97 (r)−0.592, and on CE; Var_2220 (r)−0.739, Var_9726 (r)−0.760], TMA [singlet δ 2.88 (r)
−0.642] and methionine [singlet δ2.14 (r) −0.564], can be seen at the bottom hemisphere of the ﬁgure, also highlighted in red.
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which appears to occur in the intestinal mucosa and colonic
microﬂora.4 However, the major pathway forming m-HPPA is
the reduction of caﬀeic acid to 3,4-dihydroxyphenylpropionic
acid followed by dehydroxylation tom-HPPS by the action of the
gut ﬂora. Aromatic amino acids, including tyrosine, tryptophan
and phenylalanine, are also dietary precursors of phenolic acid-
related metabolites. The metabolic end points of the intestinal
metabolism of tyrosine include phenylpropionic acid and
m-HPPS.10 The rate of excretion of m- and p-hydroxyphenyl-
proionic acid has been shown to be low in germ free animals, since
most of the m-hydroxyphenylproionic acid involves reduction of
caﬀeic acid followed by para-dehydroxylation, which does not
occur in germ free rats. m-HPPA excretion increases dramatically
(∼140 fold) upon inoculation with fecal micro-organisms,11 which
further supports the microbial origin of this metabolite.
Although the urinary concentrations of hippurate and m-HPPS
do not appear to be stoichometrically related, other than
oxalate levels, they represent the two most discriminatory
metabolites for the slc26a6 null model and are anticorrelated.
Hippurate is formed from the metabolism of dietary aromatic
compounds to benzoate by the gut microbiota and subsequent
conjugation of benzoate with glycine in the mitochondria. The
concentration of urinary hippurate has been shown to be
modulated according the composition of the intestinal micro-
biota,15 and rats have been shown to switch from excreting
hippurate as the predominant microbial metabolite to m-HPPA
and vice versa in as little as a few hours.32
Asmentioned previously, a Pearson correlation calculated for a
selected m-HPPS signal identiﬁed a range of microbial
metabolites or microbial−mammalian cometabolites including
indoxylsulfate, TMA, TMAO, and hippurate.
The signiﬁcance of urinary TMA and TMAO has been
discussed in relation to sex diﬀerences. Altered urinary excre-
tion of TMAO has been observed in previous studies, most
commonly in cases of drug-induced nephrotoxicity,5 but this
metabolite has also been positively associated with cardiovascular
disease in both humans and mouse models.33 Feeding of hyper-
lipidemic mice with either choline or TMAOwas shown to result
in higher plasma levels of TMAO, which was directly associated
with the size of atherosclerotic plaque. Higher plasma TMAO
concentrations were found in female mice, which also developed
more severe atherosclerosis than male mice.33
Another indication of potential gut microbial involvement
with oxalate excretion is that intestinal colonization with the bac-
terium Oxalobacter formigenes, a normal gut commensal, appears
to promote intestinal oxalate secretion and reduce urinary oxalate
excretion in rats and mice.12,30 Thus, although the role of the gut
microbiota in deﬁning the slc26a6 null mouse model is far from
clear, the results point to the fact that microbial metabolites are
diﬀerentially expressed in this model of anion transport. Taken
together with the literature on choline metabolism, there may be a
link with the hypertension associated with renal stone formation,
but more detailed laboratory experiments using labeled substrates
would be required to probe this link further.
■ CONCLUSIONS
In summary, we have found a strong metabolic phenotype for
slc26a6 deletion, which is deﬁned both by altered urinary
composition of anions such as oxalate, chloride and nitrates and
also by modiﬁed urinary metabolites deriving from gut microbial
metabolism including m-HPPS, hippurate and methylamines.
Diﬀerential levels of tricarboxylic acid cycle intermediates were
also contributory to the metabolic signature of the slc26a6 null
mice. The modiﬁcation of the microbial metabolites is consistent
with the fact that the slc26a6 transporter is found in a range of
tissues other than the kidney, including the intestine. Sex-related
diﬀerences were also found in the metabolic phenotype of slc26a6
null mice, which may relate to sex diﬀerences in renal stone
formation and further may have implications in hypertension.
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Breast milk metabolome characterization in a single phase extrac-
tion, multiplatform analytical approach 
Alma Villaseñor1#, Isabel GarciaPerez2, 3#, Antonia Garcia1, Joram M. Posma2, Mariano 
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SW7 2AZ London, UK. 
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 Breast milk (BM) is a biofluid, which has a fundamental role in earlylife nutrition and directly impacts on growth, 
neurodevelopment and health. Global metabolic profiling is increasingly being utilized to characterize complex metabolic changes 
in biological samples. However, in order to achieve broad metabolite coverage, it is necessary to employ more than one analytical 
platform, typically requiring multiple sample preparation protocols. In an effort to improve analytical efficiency and retain compre
hensive coverage of the metabolome, a new extraction methodology was developed that successfully retains metabolites from BM 
in a singlephase using an optimized methylbutyl ether solvent system. We conducted this singlephase extraction procedure 
on a representative pool of BM, and characterized the metabolic composition using LCQTOFMS and GCQMS for polar and 
lipidic metabolites. To ensure that the extraction method was reproducible and fitforpurpose, the analytical procedure was evalu
ated on both platforms using 18 metabolites selected to cover a range of chromatographic retention times and biochemical classes. 
Having validated the method, the metabolic signature of BM composition was mapped as a metabolic reaction network highlighting 
interconnected biological pathways and showing that the LCMS and GCMS platforms targeted largely different domains of the 
network. Subsequently, the same protocol was applied to ascertain compositional differences between BM at week 1 (n=10) and 4 
weeks (n=9) postpartum. This singlephase approach is more efficient in terms of time, simplicity, cost and sample volume than 
the existing two phase methods, and will be suited to highthroughput metabolic profiling studies of BM.  
	

	
Breast milk (BM) is considered the optimal nutrition availa
ble for neonates and is recommended as the sole source of 
nutrition in the first 6 months of infancy by the World Health 
Organization. BM contains many biologically active compo
nents, which have a fundamental role in infant growth and 
health1,2. In addition to the direct nutritional value of BM in 
promoting growth, bioactive components found in BM con
tribute to the metabolic, immune and gut microbiome devel
opment of the newborn3. 
The major groups of nutrients present in BM are lipids, car
bohydrates, proteins and many other micronutrients in smaller 
quantities1,4. BM is a compositionally variable fluid that 
changes during lactation, and is highly influenced by maternal 
dietary intake5,6. Preclinical findings show that qualitative 
changes in dietary lipids during early life may contribute to 
longterm health outcomes, such as lower neurodevelopmental 
and maturation of the digestive function7,8. Previous studies4,6 
have shown the influence of maternal nourishment on BM 
lipid content. Jensen, et. al. described temporal differences in 
lipid composition, especially fatty acid content, over time 
postpartum, compositional variation from mothers with differ
ent ethnicities and diets, and between term and preterm milk4.  
Milk is a complex biological fluid where fat is stabilized in 
the water phase by micelles due to the presence of several 
compounds acting as surfactants. After freezing, fat is agglu
tinated and the sample separates into two layers that are not 
stably mixed again after stirring or vortexing. Therefore, most 
published studies have adopted a two phase strategy and have 
analyzed the aqueous and organic phases separately. Given the 
complexity of BM, and its importance in human growth, there 
is a need for development of global metabolic profiling meth
ods that are capable of capturing as many nutrients and micro
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nutrients present in the BM to give a comprehensive coverage 
of the metabolome with a view to establishing the influence of 
the chemical interaction between mother and infant via BM.  
Over recent years there has been extensive research into un
raveling the metabolome of various biofluids9. The main aims 
of any global metabolic screening method is to achieve broad 
and rich coverage of as wide a range of endogenous and exog
enous compounds in a single and robust profile that represents 
the physiological or pathological condition of the subject 
studied10. Widespread analytical methodologies such as NMR 
spectroscopy and more recently GC, LC, and CE coupled to 
MS have proved valuable in the global assessment of metabo
lites in biofluids1113. Despite the importance of BM in human 
development, only two global metabolic profiling studies are 
reported in the literature14,15, both using 1H NMR as the analyt
ical platform. In addition, most of the analytical research in 
BM to date has been targeted and has focused primarily on the 
fatty acid content using liquid and gas chromatography1619. 
Also other specific molecular classes such as the oligosaccha
rides20 and sphingomyelins21 have been profiled; for example, 
Miller, et. al.20 have shown complex changes in oligosaccha
ride structure and composition that are unique to motherinfant 
pairs and that the oligosaccharide composition directly effects 
the composition of the infant gut microbiome.  
Apart from two studies using NMR14,15 spectroscopy, to the 
best of our knowledge, no global MSbased assays have been 
used to study the global profile of BM. A robust screening 
method for BM capturing multiple classes of metabolites is 
necessary in order to carry out effective, high throughput 
screening of this biofluid. The aim of this study was to devel
op and optimize a methodology for analyzing BM that cap
tures as many metabolites as possible using a single extraction 
phase in order to maximize the likelihood of identifying bi
omarkers associated with infant development and health.  
We developed a single optimized organic phase extraction 
method for breast milk suitable for both GCMS and LCMS 
and applied this method to the characterization of differences 
in BM composition at two distinct times postpartum. 
 
	


All standards, chemicals, reagents and solvents used in this 
study are fully described in the Supplementary Information 
(SI) and compounds used for the validation of both MS plat
forms are summarized in Table S1.  

This study was approved by the National Research Ethics 
Service (ref 12/LO/0203). A pool of human breast milk was 
obtained mixing 100 µL aliquots from samples obtained from 
52 women ranging from 1 to 76 days postpartum in order to 
characterize BM over the first four months of life. In addition, 
BM samples from mothers of healthy termborn infants were 
collected in the 1st week (n=10) and in week 4 postpartum 
(n=9), and were analyzed in order to show the applicability of 
the method characterizing differences in BM composition over 
time. These two time points were chosen since the first week 
of neonatal nutrition is markedly different from subsequent 
weeks with colostrum being produced over the first 34 days 
postpartum. This application could be important to prepare 
special formulas for newborns more similar to the stages of 
breastfeeding. All samples were stored at 80°C for long term 
storage and 20°C for short term storage before  the day of 
analysis.  


Several extraction mixtures were compared in order to op
timize the extraction protocol for as many metabolites as pos
sible from the BM sample giving coverage of both lipids and 
polar metabolite classes.  
	
	
 50 µL of BM 
was mixed with 350 µL of the solvents, methanol and MTBE 
in different ratios: methanol (0, 87, 175, 263, and 350 µL) and 
the converse volume of MTBE (350, 263, 175, 87, and 0 µL) 
were tested. The mixture then was vortex for 1 min for protein 
precipitation and compound extraction. The same protocol was 
followed for the mixture ethanol: MTBE. 
In all cases vitamin E acetate was used as internal standard 
(IS), at final concentration of 25 ppm.  

	 Once the extraction protocol was 
optimized and established, analysis of the single phase extrac
tion mixture by GCQMS was performed. The analytical 
procedure for metabolic characterization was carried out fol
lowing a methodology previously described22. Briefly, an 
aliquot of 150 PL was transferred to a GC vial taken from the 
supernatant of the extracting system. The sample was evapo
rated to dryness in a Speedvac Concentrator (Thermo Fisher 
Scientific, Waltham, MA, USA). 10µL of Omethoxyamine 
hydrochloride in pyridine (15 mg/mL) was added to each GC 
vial, and the resultant mixture was vigorously vortexmixed 
for 5 minutes. Methoxymation was carried out in the dark, at 
room temperature for 16 h. For derivatization, the solution was 
vortexmixed again for 5 min after 20PL of BSTFA with 1% 
TMCS was added as catalyst. Samples were heated in an oven 
for 1 h at 70 °C to achieve silylation. Finally 100 PL of hep
tane containing 10 ppm of C18:0 methyl ester (IS) was added 
to each GC vial and vortexmixed for 2 min before GC analy
sis (labeled sample).  
A flowchart of the extraction protocol for the optimized 
method is presented in Figure 1. 

	 Global profiling was developed us
ing a LCQTOFMS instrument following methods described 
elsewhere23. The LC system consisted of a degasser, binary 
pump, and autosampler (1200 series, Agilent). 1 µL of extract
ed sample was injected into a reversedphase column at 60°C 
(Agilent; Poroshell ECC8, 15 cm × 2.1 mm, 2.7 µm) with a 
precolumn (Supelco; Ascentis Express C8, 0.5 cm× 2.1 mm, 
2.7 µm). The gradient consisted of mobile phase A (10 mM 
ammonium formate in water) and mobile phase B (10 mM 
ammonium formate in methanol) pumped at 0.5 mL/min with
in a total run time of 60 min. The gradient started at 75% B, 
increasing to 96% B in 23 min, then held until 45 min and 
increased to 100% B by 46 min, and held until 50 min. Start
ing conditions were returned by 51 min, and a 9 min re
equilibration time was included taking the total run time to 60 
min. An online filter was added to the instrumentation. Data 
were collected in positive and negative ESI mode in separate 
runs on a QTOF analyzer (Agilent 6520) operated in full scan 
mode from 100 to 1200 m/z. The capillary voltage was 3500 V 
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for positive and 4000 V for negative with a scan rate of 1.02 
scans per second; the nebulizer gas flow rate was 10 L/min. 
During the experiment two reference masses were continuous
ly detected allowing constant mass correction of data to obtain 
accurate mass in all injections [(M1H)
+= 121.0509 (C5H4N4) 
and (M2H)
+= 922.0098 (C18H18O6N3P3F24)].  

 	 . Labeled samples were analyzed 
using a GC instrument (Agilent 7890A) coupled to mass spec
trometer with tripleAxic detector (Agilent 5975C). 2 µL of 
sample volume was injected in split mode using an Agilent 
7693 autosampler. The split ratio was 1:5 to 1:10 with 3−10 
mL/min helium split flow into a Restek 20782 deactivated 
glass wool split liner. Separation was achieved using a 10 m 
J&W precolumn (Agilent Technologies®) integrated with a 
122−5332G column DB5MS: 30m length, 0.25 mm i.d. and 
0.25Pm film consisted of 95% dimethyl/5% diphenyl pol
ysiloxane (Agilent Technologies®). The helium carrier gas 
was used at a constant flow rate of 1 mL/min. The column was 
initially maintained at 60 °C for 1 min after injection, then 
temperature was increased at the rate of 10 °C/min to reach a 
final temperature of 325 °C, and cool down after analysis for 
10 min. Temperatures of the injector, transfer line, filament 
source and quadruple were maintained at 250°C, 280°C, 
230°C and 150°C, respectively. The quadrupole detector 
(5975 inert MSD, Agilent) was controlled by ChemStation 
software. The electron ionization source was operated at −70 
eV. MS detection was achieved in scan mode over a mass 
range m/z 50−650 at a rate of 1 spectra/s. Filament of the EI 
source was turned off from minute 23 to 26. An nalkane 
mixture from C8 to C28 dissolved in dichloromethane was run 
at the beginning of experimental worklist for calibration file 
and retention index determination. All these conditions were 
optimized previously22.  
For both MS techniques, the samples from the application 
were analyzed in one randomized run. QC samples were in
jected in the beginning and at the end of the sequence, and 
after every 5 samples to check system stability and perfor
mance of the analysis. 
 


 The resulting data file was cleaned of background 
noise and molecular entities were output by the Molecular 
Feature Extraction (MFE) algorithm in the MassHunter Quali
tative Analysis Software (Agilent®, version B.05.00). The 
resulting MFE file contained a list of all molecular entities 
that, represents the full TOF mass spectral data in each sam
ple. Primary data treatment (alignment and filtering) was 
performed in Mass Profiler Professional (MPP) B.12.1 Ag
ilent® software.  

 Data were acquired with the Agilent MSD Chem
Station Software. Identification of metabolites present in the 
GCMS profiles was completed before the multivariate analy
sis. The quality of the chromatograms acquired by Total Ion 
Chromatogram (TIC) and internal standard peak were careful
ly examined. Automated Mass Spectrometry Deconvolution 
and Identiﬁcation System (AMDIS) was used for automatic 
peak detection and deconvolution (see compound identifica
tion). Compounds were identiﬁed by comparing their mass 
fragmentation patterns with those available in the NIST08 and 
Fiehn RTL mass spectral library.  
Target analysis of 18 compounds was performed. These 
compounds were used to validate the method. For LCMS, the 
Extracted Ion Chromatogram (EIC) algorithm in MassHunter 
was used; this takes the  value of each compound and look 
for this into the chromatogram (±10ppm of mass error win
dow). For GCMS, extraction and integration of a target frag
ment ion in MSD ChemStation Software was performed. 
Data obtained from the analysis of 19 breast milk samples, 
obtained at two different time points, were processed using 
multivariate pattern recognition techniques using SIMCAP13 
software (Umetrics, Sweden) such as principal component 
analysis (PCA), and partial least square discriminant analysis 
(PLSDA)24. Unit variance scaling was applied to all data 
variables. The robustness of the models was evaluated based 
on R2 (explained variance) and Q2 (capability of prediction) 
values as well as 7fold cross validation and class permutation 
validation. The regression coefficients from the PLSDA mod
els were divided by the jackknife interval standard error (SE) 
to give an estimate of the tstatistic. Variables with a |t
statistic| ≥ 1.96 (zscore, corresponding to the 97.5 percentile) 
were considered significant25. 
 
 !!"

 Tentative identification of metabolites was done by 
comparing mass accuracy of candidate metabolites against our 
own university online database CEUmass mediator 
(http://ceumass.eps.uspceu.es/mediator/), which uses KEGG, 
METLIN and LipidMAPS databases with an error mass set to 
10 ppm. Potential hits were compared to the experimental 
isotopic pattern distribution on MassHunter. 

 A standard solution (Grain FAME mix®) was ana
lyzed in order to use their retention times (Rts) to create a 
calibration data file for further adjustment of Rts in samples. 
The accuracy improvement was based on the determination of 
the Kovats retention index (RI). A wellestablished RI value is 
contained in Fiehn RTL library and this is compared to the 
experimental RI value in order to assign a match score be
tween the experimental and the theoretical spectra26. Peak 
detection and deconvolution were performed by retention 
index comparison of spectra with the Fiehn RTL library in 
AMDIS software v.2.6927. Target compounds were assessed 
by comparing their mass fragmentation patterns with those 
available in the NIST mass spectral library and Fiehn RTL 
library. A private library was created with the targets obtained 
and confirmed from retention index search correcting retention 
time to the experimental observed. Metabolites that were not 
included in Fiehn RTL library such as cholesterol and arachi
donic acid were added from the NIST library. Deconvolution 
was optimized by a second analysis performed by the use of 
retention time algorithm in AMDIS. Compounds present in at 
least 70% of all samples (QC samples + study samples) were 
kept for statistical analysis. 
 
#!$!%
The method was validated to assess selectivity, linearity, ac
curacy, instrumental precision and method precision (using 
standards and samples), limit of detection (LOD) and limit of 
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quantification (LOQ). Compounds were selected to represent a 
range of chromatographic retention times and biochemical 
classes. For LCMS (8 metabolites): carnitine, αlinolenic 
acid, palmitic shpingosine, stearic acid, vitamin E, cholesterol, 
cholesteryl linoleate (CE 18:2) and triglyceride C18:2 (TG 
18:2) were chosen whereas for GCMS (10 metabolites): cit
rate, glucose, glutamate, glycerol, lactate, myoinositol, pro
line, serine, stearic acid and urea were selected. Stearic acid 
was included as a common standard for both techniques, as a 
further check of the performance of the extraction method.  
The linearity of the method was assessed by assaying five 
different levels of concentrations of standard solutions in 
triplicate covering the ranges of 25 to 200% of mean values 
for each metabolite. Recovery was estimated by comparing in 
triplicate, the values of spiked samples prepared in a linear 
range. Withinday instrumental precision was evaluated by 
consecutive injections (n= 10) of a homogeneous standard 
solution. Intraassay precision was tested for standards pre
pared in the midrange of the calibration curve and for samples 
from a pool of BM (n= 7). Interday precision was tested by 
repeating the experiment on a different day, with freshly pre
pared standard solutions and new nodefrost BM pool. Recov
ery was tested by spiking the standards on the sample within 
the calibration range (3 replicates in 3 levels). LOQ was esti
mated calculating signal to noise ratio (SNR) in the lowest 
concentration of linearity (LP1). 
 
	
	
!
After testing several extraction mixtures with different sol
vents, proportions and conditions, extraction protocols that 
used methanol/ethanol: MTBE performed better than tertiary 
mixtures including water in terms of giving a single phase 
containing a wide range of chemical classes. Here we present 
the optimized method. 
Extraction procedures proposed and tested here, were cho
sen based on minimum manipulation of the sample and broad 
and reproducible profile of metabolites in a single phase. 
MTBE was chosen primarily because it is the second most 
widely used solvent in BM analysis used after Folch method. 
Previous publications23,2830 have shown that employment of 
MTBE avoids drying and resuspension steps reducing sample 
manipulation and human error. The high content of lipids 
intrinsically packed in the sample typically results in the for
mation of two phases. The extraction procedure used in the 
current study was selected based on comparing the results 
obtained from: (1) visual analysis of Total Ion Chromatogram 
(TIC), (2) IS recovery (Figure 2) and (3) total number of enti
ties (Table S2). 
	  	  All etha
nol/methanol: MTBE mixtures produced a single miscible 
phase instead of the two phases commonly observed with 
solvent extraction. Methanol and ethanol work as cosolvents 
allowing miscibility of MTBE with the water in the milk. 
These mixtures had the advantage of forming one phase, 
which not only made the procedure simpler but also reduces 
the potential for analytical variation and avoids the partition 
phenomenon of compounds when two phases are formed. The 
chromatograms obtained in the methanolMTBE serial showed 
that with the increase of MTBE proportion, the polarity of the 
mix solvent is diminished and therefore the amount of non
polar metabolites and signal intensity is higher (Figure 2A). 
Differences were observed mainly at the beginning of the TIC 
after comparing methanol: MTBE proportions from (50:50) to 
MTBE 100%. 
The selection of the extraction procedure was based on the 
best recovery of compounds observed throughout the chro
matograph, total signal and SI recovery. The EIC of vitamin E 
acetate was used as the IS, this is the synthetic compound of 
endogenous vitamin and had a partition coefficient (log P) of 
10.69 (http://www.chemspider.com/). Therefore, vitamin E 
acetate denotes the hydrophobicity and partition power in the 
media, and allowed ascertaining the recovery of a known 
compound with a medium polarity. As shown in Figure 2B 
and Table S2, the IS and total signal were used to compare 
the extraction methods in order to select the best solvent pro
portions. Figure 2BC and Table S2 showed that highest 
recovery of IS and TS compared to others systems were 
achieved with methanol: MTBE (50:50). 
Intentionally, an additional extraction system was tested, 
this was the mixture of methanol: H2O: MTBE (36:21:43PL)23 
to force the formation of two phases in the resultant systems, 
allowing comparison of the one and twophase extraction 
procedures. Importantly, the chromatogram from the organic 
phase of methanol: H2O: MTBE (Figure 2C) system showed 
lower intensity and less amount of compounds compared to 
one phase systems. The formation of the two phases in the 
system made the compounds split themselves into the two 
phases. 
Finally, the extraction with methanol: MTBE (50:50) was 
selected for global signature profile. From this point the char
acterization of BM profiles by the LC–MS and GC–MS was 
performed accordingly to the optimized method described in 
the flowchart in Figure 1. 

&"$'

 Metabolite characterization in the chromatogram 
was performed using the masses with a RSD less than 20% 
coming from 10 independent replicates of a BM pool. In addi
tion, features with abundance less than 105 and 104 for positive 
and negative mode respectively were discarded reducing the 
dataset dimensions for further database identification (682 out 
of 1283 for positive and 204 out of 938 for negative mode). 
Hits from data bases tended to clustered within a biochemical 
class and are depicted in a Total Ion Chromatogram (TIC) in 
Figure 3. These are summarized in Table S3. The retention 
time window for the major classes of lipids shown in Figure 
3A, matches the order of elution described with previous lip
idomics studies23,31. Among the group of compounds previous
ly reported4,6,21,3234: fatty acids, glycerophospholipids, sphin
golipids, sterol lipids, monoglycerides (MG), diglycerides 
(DG), triglycerides (TG) and cholesteryl esters (CE) were 
observed. Fewer compounds were detected in negative mode. 
Primary fatty acids, and phospholipids were detected in both 
ionization modes, and carbohydrates (mono and disaccharides) 
were identified in the deadvolume in negative mode only 
(Figure 3B). Interestingly, Table S3 shows some additional 
classes of compounds that are not described in literature, but 
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were tentatively identified here for BM such as fatty esters, 
fatty aldehydes, ceramides, glycerophosphoglycerols (PG) and 
glycerophosphates (PA). 
Extracted ion chromatograms from the most common fatty 
acids; myristic, palmitic, stearic, oleic, linoleic, αlinolenic 
and arachidonic acid in BM consistent with previous litera
ture7 are presented in Figure S1. Here, as expected, these 7 
fatty acids showed different retention times in the chromato
graphic system. Fatty acids with longer carbon chain eluted 
later, while molecules with higher number of double bonds 
were associated with shorter retention time. 
 

 The BM extraction was characterized using the 
standard “Fiehn metabolomics retention time lock (RTL)” 
method. The Total Ion Chromatogram (TIC) with the metabo
lite assignments for 60 compounds is presented in Figure 4 
and Table S4. Metabolite classes detected included; amino 
acids, organic acids, fatty acids, hexose and pentose sugars, 
tricarboxylic (TCA) intermediates, cholesterol and disaccha
rides. Disaccharides were easily extracted and identified in the 
GCMS profile. Here, for example, lactose represents one of 
the highest peaks in the chromatogram. Nevertheless, during 
the experimental analysis it was observed that due to their high 
content in the sample the filament from the EI source got dirty 
quickly and consequently the sensitivity of the analytical sig
nal was decreased. So for method optimization, the filament 
was turned off during the time that spans disaccharide elution 
in the chromatogram from 23 to 26 minutes. Most of the BM 
compounds identified were derived from maternal endogenous 
metabolism. However, heptadecanoic acid is synthesized by 
intestinal gut bacteria35 from maternal diet and is illustrative of 
the early relationship between gut bacteria and human metabo
lism. Other research focused on oligosaccharides; such as 
fucose, has shown that the primary purpose of BM oligosac
charides is to provide a nutritional source for the infant gut 
microbiota20.  
 
$!(!
Although there are no guidelines about method validation 
for fingerprinting in the metabolomics field, a traditional vali
dation method for bioanalysis was performed on 10 com
pounds for GCMS and 8 metabolites for LCMS. The metab
olites were chosen to cover a range of biochemical classes, 
polarities, functional groups, molecular weights and retention 
times spanning the chromatograms in both techniques. A 
summary of the validation parameters is provided in Tables S
5 and S6 for LC–MS and GC–MS respectively.  
For linearity, standards were fitted to the linear model (r> 
0.99) for all selected metabolites, and no bias was found for 
most of them excluding; palmitic sphingosine and cholesterol 
for LCMS, and urea and stearic acid for GCMS. No practical 
consequences were seen in the recovery yield for any metabo
lite despite the bias in the four aforementioned metabolites 
(recoveries ranged from 90.7 to 106.1%). Recoveries ranged 
from 80.2 to 106.1% for all the metabolites in both techniques, 
except for CE 18:2 and carnitine measured by LCMS where 
the recovery yield was 51.5 and 63.8% respectively. Both 
compounds denoted the matrix effect due to the other com
pounds in the sample at these particular conditions. However, 
although recovery did not meet the validation criteria for these 
two compounds, they did meet the rest of validations parame
ters and mainly precision which is the critical one when com
paring statistically two groups. As a proof of that CE 18:2 was 
found significant in the biological application described be
low. 
For LCMS, RSD for instrumental precision for the 8 chem
ical standards ranged from 2.8 to 7.0%. The highest value was 
for TG 18:2 and it was proved to be related to the temperature 
in the injector that should never be lower than 15 ºC degrees to 
avoid precipitation of lipids. RSD for intraassay precision for 
standards ranged from 1.9 to 5.9% (n= 7) and RSD for the 
corresponding interassay precision ranged from 1.9 to 5.0% 
(n= 14). Method precision for samples had RSD values rang
ing from 1.4 to 5.8% on the first day and from 3.9 to 8.2% (n 
= 14) for both days. Therefore precision met the expected 
values to be validated in all cases. Finally, the theoretical LOQ 
for LCMS compounds ranged from 15 ppb for palmitic 
sphingosine to 389 ppb for stearic acid. 
In the case of the GCMS, RSD values for instrumental pre
cision for the 10 chemical standards ranged from 2.8 to 7.7%. 
For standards intraassay precision ranged from 2.8 to 7.9% 
(n= 7) and interassay precision from 3.6 to 8.6% (n= 14). For 
samples intraassay precision RSD values ranged from 3.0 to 
6.8% and from 3.9 to 10.8% in different days (n= 14). Those 
values can be considered acceptable in all cases. Theoretical 
LOQ ranged from 0.4 ppm for proline to 15.439 ppm for glyc
erol. There was good agreement between the BM concentra
tion of stearic acid measured by GCMS (20.02 ± 1.73ppm) 
and LCMS (21.00 ± 1.22ppm) showing reproducibility across 
analytical platforms. 
	)*%"+*
Having validated the singlephase extraction method for 
both GCMS and LCMS analysis of BM, the metabolic reac
tion network of the metabolites identified in BM was explored 
using the MetaboNetworks software36. The metabolic reaction 
network highlights the interconnectivity of different domains 
of metabolism by considering the shortest connecting paths 
found in KEGG that link the identified metabolites, and re
flects the composite metabolic signature of BM (Figure S2 
and S3). In the database reactions were included if they occur 
in the human supraorganism, i.e. due to human enzymes 
and/or enzymes from the most common bacteria phyla (fir
micutes, bacteroidetes, αproteobacteria, βproteobacteria, γ
proteobacteria, δproteobacteria and actinobacteria). Metabo
lites shown in blue were identified using LCMS, metabolites 
identified using GCMS in red and metabolites identified by 
both LCMS and GCMS in magenta. The white nodes repre
sent the intermediary metabolites in pathways connecting the 
identified compounds that were not detected in the current 
study; these may play an important role in the internal inter
mediary metabolism hence they are not the final products 
detected by GC and/or LCMS analysis. In general, specific 
metabolite classes were detected mainly by one of the two 
analytical platforms employed and often multiple metabolites 
were detected per biological class. For example, branched
chain amino acids, metabolites related to glycolysis and amino 
sugars metabolism, aromatic compounds as well as TCA cycle 
intermediates and TCA anaplerotic metabolites were identified 
with GCMS. On the other hand, Figure S2 highlights that 
Page 5 of 8
ACS Paragon Plus Environment
Analytical Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
6 
 
metabolites related to lipid metabolism were identified by LC
MS. Cholesterol and related sterols (related to bile acid me
tabolism) were also found mainly with LCMS. This shows 
that each technique identifies mostly metabolites associated 
with specific pathways and highlights the advantage of analyz
ing BM samples using different analytical techniques in order 
to achieve maximal coverage of the BM metabolome. Howev
er, for certain compound classes, such as short chain fatty 
acids, both techniques were capable of detection and were in 
good agreement.  
 
,+"%+*-
(
The validated singlephase extraction method with LC and 
GCMS detection was applied to characterizing compositional 
differences in BM obtained 1 week and 4 weeks postpartum. 
Clear metabolic differences between the two time points based 
on spectral data obtained from LCMS analysis were easily 
visualized using Principal Components Analysis (PCA). The 
PCA scores plot corresponding to the LCMS data demon
strated an evolving trend in the composition of the milk along 
the first principal component (PC1) in relation to its time of 
collection postpartum (Figure S4A). However, the corre
sponding PCA scores plot for the GCMS data did not show 
any sample clustering in any of the first three components in 
relation to its time of collection (Figure S4B).  
A supervised approach based on partial least squares dis
criminant analysis (PLSDA) was subsequently applied to the 
data obtained by LCMS (Figure S4C) and GCMS (Figure S
4D) using the two sample collection time points as classifiers. 
Samples clustered according to class in both, the GCMS and 
LCMS PLSDA models. This postpartum evolution in the 
composition of the milk is concordant with published litera
ture3536. To identify the metabolites which changed in relation 
to time postpartum, loading plots of both PLSDA models 
were explored. These models identified a number of different 
metabolites changing over lactation time.  
The data from LCMS analysis identified several metabo
lites that increased in concentration in the samples taken more 
than 26 days postpartum such as linoleic acid (18:2), pal
mitoleic acid (16:1), oleic acid (18:1), LPE (18:2), hydroxy
adipic acid, and MGs, DGs and TGs. Metabolites decreasing 
in concentration over this period were: lysoand phospholip
ids, αtocopherol, cholesterol and CE 18:2. 
The loading plots of the PLSDA model corresponding to 
the GCMS data show oleic acid (18:1), palmitoleic acid 
(16:1), linoleic acid (18:2) and gluconic acid to be increased in 
concentration in samples collected at week 4 compared to 
those collected within the first 7 days postpartum. Metabo
lites decreasing in this period were: fucose, furanose isomers, 
Dglucosaminic acid and cholesterol. 
The ability to establish differences in the relative abundanc
es of metabolites present in samples, in agreement with previ
ous literature gives further weight to the validity of the method 
developed and outlined in this paper. For example, previous 
research has similarly identified a decrease in the abundance 
of cholesterol from BM samples taken as lactation proceed
ed37, as identified by GCMS and LCMS in this study. Here, 
the total amount of cholesterol and cholesterol esters declined 
over a period of 284 days postpartum, where the greatest 
difference from cholesteryl esters was observed in the content 
of CE 18:2.  
Likewise, increases in the quantity of certain fatty acids 
have been described in BM samples collected at different 
times during lactation38, in line with our findings. One such 
study examined fatty acid abundances in breast milk collected 
from day two to day 84 postpartum. Oleic acid 18:1, was 
found to be increased from 36.08± 1.03 on day two to 38.67 ± 
0.84 on day 84 postpartum38. Similar findings were reported 
for the linoleic acid 18:2, with the percentage weight increas
ing from 13.16 ± 0.80 to 17.46 ± 0.67 over the entire period 
studied38. These literature results are all reflected by our find
ings from a combination of GCMS and LCMS, see Tables S
7 and S8.  
 
 !*
We have shown for the first time how BM samples can be 
analyzed using a single phase extraction followed by the glob
al profiling analysis of that phase using GCMS and LCMS, 
which enables simultaneous characterization of both medium 
polar compounds and lipids simultaneously. Our approach is 
an improvement over existing methods for the analysis of BM 
that typically use a two phase extraction as it is more efficient 
in terms of time, cost and simplicity, and serves two different 
analytical platforms. We have applied this method to the char
acterization of the human BM metabolome and have used 
pathway mapping tools to identify representation of multiple 
interconnected pathways. These pathways include branched 
chain amino acids, aromatic amino acids, TCA cycle interme
diates and anaplerotic metabolites, short chain fatty acid me
tabolism and lipid metabolism. Unsurprisingly, the metabolic 
reaction network shows that metabolites from a specific path
way are mostly identified using a single technique. However, 
in the case of metabolic pathways that are coregulated by gut 
bacteria, both GCMS and LCMS are needed for identifica
tion. In future, analyzing the metabolic profile of BM using 
different analytical techniques will be needed to uncover the 
full metabolome of this biofluid. Finally, applicability of these 
proposed analytical methodologies was corroborated after 
studying changes in BM composition over time.  
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. /0 Optimised breast milk extraction protocol flowchart for 
LC–MS and GC–MS.  
 
 
 
.  10 Graphical comparison of the different extraction mix
tures tested using positive mode ionization. (A) LCMS Total Ion 
Chromatograms (TIC) from methanol (100, 75, 50, 25, 0%)  
MTBE (0, 25, 50, 75, 100%) proportions; (B) Extracted Ion 
Chromatogram (EIC) from Vitamin E acetate (= 473.3989) for 
the extraction mixtures aforementioned in (A); (C) TCC compari
son of methanol / ethanol – MTBE (50:50) and the TCC of the 
extraction mixture of methanol: H2O: MTBE (36:21:43%) show
ing inferior performance to the methanol: MTBE (50:50%) sol
vent system. 
 
 
. 20 (A) Total Ion Chromatogram in positive mode (TIC +) 
and (B) TIC () in negative mode, acquired by LCMS. Metabolite 
identification in BM profile by classes of lipid. (C) Extracted 
Compound Chromatogram (ECC) for negative mode showing 
carbohydrates. Extraction system [methanol: MTBE (50:50)]. 
 
.  30 (A) Total Ion Chromatogram of breast milk profiling 
obtained by GC–Q–MS. (B) expansion of the profile from 6 to 19 
minute. (C) expansion of the region from 19 min to 31 min. Lipid 
extraction [methanol: MTBE (50:50) proportion], for more details 
on analytical conditions see the text in GCMS analysis method 
section, page 9. Numbers correspond to final identified com
pounds described in Table S4. 
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